<!doctype html>
<html>
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width,initial-scale=1,viewport-fit=cover">
  <title>APEX & Trust Prototype</title>
  <link rel="stylesheet" href="../../apex_trust_panel.css">
  <style>
    @keyframes ticker {
      0% { transform: translateX(0); }
      100% { transform: translateX(-50%); }
    }
    @media (max-width: 768px) {
      #scorecard-ticker { animation: ticker 15s linear infinite; }
    }
  </style>
</head>
<body>
  <!-- CONSOLIDATED STICKY HEADER BLOCK -->
  <div style="position: sticky; top: 0; z-index: 9999; margin: 0; padding: 0; width: 100%; overflow: hidden;">
    
    <!-- Page Header -->
    <div style="background: rgb(26, 35, 54); padding: 0.3rem 1.5rem; margin: 0; border-bottom: 1px solid rgba(10, 132, 255, 0.2);">
      <div style="display: flex; align-items: center; gap: 16px;">
        <div style="font-size: 18px; font-weight: 700; color: white;">üî•APEX Intelligence Terminal</div>
      </div>
    </div>

    <!-- Stock Info Header -->
    <div id="stock-info-header" style="margin: 0; padding: 0;">
      <!-- COMPANY INFO HEADER -->
      <div style="display: flex; align-items: center; justify-content: space-between; gap: 0.75rem; background: rgb(26, 35, 54); box-shadow: 0 2px 8px rgba(0,0,0,0.3); border-bottom: 1px solid rgba(10, 132, 255, 0.4); padding: 0.6rem 1.5rem; margin: 0; width: 100%; position: relative; border-radius: 8px 8px 0 0;">
        <div style="display: flex; align-items: center; justify-content: space-between; gap: 0.6rem; width: 100%; overflow: hidden;">
          <!-- Ticker & Company Name (Left) -->
          <div style="flex: 1 1 auto; min-width: 100px; max-width: 180px;">
            <div id="header-ticker" style="color: white; font-size: 0.95rem; font-weight: 800; letter-spacing: 0.5px;">--</div>
            <div id="header-company" style="color: rgba(255,255,255,0.6); font-size: 0.65rem; line-height: 1; margin-top: 1px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</div>
          </div>
          
          <!-- Key Metrics (Center) - 3 columns -->
          <div style="display: flex; gap: 0.5rem; align-items: center; flex: 2 1 auto; overflow: hidden;">
            <!-- Current Price (with currency) -->
            <div style="text-align: center; min-width: 60px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">
                Price <span id="header-currency" style="color: #f59e0b; font-size: 0.5rem; font-weight: 600;">--</span>
              </div>
              <div id="header-price" style="color: white; font-size: 0.85rem; font-weight: 800; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
            
            <!-- Market Cap -->
            <div style="text-align: center; min-width: 55px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">Cap</div>
              <div id="header-mcap" style="color: #10b981; font-size: 0.85rem; font-weight: 800; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
            
            <!-- Exchange (combined Market + Exchange) -->
            <div style="text-align: center; min-width: 60px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">Exchange</div>
              <div id="header-exchange" style="font-size: 0.75rem; font-weight: 700; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
          </div>
        </div>
      </div>
      
      <!-- Details Row -->
      <div style="display: flex; gap: 1.5rem; font-size: 0.65rem; background: rgb(26, 35, 54); box-shadow: 0 2px 6px rgba(0,0,0,0.2); border-bottom: 1px solid rgba(10, 132, 255, 0.2); padding: 0.35rem 1.5rem 0.4rem 1.5rem; margin: 0; text-align: left; border-radius: 0 0 8px 8px;">
        <div style="display: flex; align-items: center; gap: 0.4rem; min-width: 100px;">
          <span style="color: #667eea; font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.4px; font-weight: 500; flex-shrink: 0;">Sector:</span>
          <span id="header-sector" style="color: white; font-weight: 700; font-size: 0.7rem; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</span>
        </div>
        <div style="display: flex; align-items: center; gap: 0.4rem; flex: 1; overflow: hidden;">
          <span style="color: #667eea; font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.4px; font-weight: 500; flex-shrink: 0;">Ind:</span>
          <span id="header-industry" style="color: white; font-weight: 700; font-size: 0.7rem; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</span>
        </div>
      </div>
    </div>

    <!-- Bloomberg Scorecard Ticker -->
    <div style="background: rgb(26, 35, 54); border-left: 3px solid #0a84ff; padding: 0.5rem 0; margin: 0; font-family: 'Courier New', monospace; font-size: 13px; letter-spacing: 0.5px; box-shadow: 0 2px 4px rgba(0,0,0,0.2); overflow: hidden; width: 100%;">
      <div id="scorecard-ticker" style="display: flex; white-space: nowrap; animation: ticker 20s linear infinite; width: max-content;">
        <div class="ticker-content" style="display: flex; align-items: center; gap: 1.5rem; padding: 0 1.5rem; flex-shrink: 0;">
          <span style="color: rgba(255,255,255,0.6); font-size: 11px; text-transform: uppercase; font-weight: 600;">SCORECARD</span>
          <span id="scorecard-apex" style="background: #10b981; color: white; padding: 6px 12px; border-radius: 6px; font-weight: 700; font-size: 13px;">APEX SCORE:--</span>
          <span id="scorecard-setup" style="color: #3B82F6; font-weight: 700;">SETUP:--</span>
          <span id="scorecard-trust" style="color: #8B5CF6; font-weight: 700;">TRUST:--</span>
          <span id="scorecard-panic" style="color: #EF4444; font-weight: 700;">PANIC:--</span>
          <span id="scorecard-comp" style="color: #F59E0B; font-weight: 700;">COMPRESSION:--</span>
          <span style="color: rgba(255,255,255,0.3); font-weight: 400;">‚îÇ</span>
          <span id="scorecard-timing" style="color: #3b82f6; font-weight: 700;">TIMING:--</span>
          <span style="color: rgba(255,255,255,0.3); font-weight: 400;">‚îÇ</span>
          <span id="scorecard-action" style="color: #ef4444; font-weight: 700;">ACTION:--</span>
        </div>
      </div>
    </div>
  </div>

  <div class="container">
    <!-- Narrative Section Header -->
    <div style="display: flex; align-items: center; gap: 12px; margin: 20px 0 12px 0;">
      <svg width="20" height="20" viewBox="0 0 20 20" fill="none" style="flex-shrink: 0;">
        <rect x="2" y="4" width="16" height="12" stroke="#10B981" stroke-width="1.5" fill="none" rx="2"/>
        <line x1="5" y1="4" x2="5" y2="2" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
        <line x1="15" y1="4" x2="15" y2="2" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
        <line x1="2" y1="7" x2="18" y2="7" stroke="#10B981" stroke-width="1.5"/>
        <circle cx="8" cy="11" r="1.2" fill="#10B981"/>
        <circle cx="12" cy="11" r="1.2" fill="#10B981"/>
        <circle cx="16" cy="11" r="1.2" fill="#10B981"/>
      </svg>
      <span style="color: #10B981; font-weight: 700; font-size: 13px; text-transform: uppercase; letter-spacing: 0.8px;">Company in 30 Seconds</span>
    </div>

    <!-- Narrative Card Stack -->
    <div class="card-stack" id="narrative-stack" style="position: relative; min-height: 180px; overflow: visible; touch-action: pan-y; user-select: none; margin-bottom: 30px;">
      <!-- Card 1: What They Do -->
      <div class="card component-card stack-card narrative-card" data-index="0" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(0%) scale(1); opacity: 1; pointer-events: auto; z-index: 10;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <rect x="3" y="3" width="10" height="10" stroke="#10B981" stroke-width="1.5" fill="none" rx="1"/>
            <path d="M6 3 L6 1 M10 3 L10 1 M3 6 L13 6" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
            <circle cx="8" cy="9" r="1.5" fill="#10B981"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">What They Do <span class="info-icon" data-field="what" data-tooltip="Company business model and core operations" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Company business model and core operations')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-what" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Card 2: Why It Matters -->
      <div class="card component-card stack-card narrative-card" data-index="1" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(100%) scale(0.95); opacity: 0; pointer-events: none; z-index: 5;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <circle cx="8" cy="8" r="6" stroke="#10B981" stroke-width="1.5" fill="none"/>
            <circle cx="8" cy="8" r="2" fill="#10B981"/>
            <path d="M8 2 L8 6 M8 10 L8 14 M2 8 L6 8 M10 8 L14 8" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">Why It Matters <span class="info-icon" data-field="why" data-tooltip="Market significance and investment thesis" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Market significance and investment thesis')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-why" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Card 3: Current State -->
      <div class="card component-card stack-card narrative-card" data-index="2" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(100%) scale(0.95); opacity: 0; pointer-events: none; z-index: 5;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <path d="M2 12 L5 9 L8 11 L14 4" stroke="#10B981" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
            <circle cx="5" cy="9" r="1.5" fill="#10B981"/>
            <circle cx="8" cy="11" r="1.5" fill="#10B981"/>
            <circle cx="14" cy="4" r="1.5" fill="#10B981"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">Current State <span class="info-icon" data-field="state" data-tooltip="Latest company situation and metrics" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Latest company situation and metrics')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-state" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Narrative Stack Navigation -->
      <div class="stack-nav" style="bottom: -35px;">
        <div class="stack-dots">
          <span class="stack-dot narrative-dot" data-index="0"></span>
          <span class="stack-dot narrative-dot" data-index="1"></span>
          <span class="stack-dot narrative-dot" data-index="2"></span>
        </div>
        <div class="stack-label" style="color: #10B981;">Company</div>
      </div>
    </div>

    <!-- Scorecard Breakdown Section Header -->
    <div style="display: flex; align-items: center; gap: 12px; margin: 20px 0 12px 0;">
      <svg width="20" height="20" viewBox="0 0 20 20" fill="none" style="flex-shrink: 0;">
        <rect x="2" y="6" width="3" height="12" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="7" y="3" width="3" height="15" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="12" y="8" width="3" height="10" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="17" y="5" width="1" height="13" rx="0.5" stroke="#fff" stroke-width="1.5" fill="none"/>
        <circle cx="10" cy="1" r="1.5" fill="#fff"/>
      </svg>
      <span style="color: #fff; font-weight: 700; font-size: 13px; text-transform: uppercase; letter-spacing: 0.8px;">Scorecard Breakdown</span>
    </div>

    <!-- Main swipeable cards -->
    <div id="component-grid"></div>

    <!-- Bloomberg Phase 2: Collapsible Sections -->
    <div class="bloomberg-sections" style="margin-top: 20px;">
      <!-- CrashDash Intelligence -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('crashdash')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(59, 130, 246, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="crashdash-arrow" style="color: #3b82f6; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #3b82f6; text-transform: uppercase; letter-spacing: 0.5px;">CrashDash Intelligence</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">INDUSTRY PATTERNS ¬∑ RECOVERY PATHS</span>
        </div>
        <div id="crashdash-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="crashdash-data">Loading...</div>
        </div>
      </div>

      <!-- Catalyst Pipeline -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('catalyst')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(16, 185, 129, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="catalyst-arrow" style="color: #10b981; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #10b981; text-transform: uppercase; letter-spacing: 0.5px;">Catalyst Pipeline</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">UPCOMING EVENTS ¬∑ TIMELINE</span>
        </div>
        <div id="catalyst-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="catalyst-data">Loading...</div>
        </div>
      </div>

      <!-- Market Tape -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('market')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(245, 158, 11, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="market-arrow" style="color: #f59e0b; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #f59e0b; text-transform: uppercase; letter-spacing: 0.5px;">Market Tape</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">SOCIAL SENTIMENT ¬∑ TRENDS</span>
        </div>
        <div id="market-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="market-data">Loading...</div>
        </div>
      </div>

      <!-- Investment Decision -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('decision')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(239, 68, 68, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="decision-arrow" style="color: #ef4444; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #ef4444; text-transform: uppercase; letter-spacing: 0.5px;">Investment Decision</span>
          </div>
          <span id="decision-status" style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">ANALYSIS ¬∑ ACTION</span>
        </div>
        <div id="decision-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="decision-data">Loading...</div>
        </div>
      </div>

      <!-- Top 5 Recent RNS -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('rns')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(6, 182, 212, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="rns-arrow" style="color: #06b6d4; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #06b6d4; text-transform: uppercase; letter-spacing: 0.5px;">Top 5 Recent RNS</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">REGULATORY NEWS ¬∑ ANNOUNCEMENTS</span>
        </div>
        <div id="rns-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="rns-data">Loading...</div>
        </div>
      </div>
    </div>

    <!-- Bloomberg Terminal Footer (Collapsible) -->
    <div id="footer-container" style="margin-top: 40px; background: linear-gradient(180deg, #0a1628 0%, #020617 100%); border: 1px solid #1e293b; border-radius: 12px; overflow: hidden; box-shadow: 0 20px 50px rgba(0,0,0,0.5);">
        <!-- Header Bar (Always Visible) -->
        <div style="background: rgba(59, 130, 246, 0.08); border-bottom: 1px solid rgba(59, 130, 246, 0.2); padding: 12px 16px; cursor: pointer;" onclick="toggleFooter()">
            <div style="display: flex; align-items: center; justify-content: space-between; gap: 8px; width: 100%;">
                <div style="display: flex; align-items: center; gap: 8px; flex: 1; min-width: 0; overflow: hidden;">
                    <div style="width: 8px; height: 8px; background: #3b82f6; border-radius: 50%; box-shadow: 0 0 12px rgba(59, 130, 246, 0.6); flex-shrink: 0;"></div>
                    <span style="font-family: 'Courier New', monospace; font-size: 12px; font-weight: 700; color: #3b82f6; text-transform: uppercase; letter-spacing: 0.5px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">APEX Intelligence Terminal</span>
                    <span id="footer-toggle-icon" style="font-size: 14px; color: #3b82f6; transition: transform 0.3s ease; flex-shrink: 0; margin-left: auto;">‚ñº</span>
                </div>
            </div>
            <div style="font-family: 'Courier New', monospace; font-size: 9px; color: rgba(255, 255, 255, 0.4); letter-spacing: 0.3px; margin-top: 6px; overflow: hidden;">
                GENERATED: <span style="color: #06b6d4;" id="footerDate"></span> ‚Ä¢ SESSION: <span style="color: #10b981;">LIVE</span>
            </div>
        </div>
        
        <!-- Collapsible Content Section -->
        <div id="footer-content" style="display: none;">
            <!-- Content Grid -->
            <div style="padding: 24px; display: grid; grid-template-columns: 1fr 1fr; gap: 24px;">
                <!-- Left Column -->
                <div style="display: flex; flex-direction: column; gap: 20px;">
                    <!-- System Information -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #3b82f6; margin-bottom: 8px; text-transform: uppercase; letter-spacing: 1px;">System Information</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; color: rgba(255, 255, 255, 0.7); display: flex; gap: 16px; flex-wrap: wrap; align-items: center;">
                            <span><span style="color: rgba(255, 255, 255, 0.4);">VERSION:</span> <span style="color: #06b6d4; font-weight: 700;">APEX v5.0</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">ENGINE:</span> <span style="color: #10b981;">CrashDash Intelligence</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">COVERAGE:</span> <span style="color: #a855f7;">LSE AIM Micro-Caps</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">SOURCES:</span> <span style="color: #ef4444;">RNS ‚Ä¢ Social ‚Ä¢ Trends</span></span>
                        </div>
                    </div>
                    
                    <!-- Risk Disclosure -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #ef4444; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Risk Disclosure</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; color: rgba(255, 255, 255, 0.5); line-height: 1.6;">
                            This analysis is provided for informational purposes only and does not constitute financial advice. AIM micro-cap securities carry significant volatility and liquidity risks. Past performance does not guarantee future results. Always conduct your own due diligence and consult with a qualified financial advisor before making investment decisions.
                        </div>
                    </div>
                </div>
                
                <!-- Right Column -->
                <div style="display: flex; flex-direction: column; gap: 20px;">
                    <!-- Platform Overview -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #10b981; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Platform Overview</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.7); line-height: 1.6;">
                            APEX Intelligence Terminal combines technical analysis, sentiment tracking, and regulatory news monitoring to identify high-probability contrarian setups in distressed micro-cap equities. Our proprietary scoring system evaluates setup quality, panic intensity, and compression patterns to surface opportunities before institutional recognition.
                        </div>
                    </div>
                    
                    <!-- Target Users -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #a855f7; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Target Users</div>
                        <div style="display: flex; flex-wrap: wrap; gap: 8px;">
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(168, 85, 247, 0.1); border: 1px solid rgba(168, 85, 247, 0.3); border-radius: 4px; color: #a855f7; font-weight: 600;">PROP TRADERS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(59, 130, 246, 0.1); border: 1px solid rgba(59, 130, 246, 0.3); border-radius: 4px; color: #3b82f6; font-weight: 600;">HEDGE FUNDS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(16, 185, 129, 0.1); border: 1px solid rgba(16, 185, 129, 0.3); border-radius: 4px; color: #10b981; font-weight: 600;">QUANT TEAMS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(239, 68, 68, 0.1); border: 1px solid rgba(239, 68, 68, 0.3); border-radius: 4px; color: #ef4444; font-weight: 600;">RESEARCH DESKS</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Bottom Bar -->
            <div style="background: rgba(2, 6, 23, 0.6); border-top: 1px solid rgba(59, 130, 246, 0.15); padding: 12px 24px;">
                <div style="display: flex; align-items: center; justify-content: space-between; flex-wrap: wrap; gap: 12px; font-family: 'Courier New', monospace; font-size: 10px;">
                    <div style="color: rgba(255, 255, 255, 0.4);">¬© 2026 APEX Intelligence ‚Ä¢ All Rights Reserved</div>
                    <div style="display: flex; align-items: center; gap: 20px; color: rgba(255, 255, 255, 0.5);">
                        <span>STATUS: <span style="color: #10b981; font-weight: 700;">‚óè OPERATIONAL</span></span>
                        <span>LATENCY: <span style="color: #06b6d4; font-weight: 700;">12ms</span></span>
                        <span>BUILD: <span style="color: #a855f7; font-weight: 700;">5.0.2</span></span>
                    </div>
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function toggleFooter() {
            const content = document.getElementById('footer-content');
            const icon = document.getElementById('footer-toggle-icon');
            
            if (content.style.display === 'none') {
                content.style.display = 'block';
                icon.style.transform = 'rotate(180deg)';
            } else {
                content.style.display = 'none';
                icon.style.transform = 'rotate(0deg)';
            }
        }

        // Mobile-friendly tooltip popover
        function showTooltipPopover(event, tooltipText) {
            event.stopPropagation();
            
            // Close any existing popover
            const existing = document.getElementById('tooltip-popover');
            if (existing) existing.remove();
            
            // Create popover
            const popover = document.createElement('div');
            popover.id = 'tooltip-popover';
            popover.style.cssText = 'position:fixed;background:rgba(20,25,40,0.98);color:#e5e7eb;padding:10px 14px;border-radius:6px;font-size:12px;line-height:1.4;max-width:250px;border:1px solid rgba(16,185,129,0.3);z-index:10000;box-shadow:0 4px 12px rgba(0,0,0,0.4);backdrop-filter:blur(8px);word-wrap:break-word';
            popover.textContent = tooltipText;
            document.body.appendChild(popover);
            
            // Position near clicked element
            const rect = event.target.getBoundingClientRect();
            popover.style.left = Math.min(rect.left, window.innerWidth - 270) + 'px';
            popover.style.top = (rect.bottom + 8) + 'px';
            
            // Close on outside click
            setTimeout(() => {
                document.addEventListener('click', closeTooltip, { once: true });
            }, 0);
        }

        function closeTooltip() {
            const popover = document.getElementById('tooltip-popover');
            if (popover) popover.remove();
        }
    </script>
  </div>
  
  <!-- Mobile Responsive Styles -->
  <style>
    @media(max-width:768px){
        body{padding:10px!important}
        .container{max-width:100%!important}
        #footer-container{margin-top:20px!important}
        div[style*="grid-template-columns: 1fr 1fr"]{grid-template-columns:1fr!important;gap:12px!important}
        div[style*="grid-template-columns: repeat(4"]{grid-template-columns:repeat(2,1fr)!important;gap:10px!important}
        div[style*="padding: 24px"]{padding:16px!important}
        div[style*="padding: 12px 16px"]{padding:10px 12px!important}
        div[style*="gap: 20px"]{gap:14px!important}
        div[style*="font-size: 11px"]{font-size:10px!important}
        div[style*="font-size: 12px"]{font-size:11px!important}
        div[style*="font-size: 13px"]{font-size:12px!important}
    }
    @media(max-width:480px){
        body{padding:6px!important}
        .container{padding:0!important;margin:0!important}
        #footer-container{margin-top:16px!important;margin-left:6px!important;margin-right:6px!important}
        #footer-container > div:first-child{padding:8px 10px!important}
        div[style*="grid-template-columns: 1fr 1fr"]{grid-template-columns:1fr!important;gap:8px!important}
        div[style*="grid-template-columns: repeat(4"]{grid-template-columns:1fr!important;gap:6px!important;padding:8px 10px!important}
        div[style*="grid-template-columns: repeat(2"]{grid-template-columns:1fr!important;gap:6px!important}
        div[style*="padding: 24px"]{padding:10px!important}
        div[style*="padding: 12px 16px"]{padding:8px 10px!important}
        div[style*="padding: 14px 16px"]{padding:8px 10px!important}
        div[style*="padding: 18px"]{padding:10px!important}
        div[style*="gap: 20px"]{gap:8px!important}
        div[style*="gap: 30px"]{gap:10px!important}
        div[style*="gap: 24px"]{gap:10px!important}
        div[style*="gap: 16px"]{gap:6px!important}
        div[style*="gap: 12px"]{gap:6px!important}
        div[style*="gap: 8px"]{gap:4px!important}
        div[style*="font-size: 9px"]{font-size:8px!important}
        div[style*="font-size: 10px"]{font-size:8px!important}
        div[style*="font-size: 11px"]{font-size:9px!important}
        div[style*="font-size: 12px"]{font-size:10px!important}
        div[style*="font-size: 13px"]{font-size:11px!important}
        div[style*="padding: 6px 12px"]{padding:4px 6px!important;font-size:7px!important}
        div[style*="line-height: 1.8"]{line-height:1.4!important}
        div[style*="line-height: 1.6"]{line-height:1.3!important}
        div[style*="line-height: 1.5"]{line-height:1.2!important}
        /* Footer system info on mobile - stack vertically and shrink */
        div[style*="display: flex; gap: 16px; flex-wrap: wrap; align-items: center"] {
          flex-direction: column!important;
          align-items: flex-start!important;
          gap: 4px!important;
          font-size: 7px!important;
        }
    }
  </style>
  
  <script>window.__APEX_PROFILE = {
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "VRCI.L",
  "generated_at": "2026-02-11T14:06:26.342485Z",
  "top_card": {
    "ticker": "VRCI.L",
    "company_name": "Verici Dx plc",
    "sector": "Healthcare",
    "market_cap_gbp": 9912731,
    "days_active": 1,
    "apex_score_100": 42,
    "confidence_score_100": 50,
    "ai_final_score_25": 13,
    "ai_strength": "MODERATE",
    "timing_regime": "EARLY_BUILD",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - EARLY_BUILD timing with 42/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Verici Dx plc",
      "sector": "Healthcare",
      "industry": "Diagnostics & Research",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 9912731,
      "current_close_price": 0.655
    },
    "basics": {
      "ticker": "VRCI.L",
      "current_price": 0.655,
      "ath": 94.95,
      "atl": 0.466,
      "ath_date": "2021-02-08",
      "atl_date": "2025-08-06",
      "week_52_high": 3.75,
      "week_52_low": 0.466,
      "week_52_high_date": "2025-03-06",
      "week_52_low_date": "2025-08-06",
      "drawdown_from_ath_pct": 99.31,
      "data_start": "2020-11-03",
      "data_end": "2026-02-11",
      "total_bars": 1331
    },
    "latest_signal": {
      "date": "2026-02-10",
      "scan_date": "2026-02-10",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 0.68,
      "drawdown_pct": 81.87,
      "ai_score": 11.0,
      "rsi": 0.0,
      "cycle_position": 0.0912,
      "holding_period_days": 1,
      "current_pnl_pct": -3.68,
      "rally_state": "accumulating",
      "distance_from_high_pct": 0.0,
      "Rally_Count": 0,
      "days_since_last_high": 0,
      "last_high_date": "2026-02-11",
      "lock_in_reached": false,
      "lock_in_date": NaN,
      "best_rally_pct": -3.68
    },
    "best_historical_signal": {
      "signal_date": "2023-03-20",
      "signal_type": "DEEP CRASH BOTTOM",
      "signal_color": "GREEN",
      "entry_price": 4.75,
      "peak_price": 19.0,
      "peak_date": "2023-05-04",
      "rally_pct": 300.0,
      "days_to_peak": 45,
      "ai_score": 10.0
    },
    "all_historical_signals": [
      {
        "signal_id": "VRCI.L_2022-06-22",
        "signal_date": "2022-06-22",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 16.0,
        "current_price": 0.7025,
        "current_return_pct": -95.61,
        "best_rally_pct": 43.75,
        "best_rally_date": "2022-06-30",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -96.95,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1314,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-10-03",
        "signal_date": "2022-10-03",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 14.5,
        "current_price": 0.7025,
        "current_return_pct": -95.16,
        "best_rally_pct": 20.69,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1211,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-10-04",
        "signal_date": "2022-10-04",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 14.5,
        "current_price": 0.7025,
        "current_return_pct": -95.16,
        "best_rally_pct": 20.69,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1210,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-10-10",
        "signal_date": "2022-10-10",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 13.75,
        "current_price": 0.7025,
        "current_return_pct": -94.89,
        "best_rally_pct": 27.27,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1204,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-10-12",
        "signal_date": "2022-10-12",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 13.5,
        "current_price": 0.7025,
        "current_return_pct": -94.8,
        "best_rally_pct": 29.63,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1202,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-11-23",
        "signal_date": "2022-11-23",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 11.5,
        "current_price": 0.7025,
        "current_return_pct": -93.89,
        "best_rally_pct": 52.17,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1160,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-01-17",
        "signal_date": "2023-01-17",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 10.0,
        "current_price": 0.7025,
        "current_return_pct": -92.98,
        "best_rally_pct": 75.0,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1105,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-02-14",
        "signal_date": "2023-02-14",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 8.5,
        "current_price": 0.7025,
        "current_return_pct": -91.74,
        "best_rally_pct": 105.88,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1077,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-02-15",
        "signal_date": "2023-02-15",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.5,
        "current_price": 0.7025,
        "current_return_pct": -90.63,
        "best_rally_pct": 133.33,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1076,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-02-27",
        "signal_date": "2023-02-27",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.5,
        "current_price": 0.7025,
        "current_return_pct": -90.63,
        "best_rally_pct": 133.33,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1064,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-03-17",
        "signal_date": "2023-03-17",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 5.5,
        "current_price": 0.7025,
        "current_return_pct": -87.23,
        "best_rally_pct": 218.18,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1046,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-03-20",
        "signal_date": "2023-03-20",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 4.75,
        "current_price": 0.7025,
        "current_return_pct": -85.21,
        "best_rally_pct": 268.42,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1043,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-04-07",
        "signal_date": "2025-04-07",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.5,
        "current_price": 0.7025,
        "current_return_pct": -53.17,
        "best_rally_pct": 61.33,
        "best_rally_date": "2025-04-10",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -70.97,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 294,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-05-13",
        "signal_date": "2025-05-13",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.375,
        "current_price": 0.7025,
        "current_return_pct": -48.91,
        "best_rally_pct": 18.18,
        "best_rally_date": "2025-06-03",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -56.77,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 258,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-05-16",
        "signal_date": "2025-05-16",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.125,
        "current_price": 0.7025,
        "current_return_pct": -37.56,
        "best_rally_pct": 44.44,
        "best_rally_date": "2025-06-03",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -56.77,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 255,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-05-19",
        "signal_date": "2025-05-19",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.125,
        "current_price": 0.7025,
        "current_return_pct": -37.56,
        "best_rally_pct": 44.44,
        "best_rally_date": "2025-06-03",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -56.77,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 252,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-05-21",
        "signal_date": "2025-05-21",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.25,
        "current_price": 0.7025,
        "current_return_pct": -43.8,
        "best_rally_pct": 30.0,
        "best_rally_date": "2025-06-03",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -56.77,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 250,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-06-30",
        "signal_date": "2025-06-30",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.125,
        "current_price": 0.7025,
        "current_return_pct": -37.56,
        "best_rally_pct": 0.0,
        "best_rally_date": "2025-07-01",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 210,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-18",
        "signal_date": "2025-07-18",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.875,
        "current_price": 0.7025,
        "current_return_pct": -19.71,
        "best_rally_pct": 5.71,
        "best_rally_date": "2025-10-14",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 192,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-21",
        "signal_date": "2025-07-21",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.58,
        "current_price": 0.7025,
        "current_return_pct": 21.12,
        "best_rally_pct": 59.48,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 189,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-22",
        "signal_date": "2025-07-22",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.6,
        "current_price": 0.7025,
        "current_return_pct": 17.08,
        "best_rally_pct": 54.17,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 188,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-24",
        "signal_date": "2025-07-24",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.655,
        "current_price": 0.7025,
        "current_return_pct": 7.25,
        "best_rally_pct": 41.22,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 4,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 186,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-29",
        "signal_date": "2025-07-29",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.55,
        "current_price": 0.7025,
        "current_return_pct": 27.73,
        "best_rally_pct": 68.18,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 181,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-30",
        "signal_date": "2025-07-30",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.55,
        "current_price": 0.7025,
        "current_return_pct": 27.73,
        "best_rally_pct": 68.18,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 180,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-31",
        "signal_date": "2025-07-31",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.55,
        "current_price": 0.7025,
        "current_return_pct": 27.73,
        "best_rally_pct": 68.18,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 179,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-08-06",
        "signal_date": "2025-08-06",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.525,
        "current_price": 0.7025,
        "current_return_pct": 33.81,
        "best_rally_pct": 76.19,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 173,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2026-02-05",
        "signal_date": "2026-02-05",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.7025,
        "current_price": 0.655,
        "current_return_pct": -6.76,
        "best_rally_pct": 3.2,
        "best_rally_date": "2026-02-06",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -9.66,
        "days_since_last_high": 5,
        "lock_in_reached": false,
        "age_days": 6,
        "status": "active"
      },
      {
        "signal_id": "VRCI.L_2026-02-10",
        "signal_date": "2026-02-10",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.68,
        "current_price": 0.655,
        "current_return_pct": -3.68,
        "best_rally_pct": -3.68,
        "best_rally_date": "2026-02-11",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 0,
        "lock_in_reached": false,
        "age_days": 1,
        "status": "active"
      }
    ],
    "stats": {
      "total_signals": 28,
      "win_rate_pct": 96.4,
      "avg_rally_pct": 76.85,
      "median_rally_pct": 60.39,
      "best_rally_pct": 300.0,
      "worst_rally_pct": -0.15
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-02-11 10:05:47 UTC",
    "volatility": {
      "atr_normalized": 10.0,
      "stddev_20d": 0.0
    },
    "trends": {
      "intelligence_signal": "TOPPED_OUT"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 42/100 indicates moderate opportunity quality",
      "Timing regime: EARLY_BUILD",
      "Historical profile: 0 rallies, 3% best run"
    ],
    "main_risk": "Confidence 50/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "VRCI.L",
      "latest": [
        {
          "title": "FY25 Trading Update",
          "announcement_date": "5th Feb 2026",
          "release_time": "7:01 am",
          "source": "RNS",
          "content": "Today 07:01\nRNS Number : 7865R\nVerici Dx PLC\n05 February 2026\nVerici Dx plc\n(\"Verici Dx\" or the \"Company\")\nFY25 Trading Update\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nprovides a trading update for the year ended 31 December 2025 (\"FY25\"), a year of strong growth and commercial progress for the Company.\nFinancial highlights\n\u00b7\nTotal unaudited revenues1 of $3.8m (2024: $3.3m) comprising:\no\n$3.0m from recognised revenue of Tutivia (2024: $Nil). $3.2m worth of tests were ordered during the year\no\n$0.8m from license income (2024: $3.3m), reflecting the expected timing of milestone payments under the outlicensed contract\n\u00b7\nUnaudited cash at year-end of $3.3m (2024: $4.1m), which is slightly ahead of expectations, with $1.6m accounts receivable (2024: $Nil) which continues to support\nexpected cash runway into H2 2026 as previously communicated.\nOperational highlights\n\u00b7\nSignificant commercial progress across the year with first revenues from\nTutivia\u2122 test results.\n\u00b7\nSecured Medicare coverage for Tutivia\u2122\ncovering a national estimate of 68% of all US transplant tests and\ngreatly improving patient access.\n\u00b7\nMilestone receipt of $0.8m from Thermo Fisher Scientific for the product licensing of PTRA (Clarava).\n\u00b7\nContinued increase in test adoption with:\no\n1,173\nTutivia\u2122 tests ordered\nin FY25 (Q4: 296)\ncompared to 334\nover the whole of FY24.\n\u00b7\nExpansion in centres using Tutivia\nTM\nfor a total of 34 representing 18% of annual kidney transplants in the US, with the addition of 4 new ordering centres in Q4.\n\u00b7\nSigned a Provider Participation Agreement with Prime Health Services,\na dynamic healthcare technology US based company focused on delivering innovative, data-driven solutions through its Preferred Provider Organization ('PPO') network.\n\u00b7\nAdditional commercial team member added.\n\u00b7\nContract signed with Blue Cross Blue Shield (\"BCBS\") of Illinois, announced separately today, with contracted pricing across multiple lines of business, giving in-network status for BCBS covered patients and providing the Company with access to open contract processes with other BCBS entities.\n1\nRevenue is reimbursed from two core types of payor: Medicare and commercial payors. For Medicare patients, there is a fixed price for the test. For commercial payors, there are a number of factors which determine whether, and for how much, the test is reimbursed, which can vary by commercial payor. Revenue recognition therefore requires a significant amount of judgement and estimation, as we continue to gather information to inform a reasonable average reimbursement from these commercial payors. This assessment is monitored monthly, with revisions made based on the actual reimbursement price achieved and denial rates, once known with reasonable certainty.\nNotice of Results\nThe Company currently expects to announce full year results no later than May 2026. A further announcement confirming a date for publication of the audited results will be issued in due course.\nSara Barrington, Chief Executive Officer, said:\n\"We are proud to have achieved substantial growth in FY25, reflected in the continued adoption of\nTutivia\u2122\nand an increase in sales across the year. Whilst recognised\nTutivia\u2122\nrevenues of $3.0m were slightly behind market expectations for the full year, we continue to see strong testing volume acceleration beyond the $3.2m of orders received during the year. We are confident that our clinical and regulatory foundations will continue to show successful commercial traction across 2026 and beyond.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Adam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Rachel Broad\nMob: +44 (0)7407 804 654 / +44 (0)7747 515 393\nVerici Dx\nVerici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.\nOperating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia\u2122, is a post-kidney transplant test focused on early detection of acute rejection.\nThe company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit\nhttps://vericidx.com/\nand follow us on\nLinkedIn\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTSTAKQBPDBKBOBK",
          "rns_number": "RNS Number : 7865R"
        },
        {
          "title": "Agreement with BCBS of Illinois for Tutivia\u2122",
          "announcement_date": "5th Feb 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "Today 07:00\nRNS Number : 7866R\nVerici Dx PLC\n05 February 2026\nVerici Dx plc\n(\"Verici Dx\" or the \"Company\")\nAgreement with Blue Cross and Blue Shield of Illinois for\nTutivia\u2122\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has entered into an agreement (\"the agreement\") with Blue Cross and Blue Shield (\"BCBS\") of Illinois for\nTutivia\u2122,\nthe Company's\npost-kidney transplant test focused on early detection of acute rejection.\nThe agreement ensures that\nTutivia\nis considered as an in-network benefit for patients which streamlines the claims process and ensures that patients receive testing at in-network rates. BCBS also has its own Preferred Provider Organization network, of which Verici Dx is now a member. As a result, the Company receives access to open contract processes with other BCBS entities, including BCBS Texas.\nBCBS provides health care coverage for 118 million members in all 50 states, Washington, D.C., and Puerto Rico, and more than 2 million doctors and hospitals contract with BCBS companies nationwide. BCBS has several lines of business in Illinois, including commercial payor, managed Medicaid and Medicare Advantage, all of which are covered as part of the agreement.\nThe agreement also provides access to the BCBS Association, which covers 33 BCBS member entities. In turn, this allows for a streamlined process for Verici Dx to access a CareSource agreement.\nSara Barrington, Chief Executive Officer, said:\n\"This agreement with BCBS represents a key milestone for Verici Dx as we\u00a0continue to grow our patient network and focus on expanding our commercial reach. We look forward to updating shareholders further as we progress with this agreement and continue to advance discussions with additional payors.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Adam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Rachel Broad\nMob: +44 (0)7407 804 654 / +44 (0)7747 515 393\nVerici Dx\nVerici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.\nOperating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia\u2122, is a post-kidney transplant test focused on early detection of acute rejection.\nThe company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit\nhttps://vericidx.com/\nand follow us on\nLinkedIn\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRGZGGZZDDGVZZ",
          "rns_number": "RNS Number : 7866R"
        },
        {
          "title": "Completion of CAP accreditation audit",
          "announcement_date": "12th Nov 2025",
          "release_time": "7:00 am",
          "source": "RNS-R",
          "content": "12 Nov 2025 07:00\nRNS Number : 1171H\nVerici Dx PLC\n12 November 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nCompletion of CAP accreditation audit\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has successfully completed its second biennial inspection of the Company's clinical laboratory, accredited by the College of American Pathologists (\"CAP\"). CAP is one of the leading US organisations for reviewing clinical laboratories and maintaining this accreditation is an essential part in continuing to implement the highest standards in clinical laboratory practice.\nThe inspection passed with no deficiencies, showing Verici Dx's commitment to compliance and maintaining excellence in daily clinical laboratory operations according to CAP requirements and their respective annual updates. By continuing to follow these strict CAP guidelines and pass CAP accreditation audits, Verici Dx can consistently provide reliable test results under its quality management system and further improve patient health.\nDave Schultenover, VP Quality and Regulatory Affairs\u00a0at Verici Dx, said:\n\"Verici Dx values the clinicians and patients that put their trust in our clinical laboratory, enabling a level of personalised care that has not been available to kidney transplant patients until now.\u00a0We are dedicated to continuing to meet or exceed the regulatory requirements to be a trusted partner to clinicians.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Adam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or\nvericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRABBBATMTTBBLA",
          "rns_number": "RNS Number : 1171H"
        },
        {
          "title": "Provider Participation Agreement with Prime Health",
          "announcement_date": "6th Nov 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "6 Nov 2025 07:00\nRNS Number : 3944G\nVerici Dx PLC\n06 November 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nProvider Participation Agreement with Prime Health Services\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has signed a Provider Participation Agreement ('the Agreement') with Prime Health Services ('Prime Health'), a dynamic healthcare technology US based company focused on delivering innovative, data-driven solutions through its Preferred Provider Organization ('PPO') network.\nPPO networks were established to bring predictability and consistency to pricing in healthcare. They negotiate on behalf of insurance companies to gain discounted pricing, which benefits healthcare companies by bringing a uniform price in reimbursement within the PPO network and fewer denials from the insurance reimbursement. It also provides Physicians with greater confidence in ordering as there is more certainty in the cost to their patients which in turn provides greater cost transparency to the patient. The insurance plans also benefit from having the PPO networks successfully negotiate this contracted price from both a cost efficiency perspective as well as competitive appeal.\nPrime Health is one of the fastest-growing preferred provider networks in the US and has more than 850,000 providers across the 50 states, processing around 35 million claims per year. Prime Health's PPO network serves a wide array of clients, including insurance carriers, third-party administrators, self-insured organisations, government entities, and captive insurance groups which provides significant opportunity for Verici Dx to expand its patient scope.\nPatti Connolly, Chief Operating Officer at Verici Dx, said:\n\"This agreement with Prime Health is an important milestone for Verici Dx, as we\naccelerate our commercial\nreach, expanding our patient network and supporting our approach to increased coverage from private payors. We look forward to updating shareholders on additional agreements of this nature in due course.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRFSEESIEISELF",
          "rns_number": "RNS Number : 3944G"
        },
        {
          "title": "Completion of ISO 27001 surveillance audit",
          "announcement_date": "3rd Nov 2025",
          "release_time": "7:00 am",
          "source": "RNS-R",
          "content": "3 Nov 2025 07:00\nRNS Number : 7583F\nVerici Dx PLC\n03 November 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nSuccessful completion of ISO 27001 surveillance audit\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has successfully completed the annual surveillance audit for its ISO 27001:2022 certification.\nISO 27001 is a globally recognised standard specifying data privacy and security requirements for an Information Security Management System (\"ISMS\"). The annual surveillance audit aims to confirm that the Company is following the highest level of standards enforced by the certification.\nThe Company's successful completion of this audit, along with its continued commitment to protecting sensitive data and information, reinforces its position as a trusted partner in the industry and in patient care. Continued conformity with this standard means that Verici Dx's system meets world-wide best practice with regards to managing risks related to the security of data owned or handled by the Company.\nDave Schultenover, VP Quality and Regulatory Affairs\u00a0at Verici Dx, said:\n\"\nWe take our commitment to compliance at Verici Dx very seriously and pride ourselves on performing with integrity that meets or exceeds industry regulations and standards. We are pleased maintain this strong track record to remain a trusted partner with our stakeholders and within the industry.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook /\nAdam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAEFLFXEBLXFBV",
          "rns_number": "RNS Number : 7583F"
        }
      ],
      "themes": [
        "drilling",
        "operations"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 1271,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "TOPPED_OUT"
    },
    "volatility": {
      "atr_normalized": 10.0,
      "stddev_20d": 0.0
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "all_events": [
      {
        "event_id": "RNS-12th Nov 2025-completi",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.957694Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Completion of CAP accreditation audit",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/VRCI/completion-of-cap-accreditation-audit-9wc7t08kk0m852r.html",
          "rns_number": "RNS Number : 1171H",
          "full_content": "12 Nov 2025 07:00\nRNS Number : 1171H\nVerici Dx PLC\n12 November 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nCompletion of CAP accreditation audit\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has successfully completed its second biennial inspection of the Company's clinical laboratory, accredited by the College of American Pathologists (\"CAP\"). CAP is one of the leading US organisations for reviewing clinical laboratories and maintaining this accreditation is an essential part in continuing to implement the highest standards in clinical laboratory practice.\nThe inspection passed with no deficiencies, showing Verici Dx's commitment to compliance and maintaining excellence in daily clinical laboratory operations according to CAP requirements and their respective annual updates. By continuing to follow these strict CAP guidelines and pass CAP accreditation audits, Verici Dx can consistently provide reliable test results under its quality management system and further improve patient health.\nDave Schultenover, VP Quality and Regulatory Affairs\u00a0at Verici Dx, said:\n\"Verici Dx values the clinicians and patients that put their trust in our clinical laboratory, enabling a level of personalised care that has not been available to kidney transplant patients until now.\u00a0We are dedicated to continuing to meet or exceed the regulatory requirements to be a trusted partner to clinicians.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Adam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or\nvericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRABBBATMTTBBLA",
          "content_length": 2618
        },
        "ingested_at": "2026-01-16T22:48:57.957736Z"
      },
      {
        "event_id": "RNS-6th Nov 2025-provider",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.957761Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Provider Participation Agreement with Prime Health",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/provider-participation-agreement-with-prime-health-em4z8fxr4u52f9d.html",
          "rns_number": "RNS Number : 3944G",
          "full_content": "6 Nov 2025 07:00\nRNS Number : 3944G\nVerici Dx PLC\n06 November 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nProvider Participation Agreement with Prime Health Services\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has signed a Provider Participation Agreement ('the Agreement') with Prime Health Services ('Prime Health'), a dynamic healthcare technology US based company focused on delivering innovative, data-driven solutions through its Preferred Provider Organization ('PPO') network.\nPPO networks were established to bring predictability and consistency to pricing in healthcare. They negotiate on behalf of insurance companies to gain discounted pricing, which benefits healthcare companies by bringing a uniform price in reimbursement within the PPO network and fewer denials from the insurance reimbursement. It also provides Physicians with greater confidence in ordering as there is more certainty in the cost to their patients which in turn provides greater cost transparency to the patient. The insurance plans also benefit from having the PPO networks successfully negotiate this contracted price from both a cost efficiency perspective as well as competitive appeal.\nPrime Health is one of the fastest-growing preferred provider networks in the US and has more than 850,000 providers across the 50 states, processing around 35 million claims per year. Prime Health's PPO network serves a wide array of clients, including insurance carriers, third-party administrators, self-insured organisations, government entities, and captive insurance groups which provides significant opportunity for Verici Dx to expand its patient scope.\nPatti Connolly, Chief Operating Officer at Verici Dx, said:\n\"This agreement with Prime Health is an important milestone for Verici Dx, as we\naccelerate our commercial\nreach, expanding our patient network and supporting our approach to increased coverage from private payors. We look forward to updating shareholders on additional agreements of this nature in due course.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRFSEESIEISELF",
          "content_length": 3284
        },
        "ingested_at": "2026-01-16T22:48:57.957777Z"
      },
      {
        "event_id": "RNS-3rd Nov 2025-completi",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.957792Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Completion of ISO 27001 surveillance audit",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/VRCI/completion-of-iso-27001-surveillance-audit-pmqz3qfkcqcgngt.html",
          "rns_number": "RNS Number : 7583F",
          "full_content": "3 Nov 2025 07:00\nRNS Number : 7583F\nVerici Dx PLC\n03 November 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nSuccessful completion of ISO 27001 surveillance audit\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has successfully completed the annual surveillance audit for its ISO 27001:2022 certification.\nISO 27001 is a globally recognised standard specifying data privacy and security requirements for an Information Security Management System (\"ISMS\"). The annual surveillance audit aims to confirm that the Company is following the highest level of standards enforced by the certification.\nThe Company's successful completion of this audit, along with its continued commitment to protecting sensitive data and information, reinforces its position as a trusted partner in the industry and in patient care. Continued conformity with this standard means that Verici Dx's system meets world-wide best practice with regards to managing risks related to the security of data owned or handled by the Company.\nDave Schultenover, VP Quality and Regulatory Affairs\u00a0at Verici Dx, said:\n\"\nWe take our commitment to compliance at Verici Dx very seriously and pride ourselves on performing with integrity that meets or exceeds industry regulations and standards. We are pleased maintain this strong track record to remain a trusted partner with our stakeholders and within the industry.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook /\nAdam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAEFLFXEBLXFBV",
          "content_length": 2596
        },
        "ingested_at": "2026-01-16T22:48:57.957805Z"
      },
      {
        "event_id": "RNS-30th Oct 2025-optionsr",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.957819Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Options revision & Grant of new share options",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/options-revision-grant-of-new-share-options-qmmax9o20moug84.html",
          "rns_number": "RNS Number : 3805F",
          "full_content": "30 Oct 2025 07:00\nRNS Number : 3805F\nVerici Dx PLC\n30 October 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nOptions revision\n&\nGrant of new share options\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that upon the recommendation of the Company's Remuneration Committee, it has repriced certain existing options over ordinary shares of 0.1 pence each in the capital of the Company (\"Ordinary Shares\") (\"Share Options\") over an aggregate of 15,577,304 Ordinary Shares and granted new Share Options over an aggregate 107,800,000 Ordinary Shares to certain Directors, persons discharging management responsibility (\"PDMRs\"), employees and consultants of the Company. The goal of the review was to realign with previous remuneration targets and the issued pool of options including those for new team members now represents 8.32% of the Company's total voting rights as compared with the previous pool of 7.98%.\nThe Company's Remuneration Committee recognises the importance of share options to appropriately incentivise and retain Directors and employees, as well as to ensure their interests are aligned with that of Company and its shareholders. Following a review of incentive plans, the Remuneration Committee of the Board recommended that, given the reduction in the Company's share price and the changes in the share capital following the recent fundraising, the existing awards of share options were no longer a reasonable incentive and should be amended to re-align the option scheme with the current share price and share capital.\nAccordingly, the Company has agreed with each of Sara Barrington, Chief Executive Officer, David Anderson, Chief Financial Officer and Lorenzo Gallen, Non-Executive Director, that the exercise price in respect of the options granted to Sara Barrington and David Anderson on 28 October 2020 around the time of the Company's IPO, and of those granted to Lorenzo Gallon on 6 December 2022 is amended from 20 pence to 0.525 pence per Ordinary Share. All other terms of these Share Options remain the same. All of the Share Options granted in October 2020 have vested in full and can be exercised at any time until 28 October 2030. The Share Options granted in December 2022 have vested in full and can be exercised at any time until 6 December 2032. The numbers of Share Options currently held by Directors and PDMR's and being repriced are shown in the following table:\nName\nPosition\nExisting Options\nPrevious Exercise Price (per share)\nNew Exercise Price (per share)\nSara Barrington\nChief Executive Officer\n5,669,913\n\u00a30.2\n\u00a30.00525\nDavid Anderson\nChief Financial Officer\n708,739\n\u00a30.2\n\u00a30.00525\nLorenzo Gallon\nNon-Executive Director\n354,370\n\u00a30.2\n\u00a30.00525\nAdditionally, the\nBoard has granted new options over a total of 107,800,000 Ordinary Shares (the \"New Share Options\") to\ncertain Directors, PDMRs, employees and consultants of the Company\n. Of the Company's Directors and PDMRs, this includes:\nName\nPosition\nOptions granted\nTotal Options\nResultant total holding as a % of total voting rights\nSara Barrington\nChief Executive Officer\n54,900,000\n60,569,913\n4%\nDavid Anderson\nChief Financial Officer\n6,800,000\n7,508,739\n0.5%\nLorenzo Gallon\nNon-Executive Director\n1,900,000\n2,254,370\n0.15%\nThe remaining 44,200,000 New Share Options have been granted to employees of the Company including recent joiners in the sales team, and it is also the intention to grant New Share Options to new employees who are in the process of joining the Company.\nThe New Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of 0.525 pence per ordinary share.\nThis was the price on 2 September 2025 when the Board initially resolved to grant these options but were unable to do so at the time due to the closed period ahead of the Company's interim results.\nThe vesting conditions for the New Share Options granted to the Directors and PDMR's and Chief Operating Officer are 50% performance-based and 50% time-based, with the\nshare option grant initially vesting 12 months from the date of grant. These New Share Options can be exercised until the tenth anniversary from date of grant.\nThe repricing of the Share Options and the issue of the New Share Options are deemed to be related party transactions under AIM Rule 13 of the AIM Rules for Companies. The Company's Directors (excluding those who are being awarded the Share Options) consider, having consulted with the Nominated Adviser, Singer Capital Markets, that the terms of the related party transactions are fair and reasonable insofar as the shareholders of the Company are concerned.\nFollowing the grant of the New Share Options referred above, there are 125,849,152 outstanding options over Verici's Ordinary Shares, representing 8.32% of the Company's total voting rights. The percentage of outstanding options over Verici's Ordinary Shares prior to this new grant was 7.98%.\nVerici Dx plc\nwww.ver",
          "content_length": 7401
        },
        "ingested_at": "2026-01-16T22:48:57.957835Z"
      },
      {
        "event_id": "RNS-6th Oct 2025-boardcha",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.957848Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Board Changes",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/board-changes-0iuy4chubghu0z4.html",
          "rns_number": "RNS Number : 1661C",
          "full_content": "6 Oct 2025 07:01\nRNS Number : 1661C\nVerici Dx PLC\n06 October 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nBoard Changes\nAubrey Powell appointed as Non-executive Director\nVerici Dx plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces the appointment to the Board of Aubrey Powell, as Non-executive Director, with immediate effect. At the same time, Dr Erik Lium, Non-executive Director since August 2020 and representative of Mount Sinai on the Board, will step down from the Board with immediate effect.\nAubrey has over 30 years' experience in supporting and\u00a0advising growth companies, 26 of which have been spent in investment banking and corporate finance. He trained at\u00a0Salomon Brothers (now Citi) for two years before transitioning to\u00a0small and mid-cap roles at Panmure Gordon where he spent 12 years (including buyside\u00a0investment and portfolio company support, as well as early-stage public companies at Durlacher prior to Panmure Gordon's reverse takeover in April 2005). Aubrey worked at N+1 Singer, which became Singer Capital Markets, from early 2012 to mid-2024, serving as an AIM Qualified Executive and advising Main Market companies, as Sponsor, on their obligations.\nAubrey has extensive experience in deal execution in equity capital markets and M&A, for public companies as well as private, and has focused predominantly on Healthcare and Life Sciences, TMT and other technology-enabled businesses, over the course of his career.\u00a0He brings a blend of skills from corporate finance to deal-making, as well as a strong track record of effectively guiding clients through reporting cycles, which supports his proposed role as a member of the Audit Committee, as well as advising on their wider regulatory and investor obligations including corporate governance.\nPrevious experience also includes\u00a0strategic consultancy covering growth and investment\u00a0decision-making, as well as corporate communications, and working in biotech research for ICI Pharmaceuticals.\nAubrey Powell, Non-executive Director of Verici Dx plc\nJulian Baines, MBE, Non-executive Chairman of Verici Dx, said:\n\"On behalf of the Board, I would like to thank Erik for\nhis contribution to the Company over the last five years, supporting us through our AIM IPO and the transition to a business building commercial scale.\"\n\"I am delighted to welcome Aubrey to the Board, and know from first-hand experience just how important his knowledge and expertise can be for AIM quoted growth companies in the healthcare space. Aubrey knows the Verici Dx business well, having\npreviously acted as the lead member of the advisory team at our NOMAD, Singer Capital Markets, and we know that his guidance and challenge, as we enter a pivotal stage in the Company's growth, will be invaluable.\"\nAdditional Disclosures Required under the AIM Rules for Companies\nIn accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules, Aubrey Richard Powell (aged 54) currently holds the following directorship:\n\u00b7\nAubrey Powell Consulting (APC) Limited\nPrevious directorships or partnerships of which the director has been a director or partner over the last five years:\n\u00b7\nApus Sequestration LLP\n\u00b7\nMaia Green LLP\nMr Powell holds no shares in the Company.\nThere is no further information to be disclosed in respect of the above appointment pursuant to Rule 17\nor paragraph (g) of Schedule 2 of the AIM Rules for Companies.\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser and Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Jessica Cave\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBOADGBDGUGGDGUU",
          "content_length": 4640
        },
        "ingested_at": "2026-01-16T22:48:57.957861Z"
      },
      {
        "event_id": "RNS-6th Oct 2025-updateon",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.957877Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Update on Tutivia\u2122 test adoption",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/update-on-tutivia8482-test-adoption-50qsxr0j3tre3q9.html",
          "rns_number": "RNS Number : 1660C",
          "full_content": "6 Oct 2025 07:00\nRNS Number : 1660C\nVerici Dx PLC\n06 October 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nUpdate on Tutivia\u2122 test adoption\n9 new transplant centres on-boarded\n19% increase in ordering clinicians in Q3\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces positive progress in its plans to drive strong Tutivia\u2122\nsales growth following the\nequity fundraise completed in July.\nCommercial scale-up of Tutivia test adoption, a test for acute rejection post transplant, has progressed in Q3, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from Q4 and the number of orders in Q3 were consistent with the previous two quarters.\nThe Company has expanded its commercial team with three new senior sales hires\n. In addition, a Director of Clinical Partnerships will be joining the commercial team in mid-October.\nThe Board continues to target meeting market expectations for the full year.\nInvestor presentation\nSara Barrington, Chief Executive Officer, and David Anderson, Chief Financial Officer, will provide a live presentation via the Investor Meet Company platform on 7 October at 10.00 am BST. This presentation is open to all existing and potential shareholders. Questions can be submitted at any time during the live presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via:\nhttps://www.investormeetcompany.com/verici-dx-plc/register-investor\nInvestors who already follow Verici Dx on the Investor Meet Company platform will automatically be invited.\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser and Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Adam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCBELLBEBLBFBL",
          "content_length": 2984
        },
        "ingested_at": "2026-01-16T22:48:57.957890Z"
      },
      {
        "event_id": "RNS-1st Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.957903Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-cfkkocs56f8jsk1.html",
          "rns_number": "RNS Number : 7035B",
          "full_content": "1 Oct 2025 16:55\nRNS Number : 7035B\nVerici Dx PLC\n01 October 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BM8HZD43\nIssuer Name\nVERICI DX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nHarwood Capital LLP\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\nName\nCity of registered office\nCountry of registered office\nHarwood Capital Management (Gibraltar) Limited\nGibraltar\nGibraltar\nHarwood Capital LLP\nLondon\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nOryx International Growth Fund Limited\nGuernsey\nGuernsey\nNorth Atlantic Smaller Companies Investment Trust Plc\nLondon\nUnited Kingdom\nHarwood Capital LLP\nLondon\nUnited Kingdom\n5. Date on which the threshold was crossed or reached\n30-Sep-2025\n6. Date on which Issuer notified\n01-Oct-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n12.756000\n0.000000\n12.756000\n193065843\nPosition of previous notification (if applicable)\n13.074000\n0.000000\n13.074000\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BM8HZD43\n58000000\n3.832000\nGB00BM8HZD43\n123000000\n8.127000\nGB00BM8HZD43\n12065843\n0.797000\nSub Total 8.A\n193065843\n12.756000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nChristopher Harwood Bernard Mills\nHarwood Capital LLP\n0.797000\n0.797000%\nChristopher Harwood Bernard Mills\nnorth atlantic smaller companies investment trust\n8.127000\n8.127000%\nChristopher Harwood Bernard Mills\nOryx International Growth Fund Limited\n3.832000\n3.832000%\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n01/10/2025\n13. Place Of Completion\nLondon Stock Exchange\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFEEISLLIIE",
          "content_length": 4360
        },
        "ingested_at": "2026-01-16T22:48:57.957915Z"
      },
      {
        "event_id": "RNS-30th Sep 2025-half-yea",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.957928Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Half-year Report",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/half-year-report-0g3gqsivj4mgd4k.html",
          "rns_number": "RNS Number : 2976B",
          "full_content": "30 Sep 2025 07:00\nRNS Number : 2976B\nVerici Dx PLC\n30 September 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nHalf-year report\nSignificant commercial progress with first revenues from\nTutivia\u2122 test sales\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\nannounces its unaudited interim results for the six months ended 30 June 2025 (\"H1 2025\"). The first half was a period of significant commercial progress, with two products now fully validated and commercially available, and the first revenues from lead product Tutivia\u2122 recognised.\nPost period end the Company raised \u00a36.35m (gross) to support the scale up of revenues, extending the expected cash runway into H2 2026.\nComparative unaudited data is for the six months ended 30 June 2024 (\"H1 2024\") unless stated otherwise.\nFinancial highlights\n\u00b7\nRevenue of $1.9m (H1 2024: $3.3m; FY 2024: $3.3m)\n\u00a7\n$1.16m from Tutivia\u2122 testing revenues\n\u00a7\n$0.75m from Thermo Fisher licensing revenues\n\u00b7\nEBITDA loss of $2.8m (H1 2024: EBITDA loss of $1.1m; FY 2024: EBITDA loss of $5.4m)\n\u00b7\n$0.5m cash balance as at 30 June 2025 (31 December 2024: $4.1m) with cash balance as at 30 September of c.$5.3m\n\u00b7\nNet cash outflow from operating activities in H1 2025 was $3.5m (H1 2024: $3.2m outflow; FY 2024: $6.0m outflow)\nOperational highlights\n\u00b7\nTwo products now validated and commercially available\n\u00b7\nLead product Tutivia\u2122 attained Medicare coverage at $2,650 per test, covering a national estimate of 68% of all US transplant tests and commercial payor reimbursement applications are underway\n\u00b7\nIncreasing test adoption: 591 Tutivia\u2122 tests ordered in H1 2025 (334 for the whole of FY 2024)\n\u00b7\nIn the period the Company reached a total of 21 transplant centres onboarded - representing 10% of annual US transplant volume\n\u00b7\nContinued progress with the Thermo Fisher Pre-Transplant Risk Assessment Test (PTRA) license\n\u00b7\nWell poised for growth: significant testing volume acceleration expected in H2 2025 and beyond\n\u00b7\nCommercial team expanded post period with the addition of two sales people in place and a director of clinical partnerships to join shortly\nCommenting on Outlook, Sara Barrington, Chief Executive Officer of Verici Dx, said:\n\"As a Board we have no doubt that we have an exciting opportunity to deliver accelerated commercial growth in an approximate $900m addressable market. We have significantly de-risked the business, achieving all the milestones to enable two validated products to be commercialised.\nWe have in place commercial requirements to support the business: our laboratories and logistical operations are set up, we have all the required regulatory approvals, and we have reimbursement. We are already seeing successful growth in the number of transplant centres onboarded and, funds are now in place to support further growth in testing volumes. Whilst growth financing was secured later in the year than hoped, we continue to target meeting market expectations for the full year, and we are confident that we can capitalise on the opportunity to address a significant unmet need.\"\nInvestor briefing\nSara Barrington, Chief Executive Officer, and David Anderson, Chief Financial Officer, will provide a live presentation relating to the interim results via the Investor Meet Company platform on 7 October at 10.00 am BST. This presentation is open to all existing and potential shareholders. Questions can be submitted at any time during the live presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via:\nhttps://www.investormeetcompany.com/verici-dx-plc/register-investor\nInvestors who already follow Verici Dx on the Investor Meet Company platform will automatically be invited.\nA copy of the Company's interim results report will shortly be made available on the Company's website.\nEnquiries:\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nJulian Baines, Chairman\nSinger Capital Markets (Nominated Adviser & Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Adam Pollock / Jessica Cave\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or\nvericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nAbout Verici Dx plc\nwww.vericidx.com\nVerici is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk, to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure, from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully ch",
          "content_length": 35965
        },
        "ingested_at": "2026-01-16T22:48:57.957944Z"
      },
      {
        "event_id": "RNS-1st Aug 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.957957Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-ch9mslpmtgzljup.html",
          "rns_number": "RNS Number : 6372T",
          "full_content": "1 Aug 2025 10:40\nRNS Number : 6372T\nVerici Dx PLC\n01 August 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nVerici Dx PLC\nGB00BM8HZD43\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii: Disclosure triggered by capital increase.\nX\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n30 July 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n01 August 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.817838%\n0.000000%\n7.817838%\n118,314,708\nPosition of previous notification (if\napplicable)\n8.299124%\n0.000000%\n8.299124%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BM8HZD43\n118,314,708\n7.817838%\nSUBTOTAL 8. A\n118,314,708\n7.817838%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n7.817838%\n7.817838%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nIncrease in the total number of voting rights\nPlace of completion\nZurich, Switzerland\nDate of completion\n01.08.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFIFVATTILIIE",
          "content_length": 4606
        },
        "ingested_at": "2026-01-16T22:48:57.957969Z"
      },
      {
        "event_id": "RNS-31st Jul 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.957982Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-z4bo6yb0jxlf10j.html",
          "rns_number": "RNS Number : 4921T",
          "full_content": "31 Jul 2025 17:33\nRNS Number : 4921T\nVerici Dx PLC\n31 July 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nVERICI DX PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nCANACCORD GENUITY GROUP INC\nCity and country of registered office (if applicable)\nVANCOUVER, CANADA\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nDISCRETIONARY CLIENTS\nCity and country of registered office (if applicable)\nAs above\n5. Date on which the threshold was crossed or reached\nvi\n:\n30 JULY 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n31 JULY 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n10.3825\n10.3825\n157,127,457\nPosition of previous notification (if\napplicable)\n11.0216\n11.0216\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BM8HZD43\n157,127,457\n10.3825\nSUBTOTAL 8. A\n157,127,457\n10.3825\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nCanaccord Genuity Group Inc.\n10.3825\n10.3825\nCanaccord Genuity Wealth Group Holdings Limited\n10.3825\n10.3825\nCanaccord Genuity Wealth Group Holdings (Jersey) Limited\n10.3825\n10.3825\nCanaccord Genuity Wealth Group Limited\n10.3825\n10.3825\nCanaccord Genuity Asset Management Limited\n10.3825\n10.3825\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nThe change in the percentage of shares held is due entirely to dilution, caused by the admission of 87,765,264 new shares to trading on AIM on 30/07/2025.\nPlace of completion\nBLACKPOOL, ENGLAND\nDate of completion\n31 JULY 2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFFRDTILVIE",
          "content_length": 4864
        },
        "ingested_at": "2026-01-16T22:48:57.957995Z"
      },
      {
        "event_id": "RNS-31st Jul 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958008Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-jrzdz9tqynooyoy.html",
          "rns_number": "RNS Number : 4912T",
          "full_content": "31 Jul 2025 17:28\nRNS Number : 4912T\nVerici Dx PLC\n31 July 2025\nS\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n1a. Identity of the issuer or the underlying issuer of existing shares:\nVerici DX PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of shares\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of shares outstanding\nX\nOther (please specify):\n3. Details of person subject to the notification obligation\nName\nPentwater Capital Management LP\nCity and country of registered office (if applicable)\nNaples\n,\nUnited States\n4. Full name of shareholder(s)\n(if different from 3.)\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached:\n30/07/2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n31/07/2025\n7. Total positions of person(s) subject to the notification obligation\n% of shares outstanding (total of 8. A)\n% of\nshares outstanding through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of shares outstanding held in issuer\nResulting situation on the date on which threshold was crossed or reached\n7.817444%\n7.817444%\n118,308,740.00\nPosition of previous notification (if\napplicable)\n8.298705%\n8.298705%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nv\nA: Shares\nClass/type ofshares\nISIN code (if possible)\nNumber of shares outstanding\n% of shares outstanding\nDirect\nIndirect\nDirect\nIndirect\nSUBTOTAL 8. A\nB 1: Financial Instruments as an entitlement to acquire\nType of financial instrument\nExpirationdate\nExercise/Conversion Period\nNumber shares that may be acquired if the instrument is\nexercised/converted.\n% of shares outstanding\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect\nType of financial instrument\nExpirationdate\nExercise/Conversion Period\nPhysical or cash\nsettlement\nNumber of shares\n% of shares outstanding\nSwap\nCash Settlement\n118,308,740.00\n7.817444%\nSUBTOTAL 8.B.2\n118,308,740.00\n7.817444%\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nFull\nchain of controlled undertakings through which the shares and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nX\nName\n% of shares outstanding if it equals or is higher than the notifiable threshold\n% of shares outstanding through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nMatthew Halbower\nMCH PWCM Holdings Inc.\nPentwater Capital Management LP\n7.817444%\n7.817444%\n10. Additional information\nPlace of completion\nNaples\nDate of completion\n31/07/2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFFRDRILVIE",
          "content_length": 4033
        },
        "ingested_at": "2026-01-16T22:48:57.958020Z"
      },
      {
        "event_id": "RNS-31st Jul 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958032Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-iqb3wwptc1x0bpb.html",
          "rns_number": "RNS Number : 4669T",
          "full_content": "31 Jul 2025 15:24\nRNS Number : 4669T\nVerici Dx PLC\n31 July 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nVerici DX\nplc\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nUnicorn Asset Management Limited\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUnicorn AIM VCT plc\nCity and country of registered office (if applicable)\nTeignmouth, Devon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n30 July 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n31 July 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.90%\n7.90%\n119,619,325\nPosition of previous notification (if\napplicable)\n8.39%\n8.39%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nOrdinary shares GB00BM8HZD43\n119,619,325\n7.90%\nSUBTOTAL 8. A\n119,619,325\n7.90%\nB 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nX\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nSee Section 4\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nFigures are based on total voting rights of 1,513,394,127\nPlace of completion\nUnicorn Asset Management Limited, Preachers Court, Charterhouse, Charterhouse Square, London, EC1M 6AU\nDate of completion\n31 July 2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFFSDFILVIE",
          "content_length": 4818
        },
        "ingested_at": "2026-01-16T22:48:57.958044Z"
      },
      {
        "event_id": "RNS-31st Jul 2025-tutivia\u2122",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958061Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Tutivia\u2122 abstracts for World Transplant Congress",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/tutivia8482-abstracts-for-world-transplant-congress-tyebb64o0q0r1in.html",
          "rns_number": "RNS Number : 2551T",
          "full_content": "31 Jul 2025 07:00\nRNS Number : 2551T\nVerici Dx PLC\n31 July 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nTutivia\n\u2122\nabstracts for World Transplant Congress\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that a number of abstracts relating to Tutivia\n\u2122\nhave been published ahead of presentation at the forthcoming World Transplant Congress in San Francisco in August 2025 (WTC 2025), a major international event for experts in the field of organ transplantation to share research, discuss advancements, and address challenges in transplantation.\nThe abstracts focus on the role of biomarker testing with Tutivia\n\u2122\nto support medical management in important areas of unmet need including patients with BK nephropathy and increasing BK viremia, obese patients including those who underwent robotic transplantation, patients with delayed graft function (DGF) and slow graft function, and patients with previous failed transplant or multi-organ transplant.\nThe abstracts are based on real-world evidence collected at multiple transplant centres currently utilising Tutivia\n\u2122\nto support clinical care for these complex and challenging patient populations.\nThe World Transplant Congress is organised jointly by the American Society of Transplant Surgeons (ASTS), the American Society of Transplantation (AST), and The Transplantation Society (TTS).\nhttps://wtc2025.org/\nThe abstracts are available here:\n(P1.07.253)\nUtility of Rejection Biomarker Tutivia in Managing Kidney Transplant Recipients at Risk of BK Nephropathy\n:\nhttps://cattendee.abstractsonline.com/meeting/21176/Session/306\n(P3.07.218)\nTutivia Biomarker Testing Provides Accurate Results for Medical Management in Severely Obese Kidney Transplant Patients\n:\nhttps://cattendee.abstractsonline.com/meeting/21176/Session/309\n(P3.07.196)\nUse of TUTIVIA in the Early Post-Transplant Period for Distinction of Rejection from Quiescence Among Kidney Transplant Recipients - A Single Center Experience\nhttps://cattendee.abstractsonline.com/meeting/21176/Session/309\n(P3.07.215)\nThe Role of Gene Expression Profile in Predicting Acute Rejection\nhttps://cattendee.abstractsonline.com/meeting/21176/Session/309\n(P3.07.216)\nComparison of Gene Expression Profiling with Histopathology and Molecular Pathology in Detection of Acute Rejection in Kidney Transplant Recipients\nhttps://cattendee.abstractsonline.com/meeting/21176/Session/309\nAbout Tutivia\n\u2122\nThe Tutivia\n\u2122\ntest is an advancement in biomarker testing utilising RNA expression in peripheral blood and a proprietary algorithm to report a patient's risk score for acute rejection post-transplant. The Tutivia\n\u2122\ntest is commercially available and already used in 20 ordering centres. Medicare coverage has supported the strong acceleration in adoption and test ordering volumes.\nCommenting,\nSara Barrington, CEO of Verici Dx, said:\n\"It is a great validation of our test for acute rejection post-transplantation to have clinicians at multiple transplant centres sharing how it has been used to address important areas of unmet need.. Gaining shared clinical experience at leading transplant centers is essential to increase the adoption of Tutivia\n\u2122 and in turn ultimately\nscale up\nvolumes.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser and Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Jessica Cave\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCURUVRVOUBOAR",
          "content_length": 4468
        },
        "ingested_at": "2026-01-16T22:48:57.958073Z"
      },
      {
        "event_id": "RNS-30th Jul 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958086Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-zx43mm4umq9p0fj.html",
          "rns_number": "RNS Number : 2426T",
          "full_content": "30 Jul 2025 14:32\nRNS Number : 2426T\nVerici Dx PLC\n30 July 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BM8HZD43\nIssuer Name\nVERICI DX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn event changing the breakdown of voting rights\n3. Details of person subject to the notification obligation\nName\nPuma Investment Management Limited\nCity of registered office (if applicable)\nLondon\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nPIMA AIM VCT plc\nLondon\nUnited Kingdom\n5. Date on which the threshold was crossed or reached\n30-Jul-2025\n6. Date on which Issuer notified\n30-Jul-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n10.460000\n0.000000\n10.460000\n158300000\nPosition of previous notification (if applicable)\n11.100000\n0.000000\n11.100000\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BM8HZD43\n158300000\n0\n10.460000\n0.000000\nSub Total 8.A\n158300000\n10.460000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nFigures are based on total voting rights of 1,513,394,127\n12. Date of Completion\n13. Place Of Completion\nPuma Investment Management Limited, Cassini House, 57 St James's Street, London, SW1A 1LD\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFFVDRIIVIE",
          "content_length": 3873
        },
        "ingested_at": "2026-01-16T22:48:57.958111Z"
      },
      {
        "event_id": "RNS-30th Jul 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958131Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-52rj65f8bdj9321.html",
          "rns_number": "RNS Number : 2424T",
          "full_content": "30 Jul 2025 14:26\nRNS Number : 2424T\nVerici Dx PLC\n30 July 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BM8HZD43\nIssuer Name\nVERICI DX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nSENECA PARTNERS LIMITED\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\nUK\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nPLATFORM SECURITIES NOMINEES LIMITED\nWOODSIDE NOMINEES LIMITED\nCity of registered office (if applicable)\nLONDON\nCountry of registered office (if applicable)\nUK\n5. Date on which the threshold was crossed or reached\n24-JUL-2025\n6. Date on which Issuer notified\n29-JUL-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n6.8226\n0.000000\n6.8226\n103,253,414\nPosition of previous notification (if applicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BSVYN304\n103,253,414\n6.8226\nSub Total 8.A\n103,253,414\n6.8226\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n29-07-2025\n13. Place Of Completion\nHaydock UK\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFFVDVIIVIE",
          "content_length": 3832
        },
        "ingested_at": "2026-01-16T22:48:57.958144Z"
      },
      {
        "event_id": "RNS-30th Jul 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958157Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of Annual General Meeting",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/result-of-annual-general-meeting-kw91p1mg2z3p8u1.html",
          "rns_number": "RNS Number : 0851T",
          "full_content": "30 Jul 2025 07:00\nRNS Number : 0851T\nVerici Dx PLC\n30 July 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nResult of Annual General Meeting\nVerici Dx Plc, (AIM: VRCI),\u00a0a developer of advanced clinical diagnostics for organ transplant, announces that at the\u00a0Annual General Meeting (\"AGM\") held yesterday, all resolutions were duly passed.\nThe voting results of the AGM were as follows:\nIn Favour\nAgainst\nWithheld\nResolution\nVotes\n%\nVotes\n%\nVotes\n1\n469,065,903\n99.98\n88,290\n0.02\n24,006\n2\n468,421,915\n99.85\n718,633\n0.15\n37,651\n3\n469,047,227\n99.98\n106,783\n0.02\n24,189\n4\n469,057,547\n100.00\n21,408\n0.00\n99,244\n5\n468,889,463\n99.96\n189,044\n0.04\n99,692\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker and Joint Bookrunner)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker and Joint Bookrunner)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Adam Pollock / Jessica Cave\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGBKLLLEDLEBBE",
          "content_length": 1916
        },
        "ingested_at": "2026-01-16T22:48:57.958170Z"
      },
      {
        "event_id": "RNS-29th Jul 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958182Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of WRAP Retail Offer",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/result-of-wrap-retail-offer-0ofofzkrjugmr99.html",
          "rns_number": "RNS Number : 8857S",
          "full_content": "29 Jul 2025 07:00\nRNS Number : 8857S\nVerici Dx PLC\n29 July 2025\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\n29 July 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nResult of WRAP Retail Offer\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nconfirms, further to the announcements made on 22 July 2025, the result of its WRAP Retail Offer at the Issue Price of 0.5 pence per share. The Company announces that it has raised aggregate gross proceeds of approximately \u00a30.43 million pursuant to the WRAP Retail Offer in addition to the previously announced Placing and Subscription. Accordingly, the Company will issue a total of 86,286,792 new Ordinary Shares at the Issue Price pursuant to the WRAP Retail Offer (the \"\nWRAP Retail Offer Shares\n\").\nIn total, the Fundraising has raised gross proceeds of approximately \u00a36.35 million for the Company, via the Placing and Subscription of 1,183,087,396 Placing and Subscription Shares and the 86,286,792 WRAP Retail Offer Shares.\nThe total proceeds from the Fundraising of \u00a36.35 million, will extend the Company's cash runway into H2 2026.\nAdditionally, the Company has agreed to issue 1,478,472 new Ordinary Shares at the Issue Price of 0.5 pence per share to an adviser of the Company in lieu of fees in respect of the Fundraise.\nAdmission and Total Voting Rights\nApplications have been made for the new Ordinary Shares to be admitted to trading on AIM (\"\nAdmission\n\"). Admission is expected to become effective on or around 30 July 2025.\nUpon Admission, the Company's issued ordinary share capital will consist of 1,513,394,127 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, from Admission the total number of Ordinary Shares and voting rights in the Company will be 1,513,394,127. With effect from Admission, this figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.\nThe new Ordinary Shares to be issued will be issued free of all liens, charges and encumbrances and will, on Admission, rank\npari passu\nin all respects with the new Ordinary Shares to be issued pursuant to the Placing, the Subscription and the Company's existing Ordinary Shares.\nTerms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 7am on 21 July 2025\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker and Joint Bookrunner)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker and Joint Bookrunner)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Jessica Cave\nWinterflood Retail Access Platform\nTel: +44 (0)20 3100 0286 or\nWRAP@winterflood.com\nJoe Winkley / Sophia Bechev\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or\nvericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nFurther information on the Company can be found on its website at\nwww.vericidx.com\nThe Company's LEI is 213800FI5WE4FVQ3G645\nThis announcement should be read in its entirety. In particular, the information in the \"\nImportant Notices\n\" section of the announcement should be read and understood.\nImportant Notices\nThe content of this announcement has been prepared by and is the sole responsibility of the Company.\nThis announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into or from the United States (including its territories and possessions, any state of the United States and the District of Columbia (the \"\nUnited States\n\" or \"\nUS\n\")), Australia, Canada, New Zealand, Japan, the Republic of South Africa, any member state of the EEA or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction.\nThe WRAP Retail Offer Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the \"\nUS Securities Act\n\") or under the applicable state securities laws of the United States and may not be offered or sold directly or indirectly in or into the United States. No public o\ufb00ering of the WRAP Retail Offer Shares is being made in the United States. The WRAP Retail Offer Shares are being o\ufb00ered and sold outside the United States in \"\no\ufb00shore transacti",
          "content_length": 13231
        },
        "ingested_at": "2026-01-16T22:48:57.958200Z"
      },
      {
        "event_id": "RNS-28th Jul 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958213Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-6kj5kgkpu9u6fwt.html",
          "rns_number": "RNS Number : 8728S",
          "full_content": "28 Jul 2025 17:19\nRNS Number : 8728S\nVerici Dx PLC\n28 July 2025\n.TR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nVERICI DX PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nCANACCORD GENUITY GROUP INC\nCity and country of registered office (if applicable)\nVANCOUVER, CANADA\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nDISCRETIONARY CLIENTS\nCity and country of registered office (if applicable)\nAs above\n5. Date on which the threshold was crossed or reached\nvi\n:\n24 JULY 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n28 JULY 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n11.0216\n11.0216\n157,127,457\nPosition of previous notification (if\napplicable)\n4.9888\n4.9888\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BM8HZD43\n157,127,457\n11.0216\nSUBTOTAL 8. A\n157,127,457\n11.0216\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nCanaccord Genuity Group Inc.\n11.0216\n11.0216\nCanaccord Genuity Wealth Group Holdings Limited\n11.0216\n11.0216\nCanaccord Genuity Wealth Group Holdings (Jersey) Limited\n11.0216\n11.0216\nCanaccord Genuity Wealth Group Limited\n11.0216\n11.0216\nCanaccord Genuity Asset Management Limited\n11.0216\n11.0216\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nThe change in the percentage of shares held is due entirely to participation in the placing by Verici DX plc, the shares from which were admitted to AIM on 24/07/2025.\nPlace of completion\nBLACKPOOL, ENGLAND\nDate of completion\n28 JULY 2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFLRDDITFIE",
          "content_length": 4878
        },
        "ingested_at": "2026-01-16T22:48:57.958225Z"
      },
      {
        "event_id": "RNS-28th Jul 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958237Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-dftme4aaky86nrg.html",
          "rns_number": "RNS Number : 8657S",
          "full_content": "28 Jul 2025 16:55\nRNS Number : 8657S\nVerici Dx PLC\n28 July 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nVerici Dx PLC\nGB00BM8HZD43\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n24 July 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n28 July 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n8.299124%\n0.000000%\n8.299124%\n118,314,708\nPosition of previous notification (if\napplicable)\nNo Previous Disclosure\nNo Previous Disclosure\nNo Previous Disclosure\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BM8HZD43\n118,314,708\n8.299124%\nSUBTOTAL 8. A\n118,314,708\n8.299124%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n8.299124%\n8.299124%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nIncrease in the total number of voting rights\nPlace of completion\nZurich, Switzerland\nDate of completion\n28.07.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFEEDVITFIE",
          "content_length": 4600
        },
        "ingested_at": "2026-01-16T22:48:57.958249Z"
      },
      {
        "event_id": "RNS-28th Jul 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958262Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-ewt38pxrtevytj4.html",
          "rns_number": "RNS Number : 8050S",
          "full_content": "28 Jul 2025 10:23\nRNS Number : 8050S\nVerici Dx PLC\n28 July 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BM8HZD43\nIssuer Name\nVERICI DX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn event changing the breakdown of voting rights\n3. Details of person subject to the notification obligation\nName\nMaven Capital Partners UK LLP\nCity of registered office (if applicable)\nGlasgow\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nMaven Renovar VCT PLC\nLondon\nUnited Kingdom\nMeinom Limited\nGlasgow\nUnited Kingdom\nMaven Income and Growth VCT 5 PLC\nLondon\nUnited Kingdom\nMaven Income and Growth VCT 4 PLC\nGlasgow\nUnited Kingdom\nMaven Income and Growth VCT PLC\nLondon\nUnited Kingdom\n5. Date on which the threshold was crossed or reached\n24-Jul-2025\n6. Date on which Issuer notified\n28-Jul-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n0.970100\n0.000000\n0.970100\n13830788\nPosition of previous notification (if applicable)\n5.702000\n0.000000\n5.702000\n13830788\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BM8HZD43\n13830788\n0.970100\nSub Total 8.A\n13830788\n0.970100%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nMaven Renovar VCT PLC was previously Amati AIM VCT plc.The name change occurred following a change of Investment Manager from Amati Global Investors (AGI) to Maven Capital Partners UK LLP (Maven).\n12. Date of Completion\n28-Jul-2025\n13. Place Of Completion\nGlasgow\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFIFFADFITFIE",
          "content_length": 4137
        },
        "ingested_at": "2026-01-16T22:48:57.958274Z"
      },
      {
        "event_id": "RNS-25th Jul 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958286Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-lbnpk2mdkctxvi1.html",
          "rns_number": "RNS Number : 6853S",
          "full_content": "25 Jul 2025 17:22\nRNS Number : 6853S\nVerici Dx PLC\n25 July 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BM8HZD43\nIssuer Name\nVERICI DX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights; An event changing the breakdown of voting rights\n3. Details of person subject to the notification obligation\nName\nHarwood Capital LLP\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\nName\nCity of registered office\nCountry of registered office\nHarwood Capital Management (Gibraltar) Limited\nGibraltar\nGibraltar\nHarwood Capital LLP\nLondon\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nOryx International Growth Fund Limited\nGuernsey\nGuernsey\nNorth Atlantic Smaller Companies Investment Trust Plc\nLondon\nUnited Kingdom\nHarwood Capital LLP\nLondon\nUnited Kingdom\n5. Date on which the threshold was crossed or reached\n24-Jul-2025\n6. Date on which Issuer notified\n25-Jul-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n13.074000\n0.000000\n13.074000\n186390843\nPosition of previous notification (if applicable)\n15.521700\n0.000000\n15.521700\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BM8HZD43\n58000000\n4.068000\nGB00BM8HZD43\n123000000\n8.628000\nGB00BM8HZD43\n5390843\n0.378000\nSub Total 8.A\n186390843\n13.074000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nChristopher Harwood Bernard Mills\nHarwood Capital LLP\n0.378000\n0.378000%\nChristopher Harwood Bernard Mills\nNorth Atlantic Smaller Companies Investment Trust Plc\n8.628000\n8.628000%\nChristopher Harwood Bernard Mills\nOryx International Growth Fund Limited\n4.068000\n4.068000%\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n25/7/25\n13. Place Of Completion\nLondon Stock Exchange\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFFRDIIEFIE",
          "content_length": 4408
        },
        "ingested_at": "2026-01-16T22:48:57.958298Z"
      },
      {
        "event_id": "RNS-25th Jul 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958311Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-0urshxiltazbcdm.html",
          "rns_number": "RNS Number : 6531S",
          "full_content": "25 Jul 2025 13:05\nRNS Number : 6531S\nVerici Dx PLC\n25 July 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BM8HZD43\nIssuer Name\nVERICI DX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn event changing the breakdown of voting rights\n3. Details of person subject to the notification obligation\nName\nOctopus Investments Limited\nCity of registered office (if applicable)\nLondon\nCountry of registered office (if applicable)\nEngland\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n24-Jul-2025\n6. Date on which Issuer notified\n25-Jul-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n1.510000\n0.000000\n1.510000\n21479825\nPosition of previous notification (if applicable)\n8.920000\n0.000000\n8.920000\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BM8HZD43\n21479825\n1.510000\nSub Total 8.A\n21479825\n1.510000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nOctopus Capital Limited\nOctopus Investments Limited\n1.510000\n1.510000%\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n25/07/2025\n13. Place Of Completion\n33 Holborn, London, EC1N 2HT\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFIFDVIEFIE",
          "content_length": 3915
        },
        "ingested_at": "2026-01-16T22:48:57.958323Z"
      },
      {
        "event_id": "RNS-25th Jul 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958336Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-cqq2kbh1kfogfwx.html",
          "rns_number": "RNS Number : 6530S",
          "full_content": "25 Jul 2025 13:04\nRNS Number : 6530S\nVerici Dx PLC\n25 July 2025\nS\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n1a. Identity of the issuer or the underlying issuer of existing shares:\nVerici DX PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of shares\nAn acquisition or disposal of financial instruments\nX\nAn event changing the breakdown of shares outstanding\nOther (please specify):\n3. Details of person subject to the notification obligation\nName\nPentwater Capital Management LP\nCity and country of registered office (if applicable)\nNaples\n,\nUnited States\n4. Full name of shareholder(s)\n(if different from 3.)\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached:\n24/07/2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n24/07/2025\n7. Total positions of person(s) subject to the notification obligation\n% of shares outstanding (total of 8. A)\n% of\nshares outstanding through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of shares outstanding held in issuer\nResulting situation on the date on which threshold was crossed or reached\n8.298705%\n8.298705%\n118,308,740.00\nPosition of previous notification (if\napplicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nv\nA: Shares\nClass/type ofshares\nISIN code (if possible)\nNumber of shares outstanding\n% of shares outstanding\nDirect\nIndirect\nDirect\nIndirect\nSUBTOTAL 8. A\nB 1: Financial Instruments as an entitlement to acquire\nType of financial instrument\nExpirationdate\nExercise/Conversion Period\nNumber shares that may be acquired if the instrument is\nexercised/converted.\n% of shares outstanding\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect\nType of financial instrument\nExpirationdate\nExercise/Conversion Period\nPhysical or cash\nsettlement\nNumber of shares\n% of shares outstanding\nSwap\nCash Settlement\n118,308,740.00\n8.298705%\nSUBTOTAL 8.B.2\n118,308,740.00\n8.298705%\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nFull\nchain of controlled undertakings through which the shares and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nX\nName\n% of shares outstanding if it equals or is higher than the notifiable threshold\n% of shares outstanding through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nMatthew Halbower\nMCH PWCM Holdings Inc.\nPentwater Capital Management LP\n8.298705%\n8.298705%\n10. Additional information\nPlace of completion\nNaples\nDate of completion\n24/07/2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFIFDFIEFIE",
          "content_length": 4013
        },
        "ingested_at": "2026-01-16T22:48:57.958348Z"
      },
      {
        "event_id": "RNS-24th Jul 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958360Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-szn0zbztmbe0b9u.html",
          "rns_number": "RNS Number : 4826S",
          "full_content": "24 Jul 2025 14:34\nRNS Number : 4826S\nVerici Dx PLC\n24 July 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nVerici DX Plc\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nPuma Investment Management Limited\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nPuma AIM VCT plc\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n24 July 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n24 July 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n11.1%\n0%\n11.1%\n158,300,000\nPosition of previous notification (if\napplicable)\nN/A\nN/A\nN/A\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nOrdinary Shares\nGB00BM8HZD43\n158,300,000\n0\n11.1%\n0%\nSUBTOTAL 8. A\n158,300,000\n11.1%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nX\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nSee Section 4\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nFigures are based on total voting rights of 1,425,628,863\nPlace of completion\nPuma Investment Management Limited, Cassini House, 57 St James's Street, London, SW1A 1LD\nDate of completion\n24 July 2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFVVDFISFIE",
          "content_length": 4590
        },
        "ingested_at": "2026-01-16T22:48:57.958372Z"
      },
      {
        "event_id": "RNS-22nd Jul 2025-wrapreta",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958387Z",
        "source": "LSE_RNS",
        "data": {
          "title": "WRAP Retail Offer for up to \u00a3500,000",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/wrap-retail-offer-for-up-to-163500000-0h27ssxjywj013q.html",
          "rns_number": "RNS Number : 9524R",
          "full_content": "22 Jul 2025 07:00\nRNS Number : 9524R\nVerici Dx PLC\n22 July 2025\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\nTHIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (\"FSMA\") AND HAS BEEN APPROVED BY WINTERFLOOD SECURITIES LIMITED WHICH IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY (FRN 141455).\n22 July 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nWRAP Retail Offer for up to \u00a3500,000\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces a retail offer via the Winterflood Retail Access Platform (\"\nWRAP\n\") to raise up to \u00a3\n500,000\n(the \"\nWRAP Retail Offer\n\") through the issue of new ordinary shares of 0.1 pence each in the capital of the Company (\"\nOrdinary Shares\n\"). Under the WRAP Retail Offer up to 100,000,000 new Ordinary Shares (the \"\nWRAP Retail Offer Shares\n\") will be made available at a price of\n0.5\npence per share (the \"\nWRAP Issue Price\n\").\nIn addition to the WRAP Retail Offer and as announced at 3:43pm on 21 July 2025, the Company has raised approximately \u00a35.92 million\u00a0($7.96\u00a0million) through a Placing and Subscription of new Ordinary Shares at an issue price of\n0.5\npence per Ordinary Share (the \"\nIssue Price\n\"). The Issue Price represents a discount of 42.9 per cent. to Verici Dx's closing mid-price on 18 July 2025 (being the last practicable day prior to the publication of the Proposed Fundraising announcement). The WRAP Issue Price is equal to the Issue Price.\nA separate announcement has been made regarding the Placing and its terms and sets out the reasons for the Placing and use of proceeds. The proceeds of the WRAP Retail Offer will be utilised in the same way as the proceeds of the Placing.\nThe WRAP Retail Offer is conditional on the new Ordinary Shares being admitted to trading on AIM (\"\nWRAP Admission\n\"). It is anticipated that the WRAP Admission will become effective and that dealings in the new Ordinary Shares will commence at 8 a.m. on 30 July 2025.\nWRAP Retail Offer\nThe Company values its retail shareholder base and believes that it is appropriate to provide both new and existing retail shareholders in the United Kingdom the opportunity to participate in the WRAP Retail Offer.\nTherefore, the Company is making the WRAP Retail Offer open to eligible investors in the United Kingdom, being new or existing shareholders of Verici Dx, following release of this announcement and through certain financial intermediaries.\nA number of retail platforms are able to access the WRAP Retail Offer. Non-holders or existing shareholders wishing to subscribe for Retail Offer Shares should contact their broker or wealth manager who will confirm if they are participating in the Retail Offer.\nRetail brokers wishing to participate in the Retail Offer on behalf of eligible retail investors, should contact WRAP@winterflood.com.\nThe Retail Offer\nis expected to close at 4:30pm on 28 July 2025. Eligible retail investors should note that financial intermediaries may have earlier closing times.\nThe result of the Retail Offer is expected to be announced by the Company on or around\n29 July\n2025.\nTo be eligible to participate in the Retail Offer, applicants must be a customer of a participating intermediary including individuals aged 18 years or over, companies and other bodies corporate, partnerships, trusts, associations and other unincorporated organisations.\nThere is a minimum subscription of \u00a3100 per investor under the Retail Offer. The terms and conditions on which investors subscribe will be provided by the relevant financial intermediaries including relevant commission or fee charges.\nThe Company reserves the right to amend the size of the Retail Offer at its discretion. The Company reserves the right to scale back any order and to reject any application for subscription under the WRAP Retail Offer without giving any reason for such rejection.\nIt is vital to note that once an application for Retail Offer Shares has been made and accepted via an intermediary, it cannot be withdrawn.\nThe Retail Offer Shares will, when issued, be credited as fully paid, and have the right to receive all dividends and other distributions declared, made or paid after their date of issue.\nInvestors should make their own investigations into the merits of an investment in the Company. Nothing in this announcement amounts to a recommendation to invest in the Company or amounts to investment, taxation or legal advice.\nIt should be noted that a subscription for Ordinary Shares and investment in the Company carries a",
          "content_length": 17870
        },
        "ingested_at": "2026-01-16T22:48:57.958404Z"
      },
      {
        "event_id": "RNS-21st Jul 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958417Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of Placing & Subscription",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/result-of-placing-subscription-tmff6nissiz4cel.html",
          "rns_number": "RNS Number : 9242R",
          "full_content": "21 Jul 2025 15:43\nRNS Number : 9242R\nVerici Dx PLC\n21 July 2025\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.\nTHIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO PURCHASE AND/OR SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN VERICI DX PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION, SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH ANY INVESTMENT DECISION IN RESPECT OF VERICI DX PLC OR ANY OTHER ENTITY.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION RELATING TO VERICI DX PLC AND ITS SECURITIES FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"EUWA\") AND AS MODIFIED BY OR UNDER THE EUWA OR OTHER DOMESTIC LAW, INCLUDING BUT NOT LIMITED TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) (\"UK MAR\"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR), AS PERMITTED BY UK MAR. THIS INSIDE INFORMATION IS SET OUT IN THIS ANNOUNCEMENT. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION RELATING TO VERICI DX PLC AND ITS SECURITIES, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nCapitalised terms in this announcement have the same meaning as in the announcement issued at 07.00 a.m. today relating to the launch of the Fundraising unless otherwise indicated\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nResult of Placing & Subscription raising gross proceeds of approximately \u00a35.92 million\n($\n7.96\nmillion)\nVerici Dx plc (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant, announces that further to the Company's announcement earlier today, it has successfully concluded the oversubscribed Bookbuild for its Placing to raise\ngross proceeds of approximately \u00a3\n5.88\nmillion ($\n7.90\nmillion) (before expenses), through the placing of 1,175,648,304 Placing Shares with existing and new investors at the Issue Price of\n0.5\npence.\n49.4\nper cent. of the Placing Shares are intended to be EIS/VCT qualifying (the \"\nEIS/VCT Shares\n\"). In addition, a US investor who is also an existing shareholder has subscribed for 7,439,092 Subscription Shares at the Issue Price raising a further \u00a337,195 (approximately $50,000) (before expenses).\nThe 1,175,648,304 Placing Shares represent approximately\n484.7\nper cent. of the existing issued share capital of the Company. The Subscription Shares represent approximately\n3.1\nper cent. of the existing issued share capital of the Company.\nSinger Capital Markets and Oberon Capital are acting as placing agents for and on behalf of the Company in respect of the Placing.\nAt a general meeting of the Company held on 27 May 2025, allotment and disapplication of pre-emption rights authorities were obtained which enable the Directors to issue and allot new Ordinary Shares for cash up to a maximum aggregate nominal amount of \u00a32,000,000 (representing 2,000,000,000 new Ordinary Shares in the capital of the Company) (the \"\nMay 2025 Authorities\n\"). These May 2025 Authorities will be sufficient for the proposed Fundraising and will be used for the purposes of issuing any new Ordinary Shares pursuant to the Fundraising. Consequently, the Company would not need to obtain further authorities to issue and allot new Ordinary Shares in the Fundraising on a non-pre-emptive basis.\nAdmission\nApplication will be made to the London Stock Exchange for admission of the Placing Shares, the Subscription Shares and any other New Ordinary Shares to be issued in connection with the Fundraising. It is expected that admission of the Placing Shares and the Subscription Shares (along with any other New Ordinary Shares to be issued in connection with the Fundraising (excluding any WRAP Retail Offer Shares)) will become effective and that dealings in all of the New Ordinary Shares to be issued pursuant to the Fundraising will commence at 8.00 a.m. on\n24\nJuly 2025 (\"\nAdmission\n\").\nThe Placing Shares and the Subscription Shares (and any other New Ordinary Shares issued pursuant to the Fundraising), when issued, will be fully paid and will rank\npari passu\nin all ",
          "content_length": 25585
        },
        "ingested_at": "2026-01-16T22:48:57.958434Z"
      },
      {
        "event_id": "RNS-21st Jul 2025-proposed",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958447Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Proposed Fundraising",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/proposed-fundraising-3jd8dft7yybwkkh.html",
          "rns_number": "RNS Number : 8280R",
          "full_content": "21 Jul 2025 07:00\nRNS Number : 8280R\nVerici Dx PLC\n21 July 2025\nTHIS ANNOUNCEMENT (INCLUDING APPENDICES I AND II) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.\nTHIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO PURCHASE AND/OR SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN VERICI DX PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION, SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH ANY INVESTMENT DECISION IN RESPECT OF VERICI DX PLC OR ANY OTHER ENTITY.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION RELATING TO VERICI DX PLC AND ITS SECURITIES FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"EUWA\") AND AS MODIFIED BY OR UNDER THE EUWA OR OTHER DOMESTIC LAW, INCLUDING BUT NOT LIMITED TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) (\"UK MAR\"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR), AS PERMITTED BY UK MAR. THIS INSIDE INFORMATION IS SET OUT IN THIS ANNOUNCEMENT. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION RELATING TO VERICI DX PLC AND ITS SECURITIES, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nVerici Dx plc\n(\"\nVerici\nDx\n\" or the \"\nCompany\n\")\nProposed Fundraising via Placing, Subscription and Retail Offer\nMinimum gross proceeds from the Placing and Subscription of \u00a3\n5\nmillion (approximately $\n6.7\nmillion)\nDefinitions contained within Appendix II to this Announcement apply, unless the context requires otherwise\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces, further to the announcement of 11 June 2025, a proposed equity fundraising (the \"\nFundraising\n\") to raise funds to support the commercial scale up of a suite of next generation blood-based tests for the kidney transplant market.\nThe Fundraising, consisting of a placing (the \"\nPlacing\n\") of new ordinary shares of 0.1 pence (\"\nOrdinary Shares\n\") in the capital of the Company, a subscription for new Ordinary Shares and a separate retail offer of new Ordinary Shares\n(the \"\nWRAP Retail Offer\n\") via the Winterflood Retail Access Platform (the \"\nWRAP\n\"), will be conducted at a price of\n0.5\npence per new Ordinary Share (the \"\nIssue Price\n\"). The Issue Price represents a discount of 42.9 per cent. to Verici Dx's closing mid-price on 18 July 2025 (being the last practicable day prior to the publication of this Announcement).\nThe Placing is conducted via an accelerated bookbuild (the \"\nBookbuild\n\")\nwhich will be launched immediately following this Announcement. The Placing is being made available to certain institutional investors but is not available to the public.\nThe Placing will involve the issue of not less than\n1,000,000,000\nnew Ordinary Shares (the \"\nPlacing Shares\n\"), representing at least\n412.3\nper cent. of the existing issued ordinary share capital of the Company. In addition, a US investor intends conditionally to subscribe for 7,439,092 new Ordinary Shares (\"\nSubscription Shares\n\") at the Issue Price via a direct subscription (\"\nSubscription\n\") and, separately, the Company is proposing\na WR\nAP Retail Offer to new and existing shareholders for up to\n100,000,000\nnew Ordinary Shares at the Issue Price to raise up to an additional \u00a3\n0.5\nmillion\n(before expenses).\nFundraising summary:\n\u00b7\nVerici Dx is conducting a Placing to raise a minimum of \u00a3\n5\nmillion (before expenses) through the proposed issue of a minimum of\n1,000,000,000 Placing\nShares at\nthe Issue Price.\n\u00b7\nA US investor\nintend\ns conditionally to subscribe for\n7,439,092\nSubscription Shares\nat the Issue Price, representing approximately \u00a337,195 (approximately $50,000)\n(before expenses)\nin aggregate\n.\n\u00b7\nThe net proceeds of the\u00a0Placing and Subscription, which are expected to amount to at least \u00a3\n5\nmillion (before expenses), will provide the Company with additional working capital to\nsupport the commercial scale up of a suite of next generation blood-based tests for the kidney transplant market\n.\n\u00b7\nSinger Capital Markets Securities Limited (\"\nSinger Capital Markets\n\") and Oberon Capit",
          "content_length": 138159
        },
        "ingested_at": "2026-01-16T22:48:57.958464Z"
      },
      {
        "event_id": "RNS-30th Jun 2025-finalres",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958477Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Final Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/final-results-5m3yw9f2gff1rga.html",
          "rns_number": "RNS Number : 8594O",
          "full_content": "30 Jun 2025 07:00\nRNS Number : 8594O\nVerici Dx PLC\n30 June 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nFinal results for the year ended 31 December 2024\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces its audited final results for the year ended 31 December 2024.\nFinancial Highlights\n\u00b7\nRecord revenues of US$3.3m (2023: US$1.0m) as a result of the commercial contract with Thermo Fisher for the PTRA (Pre Transplant Risk Assessment) test\n\u00b7\nAdjusted EBITDA1 loss for the year of US$5.4m (2023: US$7.6m)\n\u00b7\nCash balance at year end of US$4.1m (2023: US$2.6m)\n\u00b7\nConducted an equity fundraise in February 2024 raising US$8.2m gross proceeds (US$7.5m net) through the issue of 72,222,222 new ordinary shares\n1\nEarnings before income tax, depreciation and amortisation, adjusted to exclude exceptional items\nOperational Highlights\n\u00b7\nS\nuccessfully completed the transfer of a\nportion of the Company's urine samples\nto\nThermo Fisher,\ntriggering a milestone payment of $339,000 in June 2024\n\u00b7\nC\nompletion of the transfer and achievement of all transfer-related activities for the pre-transplant prognostic testing technology in Q2 2024, triggering a further milestone payment of US$1.5m\n\u00b7\nMaterial Service Agreement with FBB Biomed, Inc. to offer Research-Use-Only tests for clinicians seeking insights into neurologic diseases such as Multiple Sclerosis and long COVID\n\u00b7\nReceived CLIA certification and CAP accreditation for the Company's clinical laboratory, enabling Verici Dx to test samples from patients across 51 US states and confirming the Company's commitment to operating at the highest standards\n\u00b7\nCollaboration with The Westmead Institute for Medical Research based in Sydney, Australia, on a newly awarded, 4-year federal research grant\nPost Period Highlights\n\u00b7\nSecured Medicare coverage for Verici Dx's Tutivia\u2122\u00a0assay, greatly improving patient access\n\u00b7\nQ1 2025 saw a strong acceleration in the Tutivia\u2122 testing order rate of 292 tests, a\u00a068% increase over the previous quarter (Q4 2024) and compares to a total test ordering figure of 334 for FY 2024\nVerici Dx and Thermo\u00a0Fisher\u00a0jointly hosted an educational symposium at CEoT conference at the end of February 2025 on the use of RNA signatures in the clinic, citing both PTRA and Tutivia\nGoing Concern\nThe Group is in the early stages of commercialising its principal business of diagnostic assays and did not commence recognising revenues from that activity until after the reporting date, having secured Medicare Coverage for Tutivia\u2122 in\nApril 2025\n. The Group was able to generate revenues of $3.34 million in the reporting period (2023: $1.01m million) through a global licensing and commercialisation agreement over its Clarava, now renamed PTRA test.\nAs at 31 May 2025 the Group held a cash position of $1.04 million, reflecting receipt of the $750k milestone payment from Thermo Fisher, due under the commercial contract for the PTRA test. That receipt extended the Group's current cash runway to the end of July 2025.\nIn considering the appropriateness of this basis of preparation, the Directors have prepared financial forecasts and projections for the Group for a minimum of 12 months from the date of the approval of these financial statements (the Going Concern period). There are considerable uncertainties, particularly in relation to the quantum and timing of cash receipts from revenue, especially revenue from anticipated sales of tests. Those financial forecasts and projections have, therefore, considered sensitivities in relation to both quantum and timing of receipts and costs.\nAs announced on 11 June 2025, the Company is engaged in an equity fundraising (the \"Fundraising\") to extend the Group's cash runway and enable it, to achieve its commercial objectives for Tutivia\u2122.\u00a0At the date of approval of these financial statements, the Company is working with its advisers and has received positive indications of support from a number of existing and new institutional and other investors. The Fundraising, which if completed would extend the Group's cash runway beyond the Going Concern period, provide growth finance to accelerate commercial roll-out and support the scale up of Tutivia\u2122 revenues. The Company is currently progressing an application for Advance Assurance with HMRC and is also considering alternative sources of funding.\nHaving taken into account the information and estimates available at the date of approval of these financial statements, the Directors consider that the Group will require additional funding before the end of July 2025 and are taking steps to put in place such funding arrangements as may be required. If the Directors are unable to secure sufficient funding they could be forced to take all necessary steps to reduce outgoings and/or take other actions which could include the sale of assets or the winding up the Company.\nThe directors believe that additional funding can be obtained to enable the Company and",
          "content_length": 100318
        },
        "ingested_at": "2026-01-16T22:48:57.958492Z"
      },
      {
        "event_id": "RNS-11th Jun 2025-updateon",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958505Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Update on funding to accelerate commercial growth",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/update-on-funding-to-accelerate-commercial-growth-f6pj8kw7s8er2uy.html",
          "rns_number": "RNS Number : 2863M",
          "full_content": "11 Jun 2025 07:00\nRNS Number : 2863M\nVerici Dx PLC\n11 June 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nUpdate on funding to accelerate commercial growth\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant, provides an update on its plans to raise funds to enable the Company\nto accelerate commercial growth and support the scale up of Tutivia\u2122 revenues, having secured Medicare Coverage for Tutivia\u2122, as announced in\nApril 2025\n.\nFurther to the\nannouncement on\n7 April 2025\n, the Company is proposing to carry out an equity fundraising (the \"\nFundraising\n\") to extend the Company's cash runway and enable it to achieve its commercial objectives for Tutivia\u2122, its diagnostic test for acute rejection.\u00a0The Company is working with its advisers and has received positive indications of support from a number of existing and new institutional and other investors. The Fundraising,\nwhich if completed, would extend the Company's cash runway, would provide growth finance to accelerate\ncommercial roll-out and support the scale up of Tutivia\u2122 revenues.\nThe Company remains on track to deliver $3.2 million in\nTutivia\u2122\nrevenues for FY 2025, in-line with market expectations.\nThe size and structure of the Fundraising is yet to be determined by the Board, however it is anticipated to include a placing as well as the opportunity for\nparticipation by all existing shareholders via a retail offer.\nThe allotment authorities that\nwere granted at the General Meeting held on 27 May 2025\nwill be sufficient for the proposed Fundraising and so the Company would not need to obtain further authority to issue and allot new Ordinary Shares\non a non-pre-emptive basis. A further update will be provided by the Company before the end of June.\nAs at 31 May 2025 the Company held a cash position of $\n1.04\nmillion, reflecting receipt of the expected $750k milestone payment from Thermo Fisher, due under the commercial contract for the PTRA (Pre Transplant Risk Assessment) test. This and the expected receivables from the Medicare Coverage extends the Company's current cash runway, beyond previous expectations, to at least the\nend of July 2025\n.\n2024 Annual Results\nThe Company is currently working with its auditors to ensure that it announces its audited results for the year ended 31 December 2024 by the end of June as planned.\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated Adviser and Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nUPDSFFFWSEISEDM",
          "content_length": 3489
        },
        "ingested_at": "2026-01-16T22:48:57.958518Z"
      },
      {
        "event_id": "RNS-27th May 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958530Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of General Meeting",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/result-of-general-meeting-jor4uwwpuamcr8g.html",
          "rns_number": "RNS Number : 2753K",
          "full_content": "27 May 2025 14:42\nRNS Number : 2753K\nVerici Dx PLC\n27 May 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nResult of General Meeting\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that at the General Meeting (\"GM\") held earlier today, all resolutions, as set out in the GM notice published on 9 May 2025, were duly passed on a poll. Resolution 1 was passed as an ordinary resolution and resolution 2 was passed as a special resolution.\nThe voting results of the GM were as follows:\nIn Favour\nAgainst\nWithheld\nResolution\nVotes\n%\nVotes\n%\nVotes\n1\n112,453,134\n99.96\n47,616\n0.04\n23,820\n2\n112,380,881\n99.89\n119,738\n0.11\n23,951\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated Adviser and Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nROMPPUGCAUPAGWM",
          "content_length": 1806
        },
        "ingested_at": "2026-01-16T22:48:57.958542Z"
      },
      {
        "event_id": "RNS-9th May 2025-publicat",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958555Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Publication of Circular",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/publication-of-circular-yn6bcvdehh4mn1z.html",
          "rns_number": "RNS Number : 1422I",
          "full_content": "9 May 2025 16:38\nRNS Number : 1422I\nVerici Dx PLC\n09 May 2025\nVerici Dx plc\n(\"\nVerici\n\" or the \"\nCompany\n\")\nPublication of Circular\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that a Circular, containing a notice of general meeting, has been published today seeking Shareholder approval to issue and allot new Ordinary Shares on a non-pre-emptive basis at a general meeting\ndue to be held at the offices of\nShoosmiths LLP at 1 Bow Churchyard, London, EC4M 9DQ\nat 11:30 a.m. on 27 May 2025 (\"\nGeneral Meeting\n\").\nFollowing the announcement on 7 April 2025, the Company is proposing to carry out a Fundraising (the \"\nFundraising\n\") to raise funds to enable it,\ninter alia\n, to accelerate commercial growth and support the scale up of Tutivia\u2122 revenues. The Fundraising is required to extend the cash runway and enable the Company to achieve its commercial objectives having now secured Medicare Coverage for Tutivia\u2122 as announced on 10 April 2025.\nThe existing allotment authorities the Company has from its last annual general meeting are anticipated to be insufficient for the proposed Fundraising and accordingly, the Company is proposing to obtain sufficient further authority to issue and allot new Ordinary Shares\non a non-pre-emptive basis at the General Meeting.\nThe size and structure of the Fundraising is yet to be determined by the Board, however it is anticipated to include a placing with institutional and other investors. The Company, in consultation with its advisers, will determine the appropriate size, structure and timing of the Fundraising in due course and a further update will be provided by the Company as and when deemed appropriate.\nThe Circular and notices of availability of the Circular on the Company's website will be posted to Shareholders today and these documents will also be available later today on the Company's website at:\nhttps://vericidx.com/investors/documents/\nUnless otherwise defined, all definitions used in this announcement will have the same meaning as described in the Circular.\nEnquiries:\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated Adviser & Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or\nvericidx@walbrookpr.com\nPaul McManus\nMob: +44 (0)7980 541 893\nAbout Verici Dx plc\nwww.vericidx.com\nVerici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.\nThe foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCBUGDURXGDGUC",
          "content_length": 4211
        },
        "ingested_at": "2026-01-16T22:48:57.958567Z"
      },
      {
        "event_id": "RNS-6th May 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958579Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-fod6oasjwkc6kry.html",
          "rns_number": "RNS Number : 5234H",
          "full_content": "6 May 2025 12:16\nRNS Number : 5234H\nVerici Dx PLC\n06 May 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BM8HZD43\nIssuer Name\nVERICI DX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn event changing the breakdown of voting rights\n3. Details of person subject to the notification obligation\nName\nMaven Capital Partners UK LLP\nCity of registered office (if applicable)\nGlasgow\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nMeinom Limited\nGlasgow\nScotland\nMaven Renovar VCT PLC\nLondon\nEngland and Wales\nMaven Income and Growth VCT 5 PLC\nLondon\nEngland and Wales\nMaven Income and Growth VCT 4 PLC\nGlasgow\nScotland\nMaven Income and Growth VCT PLC\nLondon\nEngland and Wales\n5. Date on which the threshold was crossed or reached\n01-May-2025\n6. Date on which Issuer notified\n06-May-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n5.702000\n0.000000\n5.702000\n13830788\nPosition of previous notification (if applicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BM8HZD43\n13830788\n5.702000\nSub Total 8.A\n13830788\n5.702000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nMaven Renovar VCT PLC was previously Amati AIM VCT plc.\nThe name change occurred following a change of Investment Manager from Amati Global Investors (AGI) to Maven Capital Partners UK LLP (Maven).\n12. Date of Completion\n06-May-2025\n13. Place Of Completion\nGlasgow\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFLLEFIRIIE",
          "content_length": 4097
        },
        "ingested_at": "2026-01-16T22:48:57.958592Z"
      },
      {
        "event_id": "RNS-10th Apr 2025-vericire",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958604Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Verici Receives Medicare Coverage for Tutivia",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/verici-receives-medicare-coverage-for-tutivia-0tlhpciiabxnj0c.html",
          "rns_number": "RNS Number : 4852E",
          "full_content": "10 Apr 2025 08:06\nRNS Number : 4852E\nVerici Dx PLC\n10 April 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nVerici Receives Medicare Coverage for Tutivia\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant is pleased to announce a positive Technical Assessment by Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its Molecular Diagnostic Services Program (MolDX) allowing for Medicare coverage of its Tutivia\n\u2122\nassay, a diagnostic test for acute rejection.\nPatients with a high-risk Tutivia\u2122\nscore are nearly six times as likely to experience acute rejection over those with low-risk results\n. Tutivia already has a Medicare code (032OU) and price of $2,650.\nAs previously announced, in Q1 2025 Verici Dx had already seen a strong acceleration in its highest Tutivia\u2122 testing order rate of 292 tests. This represents a significant 68% increase in the testing order rate over the previous quarter (Q4 2024) and compares to a total test ordering figure of 334 for FY 2024. This is a highly encouraging ramp up in adoption and test ordering and the Company expects continued growth in Tutivia\u2122 with the ability of Verici to scale testing of Tutivia\u2122 through its own direct to physician sales. With the positive coverage determination now received, the Company is now able to recognise revenues.\nTutivia\n\u2122\nis the Company's post kidney transplant blood test that reports the patient's risk of all forms of acute rejection, including\nborderline, T cell-mediated, and antibody-mediated rejections\n. The test therefore\nsupports clinical care for the estimated c.100,000 global patients who undergo kidney transplant procedures annually.\nTutivia\nTM\ndelivers a significant improvement in biomarker offerings, particularly early post-transplant when patient management can be complex and other biomarkers are contraindicated or less informative.\nTutivia's\n\u2122\nhas an important role in helping improve patient outcomes with significant implications for clinical care, providing relevant information for immunosuppression management and supporting clinical decision making with regard to kidney biopsy.\nFollowing a review of clinical validity, analytical validity, and clinical utility, MolDX determined that Tutivia\n\u2122\nhas met the criteria for coverage under LCD L38568, MolDX: Molecular Testing for Solid Organ Allograft Rejection for renal transplant patients. The MolDX coverage decision signifies that Tutivia\n\u2122\nmeets requirements for Medicare coverage and will support broader access for renal transplant patients.\nCommenting on the approval,\nSara Barrington, CEO of Verici Dx, said\n:\n\"\nThe\u00a0achievement of this key milestone\u00a0reflects\u00a0the\u00a0exciting\u00a0work\u00a0that is\u00a0ongoing at Verici\u00a0and the quality of its science. Securing a positive MolDX coverage decision will improve patient access to the Tutivia\n\u2122\nassay, advancing both availability and adoption. With this decision, we hope that more patients can benefit from\na significant step forward in enhancing diagnostic accuracy and post-transplant patient care\n. With Tutivia\n\u2122\nalready seeing strong positive feedback from early adopters and the accelerated sales already coming through, we look forward to continued success in a commercial setting.\"\nEnquiries:\nVerici Dx\nwww.v\nericidx\n.com\nSara Barrington, CEO\ninvestors@vericidx.com\nJulian Baines, Chairman\nSinger Capital Markets (Nominated Adviser & Broker)\nTel: +44 20 7496 3000\nPhil Davies / Sam Butcher\nAbout Verici Dx plc\nwww.vericidx.com\nVerici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.\u00a0The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.\nThe foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with th",
          "content_length": 5302
        },
        "ingested_at": "2026-01-16T22:48:57.958619Z"
      },
      {
        "event_id": "RNS-7th Apr 2025-signific",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958632Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Significant Test Growth with Medicare Pending",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/significant-test-growth-with-medicare-pending-md2ztnwlh652w1w.html",
          "rns_number": "RNS Number : 8177D",
          "full_content": "7 Apr 2025 07:00\nRNS Number : 8177D\nVerici Dx PLC\n07 April 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nSignificant Test Growth with Medicare Pending\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\nprovides an update on operations at quarter end.\nIn Q1 2025, Verici Dx recorded its highest Tutivia\u2122 testing order rate of 292 tests. This represents a significant 68% increase in the testing order rate over the previous quarter (Q4 2024) and compares to a total test ordering figure of 334 for FY 2024. This is a highly encouraging ramp up in adoption and test ordering, even before the outcome of the Local Coverage Determination, and the Company expects continued growth in Tutivia\u2122 testing for the remainder of the calendar reporting year.\nAccounting recognition of revenues for Tutivia\u2122 will continue to be pending a decision from Medicare contractor MolDX. A\ndecision on our MolDX Technical Assessment review for coverage\nis expected imminently, and a further announcement will be made at that time. The price per test under Medicare is set at $2,650.\nIn addition, the Company notes that the milestone for a payment of $750k under the commercial contract for PTRA was achieved in Q1 2025 and has been invoiced to Thermo Fisher which we expect to receive in Q2 2025.\nThe Company has\ncontinued to demonstrate a highly disciplined approach to cost control\n, with further headcount reduction and other cost containment steps in recent months, including reducing external spend on product development. As of 31 March 2025, the Company held a cash position of $1.63 million. Cost controls are expected to provide sufficient cash runway, assuming receipt of the $750k milestone payment mentioned above, through to the end of June 2025. This funding should support the Company in reaching a MolDX insurance coverage decision before conducting an equity financing to continue its current commercial testing trajectory.\nSara Barrington, CEO of Verici Dx, said:\n\"I am extremely proud of the progress we have made since our last update, particularly when viewed in the context of limited resources and, ahead of the local coverage determination for Tutivia\nTM\n. The significant increase in orders for TutiviaTM in the last quarter reflects how it directly addresses areas of unmet need in transplant, as well as general utility, and demonstrates it is being very well received by clinicians who are passionate about improving their patient outcomes.\n\"Verici has proven to lead the way in developing a new wave of technology for transplant with both Tutivia\nTM\nand PTRA being clinically launched, and there is a high degree of interest in the progress in our other programs which have the potential to add significantly to the field.\n\"\nWe previously said that a\ndoption of innovative products is sensitive to establishing comprehensive insurance coverage and we recognise that the lack of coverage through 2024 slowed the pace of adoption. That said, we are pleased with the initial Tutivia\nTM\ntest ordering, the levels of repeat ordering, and\nwe still e\nxpect volumes to further accelerate as insurance coverage is established.\"\nTutiviaTM update\nThe Company is currently working with 19 leading US transplant centres as they embed Tutivia\nTM\ninto their current clinical pathway which will further encourage consistent and recurring utilisation\n. We are pleased with the initial TutiviaTM\ntest ordering, and particularly to see the strong levels of repeat ordering as indicated above.\nAs previously announced, the Local Coverage Determination process remains ongoing. We submitted responses to questions to Medicare in support of a coverage determination\nfor the Tutivia\nTM\ntest earlier in Q1 2025 and will provide further updates as and when appropriate.\nPTRA update\nOur\u00a0collaboration\u00a0with Thermo Fisher\u00a0Scientific\u00a0remains strong and we note that they continue to invest in the\u00a0commercialization\u00a0of PTRA. Verici and Thermo\u00a0Fisher\u00a0jointly hosted an educational symposium at CEoT conference at the end of February 2025 on the use of RNA signatures in the clinic, citing both PTRA and Tutivia\nTM\n. Notably, Thermo\u00a0Fisher is investing in new research related to PTRA\u00a0aimed at identifying the earliest stage at which the test can be utilised\u00a0before transplantation. Consequently, the second milestone originally anticipated for 2025 will be delayed\u00a0as we continue to collaborate on publishing clinical validation data and Thermo Fisher pursues these additional research efforts to help broaden utility and adoption of the assay.\nServices and other product development update\nIn line with the Company's cost management, we expect a slowdown in licensing activity during 2025. As a result, the development timelines of Protega\nTM\nand the urine product have been extended to the end of 2025.\nAdditionally, while the services business continues to generate interest and several collaborations are underway, broader market uncertainty following the introductions ",
          "content_length": 8903
        },
        "ingested_at": "2026-01-16T22:48:57.958647Z"
      },
      {
        "event_id": "RNS-14th Jan 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958659Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-fitf5komhlzqfmw.html",
          "rns_number": "RNS Number : 2827T",
          "full_content": "14 Jan 2025 11:01\nRNS Number : 2827T\nVerici Dx PLC\n14 January 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BM8HZD43\nIssuer Name\nVERICI DX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nAmati Global Investors Limited\nCity of registered office (if applicable)\nEdinburgh\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nAmati AIM VCT plc\nLondon\nUnited Kingdom\n5. Date on which the threshold was crossed or reached\n09-Jan-2025\n6. Date on which Issuer notified\n13-Jan-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n5.380000\n0.000000\n5.380000\n13061111\nPosition of previous notification (if applicable)\n6.230000\n0.000000\n6.230000\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BM8HZD43\n13061111\n5.380000\nSub Total 8.A\n13061111\n5.380000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n13-Jan-2025\n13. Place Of Completion\nEdinburgh, UK\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFEILAISLIE",
          "content_length": 3729
        },
        "ingested_at": "2026-01-16T22:48:57.958671Z"
      },
      {
        "event_id": "RNS-11th Oct 2024-updateon",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958684Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Update on Local Coverage Determination and Trading",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/update-on-local-coverage-determination-and-trading-zel8h8gpycj8sog.html",
          "rns_number": "RNS Number : 8076H",
          "full_content": "11 Oct 2024 07:00\nRNS Number : 8076H\nVerici Dx PLC\n11 October 2024\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nUpdate on Local Coverage Determination and Trading\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it is planning to submit supplemental information to Medicare in support of a coverage determination\nfor its TutiviaTM test and expects this process will continue into H1 2025 rather than the anticipated end of FY24. As such, the Company will now recognise TutiviaTM revenues from this year in FY25. The updated timeline has no effect on the Company's cash position at year end which we expect to be in line with market expectations.\nThe TutiviaTM test has been well received by clinicians. Adoption of innovative products, however, is sensitive to establishing comprehensive insurance coverage and the lack of coverage has slowed the pace of adoption. We remain pleased with the initial TutiviaTM test ordering, the levels of repeat ordering, and expect volumes to accelerate as insurance coverage is established in 2025.\nDr.\nZahraa Hajjiri, Assistant Professor of Medicine, Department of Internal Medicine, Division of Nephrology, Transplant Nephrology,\u00a0Medical Director Transplant Nephrology, said:\n\"\nValidated biomarkers for all post-transplant patients early post-transplant, including those experiencing slow allograft function and delayed allograft function\nare currently limited. As early adopters of this test, we have been exceedingly satisfied with its outcomes and high reliability. We are in the process of integrating it into our protocol for delayed graft function and biomarker assessment, anticipating a significant surge in its utilization\n.\"\nThe Company's partnerships remain strong, and licensing revenues remain on track. The services business continues to generate collaborations, with contracts signed to date now anticipated to generate revenue in 2025 rather than the last quarter of 2024.\nAs at 30 September 2024, the Company had $6.1 million in cash. Verici Dx has continued to demonstrate a disciplined approach to cost control and anticipates that the year-end cash balances will be in line with current market expectations.\nSara Barrington, CEO of Verici Dx, said:\n\"\nLocal coverage determination is important to our commercial strategy, and we are actively working with the assessment team to expedite the approval process. While this delay pushes back our short-term revenue expectations, our long-term outlook remains positive as we continue with the adoption of TutiviaTM.\n\"\nEnquiries:\nVerici Dx\nwww.v\nericidx\n.com\nSara Barrington, CEO\ninvestors@vericidx.com\nJulian Baines, Chairman\nSinger Capital Markets (Nominated Adviser & Broker)\nTel: +44 20 7496 3000\nPhil Davies / Sam Butcher\nAbout Verici Dx plc\nwww.vericidx.com\nVerici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.\u00a0The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.\nThe foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nUPDFFIEDSELSEDS",
          "content_length": 4600
        },
        "ingested_at": "2026-01-16T22:48:57.958696Z"
      },
      {
        "event_id": "RNS-31st Jul 2024-launchof",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958709Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Launch of PTRA Assay using Verici Dx's technology",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/launch-of-ptra-assay-using-verici-dxs-technology-z2km8kdhvfpxjq1.html",
          "rns_number": "RNS Number : 4798Y",
          "full_content": "31 Jul 2024 07:00\nRNS Number : 4798Y\nVerici Dx PLC\n31 July 2024\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nSuccessful completion of Thermo Fisher Scientific licensing and commercialisation agreement\nFormal launch of Pre-Transplant Risk Assessment Assay using Verici's prognostic testing technology\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\u00a0notes that Thermo Fisher Scientific, the world leader in serving science, has announced the formal launch of its One Lambda\u2122 Pre-Transplant Risk Assessment (\"PTRA\") Assay via its CLIA facility in Fishers, Indiana, utilizing the pre-transplant prognostic testing technology licensed by the Company to Thermo Fisher Scientific under the terms of a global licensing and commercialisation agreement announced on 15 November 2023 (the \"Agreement\").1\nCommenting on the milestones, Sara Barrington, CEO of Verici Dx, said:\n\"I am delighted to see that the PTRA Assay is being launched to the clinical community so swiftly and look forward to seeing how it can help transform patient outcomes. Together with the successful transfer of technology, this demonstrates our Company's commitment to timely and effective collaboration when executing these types of agreements.\"\nTina Liedtky, President, Transplant Diagnostics, Thermo Fisher Scientific said:\n\"We're excited to introduce this innovative new tool that\nmay\nhelp clinicians make more informed\ndecisions about post-transplant management\nby\nproviding\ninformation about patient risk of early acute rejection based on a patient's unique gene profile prior to transplant\n.\n\"\nEnquiries:\nVerici Dx\nwww.v\nericidx\n.com\nSara Barrington, CEO\ninvestors@vericidx.com\nJulian Baines, Chairman\nSinger Capital Markets (Nominated Adviser & Broker)\nTel: +44 20 7496 3000\nPhil Davies / Sam Butcher\nNotes\n1.\nPlease refer to RNS number 4652T for further information. A copy of this announcement can also be found on the company website\nhttps://verici-dx-plc.flint-platform.com/regulatory-news/62760\nAbout Verici Dx plc\nwww.vericidx.com\nVerici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.\u00a0The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.\nThe foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCQKKBPKBKBCON",
          "content_length": 3829
        },
        "ingested_at": "2026-01-16T22:48:57.958721Z"
      },
      {
        "event_id": "RNS-15th Jul 2024-half-yea",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958734Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Half-year Report",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/half-year-report-9atuuysypz4u6p5.html",
          "rns_number": "RNS Number : 3161W",
          "full_content": "15 Jul 2024 07:00\nRNS Number : 3161W\nVerici Dx PLC\n15 July 2024\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nHalf-year report\nContinued strategic delivery with revenues\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\nannounces its unaudited interim results for the six months ended 30 June 2024 (\"H1 2024\"). Comparative data is for the unaudited six months ended 30 June 2023 (\"H1 2023\") unless stated otherwise.\nFocus on three distinct revenue streams\nThe Company has transitioned from a purely research stage business to one with three distinct revenue streams: licensing revenues, direct sales, and other income from our Services Business. In the period, this resulted in total revenues of $3.3m (FY23: $1.0m):\n\u2022\nLicensing revenues\n.\nRecognition of\nrevenue during H1 2024\nrelating to the\nsuccessful achievement of transfer of the pre-transplant prognostic testing technology\n(formerly known as Clarava\n\u2122\n). This is in accordance with the terms of a global licensing and commercialisation agreement with\nThermo Fisher\nannounced on 15 November 2023 (the \"Thermo Agreement\").\n\u2022\nDirect sales\n. The Company is seeing increased test adoption with our first product, Tutivia\u2122. This is now being used in fifteen centres in the US\n,\nand this is growing as anticipated. Although the timing of revenue recognition from these sales is impacted by the various reimbursement processes, the adoption is in line with our expectations and now supported by additional hires in our commercial team.\n\u2022\nServices income\n.\nThis recognises the value in the data asset, collaborations, and other applications of the Company's technology and expertise. Collectively, the Company is managing these as our Services Business.\nIn the period, the successful completion of final deliverables relating to urine samples\nin accordance with the\nThermo Agreement generated revenues. This is in addition to the revenues generated in 2023\n.\nEach of these income streams is further supported going forward by our newly expanded, in-house bioinformatics capability which supports further product development and commercialisation, as well as identifying and underpinning additional value in the Company's research assets.\nSignificant progress across our lead products\nThe Company has continued to make significant progress with each of its lead products:\n\u2022\nSubmitted the Technical Assessment (\"TA\") File for Tutivia\u2122, an important step in the pathway for reimbursement coverage from Medicare. We are currently in a period of review and expect to have a Medicare determination by the end of 2024.\n\u2022\nPresented new performance data on Tutivia\u2122 in the setting of delayed graft function (\"DGF\") where there is unmet clinical need and generated interest from practitioners at\nthe June American Transplant Congress (\"ATC\") meeting.\nThe subsequent increase in adoption reflects in part interest in using Tutivia\u2122 in this context.\n\u2022\nDevelopment\nof the Company's third product, Protega\n\u2122\n, is\non track with additional funding supporting the ability to generate more robust data / better commercialisation outcomes. The first validation data is expected in H1 2025.\n\u2022\nInitiated\na new\nkey opinion leader (KOL) led education program to highlight the uses and advantages of the Company's underlying technology and its application in the lead products.\nContinued and consistent strong delivery against multiple operational milestones\nThe Company has established a strong track record of delivery across multiple projects and initiatives, and we are pleased this has continued throughout the first half of 2024:\n\u2022\nFinalised the CLIA application for the final US state, New York, where there were several additional stages to complete prior to accreditation compared to the process in other states\n. When granted, the Company's laboratory will be able to test samples from patients across all US states.\n\u2022\nLaunched\nan interactive patient-focused educational tool, the Patient Journey,\nproviding a detailed overview of all stages of the kidney transplant journey.\nThis\naligns with the Company's goal to enhance patient care and support by ensuring that patients\nand caregivers have access to the latest information and best practices for kidney transplant care\n.\n\u2022\nGained accreditation from\nthe internationally recognised College of American Pathology (CAP) for the testing laboratory in Franklin, TN, USA.\nAlong with the existing CLIA Certificate of Compliance for the Company's clinical laboratory in Nashville, TN, USA, this further reinforces\nthe Company's\non-going commitment to maintaining best in class quality systems.\n\u2022\nAnnounced an exciting collaboration with The Westmead Institute for Medical Research based in Sydney, Australia, on a newly awarded, 4-year federal research grant. The goal of the research is to enhance the prediction and management of risks associated with organ transplants across a diverse group of patients drawn from three different clinical sites.\nFinancial highlights\n\u2022\n",
          "content_length": 40250
        },
        "ingested_at": "2026-01-16T22:48:57.958749Z"
      },
      {
        "event_id": "RNS-11th Jul 2024-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958762Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of Results and Business Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/notice-of-results-and-business-update-moy9y6rpel9xl42.html",
          "rns_number": "RNS Number : 0926W",
          "full_content": "11 Jul 2024 14:00\nRNS Number : 0926W\nVerici Dx PLC\n11 July 2024\nVerici Dx plc\n(\"Verici Dx\" or the \"Company\")\nNotice of Results and Business Update\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\nannounces that it will report its interim results for the six months to 30 June 2024, together with a business update, on 15 July 2024.\nInvestor roadshow and briefings\nSara Barrington, Chief Executive Officer, and David Anderson, Chief Financial Officer, will provide a live online presentation via the Investor Meet Company platform on Tuesday 16th July 2024 at 16:30 BST. This presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00 am BST the day before the meeting or during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via:\nhttps://www.investormeetcompany.com/verici-dx-plc/register-investor\nThe Company will also be presenting in person at The Novotel, London on Wednesday 17 July 2024 at 18.00 BST as part of the regular series of \"Shares\" investor events hosted by AJ Bell. Existing shareholders and potential investors can register to attend this live evening event for free at:\nShares Magazine - Events\nEnquiries:\nVerici Dx\nwww.v\nericidx\n.com\nSara Barrington, CEO\ninvestors@vericidx.com\nJulian Baines, Chairman\nSinger Capital Markets (Nominated Adviser & Broker)\nTel: +44 20 7496 3000\nPhil Davies / Sam Butcher\nAbout Verici Dx plc\nwww.vericidx.com\nVerici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.\u00a0The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.\nThe foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNORRBMBTMTABBII",
          "content_length": 3334
        },
        "ingested_at": "2026-01-16T22:48:57.958774Z"
      },
      {
        "event_id": "RNS-1st Jul 2024-signific",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958787Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Significant milestone re Thermo Fisher agreement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/significant-milestone-re-thermo-fisher-agreement-rf5lae58iug55sa.html",
          "rns_number": "RNS Number : 4775U",
          "full_content": "1 Jul 2024 07:00\nRNS Number : 4775U\nVerici Dx PLC\n01 July 2024\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nAchievement of significant milestone under Thermo Fisher Scientific agreement\nSuccessful transfer of pre-transplant prognostic testing technology\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\u00a0notes that Thermo Fisher Scientific has confirmed the completion of the transfer and achievement of all transfer-related activities for the pre-transplant prognostic testing technology licensed by the Company to Thermo Fisher Scientific under the terms of a global licensing and commercialisation agreement announced on 15 November 2023 (the \"Agreement\")1.\nThis enables Thermo Fisher Scientific to use the technology to develop a LDT (\"Laboratory Developed Test\") in its own labs. This event triggers a further milestone payment under the Agreement, in line with previously disclosed expectations.\nCommenting on the milestone, Sara Barrington, CEO of Verici Dx, said:\n\"I am delighted to announce this smooth transition between Verici Dx and Thermo Fisher Scientific. This collaboration brings together Verici Dx's innovative technology into Thermo Fisher's new CLIA laboratory in the U.S., which will ultimately benefit patients and the field of organ transplantation.\"\nThis announcement contains inside information for the purposes of Article 7 of the UK Market Abuse Regulation (UK MAR). Upon the publication of this announcement, this inside information is now considered to be in the public domain\n.\nEnquiries:\nVerici Dx\nwww.v\nericidx\n.com\nSara Barrington, CEO\ninvestors@vericidx.com\nJulian Baines, Chairman\nSinger Capital Markets (Nominated Adviser & Broker)\nTel: +44 20 7496 3000\nAubrey Powell / Sam Butcher\nNotes\n1.\nPlease refer to RNS number 4652T for further information. A copy of this announcement can also be found on the company website\nhttps://verici-dx-plc.flint-platform.com/regulatory-news/62760\nAbout Verici Dx plc\nwww.vericidx.com\nVerici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.\u00a0The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.\nThe foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRSDEFWSELSEIM",
          "content_length": 3773
        },
        "ingested_at": "2026-01-16T22:48:57.958799Z"
      },
      {
        "event_id": "RNS-25th Jun 2024-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958811Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/result-of-agm-estvccxcf2yipj6.html",
          "rns_number": "RNS Number : 8191T",
          "full_content": "25 Jun 2024 13:27\nRNS Number : 8191T\nVerici Dx PLC\n25 June 2024\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nResult of AGM and voting results\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\u00a0announces that at the\u00a0Annual General Meeting (\"AGM\") held earlier today, all resolutions were duly passed.\nThe voting results of the AGM were as follows:\nIn Favour\nAgainst\nWithheld\nResolution\nVotes\n%\nVotes\n%\nVotes\n1\n109,919,167\n97.96\n2,287,678\n2.04\n76\n2\n112,096,318\n99.90\n110,603\n0.10\n0\n3\n112,205,310\n99.99\n1,611\n0.01\n0\n4\n112,081,736\n99.89\n125,185\n0.11\n0\n5\n112,085,956\n99.89\n120,965\n0.11\n0\n6\n111,792,090\n99.63\n414,740\n0.37\n91\n7\n112,203,528\n99.99\n3,233\n0.01\n160\n8\n112,192,472\n99.99\n14,289\n0.01\n160\n9\n112,154,800\n99.95\n51,921\n0.05\n200\nEnquiries:\nVerici Dx\nwww.v\nericidx\n.com\nSara Barrington, CEO\ninvestors@vericidx.com\nJulian Baines, Chairman\nSinger Capital Markets (Nominated Adviser & Broker)\nTel: +44 20 7496 3000\nAubrey Powell / Sam Butcher\nAbout Verici Dx plc\nwww.vericidx.com\nVerici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.\u00a0The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.\nThe foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGBDGDLRDDDGSU",
          "content_length": 2791
        },
        "ingested_at": "2026-01-16T22:48:57.958824Z"
      },
      {
        "event_id": "RNS-18th Jun 2024-transfer",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958837Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Transfer of urine samples to Thermo Fisher",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/transfer-of-urine-samples-to-thermo-fisher-syk3pco5yq65kjx.html",
          "rns_number": "RNS Number : 7733S",
          "full_content": "18 Jun 2024 07:00\nRNS Number : 7733S\nVerici Dx PLC\n18 June 2024\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nTransfer of urine samples to Thermo Fisher Scientific\nFollowing completion of the transfer, full payment has been received\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\u00a0announces it has completed successful transfer of a\nportion of the Company's urine samples as announced as part of\nthe global commercialisation and licensing agreement announced in November 20231. A\ns previously stated, it\ndemonstrates the additional value in the Company's data and sample assets for research.\nSara Barrington, CEO, said:\n\"We are delighted to announce the successful completion of this transfer, within the agreed timeline. This achievement not only highlights our commitment to delivering on our agreements, but also underscores the substantial value inherent in the Company's data and sample assets for research purposes.\n\"\nEnquiries:\nVerici Dx\nwww.v\nericidx\n.com\nSara Barrington, CEO\ninvestors@vericidx.com\nJulian Baines, Chairman\nSinger Capital Markets (Nominated Adviser & Broker)\nTel: +44 20 7496 3000\nAubrey Powell / Sam Butcher\nNotes\n1. Please refer to RNS number 4652T for further information. A copy of this announcement can also be found on the company website\nhttps://verici-dx-plc.flint-platform.com/regulatory-news/44270\nAbout Verici Dx plc\nwww.vericidx.com\nVerici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.\u00a0The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.\nThe foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCQDLFFZQLEBBK",
          "content_length": 3190
        },
        "ingested_at": "2026-01-16T22:48:57.958849Z"
      },
      {
        "event_id": "RNS-31st May 2024-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958862Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of AGM and posting of Annual Report",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/notice-of-agm-and-posting-of-annual-report-33jzuy2v27o4gye.html",
          "rns_number": "RNS Number : 6994Q",
          "full_content": "31 May 2024 13:57\nRNS Number : 6994Q\nVerici Dx PLC\n31 May 2024\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nPosting of Annual Report & Accounts\nandNotice of Annual General Meeting\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\nconfirms that the Annual Report and Accounts for the year ended 31 December 2023 (\"\n2023 Annual Report\n\") and the Notice of the 2024 Annual General Meeting\u00a0(\"\nAGM\n\") have now been published on the Company's website\nvericidx.com/investors/\n.\nThe 2023 Annual Report,\u00a0the Notice of AGM and details for voting by proxy\u00a0will be posted to shareholders who have not consented to receive electronic communications today, on 31 May 2024.\nThe AGM is to be held on 25 June 2024 at 11.30 a.m. at Shoosmiths LLP, No. 1 Bow Churchyard, London EC4M 9DQ and will consider the Resolutions set out in the Notice of AGM.\nProxy voting\nShareholders will not receive a hard copy form of proxy for the AGM in the post. Instead, shareholders will be able to vote electronically using the link\nwww.signalshares.com\n. Proxy votes must be received no later than 11.30 a.m. on 21 June 2024.\nShareholders may request a hard copy form of proxy directly from the Registrars, Link Group, on Tel: 0371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales. Alternatively, shareholders can vote by downloading the new app, LinkVote+, on Apple App Store or Google Play and following the instructions.\nEnquiries:\nVerici Dx\nwww.v\nericidx\n.com\nSara Barrington, CEO\ninvestors@vericidx.com\nJulian Baines, Chairman\nSinger Capital Markets (Nominated Adviser & Broker)\nTel: +44 20 7496 3000\nAubrey Powell / Sam Butcher\nAbout Verici Dx plc\nwww.vericidx.com\nVerici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.\u00a0The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.\nThe foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNOALFLFXZELEBBZ",
          "content_length": 3684
        },
        "ingested_at": "2026-01-16T22:48:57.958874Z"
      },
      {
        "event_id": "RNS-31st May 2024-launchof",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958887Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Launch of patient-focused educational tool",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/launch-of-patient-focused-educational-tool-uejuc7p8p5pa89p.html",
          "rns_number": "RNS Number : 6504Q",
          "full_content": "31 May 2024 10:00\nRNS Number : 6504Q\nVerici Dx PLC\n31 May 2024\nNon-regulatory announcement\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nVerici Dx Launches\nan interactive patient-focused educational tool, the Patient Journey\nProviding a detailed overview of all stages of the kidney transplant journey\nVerici Dx (AIM: VRCI),\u00a0a developer of advanced clinical diagnostics for organ transplant, is pleased to announce the introduction of its\npatient-focused education resource, for use by patients,\ncare givers\nand\ntransplant teams in the form of a new\ndedicated website showing the kidney transplant patient\njourney\u00a0(\nhttps://patientjourney.vericidx.com\n). This online tool is designed to illustrate a generalised pathway for patients as they consider their kidney healthcare and offer a platform for patients to share their own experiences digitally including video clips.\u00a0It also includes video clips from transplant team members to share their thoughts on what to expect.\nThis enhancement is part of Verici Dx's ongoing commitment to supporting patients with comprehensive and accessible information.\nAt Verici Dx, we are committed to improving patient outcomes and believe that access to reliable, detailed information is a cornerstone of effective healthcare.\nThis new tool provides a detailed overview of all stages of the kidney transplant journey-from the initial diagnosis and treatment\nof kidney disease,\nthro\nugh early-stage monitoring and on to long-term care\nafter a kidney transplant. This resource is designed to empower patients\nand caregivers with knowledge and understanding, helping them navigate the complexities\nof kidney disease and transplantation with confidence.\nThe new section of the website is intended to offer a valuable tool for those seeking guidance at each step of their journey and we look forward to demonstrating this to patients at the Transplant Games\n, which will take place in Birmingham Alabama, from 5\n- 10 July 2024\n. We\ninvite everyone interested in learning more about the kidney transplant process to join us there or visit our updated website at\nhttps://patientjourney.vericidx.com\n.\nCommenting on the update, Andrew Silverman, Director of Scientific Communications, said:\n\"We are excited to launch this new section of the website as it directly aligns with our mission to enhance patient care and support. It ensures that patients\nand caregivers have access to the latest information and best practices for kidney transplant care\n, and we are confident that it will improve communication between all parties involved in the journey\n.\"\nEnquiries:\nVerici Dx\nwww.v\nericidx\n.com\nSara Barrington, CEO\ninvestors@vericidx.com\nJulian Baines, Chairman\nSinger Capital Markets (Nominated Adviser & Broker)\nTel: +44 20 7496 3000\nAubrey Powell / Sam Butcher\nAbout Verici Dx plc\nwww.vericidx.com\nVerici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.\u00a0The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.\nThe foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAVFLBXZELEBBD",
          "content_length": 4540
        },
        "ingested_at": "2026-01-16T22:48:57.958899Z"
      },
      {
        "event_id": "RNS-30th May 2024-2023annu",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958911Z",
        "source": "LSE_RNS",
        "data": {
          "title": "2023 Annual Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/2023-annual-results-jntjp06mhqygihs.html",
          "rns_number": "RNS Number : 3597Q",
          "full_content": "30 May 2024 07:00\nRNS Number : 3597Q\nVerici Dx PLC\n30 May 2024\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\n2023 Annual Results\nStrong delivery on key strategic objectives\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\u00a0announces its audited final results for the year ended 31 December 2023.\nStrategic progress\n\u00b7\nSecured a global licensing and commercialisation agreement with One Lambda, Inc., (a company within Thermo Fisher Scientific, Inc) (\"Thermo Fisher Scientific\") in November 2023. This\nexclusive license grants Thermo Fisher Scientific the rights to commercialise the assay for pre-transplant risk assessment for further development as a Laboratory Developed Test (\"LDT\") in its CLIA laboratory in the U.S., as well as the sole right, but not the obligation, to manufacture, distribute and sell the assay worldwide.\n\u00b7\nGranted Thermo Fisher Scientific a non-exclusive license for access to a portion of the Company's urine samples, demonstrating the additional value in Verici Dx's research assets (data and sample).\n\u00b7\nAnnounced the successful clinical validation of ClaravaTM, the\npre-transplant prognosis test for the risk of early acute rejection (\"EAR\") when in recipient of a kidney transplant from a deceased donor.\n\u00b7\nCommercially launched Tutivia\nTM\n, the\npost-transplant diagnostic focused upon acute cellular rejection (\"ACR\") including sub-clinical rejection.\n\u00b7\nData from the successful international validation study for\nTutivia\nTM\nwas peer reviewed and published in\nThe American Journal of Transplantation\nin December 2023.\n\u00b7\nCompleted enrolment for the longer duration clinical validation study for the third product, Protega\nTM\n,\na liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. Post year-end, the scheduled 12-months post-transplant visits for enrolled patients were completed. To conclude the study visits for the clinical trials, there will next be visits at 24-month post-transplant to further support the long-term outcomes data. An interim update on ProtegaTM is expected in the first half of 2025.\n\u00b7\nReceived confirmation and finalised pricing\nfor both Tutivia\nTM\nand Clarava\nTM\nfrom\nthe Centers for Medicare & Medicaid Services (\"CMS\") at the proposed $2,650 rates, effective from 1 January 2024\n\u00b7\nPost period end, announced a collaboration with The Westmead Institute for Medical Research based in Sydney, Australia, on a newly awarded, 4-year federal research grant allowing the Company to contribute to significant advancements in biomarker development and for Verici Dx to expand its reach in Australia.\n\u00b7\nPrevious guidance and assumptions regarding the extended cash runway as a result of the Thermo Fisher Scientific transaction and the successful equity fundraise are unchanged. This is discussed further below.\nOperational highlights\n\u00b7\nReceived further recognition for the clinical laboratory which has now achieved CLIA certification in respect of samples from patients located in 51 states\nwith the process underway for accreditation in the final state of New York where there are several additional steps. This means clinicians at transplant medical centres in these 51 states are now enabled to order Verici Dx's transplant tests, expanding the Company's commercial reach.\n\u00b7\nGained accreditation for the laboratory from the\ninternationally recognised College of American Pathology (CAP).\n\u00b7\nSecured additional protection of the Company's intellectual property, registering two significant new patents in the United States.\nThe patents cover broad molecular methods for predicting and diagnosing subclinical and clinical acute rejection, both pre- and post- kidney transplant by algorithmic analysis of gene sets and underpin both of Verici Dx's lead products, Tutivia\u2122 and Clarava\u2122, and provide protection until 2036 and 2039 respectively. The patents underpinning Tutivia\u2122 have also been previously granted in Europe, China and Australia.\n\u00b7\nAchieved ISO 27001 certification for our Information Security Management System demonstrating\nthe robustness of the systems and processes.\nFinancial highlights\n\u00b7\nAdjusted EBITDA\n1\nloss of $7.6m (2022: loss of $10.5m).\n\u00b7\nCash balance at 31 December 2023 of $2.6m (2022: $9.8m).\n\u00b7\nSignificantly strengthened our financial position going forward through both the Thermo Fisher Scientific agreement and fundraising activities.\n\u00b7\nRaised a total of \u00a36.5m in gross proceeds (\u00a36.0m net) through the issue of 72,222,222 new ordinary shares via a Placing and Retail Offer in early 2024.\n\u00b7\nAs a result of the Thermo Fisher Scientific transaction and the successful equity fundraise, the Company forecasts the cash runway has been extended into 2026. This reflects a number of assumptions relating to the timing and/or quantum of the additional milestone payments under the Thermo Fisher Scientific transaction, the ongoing rollout of TutiviaTM, as well as other licensing revenues and research collaborations.\nBusiness update and investor",
          "content_length": 87567
        },
        "ingested_at": "2026-01-16T22:48:57.958927Z"
      },
      {
        "event_id": "RNS-24th May 2024-newdatat",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958940Z",
        "source": "LSE_RNS",
        "data": {
          "title": "New data to be presented at ATC",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/new-data-to-be-presented-at-atc-nhe3wt1zvnjd4wx.html",
          "rns_number": "RNS Number : 7206P",
          "full_content": "24 May 2024 07:00\nRNS Number : 7206P\nVerici Dx PLC\n24 May 2024\nNon-regulatory announcement\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nNew data to be presented at American Transplant Conference\nImportant potential role of TutiviaTM as a novel risk assessment tool in the context of delayed graft function (\"DGF\")\nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\u00a0announces it will attend the American Transplant Congress (\"ATC\") in Philadelphia hosted by the American Society of Transplantation and the American Society of Transplant Surgeons from 1-5 June 2024. We look forward to sharing our work on \"\nPerformance of Next-Gen Sequencing Biomarker TutiviaTM in the Setting of Kidney Delayed Graft Function\" on Saturday 1 June 2024,\nas well as meeting with others to discuss ideas and opportunities at\nATC_Booth-215.\nATC provides a forum for the exchange of new scientific data and clinical information relevant to solid organ and tissue transplantation. The event brings together transplant physicians, scientists, nurses, organ procurement personnel, pharmacists, allied health professionals and other transplant professionals.\nCommenting on the conference, Dr. Joshua Lee, VP Medical Affairs said:\n\"DGF is a condition that can lead to a higher risk of rejection. Identifying which patients are likely to experience rejection in this population is an unmet need in transplantation. Verici Dx is excited to present findings in this population from our clinical trial at this prestigious conference.\nATC in Philadelphia is such a great venue to bring together the global transplant community. We are looking forward to discussions in the halls and seeing friends in the community, as well as learning about new developing approaches to treatments and diagnostics that can make the lives of transplant patients better.\"\nEnquiries:\nVerici Dx\nwww.v\nericidx\n.com\nSara Barrington, CEO\ninvestors@vericidx.com\nJulian Baines, Chairman\nSinger Capital Markets (Nominated Adviser & Broker)\nTel: +44 20 7496 3000\nAubrey Powell / Sam Butcher\nAbout Verici Dx plc\nwww.vericidx.com\nVerici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.\u00a0The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.\nThe foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAFLFSSELIVFIS",
          "content_length": 3823
        },
        "ingested_at": "2026-01-16T22:48:57.958952Z"
      },
      {
        "event_id": "RNS-27th Feb 2024-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958965Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-qj84316b463g0rx.html",
          "rns_number": "RNS Number : 6711E",
          "full_content": "27 Feb 2024 16:08\nRNS Number : 6711E\nVerici Dx PLC\n27 February 2024\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BM8HZD43\nIssuer Name\nVERICI DX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nHarwood Capital LLP\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\nName\nCity of registered office\nCountry of registered office\nHarwood Capital LLP\nLondon\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nNorth Atlantic Smaller Companies Investment Trust\nLondon\nUnited Kingdom\nHarwood Capital LLP\nLondon\nUnited Kingdom\nOryx International Growth Fund Limited\nGuernsey\nGuernsey\n5. Date on which the threshold was crossed or reached\n20-Feb-2024\n6. Date on which Issuer notified\n27-Feb-2024\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n15.521700\n0.000000\n15.521700\n37646569\nPosition of previous notification (if applicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BM8HZD43\n8000000\n3.298410\nGB00BM8HZD43\n23000000\n9.482910\nGB00BM8HZD43\n6646569\n2.740380\nSub Total 8.A\n37646569\n15.521700%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nChristopher Harwood Bernard Mills\nHarwood Capital LLP\n2.740380\n2.740380%\nChristopher Harwood Bernard Mills\nNorth Atlantic Smaller Companies Investment Trust\n9.482910\n9.482910%\nChristopher Harwood Bernard Mills\nOryx International Growth Fund Limited\n3.298410\n3.298410%\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n27 February 2024\n13. Place Of Completion\nLondon Stock Exchange\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFIRFDIDFIS",
          "content_length": 4263
        },
        "ingested_at": "2026-01-16T22:48:57.958977Z"
      },
      {
        "event_id": "RNS-22nd Feb 2024-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.958989Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-ww7hfa6oufloean.html",
          "rns_number": "RNS Number : 0122E",
          "full_content": "22 Feb 2024 07:00\nRNS Number : 0122E\nVerici Dx PLC\n22 February 2024\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BM8HZD43\nIssuer Name\nVERICI DX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights; An event changing the breakdown of voting rights\n3. Details of person subject to the notification obligation\nName\nOctopus Investments Limited\nCity of registered office (if applicable)\nLondon\nCountry of registered office (if applicable)\nEngland\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n20-Feb-2024\n6. Date on which Issuer notified\n21-Feb-2024\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n8.920000\n0.000000\n8.920000\n21645096\nPosition of previous notification (if applicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BM8HZD43\n21645096\n8.920000\nSub Total 8.A\n21645096\n8.920000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nOctopus Capital Limited\nOctopus Investments Limited\n8.920000\n8.920000%\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n21-Feb-2024\n13. Place Of Completion\n33 Holborn, London, EC1N 2HT\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFFFSLFRILFIS",
          "content_length": 3938
        },
        "ingested_at": "2026-01-16T22:48:57.959001Z"
      },
      {
        "event_id": "RNS-21st Feb 2024-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.959014Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-iz0hza78mku0ak4.html",
          "rns_number": "RNS Number : 9925D",
          "full_content": "21 Feb 2024 16:53\nRNS Number : 9925D\nVerici Dx PLC\n21 February 2024\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BM8HZD43\nIssuer Name\nVERICI DX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nAmati Global Investors Limited\nCity of registered office (if applicable)\nEdinburgh\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nAmati AIM VCT plc\nLondon\nUnited Kingdom\n5. Date on which the threshold was crossed or reached\n20-Feb-2024\n6. Date on which Issuer notified\n21-Feb-2024\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n6.230000\n0.000000\n6.230000\n15111111\nPosition of previous notification (if applicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BM8HZD43\n15111111\n6.230000\nSub Total 8.A\n15111111\n6.230000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n21-Feb-2024\n13. Place Of Completion\nEdinburgh, UK\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFSRFAILFIS",
          "content_length": 3703
        },
        "ingested_at": "2026-01-16T22:48:57.959026Z"
      },
      {
        "event_id": "RNS-21st Feb 2024-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:48:57.959038Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/holdings-in-company-tddeygicjovkthm.html",
          "rns_number": "RNS Number : 8337D",
          "full_content": "21 Feb 2024 07:00\nRNS Number : 8337D\nVerici Dx PLC\n21 February 2024\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nVerici DX\nplc\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nUnicorn Asset Management Limited\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUnicorn AIM VCT plc\nCity and country of registered office (if applicable)\nNewton Abbot, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n20 February 2024\n6.\nDate on which issuer notified (DD/MM/YYYY):\n20 February 2024\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n8.39%\n8.39%\n20,350,771\nPosition of previous notification (if\napplicable)\n5.43%\n5.43%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nOrdinary shares GB00BM8HZD43\n20,350,771\n8.39%\nSUBTOTAL 8. A\n20,350,771\n8.39%\nB 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nX\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nSee Section 4\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nFigures are based on total voting rights of 242,541,467\nPlace of completion\nUnicorn Asset Management Limited, Preachers Court, Charterhouse, Charterhouse Square, London, EC1M 6AU\nDate of completion\n20 February 2024\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFIAFIIIFIS",
          "content_length": 4824
        },
        "ingested_at": "2026-01-16T22:48:57.959051Z"
      },
      {
        "event_id": "SOCIAL-11Nov20251025-B_Positi-65629280",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.151945",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Yes absolutely MASSIVE market and already well underway into tapping into it with the fast rollout into transplant centres",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.163536+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251205-oogleflu-15412538",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.151534",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Addressable market doesn\u2019t mean they capture all of it.  They might get 1 or 2 percent which is still sizeable if lucky. Even singer, their broker,  have only raised the sp to 3p. That\u2019s still 4 times current market cap! The other thing is will they need to expand the lab or open another one as their market share increases. They have got a captured market in that there is no competition and the tests are becoming mandatory. No plans to adopt outside the US yet. Maybe 20p in 5 years certainly not months I\u2019m afraid but good luck",
          "sentiment": 0.0,
          "engagement": "5,454",
          "price_at_post": "0.775",
          "thread_title": "RE: Quantifying the opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=D3DE9F2B-871D-47DE-96C8-2D6BB08D16A4"
        },
        "ingested_at": "2026-01-22T21:16:45.163519+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251217-B_Positi--4544271",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.151122",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.163501+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251236-geraldus-31325334",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.150671",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "With their 'AI' solution for optimising transplants,it is undoubtly an interesting opportunity here. They have spent millions on this and they are confident that it is payback time. With no competition at this level,it could possibly become the defacto standard.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.163483+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251239-donmac10-91654099",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.150257",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "American market waking up to the potential with Verici dx in their own backyard They love an AI stock.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.163464+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251241-B_Positi--7422878",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.149838",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Geraldus Tutivia is the standard now. Hence why Thermo-Fisher has gone all in and is backing all the way. Market slowly beginning to wake up that this company is grossly undervalued. I mean the FDA approval, ip, tech alone is worth multiples and then whack on the huge growth already in 2025 and coming in 2026 with over 30 transplant centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.163446+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251247-geraldus-10014623",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.149420",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "Still early days here,and they will have to take some market share from the incumbent bio markers. Shaping up well so far and with a miserly market cap in comparison with other counters.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.825",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.163429+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251256-donmac10--4025480",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.148999",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "1.20p close today and more updates in coming days on quickly to 2.00p",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.163411+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251354-donmac10--6884988",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.148595",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "It feels to me we are about to get a trading update on testing numbers shortly .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.163392+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251448-oogleflu-23470888",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.148184",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Tom. I know exactly what you\u2019re saying is correct . Unfortunately risk appetite is much lower in the UK probably because the FA are like a bunch of frightened rabbits. Fund managers continue to unwind oversold positions in uk to chase  the way overpriced \u2018American dream stocks\u2019 which are overdue a big correction there by loosing even more of the inadequate fund managers clients money. It\u2019s not all Uk stocks but quite a few as admitted in an interview recently with a fund manager. Certainly since the pandemic Uk stocks are valued much more realistically i.e. sound balance sheet which Vrci  now has, realistic forecast which Vrci now has, realistic targets for growth which Vrci now has. But we don\u2019t tend to look further than a year ahead. One step at a time . There will be /is FOMO with a stock like Vrci which will cause some volatility till they establish a more constant earnings stream.",
          "sentiment": 0.0,
          "engagement": "5,454",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.163374+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250809-2Phones-22241066",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.147763",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Interesting news today \u2013 initially I thought why? This has little bearing on shareholders interests \u2013 however, on further concideration, while successful audits add little to the bottom line or turnover or even shareholder value \u2013 in our case it is very much a Critical Failure Factor, where failure to pass a quality audit could seriously damage the company in the short/medium term.  Also it does point to a well run, disciplined business. So well done Verici.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.95",
          "thread_title": "RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-22T21:16:45.163356+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250830-donmac10-40854907",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.147351",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Tells me ,anyone looking to make money would be well served to get in now .Futher big rise going into year end.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.95",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-22T21:16:45.163338+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250843-donmac10--2970194",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.146933",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Verici also more forthcoming informing the market with updates .Beats last years 6 month radio silence .Just waiting now for testing update which i know will further boost price.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.925",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-22T21:16:45.163320+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250845-donmac10--3141623",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.146516",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Analysts expecting 3p per share next year big upside from here.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.90",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-22T21:16:45.163302+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250856-2Phones-34075468",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.146091",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac agreed - two of the latest RNS are very positive about the rate of revenue growth and market penetration - can't help but think the next sales based RNS will be a gamechanger.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.875",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-22T21:16:45.163284+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251522-Silverbl-25681160",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.145680",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Based on what we already know - VRCI sold c.600 Tutivia tests in H1 2025 - securing revenue of $1.2m ($2k per test - blend of public and private payers). They sold same in Q3 - so lets assume pro-rata they secured a further $600k revenue. Sara B confirmed FY Tutivia target was $3.2m - so that leaves $1.4 revenue to be secured in Q4 - or c.700 tests at $2k. Seems a huge leap - or possible they are looking at a slight increase to average test $ - although Prime Health RNS appears to push towards discounted volume in private market. She has certainly set high expectations for Q4 trading. If this is achieved it will be a significant acceleration - and will be crucial in supporting the share price/market cap as the company requires additional funding in the next 4/5 months. Additional licensing revenue from Thermo (c.$4m received to date - $3.3m in 2024 and $0.75m in 2025) remains on hold as they progress their approach to the PTRA test. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.725",
          "thread_title": "2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-22T21:16:45.163266+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251604-Fevertre-12151854",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.145267",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Worryingly her bullishness has cost investors dearly so far. Apart from having virtually no skin in the game she hasn't been gifted,  or regifted (look at the outrageous revision of option pricing). The fact that the sp is still at 3/4 of a penny tells you everything you need to know about how the market views her!",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-22T21:16:45.163248+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251627-donmac10--2846553",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.144848",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "markets falling and the doom and gloom ****roaches appear in force.sell up ,thats even if yeh hod any and gie us aw peace!",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-22T21:16:45.163230+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251644-Fevertre--8556904",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.144432",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Nonsense Donmac.....look at the maths around Barrington's targets: On my maths I don't see how she hits revs from Tutivia $3.2m... Tutivia:  1H Revs: $1.16m: 591 tests @ ave $1900 ($1.16m divided by 591) 2H Revs:  3Q Tutivia same rate as Q1/Q2 ..c300 tests at 1900 = $570k  ...so to meet her target she needs to sell c$1.5m of tests. Assume same ave price of $1900....she needs to sell c790 tests....that's a massive uplift, even with onboarding another 9 more centres...",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-22T21:16:45.163212+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251647-Fevertre-25711722",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.143999",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "She has never fully explained the onboarding process. If a new centre gets onboarded, typically how long does it take for clinicians to order first tests",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-22T21:16:45.163194+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251709-Silverbl--3589768",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.143585",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not a fan to date either fevertree - its been a disaster for all shareholders here - but I still hold a position here and am trying to look forward not back given the past is what it is. If Q4 goes well I expect a trading update early 2026 - which doesn't usually happen but positive momentum will be required to avoid a total wipe out in any subsequent capital raise. Failure to deliver (again) then more questions will be raised on leadership competencies.  SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-22T21:16:45.163176+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251734-Mikemine-14085563",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.143173",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "VRCI is a small company so hiring an extra 3 salespersons is huge for them and points to their determination to hit their target. It's a big ask but you can be sure they recognise that their credibility is on the line. From a practical point of view, hiring new salespeople  takes time for their impact to come through. They have to get used of the systems, the product and VRCI's method of selling. I wish them luck and, if they do reach their target, it will be noticed by the Market.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-22T21:16:45.163157+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20250050-donmac10--3486966",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.142739",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sell up move on thank you.....give me the chance ar more aroon the 55 mark slanj .And a will catch yeh in wetherspoons oan the wae otta rah ritz.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-22T21:16:45.163137+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251059-Silverbl--1146209",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.142321",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There you go donmac almost at your buy price already. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-22T21:16:45.163090+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251147-Fevertre--3909270",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:45.141873",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "The Board and non-execs have overseen an absolute shamble here. Barrington completely unaffected by disastrous dilution as she has virtually no bloody shares in teh company she purports to lead.  The CFo isnt fit for purpose frankly. The Q4 figs appear to be the stuff of fantasy - I would give more creedance if  Barrington was able to explain how she gets to the forecast but she appears to be just making it up as she goes along... we have no timelines on onboarding; Barrington cant set out how she arrived at the numbers... she continues to be utterly hopeless as the CEO of supposedly a cutting edge business.",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-22T21:16:45.163072+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251148-Fevertre--4301596",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.318278",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Just out of interest what are Barrington's competencies?",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-22T21:16:45.163053+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251456-Mikemine-58494091",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.317850",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, your posts have got  very repetitive and quite frankly, boring. Unless your rants help your mental state I for one would be grateful if you would keep your posts to new views or information.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-22T21:16:45.163035+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251031-B_Positi--4544271",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.317442",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.163017+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251039-donmac10-84492811",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.316993",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Expecting a trading update in the run up to xmas should make for good reading!",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162999+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251045-donmac10-81700851",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.316578",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And its beginning to look like word is out?",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162981+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251104-B_Positi-70376372",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.316168",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "So with less than 10% of transplant centres onboarded and already at the start of the mass rollout they averaged about 300 tests per quarter in Q1, Q2 and Q3, just short of 900, vs 334 for the entirety of 2024, representng significant growth. We now know they are at at least 16% of transplant centres onboarded now (less than 10% for Q1, Q2, Q2, perhaps around 20% now and are increasing this fast. You quickly realise how mad the revenues can become here at $2,650 a test with the medicaid coverage +Thermo Fisher licencing revenues. I know many, many pharma stocks that have literally $0 revenue, no proven tech, no FDA approval, no big deal with a giant like this does with Thermo Fisher that are trading at many multiples of the Verici market cap.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162963+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251235-B_Positi-73439209",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.315732",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Donmac, absolutely buzzing for the trading update this month Hopefully see's this head back to the 3 to 5p level",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162945+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251443-donmac10-64394260",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.315318",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Nice 2mill buy this morning.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162927+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251230-tbcx-66568975",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.314888",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Buying pressure certainly returning this week, this remains extremely undervalued.",
          "sentiment": 0.0,
          "engagement": "748",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162909+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251234-B_Positi-52196303",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.314480",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "MMs caught wind of an update? I'm amazed this isn't over 2p at least. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162891+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251245-donmac10-67239864",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.314012",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Update this week and more deals with distributors .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162872+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251320-B_Positi--9211653",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.313600",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Yes it was due. Thermo-Fisher $220BILLION backing this and tied in. Update on them or something new will wake the market up.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162854+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251535-Silverbl--1196178",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.313180",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Would be unusual for a trading update pre-xmas imo although any kind of an update in relation to hitting revenue targets would assist progress here - the bar has been set very high by CEO. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162836+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251941-donmac10-36346014",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.312759",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Company is no longer research orientated so past rns at this time of year irrelevant trust me as tests ramp up as they will be the company will be eager to broadcast positive newsflow asap.noh whit a meen an that man getmeh!",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162818+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251945-donmac10--4910201",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.312350",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "3p per share nailed on short term if you guys sit oan yer tuffetts like miss muffet know whit ah mean?",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162800+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251953-B_Positi--7167188",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.311925",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Will add another 2m sub 1p Way too cheap here for me personally.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162782+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251227-B_Positi--5574213",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.311508",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I'm personally amazed more aren't piling in whilst under 1p and this isn't at 3-5p already. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162764+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251244-B_Positi-72662353",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.311043",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Once it breaks 1p it will fly to 2p and then 3p gets smashed with ease considering the test orders are going to be around 300-400% from the digging below. 3p as a base and then a move back to 5-10p.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162746+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251255-donmac10--2152827",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.310621",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Genincode signed a deal with Thermo read across to Verici Verici so undervalued at the moment something has to give.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162727+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251302-B_Positi-23941574",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.310203",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Wow now way just saw that. Huge implications for Thermo and its partners!",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162709+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-B_Positi-32770625",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.309766",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I would wager a big Thermo-Fisher update is due here. Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162691+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251547-B_Positi-65101166",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.309305",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162672+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251441-Silverbl--1066891",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.308829",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - FYI Thermo Fisher are not currently involved in Tutivia - so they are not involved in any roll out. Despite claims here to the contrary there has been no trading update - so we await evidence that Q4 delivers the level of sales anticipated by the CEO on achieving the 2025 Tutivia revenue target - which as you note would be a significant increase on 2024 sales. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162654+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251216-Sandyman-43254626",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.308410",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "Is the placing going to be at 0.25p or 0.5p? Or both?",
          "sentiment": 0.0,
          "engagement": "991",
          "price_at_post": "0.775",
          "thread_title": "Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-22T21:16:45.162636+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251243-Romanby-15459236",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:42.307946",
        "source": "LSE_CHAT",
        "data": {
          "author": "Romanby",
          "content": "No placing you idiot",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-22T21:16:45.162619+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251522-Silverbl-82920277",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.622311",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There will be a placing in early 2026 - probably March/April time. The placing will of course be determined by the prevailing share price at the time. And that in turn will reflect the numbers for FY 2025 - there is a lot of expectation here so lets see what the company has to say for itself hopefully with a trading update in January. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-22T21:16:45.162601+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251557-B_Positi-65101166",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.621891",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162583+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251618-Silverbl--2053717",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.621434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Same old nonsense B_Positive. Thermo are not involved in Tutivia. Stop spreading false information. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162564+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251728-2reincar-20930412",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.621000",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Agree Silverblade. We could have one in Aprilish at 0.5p and one in Octoberish at 0.25p and then a rocket to + 2p ?",
          "sentiment": 0.0,
          "engagement": "5,828",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-22T21:16:45.162546+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20250753-2Phones--1703884",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.620502",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I don't agree - the operational update earlier this year had a predicted cash runway to H2 next year - when you couple that with the recruitment of 2 sales people and a director of clinical partnerships, I would anticipate growth in cash inflow.  However, they are a small team and they are going to have to increase production to accommodate the anticipated sales.  This will need funding, but where they get it is uncertain \u2013 one option being a placing.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-22T21:16:45.162528+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251223-Silverbl-79753361",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.620070",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "2Phones - from the company itself: \" With minimum gross proceeds from the Placing and Subscription of \u00a35 million, the Company's cash runway will be extended to mid Q2 2026.\". Hence my thinking spring will be the time to raise. And yes revenue is expected to increase (we will know by how much in a few weeks) - but annual expenses are c.$9m - so sales would need a dramatic (and unlikely) increase to negate the need for more funds. And you seem to agree that a placing is an option (imo the only likely one and the route the company has taken to date in all its efforts to secure more funding). So not sure what you were disagreeing with? SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-22T21:16:45.162510+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251515-B_Positi-85708779",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.619648",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162491+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261022-2reincar-12624976",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.619113",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "At 0.25p?",
          "sentiment": 0.0,
          "engagement": "5,828",
          "price_at_post": "0.725",
          "thread_title": "Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-01-22T21:16:45.162472+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20260629-2Phones--4927669",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.618690",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "How can any one disagree with such a cogent arguement - and clearly not the rantings of a one track numpty.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.725",
          "thread_title": "RE: Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-01-22T21:16:45.162454+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261210-B_Positi-85708779",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.618277",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162436+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-2reincar--6213777",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.617818",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Conversions this summer will see us at sub 0.25p!",
          "sentiment": 0.0,
          "engagement": "5,828",
          "price_at_post": "0.75",
          "thread_title": "100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-01-22T21:16:45.162419+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261228-B_Positi--4358262",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.617404",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162401+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261346-Silverbl--2960483",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.616942",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Despite the view expressed by several contributors here we have heard nothing from the business on Q4 trading. Not unexpected - if there was anything to report on I would expect to hear later on in January. The issue looming very shortly relates to the required fund raising. In previous years the company has elected not to divulge FY trading until May.  This is likely to be beyond the point at which the company runs out of cash. We should therefore be able to read the signals loud and clear - no trading update - then Q4 has not delivered the targeted sales and the fund raise will be brutal.  If a positive Q4 trading update is issued then there should be a healthy price response despite the recognition funds will still be required. Remember last year the first fundraise was at 9p - then 0.5p after bewildering timing mismanagement by the company.  All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: 100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-01-22T21:16:45.162382+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261401-B_Positi--4782374",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.616533",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Cashed up until the end of 2026 and now they've been securing record orders as per below. Next time they raise it will be in the pennies, which is what they will want given the new option prices. Test update going to drop soon. More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162364+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261402-Mikemine--1475695",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.616056",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "They've set themselves a big revenue target of over \u00a33mn for 2025. Small in world terms but a big % increase for VRCI. Should they be chastised if they do not reach the target or should it be viewed in the context of what they do achieve and what they forecast for this year? Getting close to \u00a33mn would be an achievement in my book as that would point to things being on track for further increases especially as the new sales guys have probably only just got their acts together and their contacts in line. Not sure what to think of the Thermo-Fisher deal and its seemingly lack of traction. Big companies are not nimble nor quick so the jury's out on that one for me. My guess is for an update this month and it will be positive but will not please everybody.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162346+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261416-B_Positi--2426722",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.615648",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10 centres onboarded. It must now be around 25-35 going by the last report.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162328+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261518-Silverbl-68734612",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.615177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "No licencing revenue in H2 2025 and average received revenue per test is $1900. Do some actual research please. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162311+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261523-Silverbl--1274023",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.614739",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Mikemine -  your points are valid - but highlight one of the main issues here. Why set a target and fail. Undermines confidence, craters the share price, makes fund raising tricky and makes investors wary on growth. Much better to overdeliver on achievable targets than underdeliver? But maybe we will be get a pleasant surprise. Thermo are just doing their own thing on the PRTA at present. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162293+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261524-B_Positi--7445786",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.614324",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Nope it's $2,650 as per the Medicare coverage RNS and more recently as per the HY report. \u00b7 Lead product Tutivia\u2122 attained Medicare coverage at $2,650 per test, covering a national estimate of 68% of all US transplant tests and commercial payor reimbursement applications are underway They receive licencing revenues both H1 and H2. It was $750k in H1.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162276+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262026-Silverbl--5361030",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.613884",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not really sure why I need to explain this, but here you go B_Positive. Your bullet point regarding Tutivia sums the position up very well. Transplant centres service both Medicare patients and private paying patients. So whilst the Medicare payment of $2650 is being provided by the US healthcare system for patients who benefit from the Medicare and Medicare plus programmes - there are actually six key revenue streams for test sales of which Medicare is one (albeit the largest - 68% of tests being undertaken are covered by Medicare seems to be the claim from the company). Private payers (via healthcare insurance) do not pay the $2650 - they receive discounts. Clinical trials pay nothing. And there others. If you divide the H1 Tutivia revenue of $1.16m by the 591 tests in H1 it comes out at $1962 . That is the current revenue reality for test sales. The recent RNS highlighting the agreement with Prime Health Services is all about trying to establish consistent pricing of the Tutivia test with the private payment market and clearly with the goal to increase current pricing which is diluting the Medicare $2650. In relation to your H2 licencing point the following clarifies the position \" Thermo Fisher is investing in new research related to PTRA aimed at identifying the earliest stage at which the test can be utilised before transplantation. Consequently, the second milestone originally anticipated for 2025 will be delayed as we continue to collaborate on publishing clinical validation data and Thermo Fisher pursues these additional research efforts to help broaden utility and adoption of the assay.\" FYI the breakeven position for Verici is c.$12m - so that provides an indication of the revenue which is required from test sales, licence revenue, protega etc to cover vrci operating costs. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162258+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260205-donmac10--3520441",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.613448",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Where do you get the 12mill breakeven point? You sound like a bot with your precise figures. And you always have a way of sounding positive but are really negative .So cant be taken seriously .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162241+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260728-B_Positi--1929783",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.613011",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162223+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260830-Silverbl--4868608",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.612544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "$12m was a direct quote from Vrci CEO in latest Vox markets interview. As for my 'precise' figures - strangely enough when it comes to investing I prefer to deal in fact rather than making it up (refer B_Positive). As for my views on the business - I remain invested so I am hopeful there is a future here or would have taken my medicine and moved on. That does not mean to say I will not vocalise my thoughts on areas of mismanagement where the company could and should be doing better; or to call out posters who are just making it up as they go along. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162202+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261504-B_Positi--4093987",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.612126",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We should all be extremely excited having now onboarded over 30 transplant centres, up from 10 in 2024. We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,396",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162182+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261715-Silverbl--6507371",
        "event_type": "social_post",
        "date": "2026-01-22T21:16:38.611614",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - feel free to use the actual numbers in your updates. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 (INCORRECT: H1 actual revenue was $1.16m = $1962 average revenue per test). H1 2025 licencing revenue = $750,000 (CORRECT) Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. (Test numbers CORRECT. Centres INCORRECT - there were 21 onboarded at time of results). 286 x $2,650 = $757,900 (Likely INCORRECT based on average revenue per test of $1962 achieved in H1 2025 - likely revenue $560K). Q4 2025, 20 centres onboarded and let's be conservative and say 300 tests. (INCORRECT. There are now 30 centres onboarded. Company is targeting in the region of 750 tests in Q4 in order to meet its Q4 revenue target of c.$1.5m) 300 x $2,650 = $795,000 revenue (We will find out in due course what was achieved in terms of test numbers and average revenue per test) H2 2025 licensing revenue, let's be conservative and say $500,000. (INCORRECT. No licencing revenue will come from Thermo in H2) Combine all of that above and you get = $4.3mil or \u00a33.2m. (H1 revenue was $1.9m/ Q3 likely $560K. Q4 not yet reported. Company is targeting total FY 2025 revenue of $3.95m, comprising $3.2 Tutivia tests and $750K licencing revenue) Still nothing in the way of a trading update from the team at vrci. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-22T21:16:45.162159+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20251015-donmac10-43667803",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.212966",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And deep dive on open AI gives a value for vrci IP value at 3.77 pence per share.So if vaguely realistic means massive upside.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231895+00:00"
      },
      {
        "event_id": "SOCIAL-20Oct20251020-donmac10--7222341",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.212564",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And bio tech is starting to gain traction in US markets UK markets will follow.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231877+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250801-Cliveas--8626768",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.212160",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cliveas",
          "content": "So the BOD trash the shareprice and then award themselves adjusted options at a massive discount to current SP! Reward for abject failure imho! GL.",
          "sentiment": 0.0,
          "engagement": "7,911",
          "price_at_post": "0.725",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T21:27:10.231859+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250812-Silverbl-34158378",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.211731",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Another AIM company taking the michael. No regard for shareholders whatsoever but we knew that earlier this year with the fund raise shambles. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T21:27:10.231841+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250816-Karlvonw--4291775",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.211331",
        "source": "LSE_CHAT",
        "data": {
          "author": "Karlvonwise",
          "content": "Unsure what to think now.",
          "sentiment": 0.0,
          "engagement": "663",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T21:27:10.231823+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250846-bigpunt--4571740",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.210916",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Of course the exercise price should be reasonable, or the options do not function as an incentive. My issue is that there is no detail on vesting conditions.  However the timing is interesting, management obviously expect share price to boooooom",
          "sentiment": 0.0,
          "engagement": "354",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T21:27:10.231805+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250852-oogleflu-28079042",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.210512",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "8 percent of the company for one of the most spectacularly dreadful performances by directors is what Aim is all about. If at first you don\u2019t succeed award yourself a huge chunk of the company at a ridiculously low price risk free! Whoppee off to the races again Sara",
          "sentiment": 0.0,
          "engagement": "5,451",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T21:27:10.231787+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250853-tbcx-17859773",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.210092",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "No getting away from it, this is what Aim management tends to do. Will struggle to find one that doesn't award options at a board level. At least they have skin in game now and incentive to ramp this up so that if there is good news forthcoming, especially around Thermo Fischer JV, they'll want to ensure they're positioned beforehand like anyone else who has invested here. Bigger picture they are still delivering a commercial product with proven science that improves the outcome for patients undergoing transplants, in partnership with a company valued at $200bn+. The potential speaks for itself. Let's see what news they now deliver.",
          "sentiment": 0.0,
          "engagement": "748",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T21:27:10.231769+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250920-oogleflu-64661434",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.209668",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "It\u2019s in the rules gov. I had a holding in a company a few years ago after holding a placing they awarded themselves 10 percent of the company with free shares. Seems at lot more honest. I mean why come up with some derisory token price? Anyway it 5 bagged in 2 years. Things is they worked their socks off. Had to get rid of duff auditors, refinanced and built the business up into a leading international company. There could and should be scope to do that here with the amount already invested by shareholders.",
          "sentiment": 0.0,
          "engagement": "5,451",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T21:27:10.231751+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250943-donmac10-24234201",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.209260",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "7.9% to 8.3% dont know what all yer fussin is aboot just a normal realignment .Best to have a board pushing for success with skin in the game .Its no wonder 90% of PIs lose money nae patience !",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T21:27:10.231733+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251003-tbcx-14168200",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.208838",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Exactly donmac101. There is no point crying about options, especially an adjustment like this, that is the name of the game where Aim boards are concerned, just have to suck it up I'm afraid. Now they are aligned with other shareholders let's  see what they deliver.",
          "sentiment": 0.0,
          "engagement": "748",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T21:27:10.231715+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251624-HideInPl-64072390",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.208421",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Agree. Normal way of things. I'd sooner have an incentivised management team with renewed focus and drive than the opposite.",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T21:27:10.231698+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20250952-Cliveas--2027339",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.207998",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cliveas",
          "content": "incentivised how exactly when the options are already priced way below current sp? no sweat to them to increase the sp they don't need to. let's see if they take them up. **** poor as always. gl.",
          "sentiment": 0.0,
          "engagement": "7,911",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T21:27:10.231680+00:00"
      },
      {
        "event_id": "SOCIAL-1Nov20251128-Fevertre-59766934",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.207571",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Couldn\u2019t agree more! Having totally f***** up the fundraiser, which destroyed existing s/holders, Barrington who has virtually no shares in the company she\u2019s paid for herself, gets her options repriced ( no such luck for her bloody s/holders) and a ton more in the money options  Baines has the gall to suggest that this is an incentive. The woman trousered US$383,400 in 2024 ; the company has a grand total of 15\u2026.yes\u2026..15 staff!",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T21:27:10.231662+00:00"
      },
      {
        "event_id": "SOCIAL-1Nov20251131-Fevertre-31260110",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.207164",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Has it never occurred to you that this I actually a disincentive !!! She has been given free options that are already in the money. The woman is laughing at us as is Baines!",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T21:27:10.231644+00:00"
      },
      {
        "event_id": "SOCIAL-1Nov20252040-saxman30-72638886",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.206751",
        "source": "LSE_CHAT",
        "data": {
          "author": "saxman303",
          "content": "Me looking to top up on any dip in the price",
          "sentiment": 0.0,
          "engagement": "692",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T21:27:10.231626+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20250741-joeblog1-14702855",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.206345",
        "source": "LSE_CHAT",
        "data": {
          "author": "joeblog1000",
          "content": "Rns  sounds positive??!",
          "sentiment": 0.0,
          "engagement": "412",
          "price_at_post": "0.625",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=B6EBEEF8-AEC7-4979-A053-5E1A792DECCA"
        },
        "ingested_at": "2026-01-21T21:27:10.231608+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20250752-donmac10--2072068",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.205932",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "The company is gearing up to suprise on the upside big time.Much more consistent newsflow all positive .Tests in the market that a surgeon will need for much better patient outcomes life or death outcomes.Any sellers offloading now should well head examined springs to mind.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.70",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=B6EBEEF8-AEC7-4979-A053-5E1A792DECCA"
        },
        "ingested_at": "2026-01-21T21:27:10.231590+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20250829-B_Positi-90099995",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.205524",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Should be sitting at 3p to 5p right now. It's so undervalued it's ridiculous. Thermo Fisher licences due too Post period end the Company raised \u00a36.35m (gross) to support the scale up of revenues, extending the expected cash runway into H2 2026. They sold 591 tests in H1 2025. They sold just 334 for the entirety of 2024. Q3 sales inline with H1, Q4 big growth expected. Therefore H2 = 591+ it sounds like. They expect significant growth in H2 2025, which would suggest they will finish the year selling well north of 1000 tests. That would mean around 300-500% sales growth over 2024 if they sell 1000-1500 tests which is quite crazy. Then factor they have only just started the sales ramp up too and are expanding hard and fast. Also medicare coverage only kicked in end of April too so not reflected in the H1 results at all for the most part. Looks set for 1200-1500 tests sold an uplift of 400-500% over 2024 with massive onboarding of new test centres.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.625",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231571+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20250831-tbcx-65641676",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.205062",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Anything that reduces friction for getting the product to patients has to be a good thing. Plus US focus promising when it's the biggest healthcare market in the world. The company appear to be making significant strides in actually commercialising the offering, not something you see on a biotech with market cap this low",
          "sentiment": 0.0,
          "engagement": "748",
          "price_at_post": "0.625",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=B6EBEEF8-AEC7-4979-A053-5E1A792DECCA"
        },
        "ingested_at": "2026-01-21T21:27:10.231553+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20250833-B_Positi-16321331",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.204650",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "In a nutshell, they are looking at about 400-500% sales growth in 2025 over 2024 and that's before the full impact of the massive rollout in to dozens of centres is felt. We could quite quickly be trading over 10p again here",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.625",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231535+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20250840-donmac10--8477126",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.204238",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "The main positives is the constant newsflow .Last year at this time 1 rns in 6 months now 1 a week.Next rns will be large uptick in tests ordered  and well who knows where the share price goes.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.65",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231517+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20250842-donmac10-18304039",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.203819",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Question= What price Verici if it was listed on Nasdaq! Americans would be allover it .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231499+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20250850-donmac10-22302714",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.203403",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Ive left Uk markets over the last few months for the US markets AI boom but 1 Uk share i hold .Will give you 3 guesses.?",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231481+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20250851-B_Positi-28261899",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:10.202959",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "334 tests ordered for the whole of FY 2024. They make $2,650 per test. Q1+ Q2 = 591 Tutivia\u2122 tests ordered in H1 2025 Q3 = 286 tests ordered, as per investor presentation. Q1 + Q2 + Q3 = 877 vs 334 last year. As fo Q4:  Commercial scale-up of Tutivia test adoption, a test for acute rejection post transplant, has progressed in Q3, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from Q4 and the number of orders in Q3 were consistent with the previous two quarters. So they expect a big rise in orders in Q4. Assume it's about 350 tests to be conservative (likely higher given the number of new centres onboarded) then that is 1,227 tests for the entirety of 2025 compared to just about 300 in 2024. Then imagine the scale up in 2026. About $3.4mil revenue just from these tests + about $1.5mil licensing revenues from Thermo for 2025. The turnaround is hard and fast.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231461+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20250953-donmac10-80967127",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.682314",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Prime health have over 1 million healthcare providers in the US thats between 33 to 50 % of all providers total in America This is much bigger than has been factored in share price.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231443+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20250955-B_Positi--5738634",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.681894",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Donmac that is stunning. Excellent digging",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231425+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20251002-donmac10-21097354",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.681483",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And they are in talks as we speak with more providers.Plenty to look forward to! Exciting times for much needed best in class tests that will speak for themselves.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231407+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20251006-donmac10-21560203",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.681063",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "\"We look forward to updating shareholders fur mehr ahh rah same \" am gonny be rich cum rah spring!",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231389+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20251010-B_Positi--8600550",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.680653",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Summary of research. Thermo Fisher: $213B market cap on NASDAQ backing this company. 334 tests ordered for the whole of FY 2024. They make $2,650 per test. Q1+ Q2 = 591 Tutivia\u2122 tests ordered in H1 2025 Q3 = 286 tests ordered, as per investor presentation. Q1 + Q2 + Q3 = 877 vs 334 last year. As fo Q4: Commercial scale-up of Tutivia test adoption, a test for acute rejection post transplant, has progressed in Q3, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from Q4 and the number of orders in Q3 were consistent with the previous two quarters. So they expect a big rise in orders in Q4. Assume it's about 350 tests to be conservative (likely higher given the number of new centres onboarded) then that is 1,227 tests for the entirety of 2025 compared to just about 300 in 2024. Then imagine the scale up in 2026. About $3.4mil revenue just from these tests + about $1.5mil licensing revenues from Thermo for 2025. The turnaround is hard and fast. __ This is what excites me: *The addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Most of the orders you references was when the company only had about 5-7% centres onboarded and they are now at 16%, which is still just a fraction of the centres in the US. Then also consider international expansion. Also: Tutivia is the best in class. Also: Multiple tests per patient is essentially a requirement When you factor it altogether the market value down here is absolutely insane. Especially as the IP, tech, patents, FDA approval is all worth so much more. No wonder we have a monster in Thermo Fisher leading here __ Prime health have over 1 million healthcare providers in the US thats between 33 to 50 % of all providers total in America This is much bigger than has been factored in share price. And they are in talks as we speak with more providers.Plenty to look forward to! Exciting times for much needed best in class tests that will speak for themselves.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231371+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20251020-donmac10-74462325",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.680158",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Verici at this stage reminds me of a song. \"If you could see what I see\"",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231352+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20251056-donmac10--7957465",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.679739",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Nice 2mill buy at 8.25 somebody sees what i see.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231334+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20251212-Bobat123-88783780",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.679330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat1234",
          "content": "Verici Dx PLC, up 16% at 0.73p, 12-month range 6.50p-0.48p. The Cardiff, Wales-based developer of advanced clinical diagnostics for organ transplants signs a provider participation agreement with Prime Health Services. Prime Health is a US-based company focused on delivering data-driven solutions through its preferred provider organisation network. PPO networks negotiate on behalf of insurance companies to gain discounted pricing. Prime Health is one of the fastest-growing preferred provider networks in the US and has more than 850,000 providers, Verici says. The deal provides Verici with the opportunity to expand its patient scope, the firm adds. \"This agreement with Prime Health is an important milestone for Verici Dx, as we accelerate our commercial reach, expanding our patient network and supporting our approach to increased coverage from private payors,\" says Verici Dx Chief Operating Officer Patti Connolly.",
          "sentiment": 0.5,
          "engagement": "1,149",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231315+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20251257-donmac10--6872147",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.678906",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "10 -1 on the buy side ready for move up Vrci just needs to keep up the positive newsflow.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231298+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20251359-B_Positi--8600550",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.678493",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Summary of research. Thermo Fisher: $213B market cap on NASDAQ backing this company. 334 tests ordered for the whole of FY 2024. They make $2,650 per test. Q1+ Q2 = 591 Tutivia\u2122 tests ordered in H1 2025 Q3 = 286 tests ordered, as per investor presentation. Q1 + Q2 + Q3 = 877 vs 334 last year. As fo Q4: Commercial scale-up of Tutivia test adoption, a test for acute rejection post transplant, has progressed in Q3, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from Q4 and the number of orders in Q3 were consistent with the previous two quarters. So they expect a big rise in orders in Q4. Assume it's about 350 tests to be conservative (likely higher given the number of new centres onboarded) then that is 1,227 tests for the entirety of 2025 compared to just about 300 in 2024. Then imagine the scale up in 2026. About $3.4mil revenue just from these tests + about $1.5mil licensing revenues from Thermo for 2025. The turnaround is hard and fast. __ This is what excites me: *The addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Most of the orders you references was when the company only had about 5-7% centres onboarded and they are now at 16%, which is still just a fraction of the centres in the US. Then also consider international expansion. Also: Tutivia is the best in class. Also: Multiple tests per patient is essentially a requirement When you factor it altogether the market value down here is absolutely insane. Especially as the IP, tech, patents, FDA approval is all worth so much more. No wonder we have a monster in Thermo Fisher leading here __ Prime health have over 1 million healthcare providers in the US thats between 33 to 50 % of all providers total in America This is much bigger than has been factored in share price. And they are in talks as we speak with more providers.Plenty to look forward to! Exciting times for much needed best in class tests that will speak for themselves.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231279+00:00"
      },
      {
        "event_id": "SOCIAL-6Nov20251822-tbcx-27013281",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.677987",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Another strong day here and well deserved. New sale bods hired seem to be having tangible impact already. Very different from your usual London listed biotech at this sort of market cap with an idea that never leaves the lab. They are very well positioned here to ramp up rapid commercialisation of product in US. I see huge upside here.",
          "sentiment": 0.0,
          "engagement": "748",
          "price_at_post": "0.725",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=B6EBEEF8-AEC7-4979-A053-5E1A792DECCA"
        },
        "ingested_at": "2026-01-21T21:27:10.231261+00:00"
      },
      {
        "event_id": "SOCIAL-7Nov20250821-Bobat123-45555140",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.677574",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat1234",
          "content": "Code 2 getting printed.  Mms need shares",
          "sentiment": 0.5,
          "engagement": "1,149",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231244+00:00"
      },
      {
        "event_id": "SOCIAL-7Nov20250846-Bobat123-34579222",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.677168",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat1234",
          "content": "52 Week High\t6.12",
          "sentiment": 0.5,
          "engagement": "1,149",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231226+00:00"
      },
      {
        "event_id": "SOCIAL-9Nov20251447-B_Positi-88796873",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.676748",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI \u00a310m mcap AVCT \u00a3300m mcap I believe VRCI can do a 30x move from here and hit something akin to the AVCT market cap I",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231207+00:00"
      },
      {
        "event_id": "SOCIAL-10Nov20251446-Fevertre--5272701",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.676326",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Really? With 15 employees led by a CEO who absolutely destroyed shareholder value with the most botched raise ; who then got gifted in the money options; to replace the lot that were massively out of the money. This is a woman who hasn't purchased a single share outside of what she got gifted.....what have you been smoking?",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231189+00:00"
      },
      {
        "event_id": "SOCIAL-10Nov20251451-donmac10--1735456",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.675906",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Well sell up and F..k aff canny beh ars.d listening tae yer constant whining!",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231171+00:00"
      },
      {
        "event_id": "SOCIAL-10Nov20251458-Fevertre--7350214",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.675491",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Ahahhahahhah",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231153+00:00"
      },
      {
        "event_id": "SOCIAL-10Nov20251600-B_Positi--8600550",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.675067",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Summary of research. Thermo Fisher: $213B market cap on NASDAQ backing this company. 334 tests ordered for the whole of FY 2024. They make $2,650 per test. Q1+ Q2 = 591 Tutivia\u2122 tests ordered in H1 2025 Q3 = 286 tests ordered, as per investor presentation. Q1 + Q2 + Q3 = 877 vs 334 last year. As fo Q4: Commercial scale-up of Tutivia test adoption, a test for acute rejection post transplant, has progressed in Q3, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from Q4 and the number of orders in Q3 were consistent with the previous two quarters. So they expect a big rise in orders in Q4. Assume it's about 350 tests to be conservative (likely higher given the number of new centres onboarded) then that is 1,227 tests for the entirety of 2025 compared to just about 300 in 2024. Then imagine the scale up in 2026. About $3.4mil revenue just from these tests + about $1.5mil licensing revenues from Thermo for 2025. The turnaround is hard and fast. __ This is what excites me: *The addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Most of the orders you references was when the company only had about 5-7% centres onboarded and they are now at 16%, which is still just a fraction of the centres in the US. Then also consider international expansion. Also: Tutivia is the best in class. Also: Multiple tests per patient is essentially a requirement When you factor it altogether the market value down here is absolutely insane. Especially as the IP, tech, patents, FDA approval is all worth so much more. No wonder we have a monster in Thermo Fisher leading here __ Prime health have over 1 million healthcare providers in the US thats between 33 to 50 % of all providers total in America This is much bigger than has been factored in share price. And they are in talks as we speak with more providers.Plenty to look forward to! Exciting times for much needed best in class tests that will speak for themselves.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231134+00:00"
      },
      {
        "event_id": "SOCIAL-10Nov20251624-donmac10-26007572",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.674566",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "More PPA news this week.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231114+00:00"
      },
      {
        "event_id": "SOCIAL-10Nov20251712-B_Positi-43315393",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.674045",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "So with less than 10% of transplant centres onboarded and already at the start of the mass rollout they averaged about 300 tests per quarter in Q1, Q2 and Q3, just short of 900, vs 334 for the entirety of 2024, representng significant growth. We now know they are at at least 16% of transplant centres onboarded now (less than 10% for Q1, Q2, Q2, perhaps around 20% now and are increasing this fast. You quickly realise how mad the revenues can become here at $2,650 a test with the medicaid coverage +Thermo Fisher licencing revenues. I know many, many pharma stocks that have literally $0 revenue, no proven tech, no FDA approval, no big deal with a giant like this does with Thermo Fisher that are trading at many multiples of the Verici market cap.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231081+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20250826-donmac10--3355797",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.673616",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Verici is on the cusp of a major breakout .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231063+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20250840-B_Positi-13894059",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.673143",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Herd will be taking note when this is marching to 5p and again.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231045+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20250933-B_Positi--6495629",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.672698",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.231027+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251000-2Phones-59409704",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.672246",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Another way to look at the size of the opportunity in the US alone, is the number of Kidney transplants per year.  This stood at 27332 in 2023, and there were 90323 people on waiting lists in 2024.  If we get to enough of the providers and they use multiple tests per transplant the size of this will be huge.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.75",
          "thread_title": "Quantifying the opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=D3DE9F2B-871D-47DE-96C8-2D6BB08D16A4"
        },
        "ingested_at": "2026-01-21T21:27:10.231008+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251016-2Phones--4531874",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:07.671796",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I guess this is what comprises Sara Barrington\u2019s addressable market of $900m in the Half year report RNS on September 30.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.75",
          "thread_title": "RE: Quantifying the opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=D3DE9F2B-871D-47DE-96C8-2D6BB08D16A4"
        },
        "ingested_at": "2026-01-21T21:27:10.230990+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251025-B_Positi-71661639",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.368458",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Yes absolutely MASSIVE market and already well underway into tapping into it with the fast rollout into transplant centres",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230972+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251205-oogleflu-82804242",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.368034",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Addressable market doesn\u2019t mean they capture all of it.  They might get 1 or 2 percent which is still sizeable if lucky. Even singer, their broker,  have only raised the sp to 3p. That\u2019s still 4 times current market cap! The other thing is will they need to expand the lab or open another one as their market share increases. They have got a captured market in that there is no competition and the tests are becoming mandatory. No plans to adopt outside the US yet. Maybe 20p in 5 years certainly not months I\u2019m afraid but good luck",
          "sentiment": 0.0,
          "engagement": "5,451",
          "price_at_post": "0.775",
          "thread_title": "RE: Quantifying the opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=D3DE9F2B-871D-47DE-96C8-2D6BB08D16A4"
        },
        "ingested_at": "2026-01-21T21:27:10.230814+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251217-B_Positi--6495629",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.367621",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230794+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251236-geraldus--6667713",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.367174",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "With their 'AI' solution for optimising transplants,it is undoubtly an interesting opportunity here. They have spent millions on this and they are confident that it is payback time. With no competition at this level,it could possibly become the defacto standard.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230776+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251239-donmac10--9448870",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.366748",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "American market waking up to the potential with Verici dx in their own backyard They love an AI stock.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230758+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251241-B_Positi-77545565",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.366336",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Geraldus Tutivia is the standard now. Hence why Thermo-Fisher has gone all in and is backing all the way. Market slowly beginning to wake up that this company is grossly undervalued. I mean the FDA approval, ip, tech alone is worth multiples and then whack on the huge growth already in 2025 and coming in 2026 with over 30 transplant centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230740+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251247-geraldus--8549234",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.365906",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "Still early days here,and they will have to take some market share from the incumbent bio markers. Shaping up well so far and with a miserly market cap in comparison with other counters.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.825",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230722+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251256-donmac10-77262872",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.365490",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "1.20p close today and more updates in coming days on quickly to 2.00p",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230703+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251354-donmac10-46110857",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.365069",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "It feels to me we are about to get a trading update on testing numbers shortly .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230685+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251448-oogleflu-40353226",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.364659",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Tom. I know exactly what you\u2019re saying is correct . Unfortunately risk appetite is much lower in the UK probably because the FA are like a bunch of frightened rabbits. Fund managers continue to unwind oversold positions in uk to chase  the way overpriced \u2018American dream stocks\u2019 which are overdue a big correction there by loosing even more of the inadequate fund managers clients money. It\u2019s not all Uk stocks but quite a few as admitted in an interview recently with a fund manager. Certainly since the pandemic Uk stocks are valued much more realistically i.e. sound balance sheet which Vrci  now has, realistic forecast which Vrci now has, realistic targets for growth which Vrci now has. But we don\u2019t tend to look further than a year ahead. One step at a time . There will be /is FOMO with a stock like Vrci which will cause some volatility till they establish a more constant earnings stream.",
          "sentiment": 0.0,
          "engagement": "5,451",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230667+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250809-2Phones--3937264",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.364243",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Interesting news today \u2013 initially I thought why? This has little bearing on shareholders interests \u2013 however, on further concideration, while successful audits add little to the bottom line or turnover or even shareholder value \u2013 in our case it is very much a Critical Failure Factor, where failure to pass a quality audit could seriously damage the company in the short/medium term.  Also it does point to a well run, disciplined business. So well done Verici.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.95",
          "thread_title": "RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-21T21:27:10.230649+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250830-donmac10--5475554",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.363818",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Tells me ,anyone looking to make money would be well served to get in now .Futher big rise going into year end.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.95",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-21T21:27:10.230631+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250843-donmac10--3206981",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.363408",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Verici also more forthcoming informing the market with updates .Beats last years 6 month radio silence .Just waiting now for testing update which i know will further boost price.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.925",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-21T21:27:10.230613+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250845-donmac10--8234458",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.362977",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Analysts expecting 3p per share next year big upside from here.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.90",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-21T21:27:10.230595+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250856-2Phones--8012914",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.362565",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac agreed - two of the latest RNS are very positive about the rate of revenue growth and market penetration - can't help but think the next sales based RNS will be a gamechanger.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.875",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-21T21:27:10.230576+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251522-Silverbl-90518375",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.362150",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Based on what we already know - VRCI sold c.600 Tutivia tests in H1 2025 - securing revenue of $1.2m ($2k per test - blend of public and private payers). They sold same in Q3 - so lets assume pro-rata they secured a further $600k revenue. Sara B confirmed FY Tutivia target was $3.2m - so that leaves $1.4 revenue to be secured in Q4 - or c.700 tests at $2k. Seems a huge leap - or possible they are looking at a slight increase to average test $ - although Prime Health RNS appears to push towards discounted volume in private market. She has certainly set high expectations for Q4 trading. If this is achieved it will be a significant acceleration - and will be crucial in supporting the share price/market cap as the company requires additional funding in the next 4/5 months. Additional licensing revenue from Thermo (c.$4m received to date - $3.3m in 2024 and $0.75m in 2025) remains on hold as they progress their approach to the PTRA test. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.725",
          "thread_title": "2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-21T21:27:10.230558+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251604-Fevertre-12526891",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.361719",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Worryingly her bullishness has cost investors dearly so far. Apart from having virtually no skin in the game she hasn't been gifted,  or regifted (look at the outrageous revision of option pricing). The fact that the sp is still at 3/4 of a penny tells you everything you need to know about how the market views her!",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-21T21:27:10.230540+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251627-donmac10-74929398",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.361309",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "markets falling and the doom and gloom ****roaches appear in force.sell up ,thats even if yeh hod any and gie us aw peace!",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-21T21:27:10.230522+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251644-Fevertre-46533477",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.360879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Nonsense Donmac.....look at the maths around Barrington's targets: On my maths I don't see how she hits revs from Tutivia $3.2m... Tutivia:  1H Revs: $1.16m: 591 tests @ ave $1900 ($1.16m divided by 591) 2H Revs:  3Q Tutivia same rate as Q1/Q2 ..c300 tests at 1900 = $570k  ...so to meet her target she needs to sell c$1.5m of tests. Assume same ave price of $1900....she needs to sell c790 tests....that's a massive uplift, even with onboarding another 9 more centres...",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-21T21:27:10.230504+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251647-Fevertre-51883245",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.360456",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "She has never fully explained the onboarding process. If a new centre gets onboarded, typically how long does it take for clinicians to order first tests",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-21T21:27:10.230485+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251709-Silverbl--8390804",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.360013",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not a fan to date either fevertree - its been a disaster for all shareholders here - but I still hold a position here and am trying to look forward not back given the past is what it is. If Q4 goes well I expect a trading update early 2026 - which doesn't usually happen but positive momentum will be required to avoid a total wipe out in any subsequent capital raise. Failure to deliver (again) then more questions will be raised on leadership competencies.  SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.75",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-21T21:27:10.230467+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251734-Mikemine-52368582",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.359562",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "VRCI is a small company so hiring an extra 3 salespersons is huge for them and points to their determination to hit their target. It's a big ask but you can be sure they recognise that their credibility is on the line. From a practical point of view, hiring new salespeople  takes time for their impact to come through. They have to get used of the systems, the product and VRCI's method of selling. I wish them luck and, if they do reach their target, it will be noticed by the Market.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-21T21:27:10.230449+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20250050-donmac10--6324040",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.359136",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sell up move on thank you.....give me the chance ar more aroon the 55 mark slanj .And a will catch yeh in wetherspoons oan the wae otta rah ritz.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-21T21:27:10.230430+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251059-Silverbl--5846806",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.358710",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There you go donmac almost at your buy price already. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-21T21:27:10.230412+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251147-Fevertre--6291925",
        "event_type": "social_post",
        "date": "2026-01-21T21:27:02.358277",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "The Board and non-execs have overseen an absolute shamble here. Barrington completely unaffected by disastrous dilution as she has virtually no bloody shares in teh company she purports to lead.  The CFo isnt fit for purpose frankly. The Q4 figs appear to be the stuff of fantasy - I would give more creedance if  Barrington was able to explain how she gets to the forecast but she appears to be just making it up as she goes along... we have no timelines on onboarding; Barrington cant set out how she arrived at the numbers... she continues to be utterly hopeless as the CEO of supposedly a cutting edge business.",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-21T21:27:10.230394+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251148-Fevertre--5288766",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.783360",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Just out of interest what are Barrington's competencies?",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-21T21:27:10.230375+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251456-Mikemine--7040118",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.782943",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, your posts have got  very repetitive and quite frankly, boring. Unless your rants help your mental state I for one would be grateful if you would keep your posts to new views or information.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-21T21:27:10.230357+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251031-B_Positi--6495629",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.782538",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230338+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251039-donmac10-42133066",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.782104",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Expecting a trading update in the run up to xmas should make for good reading!",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230320+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251045-donmac10-46348444",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.781686",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And its beginning to look like word is out?",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230301+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251104-B_Positi-43315393",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.781280",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "So with less than 10% of transplant centres onboarded and already at the start of the mass rollout they averaged about 300 tests per quarter in Q1, Q2 and Q3, just short of 900, vs 334 for the entirety of 2024, representng significant growth. We now know they are at at least 16% of transplant centres onboarded now (less than 10% for Q1, Q2, Q2, perhaps around 20% now and are increasing this fast. You quickly realise how mad the revenues can become here at $2,650 a test with the medicaid coverage +Thermo Fisher licencing revenues. I know many, many pharma stocks that have literally $0 revenue, no proven tech, no FDA approval, no big deal with a giant like this does with Thermo Fisher that are trading at many multiples of the Verici market cap.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230283+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251235-B_Positi-67742847",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.780848",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Donmac, absolutely buzzing for the trading update this month Hopefully see's this head back to the 3 to 5p level",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230265+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251443-donmac10-17721552",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.780440",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Nice 2mill buy this morning.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230246+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251230-tbcx-46739711",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.780018",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Buying pressure certainly returning this week, this remains extremely undervalued.",
          "sentiment": 0.0,
          "engagement": "748",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230225+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251234-B_Positi--8754631",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.779612",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "MMs caught wind of an update? I'm amazed this isn't over 2p at least. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230192+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251245-donmac10--6034557",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.779155",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Update this week and more deals with distributors .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230161+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251320-B_Positi--3628510",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.778740",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Yes it was due. Thermo-Fisher $220BILLION backing this and tied in. Update on them or something new will wake the market up.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230130+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251535-Silverbl-42249865",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.778323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Would be unusual for a trading update pre-xmas imo although any kind of an update in relation to hitting revenue targets would assist progress here - the bar has been set very high by CEO. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230089+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251941-donmac10--4643576",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.777906",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Company is no longer research orientated so past rns at this time of year irrelevant trust me as tests ramp up as they will be the company will be eager to broadcast positive newsflow asap.noh whit a meen an that man getmeh!",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230071+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251945-donmac10-53302361",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.777501",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "3p per share nailed on short term if you guys sit oan yer tuffetts like miss muffet know whit ah mean?",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230053+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251953-B_Positi-63962723",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.777077",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Will add another 2m sub 1p Way too cheap here for me personally.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230035+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251227-B_Positi--7514832",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.776669",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I'm personally amazed more aren't piling in whilst under 1p and this isn't at 3-5p already. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.230017+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251244-B_Positi-32829241",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.776219",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Once it breaks 1p it will fly to 2p and then 3p gets smashed with ease considering the test orders are going to be around 300-400% from the digging below. 3p as a base and then a move back to 5-10p.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229999+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251255-donmac10-19576394",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.775795",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Genincode signed a deal with Thermo read across to Verici Verici so undervalued at the moment something has to give.",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229982+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251302-B_Positi--1408125",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.775384",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Wow now way just saw that. Huge implications for Thermo and its partners!",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229964+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-B_Positi-59636773",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.774957",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I would wager a big Thermo-Fisher update is due here. Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229946+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251547-B_Positi--3815143",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.774503",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229928+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251441-Silverbl-15978977",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.774034",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - FYI Thermo Fisher are not currently involved in Tutivia - so they are not involved in any roll out. Despite claims here to the contrary there has been no trading update - so we await evidence that Q4 delivers the level of sales anticipated by the CEO on achieving the 2025 Tutivia revenue target - which as you note would be a significant increase on 2024 sales. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229910+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251216-Sandyman--2212836",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.773618",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "Is the placing going to be at 0.25p or 0.5p? Or both?",
          "sentiment": 0.0,
          "engagement": "991",
          "price_at_post": "0.775",
          "thread_title": "Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-21T21:27:10.229892+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251243-Romanby--3243966",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:58.773177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Romanby",
          "content": "No placing you idiot",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-21T21:27:10.229874+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251522-Silverbl--8628443",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.045201",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There will be a placing in early 2026 - probably March/April time. The placing will of course be determined by the prevailing share price at the time. And that in turn will reflect the numbers for FY 2025 - there is a lot of expectation here so lets see what the company has to say for itself hopefully with a trading update in January. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-21T21:27:10.229856+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251557-B_Positi--3815143",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.044779",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229838+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251618-Silverbl--2867803",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.044190",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Same old nonsense B_Positive. Thermo are not involved in Tutivia. Stop spreading false information. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229819+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251728-2reincar--3553760",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.043771",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Agree Silverblade. We could have one in Aprilish at 0.5p and one in Octoberish at 0.25p and then a rocket to + 2p ?",
          "sentiment": 0.0,
          "engagement": "5,816",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-21T21:27:10.229801+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20250753-2Phones--8605309",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.043360",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I don't agree - the operational update earlier this year had a predicted cash runway to H2 next year - when you couple that with the recruitment of 2 sales people and a director of clinical partnerships, I would anticipate growth in cash inflow.  However, they are a small team and they are going to have to increase production to accommodate the anticipated sales.  This will need funding, but where they get it is uncertain \u2013 one option being a placing.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-21T21:27:10.229783+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251223-Silverbl-84809953",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.042940",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "2Phones - from the company itself: \" With minimum gross proceeds from the Placing and Subscription of \u00a35 million, the Company's cash runway will be extended to mid Q2 2026.\". Hence my thinking spring will be the time to raise. And yes revenue is expected to increase (we will know by how much in a few weeks) - but annual expenses are c.$9m - so sales would need a dramatic (and unlikely) increase to negate the need for more funds. And you seem to agree that a placing is an option (imo the only likely one and the route the company has taken to date in all its efforts to secure more funding). So not sure what you were disagreeing with? SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-21T21:27:10.229765+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251515-B_Positi-86391469",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.042535",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229746+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261022-2reincar--2645815",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.042084",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "At 0.25p?",
          "sentiment": 0.0,
          "engagement": "5,816",
          "price_at_post": "0.725",
          "thread_title": "Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-01-21T21:27:10.229728+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20260629-2Phones--8856755",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.041677",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "How can any one disagree with such a cogent arguement - and clearly not the rantings of a one track numpty.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.725",
          "thread_title": "RE: Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-01-21T21:27:10.229709+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261210-B_Positi-86391469",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.041273",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229691+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-2reincar--4587715",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.040818",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Conversions this summer will see us at sub 0.25p!",
          "sentiment": 0.0,
          "engagement": "5,816",
          "price_at_post": "0.75",
          "thread_title": "100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-01-21T21:27:10.229673+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261228-B_Positi--9013148",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.040414",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229655+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261346-Silverbl--7533207",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.039955",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Despite the view expressed by several contributors here we have heard nothing from the business on Q4 trading. Not unexpected - if there was anything to report on I would expect to hear later on in January. The issue looming very shortly relates to the required fund raising. In previous years the company has elected not to divulge FY trading until May.  This is likely to be beyond the point at which the company runs out of cash. We should therefore be able to read the signals loud and clear - no trading update - then Q4 has not delivered the targeted sales and the fund raise will be brutal.  If a positive Q4 trading update is issued then there should be a healthy price response despite the recognition funds will still be required. Remember last year the first fundraise was at 9p - then 0.5p after bewildering timing mismanagement by the company.  All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.75",
          "thread_title": "RE: 100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-01-21T21:27:10.229636+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261401-B_Positi--5676705",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.039552",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Cashed up until the end of 2026 and now they've been securing record orders as per below. Next time they raise it will be in the pennies, which is what they will want given the new option prices. Test update going to drop soon. More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229618+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261402-Mikemine-84300386",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.039081",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "They've set themselves a big revenue target of over \u00a33mn for 2025. Small in world terms but a big % increase for VRCI. Should they be chastised if they do not reach the target or should it be viewed in the context of what they do achieve and what they forecast for this year? Getting close to \u00a33mn would be an achievement in my book as that would point to things being on track for further increases especially as the new sales guys have probably only just got their acts together and their contacts in line. Not sure what to think of the Thermo-Fisher deal and its seemingly lack of traction. Big companies are not nimble nor quick so the jury's out on that one for me. My guess is for an update this month and it will be positive but will not please everybody.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229600+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261416-B_Positi-84956144",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.038677",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10 centres onboarded. It must now be around 25-35 going by the last report.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229581+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261518-Silverbl--6921849",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.038218",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "No licencing revenue in H2 2025 and average received revenue per test is $1900. Do some actual research please. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229559+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261523-Silverbl-56347833",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.037798",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Mikemine -  your points are valid - but highlight one of the main issues here. Why set a target and fail. Undermines confidence, craters the share price, makes fund raising tricky and makes investors wary on growth. Much better to overdeliver on achievable targets than underdeliver? But maybe we will be get a pleasant surprise. Thermo are just doing their own thing on the PRTA at present. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229541+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261524-B_Positi-79546553",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.037392",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Nope it's $2,650 as per the Medicare coverage RNS and more recently as per the HY report. \u00b7 Lead product Tutivia\u2122 attained Medicare coverage at $2,650 per test, covering a national estimate of 68% of all US transplant tests and commercial payor reimbursement applications are underway They receive licencing revenues both H1 and H2. It was $750k in H1.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229523+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262026-Silverbl--1559652",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.036959",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not really sure why I need to explain this, but here you go B_Positive. Your bullet point regarding Tutivia sums the position up very well. Transplant centres service both Medicare patients and private paying patients. So whilst the Medicare payment of $2650 is being provided by the US healthcare system for patients who benefit from the Medicare and Medicare plus programmes - there are actually six key revenue streams for test sales of which Medicare is one (albeit the largest - 68% of tests being undertaken are covered by Medicare seems to be the claim from the company). Private payers (via healthcare insurance) do not pay the $2650 - they receive discounts. Clinical trials pay nothing. And there others. If you divide the H1 Tutivia revenue of $1.16m by the 591 tests in H1 it comes out at $1962 . That is the current revenue reality for test sales. The recent RNS highlighting the agreement with Prime Health Services is all about trying to establish consistent pricing of the Tutivia test with the private payment market and clearly with the goal to increase current pricing which is diluting the Medicare $2650. In relation to your H2 licencing point the following clarifies the position \" Thermo Fisher is investing in new research related to PTRA aimed at identifying the earliest stage at which the test can be utilised before transplantation. Consequently, the second milestone originally anticipated for 2025 will be delayed as we continue to collaborate on publishing clinical validation data and Thermo Fisher pursues these additional research efforts to help broaden utility and adoption of the assay.\" FYI the breakeven position for Verici is c.$12m - so that provides an indication of the revenue which is required from test sales, licence revenue, protega etc to cover vrci operating costs. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229505+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260205-donmac10-74358665",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.036524",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Where do you get the 12mill breakeven point? You sound like a bot with your precise figures. And you always have a way of sounding positive but are really negative .So cant be taken seriously .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229486+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260728-B_Positi--3667640",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.036093",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229467+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260830-Silverbl-20456108",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.035630",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "$12m was a direct quote from Vrci CEO in latest Vox markets interview. As for my 'precise' figures - strangely enough when it comes to investing I prefer to deal in fact rather than making it up (refer B_Positive). As for my views on the business - I remain invested so I am hopeful there is a future here or would have taken my medicine and moved on. That does not mean to say I will not vocalise my thoughts on areas of mismanagement where the company could and should be doing better; or to call out posters who are just making it up as they go along. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229441+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261504-B_Positi--1088049",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.035211",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We should all be extremely excited having now onboarded over 30 transplant centres, up from 10 in 2024. We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,384",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229404+00:00"
      },
      {
        "event_id": "SOCIAL-Today1715-Silverbl--1745671",
        "event_type": "social_post",
        "date": "2026-01-21T21:26:54.034594",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - feel free to use the actual numbers in your updates. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 (INCORRECT: H1 actual revenue was $1.16m = $1962 average revenue per test). H1 2025 licencing revenue = $750,000 (CORRECT) Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. (Test numbers CORRECT. Centres INCORRECT - there were 21 onboarded at time of results). 286 x $2,650 = $757,900 (Likely INCORRECT based on average revenue per test of $1962 achieved in H1 2025 - likely revenue $560K). Q4 2025, 20 centres onboarded and let's be conservative and say 300 tests. (INCORRECT. There are now 30 centres onboarded. Company is targeting in the region of 750 tests in Q4 in order to meet its Q4 revenue target of c.$1.5m) 300 x $2,650 = $795,000 revenue (We will find out in due course what was achieved in terms of test numbers and average revenue per test) H2 2025 licensing revenue, let's be conservative and say $500,000. (INCORRECT. No licencing revenue will come from Thermo in H2) Combine all of that above and you get = $4.3mil or \u00a33.2m. (H1 revenue was $1.9m/ Q3 likely $560K. Q4 not yet reported. Company is targeting total FY 2025 revenue of $3.95m, comprising $3.2 Tutivia tests and $750K licencing revenue) Still nothing in the way of a trading update from the team at vrci. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T21:27:10.229367+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251243-Romanby--2361019",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.619454",
        "source": "LSE_CHAT",
        "data": {
          "author": "Romanby",
          "content": "No placing you idiot",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-21T01:14:37.257923Z"
      },
      {
        "event_id": "SOCIAL-26Dec20251522-Silverbl-92029850",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.619036",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There will be a placing in early 2026 - probably March/April time. The placing will of course be determined by the prevailing share price at the time. And that in turn will reflect the numbers for FY 2025 - there is a lot of expectation here so lets see what the company has to say for itself hopefully with a trading update in January. SB",
          "sentiment": 0.0,
          "engagement": "1,916",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-21T01:14:37.257896Z"
      },
      {
        "event_id": "SOCIAL-26Dec20251557-B_Positi-17918859",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.618626",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,368",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257870Z"
      },
      {
        "event_id": "SOCIAL-26Dec20251618-Silverbl--2003672",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.618175",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Same old nonsense B_Positive. Thermo are not involved in Tutivia. Stop spreading false information. SB",
          "sentiment": 0.0,
          "engagement": "1,916",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257843Z"
      },
      {
        "event_id": "SOCIAL-26Dec20251728-2reincar--4173099",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.617759",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Agree Silverblade. We could have one in Aprilish at 0.5p and one in Octoberish at 0.25p and then a rocket to + 2p ?",
          "sentiment": 0.0,
          "engagement": "5,812",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-21T01:14:37.257817Z"
      },
      {
        "event_id": "SOCIAL-27Dec20250753-2Phones-17116316",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.617351",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I don't agree - the operational update earlier this year had a predicted cash runway to H2 next year - when you couple that with the recruitment of 2 sales people and a director of clinical partnerships, I would anticipate growth in cash inflow.  However, they are a small team and they are going to have to increase production to accommodate the anticipated sales.  This will need funding, but where they get it is uncertain \u2013 one option being a placing.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-21T01:14:37.257791Z"
      },
      {
        "event_id": "SOCIAL-27Dec20251223-Silverbl-71861341",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.616932",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "2Phones - from the company itself: \" With minimum gross proceeds from the Placing and Subscription of \u00a35 million, the Company's cash runway will be extended to mid Q2 2026.\". Hence my thinking spring will be the time to raise. And yes revenue is expected to increase (we will know by how much in a few weeks) - but annual expenses are c.$9m - so sales would need a dramatic (and unlikely) increase to negate the need for more funds. And you seem to agree that a placing is an option (imo the only likely one and the route the company has taken to date in all its efforts to secure more funding). So not sure what you were disagreeing with? SB",
          "sentiment": 0.0,
          "engagement": "1,916",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-21T01:14:37.257764Z"
      },
      {
        "event_id": "SOCIAL-27Dec20251515-B_Positi-60137329",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.616524",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,368",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257738Z"
      },
      {
        "event_id": "SOCIAL-1Jan20261022-2reincar-68510793",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.616067",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "At 0.25p?",
          "sentiment": 0.0,
          "engagement": "5,812",
          "price_at_post": "0.725",
          "thread_title": "Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-01-21T01:14:37.257711Z"
      },
      {
        "event_id": "SOCIAL-2Jan20260629-2Phones--5649931",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.615659",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "How can any one disagree with such a cogent arguement - and clearly not the rantings of a one track numpty.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.725",
          "thread_title": "RE: Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-01-21T01:14:37.257685Z"
      },
      {
        "event_id": "SOCIAL-2Jan20261210-B_Positi-60137329",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.615252",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,368",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257659Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-2reincar-39253819",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.614797",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Conversions this summer will see us at sub 0.25p!",
          "sentiment": 0.0,
          "engagement": "5,812",
          "price_at_post": "0.75",
          "thread_title": "100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-01-21T01:14:37.257633Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261228-B_Positi-40122606",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.614390",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,368",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257606Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261346-Silverbl--9065371",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.613929",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Despite the view expressed by several contributors here we have heard nothing from the business on Q4 trading. Not unexpected - if there was anything to report on I would expect to hear later on in January. The issue looming very shortly relates to the required fund raising. In previous years the company has elected not to divulge FY trading until May.  This is likely to be beyond the point at which the company runs out of cash. We should therefore be able to read the signals loud and clear - no trading update - then Q4 has not delivered the targeted sales and the fund raise will be brutal.  If a positive Q4 trading update is issued then there should be a healthy price response despite the recognition funds will still be required. Remember last year the first fundraise was at 9p - then 0.5p after bewildering timing mismanagement by the company.  All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,916",
          "price_at_post": "0.75",
          "thread_title": "RE: 100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-01-21T01:14:37.257580Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261401-B_Positi--1814861",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.613522",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Cashed up until the end of 2026 and now they've been securing record orders as per below. Next time they raise it will be in the pennies, which is what they will want given the new option prices. Test update going to drop soon. More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,368",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257553Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261402-Mikemine--4820660",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.613043",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "They've set themselves a big revenue target of over \u00a33mn for 2025. Small in world terms but a big % increase for VRCI. Should they be chastised if they do not reach the target or should it be viewed in the context of what they do achieve and what they forecast for this year? Getting close to \u00a33mn would be an achievement in my book as that would point to things being on track for further increases especially as the new sales guys have probably only just got their acts together and their contacts in line. Not sure what to think of the Thermo-Fisher deal and its seemingly lack of traction. Big companies are not nimble nor quick so the jury's out on that one for me. My guess is for an update this month and it will be positive but will not please everybody.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257526Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261416-B_Positi-85053238",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.612638",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10 centres onboarded. It must now be around 25-35 going by the last report.",
          "sentiment": 0.0,
          "engagement": "4,368",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257499Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261518-Silverbl-39095075",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.612173",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "No licencing revenue in H2 2025 and average received revenue per test is $1900. Do some actual research please. SB",
          "sentiment": 0.0,
          "engagement": "1,916",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257473Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261523-Silverbl--6908866",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.611757",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Mikemine -  your points are valid - but highlight one of the main issues here. Why set a target and fail. Undermines confidence, craters the share price, makes fund raising tricky and makes investors wary on growth. Much better to overdeliver on achievable targets than underdeliver? But maybe we will be get a pleasant surprise. Thermo are just doing their own thing on the PRTA at present. SB",
          "sentiment": 0.0,
          "engagement": "1,916",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257446Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261524-B_Positi-63793426",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.611348",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Nope it's $2,650 as per the Medicare coverage RNS and more recently as per the HY report. \u00b7 Lead product Tutivia\u2122 attained Medicare coverage at $2,650 per test, covering a national estimate of 68% of all US transplant tests and commercial payor reimbursement applications are underway They receive licencing revenues both H1 and H2. It was $750k in H1.",
          "sentiment": 0.0,
          "engagement": "4,368",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257419Z"
      },
      {
        "event_id": "SOCIAL-8Jan20262026-Silverbl-47459447",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.610910",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not really sure why I need to explain this, but here you go B_Positive. Your bullet point regarding Tutivia sums the position up very well. Transplant centres service both Medicare patients and private paying patients. So whilst the Medicare payment of $2650 is being provided by the US healthcare system for patients who benefit from the Medicare and Medicare plus programmes - there are actually six key revenue streams for test sales of which Medicare is one (albeit the largest - 68% of tests being undertaken are covered by Medicare seems to be the claim from the company). Private payers (via healthcare insurance) do not pay the $2650 - they receive discounts. Clinical trials pay nothing. And there others. If you divide the H1 Tutivia revenue of $1.16m by the 591 tests in H1 it comes out at $1962 . That is the current revenue reality for test sales. The recent RNS highlighting the agreement with Prime Health Services is all about trying to establish consistent pricing of the Tutivia test with the private payment market and clearly with the goal to increase current pricing which is diluting the Medicare $2650. In relation to your H2 licencing point the following clarifies the position \" Thermo Fisher is investing in new research related to PTRA aimed at identifying the earliest stage at which the test can be utilised before transplantation. Consequently, the second milestone originally anticipated for 2025 will be delayed as we continue to collaborate on publishing clinical validation data and Thermo Fisher pursues these additional research efforts to help broaden utility and adoption of the assay.\" FYI the breakeven position for Verici is c.$12m - so that provides an indication of the revenue which is required from test sales, licence revenue, protega etc to cover vrci operating costs. SB",
          "sentiment": 0.0,
          "engagement": "1,916",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257392Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260205-donmac10--1305362",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.610477",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Where do you get the 12mill breakeven point? You sound like a bot with your precise figures. And you always have a way of sounding positive but are really negative .So cant be taken seriously .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257366Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260728-B_Positi-16837939",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.610044",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,368",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257339Z"
      },
      {
        "event_id": "SOCIAL-9Jan20260830-Silverbl--3755320",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.609572",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "$12m was a direct quote from Vrci CEO in latest Vox markets interview. As for my 'precise' figures - strangely enough when it comes to investing I prefer to deal in fact rather than making it up (refer B_Positive). As for my views on the business - I remain invested so I am hopeful there is a future here or would have taken my medicine and moved on. That does not mean to say I will not vocalise my thoughts on areas of mismanagement where the company could and should be doing better; or to call out posters who are just making it up as they go along. SB",
          "sentiment": 0.0,
          "engagement": "1,916",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257310Z"
      },
      {
        "event_id": "SOCIAL-9Jan20261504-B_Positi-23225968",
        "event_type": "social_post",
        "date": "2026-01-21T01:14:19.609136",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We should all be extremely excited having now onboarded over 30 transplant centres, up from 10 in 2024. We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,368",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.257278Z"
      },
      {
        "event_id": "SOCIAL-19Oct20251121-donmac10--2866646",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.540588",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Did a deep dive utilizing Gemini. What stood out is the IP value of Verici is worth as much as the 2 lead products .Very saleable research to Big Pharma.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.192115Z"
      },
      {
        "event_id": "SOCIAL-19Oct20251121-donmac10-69359275",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.540588",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Did a deep dive utilizing Gemini. What stood out is the IP value of Verici is worth as much as the 2 lead products .Very saleable research to Big Pharma.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.260636Z"
      },
      {
        "event_id": "SOCIAL-20Oct20251015-donmac10--1785895",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.540173",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And deep dive on open AI gives a value for vrci IP value at 3.77 pence per share.So if vaguely realistic means massive upside.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.192079Z"
      },
      {
        "event_id": "SOCIAL-20Oct20251015-donmac10--4187482",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.540173",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And deep dive on open AI gives a value for vrci IP value at 3.77 pence per share.So if vaguely realistic means massive upside.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.260609Z"
      },
      {
        "event_id": "SOCIAL-20Oct20251020-donmac10-46489775",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.539701",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And bio tech is starting to gain traction in US markets UK markets will follow.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.192052Z"
      },
      {
        "event_id": "SOCIAL-20Oct20251020-donmac10-41286847",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.539701",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And bio tech is starting to gain traction in US markets UK markets will follow.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.260583Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250801-Cliveas--4753080",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.539202",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cliveas",
          "content": "So the BOD trash the shareprice and then award themselves adjusted options at a massive discount to current SP! Reward for abject failure imho! GL.",
          "sentiment": 0.0,
          "engagement": "7,896",
          "price_at_post": "0.725",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-16T22:49:18.192025Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250801-Cliveas--4844530",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.539202",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cliveas",
          "content": "So the BOD trash the shareprice and then award themselves adjusted options at a massive discount to current SP! Reward for abject failure imho! GL.",
          "sentiment": 0.0,
          "engagement": "7,896",
          "price_at_post": "0.725",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T01:14:37.260557Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250812-Silverbl--6202790",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.538753",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Another AIM company taking the michael. No regard for shareholders whatsoever but we knew that earlier this year with the fund raise shambles. SB",
          "sentiment": 0.0,
          "engagement": "1,914",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-16T22:49:18.191999Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250812-Silverbl-33975761",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.538753",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Another AIM company taking the michael. No regard for shareholders whatsoever but we knew that earlier this year with the fund raise shambles. SB",
          "sentiment": 0.0,
          "engagement": "1,914",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T01:14:37.260530Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250816-Karlvonw--2187980",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.538187",
        "source": "LSE_CHAT",
        "data": {
          "author": "Karlvonwise",
          "content": "Unsure what to think now.",
          "sentiment": 0.0,
          "engagement": "663",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-16T22:49:18.191973Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250816-Karlvonw--6297150",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.538187",
        "source": "LSE_CHAT",
        "data": {
          "author": "Karlvonwise",
          "content": "Unsure what to think now.",
          "sentiment": 0.0,
          "engagement": "663",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T01:14:37.260504Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250846-bigpunt-27637757",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.537748",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Of course the exercise price should be reasonable, or the options do not function as an incentive. My issue is that there is no detail on vesting conditions.  However the timing is interesting, management obviously expect share price to boooooom",
          "sentiment": 0.0,
          "engagement": "351",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-16T22:49:18.191947Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250846-bigpunt--3960999",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.537748",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Of course the exercise price should be reasonable, or the options do not function as an incentive. My issue is that there is no detail on vesting conditions.  However the timing is interesting, management obviously expect share price to boooooom",
          "sentiment": 0.0,
          "engagement": "351",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T01:14:37.260478Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250852-oogleflu--6659521",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.537333",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "8 percent of the company for one of the most spectacularly dreadful performances by directors is what Aim is all about. If at first you don\u2019t succeed award yourself a huge chunk of the company at a ridiculously low price risk free! Whoppee off to the races again Sara",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-16T22:49:18.191921Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250852-oogleflu--5244498",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.537333",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "8 percent of the company for one of the most spectacularly dreadful performances by directors is what Aim is all about. If at first you don\u2019t succeed award yourself a huge chunk of the company at a ridiculously low price risk free! Whoppee off to the races again Sara",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T01:14:37.260452Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250853-tbcx--1804229",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.536912",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "No getting away from it, this is what Aim management tends to do. Will struggle to find one that doesn't award options at a board level. At least they have skin in game now and incentive to ramp this up so that if there is good news forthcoming, especially around Thermo Fischer JV, they'll want to ensure they're positioned beforehand like anyone else who has invested here. Bigger picture they are still delivering a commercial product with proven science that improves the outcome for patients undergoing transplants, in partnership with a company valued at $200bn+. The potential speaks for itself. Let's see what news they now deliver.",
          "sentiment": 0.0,
          "engagement": "721",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-16T22:49:18.191894Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250853-tbcx--4552927",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.536912",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "No getting away from it, this is what Aim management tends to do. Will struggle to find one that doesn't award options at a board level. At least they have skin in game now and incentive to ramp this up so that if there is good news forthcoming, especially around Thermo Fischer JV, they'll want to ensure they're positioned beforehand like anyone else who has invested here. Bigger picture they are still delivering a commercial product with proven science that improves the outcome for patients undergoing transplants, in partnership with a company valued at $200bn+. The potential speaks for itself. Let's see what news they now deliver.",
          "sentiment": 0.0,
          "engagement": "721",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T01:14:37.260425Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250920-oogleflu--3749732",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.536486",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "It\u2019s in the rules gov. I had a holding in a company a few years ago after holding a placing they awarded themselves 10 percent of the company with free shares. Seems at lot more honest. I mean why come up with some derisory token price? Anyway it 5 bagged in 2 years. Things is they worked their socks off. Had to get rid of duff auditors, refinanced and built the business up into a leading international company. There could and should be scope to do that here with the amount already invested by shareholders.",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-16T22:49:18.191868Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250920-oogleflu-79000093",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.536486",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "It\u2019s in the rules gov. I had a holding in a company a few years ago after holding a placing they awarded themselves 10 percent of the company with free shares. Seems at lot more honest. I mean why come up with some derisory token price? Anyway it 5 bagged in 2 years. Things is they worked their socks off. Had to get rid of duff auditors, refinanced and built the business up into a leading international company. There could and should be scope to do that here with the amount already invested by shareholders.",
          "sentiment": 0.0,
          "engagement": "5,436",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T01:14:37.260399Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250943-donmac10-26693032",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.536011",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "7.9% to 8.3% dont know what all yer fussin is aboot just a normal realignment .Best to have a board pushing for success with skin in the game .Its no wonder 90% of PIs lose money nae patience !",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-16T22:49:18.191841Z"
      },
      {
        "event_id": "SOCIAL-30Oct20250943-donmac10-18461107",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.536011",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "7.9% to 8.3% dont know what all yer fussin is aboot just a normal realignment .Best to have a board pushing for success with skin in the game .Its no wonder 90% of PIs lose money nae patience !",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T01:14:37.260372Z"
      },
      {
        "event_id": "SOCIAL-30Oct20251003-tbcx-60558652",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.535393",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Exactly donmac101. There is no point crying about options, especially an adjustment like this, that is the name of the game where Aim boards are concerned, just have to suck it up I'm afraid. Now they are aligned with other shareholders let's  see what they deliver.",
          "sentiment": 0.0,
          "engagement": "721",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-16T22:49:18.191815Z"
      },
      {
        "event_id": "SOCIAL-30Oct20251003-tbcx--6597195",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.535393",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Exactly donmac101. There is no point crying about options, especially an adjustment like this, that is the name of the game where Aim boards are concerned, just have to suck it up I'm afraid. Now they are aligned with other shareholders let's  see what they deliver.",
          "sentiment": 0.0,
          "engagement": "721",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T01:14:37.260346Z"
      },
      {
        "event_id": "SOCIAL-30Oct20251624-HideInPl--7412527",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.534973",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Agree. Normal way of things. I'd sooner have an incentivised management team with renewed focus and drive than the opposite.",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-16T22:49:18.191788Z"
      },
      {
        "event_id": "SOCIAL-30Oct20251624-HideInPl--1306802",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.534973",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Agree. Normal way of things. I'd sooner have an incentivised management team with renewed focus and drive than the opposite.",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T01:14:37.260320Z"
      },
      {
        "event_id": "SOCIAL-31Oct20250952-Cliveas--8919099",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.534570",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cliveas",
          "content": "incentivised how exactly when the options are already priced way below current sp? no sweat to them to increase the sp they don't need to. let's see if they take them up. **** poor as always. gl.",
          "sentiment": 0.0,
          "engagement": "7,896",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-16T22:49:18.191761Z"
      },
      {
        "event_id": "SOCIAL-31Oct20250952-Cliveas-58926284",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.534570",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cliveas",
          "content": "incentivised how exactly when the options are already priced way below current sp? no sweat to them to increase the sp they don't need to. let's see if they take them up. **** poor as always. gl.",
          "sentiment": 0.0,
          "engagement": "7,896",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T01:14:37.260293Z"
      },
      {
        "event_id": "SOCIAL-1Nov20251128-Fevertre--6922750",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.534141",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Couldn\u2019t agree more! Having totally f***** up the fundraiser, which destroyed existing s/holders, Barrington who has virtually no shares in the company she\u2019s paid for herself, gets her options repriced ( no such luck for her bloody s/holders) and a ton more in the money options  Baines has the gall to suggest that this is an incentive. The woman trousered US$383,400 in 2024 ; the company has a grand total of 15\u2026.yes\u2026..15 staff!",
          "sentiment": 0.0,
          "engagement": "2,266",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-16T22:49:18.191735Z"
      },
      {
        "event_id": "SOCIAL-1Nov20251128-Fevertre-78440576",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.534141",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Couldn\u2019t agree more! Having totally f***** up the fundraiser, which destroyed existing s/holders, Barrington who has virtually no shares in the company she\u2019s paid for herself, gets her options repriced ( no such luck for her bloody s/holders) and a ton more in the money options  Baines has the gall to suggest that this is an incentive. The woman trousered US$383,400 in 2024 ; the company has a grand total of 15\u2026.yes\u2026..15 staff!",
          "sentiment": 0.0,
          "engagement": "2,266",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T01:14:37.260266Z"
      },
      {
        "event_id": "SOCIAL-1Nov20251131-Fevertre-88030482",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.533725",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Has it never occurred to you that this I actually a disincentive !!! She has been given free options that are already in the money. The woman is laughing at us as is Baines!",
          "sentiment": 0.0,
          "engagement": "2,266",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-16T22:49:18.191709Z"
      },
      {
        "event_id": "SOCIAL-1Nov20251131-Fevertre-81214355",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.533725",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Has it never occurred to you that this I actually a disincentive !!! She has been given free options that are already in the money. The woman is laughing at us as is Baines!",
          "sentiment": 0.0,
          "engagement": "2,266",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T01:14:37.260240Z"
      },
      {
        "event_id": "SOCIAL-1Nov20252040-saxman30--2193713",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.533316",
        "source": "LSE_CHAT",
        "data": {
          "author": "saxman303",
          "content": "Me looking to top up on any dip in the price",
          "sentiment": 0.0,
          "engagement": "692",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-16T22:49:18.191682Z"
      },
      {
        "event_id": "SOCIAL-1Nov20252040-saxman30-30550616",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.533316",
        "source": "LSE_CHAT",
        "data": {
          "author": "saxman303",
          "content": "Me looking to top up on any dip in the price",
          "sentiment": 0.0,
          "engagement": "692",
          "price_at_post": "0.70",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=51AEE5D5-00BE-4C23-80EA-5212AE858CDE"
        },
        "ingested_at": "2026-01-21T01:14:37.260214Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250741-joeblog1-85828889",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.532898",
        "source": "LSE_CHAT",
        "data": {
          "author": "joeblog1000",
          "content": "Rns  sounds positive??!",
          "sentiment": 0.0,
          "engagement": "411",
          "price_at_post": "0.625",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=B6EBEEF8-AEC7-4979-A053-5E1A792DECCA"
        },
        "ingested_at": "2026-01-16T22:49:18.191656Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250741-joeblog1-79808119",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.532898",
        "source": "LSE_CHAT",
        "data": {
          "author": "joeblog1000",
          "content": "Rns  sounds positive??!",
          "sentiment": 0.0,
          "engagement": "411",
          "price_at_post": "0.625",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=B6EBEEF8-AEC7-4979-A053-5E1A792DECCA"
        },
        "ingested_at": "2026-01-21T01:14:37.260187Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250752-donmac10-33110718",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.532494",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "The company is gearing up to suprise on the upside big time.Much more consistent newsflow all positive .Tests in the market that a surgeon will need for much better patient outcomes life or death outcomes.Any sellers offloading now should well head examined springs to mind.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.70",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=B6EBEEF8-AEC7-4979-A053-5E1A792DECCA"
        },
        "ingested_at": "2026-01-16T22:49:18.191629Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250752-donmac10--3006857",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.532494",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "The company is gearing up to suprise on the upside big time.Much more consistent newsflow all positive .Tests in the market that a surgeon will need for much better patient outcomes life or death outcomes.Any sellers offloading now should well head examined springs to mind.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.70",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=B6EBEEF8-AEC7-4979-A053-5E1A792DECCA"
        },
        "ingested_at": "2026-01-21T01:14:37.260161Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250829-B_Positi--7144732",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.532072",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Should be sitting at 3p to 5p right now. It's so undervalued it's ridiculous. Thermo Fisher licences due too Post period end the Company raised \u00a36.35m (gross) to support the scale up of revenues, extending the expected cash runway into H2 2026. They sold 591 tests in H1 2025. They sold just 334 for the entirety of 2024. Q3 sales inline with H1, Q4 big growth expected. Therefore H2 = 591+ it sounds like. They expect significant growth in H2 2025, which would suggest they will finish the year selling well north of 1000 tests. That would mean around 300-500% sales growth over 2024 if they sell 1000-1500 tests which is quite crazy. Then factor they have only just started the sales ramp up too and are expanding hard and fast. Also medicare coverage only kicked in end of April too so not reflected in the H1 results at all for the most part. Looks set for 1200-1500 tests sold an uplift of 400-500% over 2024 with massive onboarding of new test centres.",
          "sentiment": 0.0,
          "engagement": "4,316",
          "price_at_post": "0.625",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191603Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250829-B_Positi--7233968",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.532072",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Should be sitting at 3p to 5p right now. It's so undervalued it's ridiculous. Thermo Fisher licences due too Post period end the Company raised \u00a36.35m (gross) to support the scale up of revenues, extending the expected cash runway into H2 2026. They sold 591 tests in H1 2025. They sold just 334 for the entirety of 2024. Q3 sales inline with H1, Q4 big growth expected. Therefore H2 = 591+ it sounds like. They expect significant growth in H2 2025, which would suggest they will finish the year selling well north of 1000 tests. That would mean around 300-500% sales growth over 2024 if they sell 1000-1500 tests which is quite crazy. Then factor they have only just started the sales ramp up too and are expanding hard and fast. Also medicare coverage only kicked in end of April too so not reflected in the H1 results at all for the most part. Looks set for 1200-1500 tests sold an uplift of 400-500% over 2024 with massive onboarding of new test centres.",
          "sentiment": 0.0,
          "engagement": "4,316",
          "price_at_post": "0.625",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.260135Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250831-tbcx--8080795",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.531619",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Anything that reduces friction for getting the product to patients has to be a good thing. Plus US focus promising when it's the biggest healthcare market in the world. The company appear to be making significant strides in actually commercialising the offering, not something you see on a biotech with market cap this low",
          "sentiment": 0.0,
          "engagement": "721",
          "price_at_post": "0.625",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=B6EBEEF8-AEC7-4979-A053-5E1A792DECCA"
        },
        "ingested_at": "2026-01-16T22:49:18.191576Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250831-tbcx--2310191",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.531619",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Anything that reduces friction for getting the product to patients has to be a good thing. Plus US focus promising when it's the biggest healthcare market in the world. The company appear to be making significant strides in actually commercialising the offering, not something you see on a biotech with market cap this low",
          "sentiment": 0.0,
          "engagement": "721",
          "price_at_post": "0.625",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=B6EBEEF8-AEC7-4979-A053-5E1A792DECCA"
        },
        "ingested_at": "2026-01-21T01:14:37.260106Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250833-B_Positi-56026607",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.531200",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "In a nutshell, they are looking at about 400-500% sales growth in 2025 over 2024 and that's before the full impact of the massive rollout in to dozens of centres is felt. We could quite quickly be trading over 10p again here",
          "sentiment": 0.0,
          "engagement": "4,316",
          "price_at_post": "0.625",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191550Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250833-B_Positi--8719534",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.531200",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "In a nutshell, they are looking at about 400-500% sales growth in 2025 over 2024 and that's before the full impact of the massive rollout in to dozens of centres is felt. We could quite quickly be trading over 10p again here",
          "sentiment": 0.0,
          "engagement": "4,316",
          "price_at_post": "0.625",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.260072Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250840-donmac10-80244360",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.530769",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "The main positives is the constant newsflow .Last year at this time 1 rns in 6 months now 1 a week.Next rns will be large uptick in tests ordered  and well who knows where the share price goes.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.65",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191523Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250840-donmac10-79789053",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.530769",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "The main positives is the constant newsflow .Last year at this time 1 rns in 6 months now 1 a week.Next rns will be large uptick in tests ordered  and well who knows where the share price goes.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.65",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.260046Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250842-donmac10--4478211",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.530354",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Question= What price Verici if it was listed on Nasdaq! Americans would be allover it .",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191497Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250842-donmac10--4408377",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.530354",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Question= What price Verici if it was listed on Nasdaq! Americans would be allover it .",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.260019Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250850-donmac10-54265744",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.529897",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Ive left Uk markets over the last few months for the US markets AI boom but 1 Uk share i hold .Will give you 3 guesses.?",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191470Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250850-donmac10-24648630",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:07.529897",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Ive left Uk markets over the last few months for the US markets AI boom but 1 Uk share i hold .Will give you 3 guesses.?",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.259992Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250851-B_Positi--8340457",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.049336",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "334 tests ordered for the whole of FY 2024. They make $2,650 per test. Q1+ Q2 = 591 Tutivia\u2122 tests ordered in H1 2025 Q3 = 286 tests ordered, as per investor presentation. Q1 + Q2 + Q3 = 877 vs 334 last year. As fo Q4:  Commercial scale-up of Tutivia test adoption, a test for acute rejection post transplant, has progressed in Q3, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from Q4 and the number of orders in Q3 were consistent with the previous two quarters. So they expect a big rise in orders in Q4. Assume it's about 350 tests to be conservative (likely higher given the number of new centres onboarded) then that is 1,227 tests for the entirety of 2025 compared to just about 300 in 2024. Then imagine the scale up in 2026. About $3.4mil revenue just from these tests + about $1.5mil licensing revenues from Thermo for 2025. The turnaround is hard and fast.",
          "sentiment": 0.0,
          "engagement": "4,316",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191444Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250851-B_Positi-32872638",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.049336",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "334 tests ordered for the whole of FY 2024. They make $2,650 per test. Q1+ Q2 = 591 Tutivia\u2122 tests ordered in H1 2025 Q3 = 286 tests ordered, as per investor presentation. Q1 + Q2 + Q3 = 877 vs 334 last year. As fo Q4:  Commercial scale-up of Tutivia test adoption, a test for acute rejection post transplant, has progressed in Q3, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from Q4 and the number of orders in Q3 were consistent with the previous two quarters. So they expect a big rise in orders in Q4. Assume it's about 350 tests to be conservative (likely higher given the number of new centres onboarded) then that is 1,227 tests for the entirety of 2025 compared to just about 300 in 2024. Then imagine the scale up in 2026. About $3.4mil revenue just from these tests + about $1.5mil licensing revenues from Thermo for 2025. The turnaround is hard and fast.",
          "sentiment": 0.0,
          "engagement": "4,316",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.259966Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250953-donmac10--7123637",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.048884",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Prime health have over 1 million healthcare providers in the US thats between 33 to 50 % of all providers total in America This is much bigger than has been factored in share price.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191416Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250953-donmac10-50460955",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.048884",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Prime health have over 1 million healthcare providers in the US thats between 33 to 50 % of all providers total in America This is much bigger than has been factored in share price.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.259939Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250955-B_Positi-48438845",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.048481",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Donmac that is stunning. Excellent digging",
          "sentiment": 0.0,
          "engagement": "4,316",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191390Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250955-B_Positi--5358717",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.048481",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Donmac that is stunning. Excellent digging",
          "sentiment": 0.0,
          "engagement": "4,316",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.259913Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251002-donmac10-85785627",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.048060",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And they are in talks as we speak with more providers.Plenty to look forward to! Exciting times for much needed best in class tests that will speak for themselves.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191363Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251002-donmac10--8406135",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.048060",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And they are in talks as we speak with more providers.Plenty to look forward to! Exciting times for much needed best in class tests that will speak for themselves.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.259886Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251006-donmac10--2935413",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.047651",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "\"We look forward to updating shareholders fur mehr ahh rah same \" am gonny be rich cum rah spring!",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191337Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251006-donmac10-43427738",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.047651",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "\"We look forward to updating shareholders fur mehr ahh rah same \" am gonny be rich cum rah spring!",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.259860Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251010-B_Positi--1947979",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.047241",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Summary of research. Thermo Fisher: $213B market cap on NASDAQ backing this company. 334 tests ordered for the whole of FY 2024. They make $2,650 per test. Q1+ Q2 = 591 Tutivia\u2122 tests ordered in H1 2025 Q3 = 286 tests ordered, as per investor presentation. Q1 + Q2 + Q3 = 877 vs 334 last year. As fo Q4: Commercial scale-up of Tutivia test adoption, a test for acute rejection post transplant, has progressed in Q3, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from Q4 and the number of orders in Q3 were consistent with the previous two quarters. So they expect a big rise in orders in Q4. Assume it's about 350 tests to be conservative (likely higher given the number of new centres onboarded) then that is 1,227 tests for the entirety of 2025 compared to just about 300 in 2024. Then imagine the scale up in 2026. About $3.4mil revenue just from these tests + about $1.5mil licensing revenues from Thermo for 2025. The turnaround is hard and fast. __ This is what excites me: *The addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Most of the orders you references was when the company only had about 5-7% centres onboarded and they are now at 16%, which is still just a fraction of the centres in the US. Then also consider international expansion. Also: Tutivia is the best in class. Also: Multiple tests per patient is essentially a requirement When you factor it altogether the market value down here is absolutely insane. Especially as the IP, tech, patents, FDA approval is all worth so much more. No wonder we have a monster in Thermo Fisher leading here __ Prime health have over 1 million healthcare providers in the US thats between 33 to 50 % of all providers total in America This is much bigger than has been factored in share price. And they are in talks as we speak with more providers.Plenty to look forward to! Exciting times for much needed best in class tests that will speak for themselves.",
          "sentiment": 0.0,
          "engagement": "4,316",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191311Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251010-B_Positi--7755640",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.047241",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Summary of research. Thermo Fisher: $213B market cap on NASDAQ backing this company. 334 tests ordered for the whole of FY 2024. They make $2,650 per test. Q1+ Q2 = 591 Tutivia\u2122 tests ordered in H1 2025 Q3 = 286 tests ordered, as per investor presentation. Q1 + Q2 + Q3 = 877 vs 334 last year. As fo Q4: Commercial scale-up of Tutivia test adoption, a test for acute rejection post transplant, has progressed in Q3, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from Q4 and the number of orders in Q3 were consistent with the previous two quarters. So they expect a big rise in orders in Q4. Assume it's about 350 tests to be conservative (likely higher given the number of new centres onboarded) then that is 1,227 tests for the entirety of 2025 compared to just about 300 in 2024. Then imagine the scale up in 2026. About $3.4mil revenue just from these tests + about $1.5mil licensing revenues from Thermo for 2025. The turnaround is hard and fast. __ This is what excites me: *The addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Most of the orders you references was when the company only had about 5-7% centres onboarded and they are now at 16%, which is still just a fraction of the centres in the US. Then also consider international expansion. Also: Tutivia is the best in class. Also: Multiple tests per patient is essentially a requirement When you factor it altogether the market value down here is absolutely insane. Especially as the IP, tech, patents, FDA approval is all worth so much more. No wonder we have a monster in Thermo Fisher leading here __ Prime health have over 1 million healthcare providers in the US thats between 33 to 50 % of all providers total in America This is much bigger than has been factored in share price. And they are in talks as we speak with more providers.Plenty to look forward to! Exciting times for much needed best in class tests that will speak for themselves.",
          "sentiment": 0.0,
          "engagement": "4,316",
          "price_at_post": "0.675",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.259833Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251020-donmac10--5251831",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.046700",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Verici at this stage reminds me of a song. \"If you could see what I see\"",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191284Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251020-donmac10--8530580",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.046700",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Verici at this stage reminds me of a song. \"If you could see what I see\"",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.259805Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251056-donmac10--5714043",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.046289",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Nice 2mill buy at 8.25 somebody sees what i see.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191258Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251056-donmac10--8192275",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.046289",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Nice 2mill buy at 8.25 somebody sees what i see.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.259778Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251212-Bobat123--8759535",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.045873",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat1234",
          "content": "Verici Dx PLC, up 16% at 0.73p, 12-month range 6.50p-0.48p. The Cardiff, Wales-based developer of advanced clinical diagnostics for organ transplants signs a provider participation agreement with Prime Health Services. Prime Health is a US-based company focused on delivering data-driven solutions through its preferred provider organisation network. PPO networks negotiate on behalf of insurance companies to gain discounted pricing. Prime Health is one of the fastest-growing preferred provider networks in the US and has more than 850,000 providers, Verici says. The deal provides Verici with the opportunity to expand its patient scope, the firm adds. \"This agreement with Prime Health is an important milestone for Verici Dx, as we accelerate our commercial reach, expanding our patient network and supporting our approach to increased coverage from private payors,\" says Verici Dx Chief Operating Officer Patti Connolly.",
          "sentiment": 0.5,
          "engagement": "1,149",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191231Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251212-Bobat123-74583796",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.045873",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat1234",
          "content": "Verici Dx PLC, up 16% at 0.73p, 12-month range 6.50p-0.48p. The Cardiff, Wales-based developer of advanced clinical diagnostics for organ transplants signs a provider participation agreement with Prime Health Services. Prime Health is a US-based company focused on delivering data-driven solutions through its preferred provider organisation network. PPO networks negotiate on behalf of insurance companies to gain discounted pricing. Prime Health is one of the fastest-growing preferred provider networks in the US and has more than 850,000 providers, Verici says. The deal provides Verici with the opportunity to expand its patient scope, the firm adds. \"This agreement with Prime Health is an important milestone for Verici Dx, as we accelerate our commercial reach, expanding our patient network and supporting our approach to increased coverage from private payors,\" says Verici Dx Chief Operating Officer Patti Connolly.",
          "sentiment": 0.5,
          "engagement": "1,149",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.259752Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251257-donmac10--8085146",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.045463",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "10 -1 on the buy side ready for move up Vrci just needs to keep up the positive newsflow.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191205Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251257-donmac10-80864681",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.045463",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "10 -1 on the buy side ready for move up Vrci just needs to keep up the positive newsflow.",
          "sentiment": 0.0,
          "engagement": "2,867",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.259726Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251359-B_Positi--1947979",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.045042",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Summary of research. Thermo Fisher: $213B market cap on NASDAQ backing this company. 334 tests ordered for the whole of FY 2024. They make $2,650 per test. Q1+ Q2 = 591 Tutivia\u2122 tests ordered in H1 2025 Q3 = 286 tests ordered, as per investor presentation. Q1 + Q2 + Q3 = 877 vs 334 last year. As fo Q4: Commercial scale-up of Tutivia test adoption, a test for acute rejection post transplant, has progressed in Q3, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from Q4 and the number of orders in Q3 were consistent with the previous two quarters. So they expect a big rise in orders in Q4. Assume it's about 350 tests to be conservative (likely higher given the number of new centres onboarded) then that is 1,227 tests for the entirety of 2025 compared to just about 300 in 2024. Then imagine the scale up in 2026. About $3.4mil revenue just from these tests + about $1.5mil licensing revenues from Thermo for 2025. The turnaround is hard and fast. __ This is what excites me: *The addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Most of the orders you references was when the company only had about 5-7% centres onboarded and they are now at 16%, which is still just a fraction of the centres in the US. Then also consider international expansion. Also: Tutivia is the best in class. Also: Multiple tests per patient is essentially a requirement When you factor it altogether the market value down here is absolutely insane. Especially as the IP, tech, patents, FDA approval is all worth so much more. No wonder we have a monster in Thermo Fisher leading here __ Prime health have over 1 million healthcare providers in the US thats between 33 to 50 % of all providers total in America This is much bigger than has been factored in share price. And they are in talks as we speak with more providers.Plenty to look forward to! Exciting times for much needed best in class tests that will speak for themselves.",
          "sentiment": 0.0,
          "engagement": "4,316",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191178Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251359-B_Positi--7755640",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.045042",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Summary of research. Thermo Fisher: $213B market cap on NASDAQ backing this company. 334 tests ordered for the whole of FY 2024. They make $2,650 per test. Q1+ Q2 = 591 Tutivia\u2122 tests ordered in H1 2025 Q3 = 286 tests ordered, as per investor presentation. Q1 + Q2 + Q3 = 877 vs 334 last year. As fo Q4: Commercial scale-up of Tutivia test adoption, a test for acute rejection post transplant, has progressed in Q3, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from Q4 and the number of orders in Q3 were consistent with the previous two quarters. So they expect a big rise in orders in Q4. Assume it's about 350 tests to be conservative (likely higher given the number of new centres onboarded) then that is 1,227 tests for the entirety of 2025 compared to just about 300 in 2024. Then imagine the scale up in 2026. About $3.4mil revenue just from these tests + about $1.5mil licensing revenues from Thermo for 2025. The turnaround is hard and fast. __ This is what excites me: *The addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Most of the orders you references was when the company only had about 5-7% centres onboarded and they are now at 16%, which is still just a fraction of the centres in the US. Then also consider international expansion. Also: Tutivia is the best in class. Also: Multiple tests per patient is essentially a requirement When you factor it altogether the market value down here is absolutely insane. Especially as the IP, tech, patents, FDA approval is all worth so much more. No wonder we have a monster in Thermo Fisher leading here __ Prime health have over 1 million healthcare providers in the US thats between 33 to 50 % of all providers total in America This is much bigger than has been factored in share price. And they are in talks as we speak with more providers.Plenty to look forward to! Exciting times for much needed best in class tests that will speak for themselves.",
          "sentiment": 0.0,
          "engagement": "4,316",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-21T01:14:37.259699Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251822-tbcx-74453832",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.044555",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Another strong day here and well deserved. New sale bods hired seem to be having tangible impact already. Very different from your usual London listed biotech at this sort of market cap with an idea that never leaves the lab. They are very well positioned here to ramp up rapid commercialisation of product in US. I see huge upside here.",
          "sentiment": 0.0,
          "engagement": "721",
          "price_at_post": "0.725",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=B6EBEEF8-AEC7-4979-A053-5E1A792DECCA"
        },
        "ingested_at": "2026-01-16T22:49:18.191151Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251822-tbcx--8593609",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.044555",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Another strong day here and well deserved. New sale bods hired seem to be having tangible impact already. Very different from your usual London listed biotech at this sort of market cap with an idea that never leaves the lab. They are very well positioned here to ramp up rapid commercialisation of product in US. I see huge upside here.",
          "sentiment": 0.0,
          "engagement": "721",
          "price_at_post": "0.725",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=B6EBEEF8-AEC7-4979-A053-5E1A792DECCA"
        },
        "ingested_at": "2026-01-21T01:14:37.259673Z"
      },
      {
        "event_id": "SOCIAL-7Nov20250821-Bobat123--4740212",
        "event_type": "social_post",
        "date": "2026-01-10T01:11:03.044138",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat1234",
          "content": "Code 2 getting printed.  Mms need shares",
          "sentiment": 0.5,
          "engagement": "1,149",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-16T22:49:18.191124Z"
      },
      {
        "event_id": "SOCIAL-21Jan20261715-Silverbl--7695300",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - feel free to use the actual numbers in your updates. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 (INCORRECT: H1 actual revenue was $1.16m = $1962 average revenue per test). H1 2025 licencing revenue = $750,000 (CORRECT) Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. (Test numbers CORRECT. Centres INCORRECT - there were 21 onboarded at time of results). 286 x $2,650 = $757,900 (Likely INCORRECT based on average revenue per test of $1962 achieved in H1 2025 - likely revenue $560K). Q4 2025, 20 centres onboarded and let's be conservative and say 300 tests. (INCORRECT. There are now 30 centres onboarded. Company is targeting in the region of 750 tests in Q4 in order to meet its Q4 revenue target of c.$1.5m) 300 x $2,650 = $795,000 revenue (We will find out in due course what was achieved in terms of test numbers and average revenue per test) H2 2025 licensing revenue, let's be conservative and say $500,000. (INCORRECT. No licencing revenue will come from Thermo in H2) Combine all of that above and you get = $4.3mil or \u00a33.2m. (H1 revenue was $1.9m/ Q3 likely $560K. Q4 not yet reported. Company is targeting total FY 2025 revenue of $3.95m, comprising $3.2 Tutivia tests and $750K licencing revenue) Still nothing in the way of a trading update from the team at vrci. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349300+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261504-B_Positi-55275610",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332720",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We should all be extremely excited having now onboarded over 30 transplant centres, up from 10 in 2024. We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349323+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260830-Silverbl--4399709",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333151",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "$12m was a direct quote from Vrci CEO in latest Vox markets interview. As for my 'precise' figures - strangely enough when it comes to investing I prefer to deal in fact rather than making it up (refer B_Positive). As for my views on the business - I remain invested so I am hopeful there is a future here or would have taken my medicine and moved on. That does not mean to say I will not vocalise my thoughts on areas of mismanagement where the company could and should be doing better; or to call out posters who are just making it up as they go along. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349343+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260728-B_Positi--2751246",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333626",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349366+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260205-donmac10--4727184",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334054",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Where do you get the 12mill breakeven point? You sound like a bot with your precise figures. And you always have a way of sounding positive but are really negative .So cant be taken seriously .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349384+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262026-Silverbl--4124042",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334501",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not really sure why I need to explain this, but here you go B_Positive. Your bullet point regarding Tutivia sums the position up very well. Transplant centres service both Medicare patients and private paying patients. So whilst the Medicare payment of $2650 is being provided by the US healthcare system for patients who benefit from the Medicare and Medicare plus programmes - there are actually six key revenue streams for test sales of which Medicare is one (albeit the largest - 68% of tests being undertaken are covered by Medicare seems to be the claim from the company). Private payers (via healthcare insurance) do not pay the $2650 - they receive discounts. Clinical trials pay nothing. And there others. If you divide the H1 Tutivia revenue of $1.16m by the 591 tests in H1 it comes out at $1962 . That is the current revenue reality for test sales. The recent RNS highlighting the agreement with Prime Health Services is all about trying to establish consistent pricing of the Tutivia test with the private payment market and clearly with the goal to increase current pricing which is diluting the Medicare $2650. In relation to your H2 licencing point the following clarifies the position \" Thermo Fisher is investing in new research related to PTRA aimed at identifying the earliest stage at which the test can be utilised before transplantation. Consequently, the second milestone originally anticipated for 2025 will be delayed as we continue to collaborate on publishing clinical validation data and Thermo Fisher pursues these additional research efforts to help broaden utility and adoption of the assay.\" FYI the breakeven position for Verici is c.$12m - so that provides an indication of the revenue which is required from test sales, licence revenue, protega etc to cover vrci operating costs. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349403+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261524-B_Positi-11416720",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334932",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Nope it's $2,650 as per the Medicare coverage RNS and more recently as per the HY report. \u00b7 Lead product Tutivia\u2122 attained Medicare coverage at $2,650 per test, covering a national estimate of 68% of all US transplant tests and commercial payor reimbursement applications are underway They receive licencing revenues both H1 and H2. It was $750k in H1.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349430+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261523-Silverbl--4294271",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335360",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Mikemine -  your points are valid - but highlight one of the main issues here. Why set a target and fail. Undermines confidence, craters the share price, makes fund raising tricky and makes investors wary on growth. Much better to overdeliver on achievable targets than underdeliver? But maybe we will be get a pleasant surprise. Thermo are just doing their own thing on the PRTA at present. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349468+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261518-Silverbl--6191726",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335771",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "No licencing revenue in H2 2025 and average received revenue per test is $1900. Do some actual research please. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349488+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261416-B_Positi--4102458",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336264",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10 centres onboarded. It must now be around 25-35 going by the last report.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349507+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261402-Mikemine--9118709",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336713",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "They've set themselves a big revenue target of over \u00a33mn for 2025. Small in world terms but a big % increase for VRCI. Should they be chastised if they do not reach the target or should it be viewed in the context of what they do achieve and what they forecast for this year? Getting close to \u00a33mn would be an achievement in my book as that would point to things being on track for further increases especially as the new sales guys have probably only just got their acts together and their contacts in line. Not sure what to think of the Thermo-Fisher deal and its seemingly lack of traction. Big companies are not nimble nor quick so the jury's out on that one for me. My guess is for an update this month and it will be positive but will not please everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349525+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261401-B_Positi-95705182",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337193",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Cashed up until the end of 2026 and now they've been securing record orders as per below. Next time they raise it will be in the pennies, which is what they will want given the new option prices. Test update going to drop soon. More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349543+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261346-Silverbl--2287163",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Despite the view expressed by several contributors here we have heard nothing from the business on Q4 trading. Not unexpected - if there was anything to report on I would expect to hear later on in January. The issue looming very shortly relates to the required fund raising. In previous years the company has elected not to divulge FY trading until May.  This is likely to be beyond the point at which the company runs out of cash. We should therefore be able to read the signals loud and clear - no trading update - then Q4 has not delivered the targeted sales and the fund raise will be brutal.  If a positive Q4 trading update is issued then there should be a healthy price response despite the recognition funds will still be required. Remember last year the first fundraise was at 9p - then 0.5p after bewildering timing mismanagement by the company.  All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: 100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-01-24T01:57:04.349560+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261228-B_Positi--8954171",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338063",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349578+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-2reincar--8431908",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338488",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Conversions this summer will see us at sub 0.25p!",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.75",
          "thread_title": "100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-01-24T01:57:04.349596+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261210-B_Positi-67875004",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338938",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349615+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20260629-2Phones-88269756",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339362",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "How can any one disagree with such a cogent arguement - and clearly not the rantings of a one track numpty.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.725",
          "thread_title": "RE: Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-01-24T01:57:04.349634+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261022-2reincar-19558323",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339773",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "At 0.25p?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.725",
          "thread_title": "Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-01-24T01:57:04.349652+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251515-B_Positi-67875004",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340229",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349671+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251223-Silverbl-36442019",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "2Phones - from the company itself: \" With minimum gross proceeds from the Placing and Subscription of \u00a35 million, the Company's cash runway will be extended to mid Q2 2026.\". Hence my thinking spring will be the time to raise. And yes revenue is expected to increase (we will know by how much in a few weeks) - but annual expenses are c.$9m - so sales would need a dramatic (and unlikely) increase to negate the need for more funds. And you seem to agree that a placing is an option (imo the only likely one and the route the company has taken to date in all its efforts to secure more funding). So not sure what you were disagreeing with? SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-24T01:57:04.349689+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20250753-2Phones--9154036",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341050",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I don't agree - the operational update earlier this year had a predicted cash runway to H2 next year - when you couple that with the recruitment of 2 sales people and a director of clinical partnerships, I would anticipate growth in cash inflow.  However, they are a small team and they are going to have to increase production to accommodate the anticipated sales.  This will need funding, but where they get it is uncertain \u2013 one option being a placing.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-24T01:57:04.349707+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251728-2reincar-76255097",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341472",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Agree Silverblade. We could have one in Aprilish at 0.5p and one in Octoberish at 0.25p and then a rocket to + 2p ?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-24T01:57:04.349726+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251618-Silverbl-55786382",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Same old nonsense B_Positive. Thermo are not involved in Tutivia. Stop spreading false information. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349744+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251557-B_Positi--7691676",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342355",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-24T01:57:04.349763+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251522-Silverbl-56239039",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342765",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There will be a placing in early 2026 - probably March/April time. The placing will of course be determined by the prevailing share price at the time. And that in turn will reflect the numbers for FY 2025 - there is a lot of expectation here so lets see what the company has to say for itself hopefully with a trading update in January. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-24T01:57:04.349781+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261447-donmac10-84133449",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:31.826472",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Very good research note out last few day by Singer .Talking up Prime health deal 300 mill mkt.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.412734+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251243-Romanby--2108186",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.788345",
        "source": "LSE_CHAT",
        "data": {
          "author": "Romanby",
          "content": "No placing you idiot",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-29T10:03:39.412781+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251216-Sandyman-64444382",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "Is the placing going to be at 0.25p or 0.5p? Or both?",
          "sentiment": 0.0,
          "engagement": "999",
          "price_at_post": "0.775",
          "thread_title": "Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-29T10:03:39.412822+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251441-Silverbl--4075125",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - FYI Thermo Fisher are not currently involved in Tutivia - so they are not involved in any roll out. Despite claims here to the contrary there has been no trading update - so we await evidence that Q4 delivers the level of sales anticipated by the CEO on achieving the 2025 Tutivia revenue target - which as you note would be a significant increase on 2024 sales. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.412863+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251547-B_Positi--9124039",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.790830",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.412902+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-B_Positi--8376282",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.791703",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I would wager a big Thermo-Fisher update is due here. Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.412942+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251302-B_Positi-19428677",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.792503",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Wow now way just saw that. Huge implications for Thermo and its partners!",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.412980+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251255-donmac10-64955843",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.793297",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Genincode signed a deal with Thermo read across to Verici Verici so undervalued at the moment something has to give.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413019+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251244-B_Positi-81414169",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794085",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Once it breaks 1p it will fly to 2p and then 3p gets smashed with ease considering the test orders are going to be around 300-400% from the digging below. 3p as a base and then a move back to 5-10p.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413056+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251227-B_Positi-11032478",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794962",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I'm personally amazed more aren't piling in whilst under 1p and this isn't at 3-5p already. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413093+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251953-B_Positi-75252659",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.795766",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Will add another 2m sub 1p Way too cheap here for me personally.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413148+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251945-donmac10--6109996",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.796575",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "3p per share nailed on short term if you guys sit oan yer tuffetts like miss muffet know whit ah mean?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413187+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251941-donmac10-52989943",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.797364",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Company is no longer research orientated so past rns at this time of year irrelevant trust me as tests ramp up as they will be the company will be eager to broadcast positive newsflow asap.noh whit a meen an that man getmeh!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413225+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251535-Silverbl-82378811",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798154",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Would be unusual for a trading update pre-xmas imo although any kind of an update in relation to hitting revenue targets would assist progress here - the bar has been set very high by CEO. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413263+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251320-B_Positi--8033729",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798939",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Yes it was due. Thermo-Fisher $220BILLION backing this and tied in. Update on them or something new will wake the market up.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413302+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251245-donmac10--8273231",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.799717",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Update this week and more deals with distributors .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413340+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251234-B_Positi-26785698",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.800588",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "MMs caught wind of an update? I'm amazed this isn't over 2p at least. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413379+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251230-tbcx-47767720",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.801373",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Buying pressure certainly returning this week, this remains extremely undervalued.",
          "sentiment": 0.0,
          "engagement": "766",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413419+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251443-donmac10-94395060",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802148",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Nice 2mill buy this morning.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413458+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251235-B_Positi--1861762",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802905",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Donmac, absolutely buzzing for the trading update this month Hopefully see's this head back to the 3 to 5p level",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413499+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251104-B_Positi--2223951",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.803727",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "So with less than 10% of transplant centres onboarded and already at the start of the mass rollout they averaged about 300 tests per quarter in Q1, Q2 and Q3, just short of 900, vs 334 for the entirety of 2024, representng significant growth. We now know they are at at least 16% of transplant centres onboarded now (less than 10% for Q1, Q2, Q2, perhaps around 20% now and are increasing this fast. You quickly realise how mad the revenues can become here at $2,650 a test with the medicaid coverage +Thermo Fisher licencing revenues. I know many, many pharma stocks that have literally $0 revenue, no proven tech, no FDA approval, no big deal with a giant like this does with Thermo Fisher that are trading at many multiples of the Verici market cap.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413538+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251045-donmac10-58276316",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.804510",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And its beginning to look like word is out?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413576+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251039-donmac10--4026473",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.805293",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Expecting a trading update in the run up to xmas should make for good reading!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413615+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251031-B_Positi--3011841",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806132",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.413655+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251456-Mikemine--4909131",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806901",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, your posts have got  very repetitive and quite frankly, boring. Unless your rants help your mental state I for one would be grateful if you would keep your posts to new views or information.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-29T10:03:39.413694+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251148-Fevertre--6733565",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.375637",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Just out of interest what are Barrington's competencies?",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-29T10:03:39.413733+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251147-Fevertre-82397507",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.376396",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "The Board and non-execs have overseen an absolute shamble here. Barrington completely unaffected by disastrous dilution as she has virtually no bloody shares in teh company she purports to lead.  The CFo isnt fit for purpose frankly. The Q4 figs appear to be the stuff of fantasy - I would give more creedance if  Barrington was able to explain how she gets to the forecast but she appears to be just making it up as she goes along... we have no timelines on onboarding; Barrington cant set out how she arrived at the numbers... she continues to be utterly hopeless as the CEO of supposedly a cutting edge business.",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-29T10:03:39.413780+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251059-Silverbl--8348576",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377214",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There you go donmac almost at your buy price already. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-29T10:03:39.413819+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20250050-donmac10-57649655",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377985",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sell up move on thank you.....give me the chance ar more aroon the 55 mark slanj .And a will catch yeh in wetherspoons oan the wae otta rah ritz.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-29T10:03:39.413857+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251734-Mikemine-87961764",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.378810",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "VRCI is a small company so hiring an extra 3 salespersons is huge for them and points to their determination to hit their target. It's a big ask but you can be sure they recognise that their credibility is on the line. From a practical point of view, hiring new salespeople  takes time for their impact to come through. They have to get used of the systems, the product and VRCI's method of selling. I wish them luck and, if they do reach their target, it will be noticed by the Market.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-29T10:03:39.413896+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251709-Silverbl--6018024",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.379608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not a fan to date either fevertree - its been a disaster for all shareholders here - but I still hold a position here and am trying to look forward not back given the past is what it is. If Q4 goes well I expect a trading update early 2026 - which doesn't usually happen but positive momentum will be required to avoid a total wipe out in any subsequent capital raise. Failure to deliver (again) then more questions will be raised on leadership competencies.  SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.75",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-29T10:03:39.413935+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251647-Fevertre-39689978",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.380414",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "She has never fully explained the onboarding process. If a new centre gets onboarded, typically how long does it take for clinicians to order first tests",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-29T10:03:39.413975+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251644-Fevertre--4665472",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.381220",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Nonsense Donmac.....look at the maths around Barrington's targets: On my maths I don't see how she hits revs from Tutivia $3.2m... Tutivia:  1H Revs: $1.16m: 591 tests @ ave $1900 ($1.16m divided by 591) 2H Revs:  3Q Tutivia same rate as Q1/Q2 ..c300 tests at 1900 = $570k  ...so to meet her target she needs to sell c$1.5m of tests. Assume same ave price of $1900....she needs to sell c790 tests....that's a massive uplift, even with onboarding another 9 more centres...",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-29T10:03:39.414015+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251627-donmac10-74242666",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382010",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "markets falling and the doom and gloom ****roaches appear in force.sell up ,thats even if yeh hod any and gie us aw peace!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-29T10:03:39.414053+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251604-Fevertre--4711801",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382802",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Worryingly her bullishness has cost investors dearly so far. Apart from having virtually no skin in the game she hasn't been gifted,  or regifted (look at the outrageous revision of option pricing). The fact that the sp is still at 3/4 of a penny tells you everything you need to know about how the market views her!",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-29T10:03:39.414094+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251522-Silverbl--4925536",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.383604",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Based on what we already know - VRCI sold c.600 Tutivia tests in H1 2025 - securing revenue of $1.2m ($2k per test - blend of public and private payers). They sold same in Q3 - so lets assume pro-rata they secured a further $600k revenue. Sara B confirmed FY Tutivia target was $3.2m - so that leaves $1.4 revenue to be secured in Q4 - or c.700 tests at $2k. Seems a huge leap - or possible they are looking at a slight increase to average test $ - although Prime Health RNS appears to push towards discounted volume in private market. She has certainly set high expectations for Q4 trading. If this is achieved it will be a significant acceleration - and will be crucial in supporting the share price/market cap as the company requires additional funding in the next 4/5 months. Additional licensing revenue from Thermo (c.$4m received to date - $3.3m in 2024 and $0.75m in 2025) remains on hold as they progress their approach to the PTRA test. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.725",
          "thread_title": "2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-29T10:03:39.414146+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250856-2Phones--2106071",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.384401",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac agreed - two of the latest RNS are very positive about the rate of revenue growth and market penetration - can't help but think the next sales based RNS will be a gamechanger.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.875",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-29T10:03:39.414184+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250845-donmac10-22898222",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385202",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Analysts expecting 3p per share next year big upside from here.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.90",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-29T10:03:39.414223+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250843-donmac10--1039833",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385990",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Verici also more forthcoming informing the market with updates .Beats last years 6 month radio silence .Just waiting now for testing update which i know will further boost price.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-29T10:03:39.414262+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250830-donmac10-43284317",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.386775",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Tells me ,anyone looking to make money would be well served to get in now .Futher big rise going into year end.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.95",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-29T10:03:39.414301+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250809-2Phones--4961946",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.387576",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Interesting news today \u2013 initially I thought why? This has little bearing on shareholders interests \u2013 however, on further concideration, while successful audits add little to the bottom line or turnover or even shareholder value \u2013 in our case it is very much a Critical Failure Factor, where failure to pass a quality audit could seriously damage the company in the short/medium term.  Also it does point to a well run, disciplined business. So well done Verici.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.95",
          "thread_title": "RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-29T10:03:39.414341+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251448-oogleflu-21747464",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.388340",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Tom. I know exactly what you\u2019re saying is correct . Unfortunately risk appetite is much lower in the UK probably because the FA are like a bunch of frightened rabbits. Fund managers continue to unwind oversold positions in uk to chase  the way overpriced \u2018American dream stocks\u2019 which are overdue a big correction there by loosing even more of the inadequate fund managers clients money. It\u2019s not all Uk stocks but quite a few as admitted in an interview recently with a fund manager. Certainly since the pandemic Uk stocks are valued much more realistically i.e. sound balance sheet which Vrci  now has, realistic forecast which Vrci now has, realistic targets for growth which Vrci now has. But we don\u2019t tend to look further than a year ahead. One step at a time . There will be /is FOMO with a stock like Vrci which will cause some volatility till they establish a more constant earnings stream.",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414380+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251354-donmac10-26177191",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389131",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "It feels to me we are about to get a trading update on testing numbers shortly .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414419+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251256-donmac10-90278893",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389888",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "1.20p close today and more updates in coming days on quickly to 2.00p",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414458+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251247-geraldus-19792352",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.390653",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "Still early days here,and they will have to take some market share from the incumbent bio markers. Shaping up well so far and with a miserly market cap in comparison with other counters.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.825",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414497+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251241-B_Positi-80945119",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.391431",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Geraldus Tutivia is the standard now. Hence why Thermo-Fisher has gone all in and is backing all the way. Market slowly beginning to wake up that this company is grossly undervalued. I mean the FDA approval, ip, tech alone is worth multiples and then whack on the huge growth already in 2025 and coming in 2026 with over 30 transplant centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414536+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251239-donmac10--5795075",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392203",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "American market waking up to the potential with Verici dx in their own backyard They love an AI stock.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414574+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251236-geraldus--5483034",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392989",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "With their 'AI' solution for optimising transplants,it is undoubtly an interesting opportunity here. They have spent millions on this and they are confident that it is payback time. With no competition at this level,it could possibly become the defacto standard.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414613+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251217-B_Positi--3011841",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.393835",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414652+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251205-oogleflu-10227688",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.394621",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Addressable market doesn\u2019t mean they capture all of it.  They might get 1 or 2 percent which is still sizeable if lucky. Even singer, their broker,  have only raised the sp to 3p. That\u2019s still 4 times current market cap! The other thing is will they need to expand the lab or open another one as their market share increases. They have got a captured market in that there is no competition and the tests are becoming mandatory. No plans to adopt outside the US yet. Maybe 20p in 5 years certainly not months I\u2019m afraid but good luck",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.775",
          "thread_title": "RE: Quantifying the opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=D3DE9F2B-871D-47DE-96C8-2D6BB08D16A4"
        },
        "ingested_at": "2026-01-29T10:03:39.414691+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261715-Silverbl--4616859",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - feel free to use the actual numbers in your updates. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 (INCORRECT: H1 actual revenue was $1.16m = $1962 average revenue per test). H1 2025 licencing revenue = $750,000 (CORRECT) Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. (Test numbers CORRECT. Centres INCORRECT - there were 21 onboarded at time of results). 286 x $2,650 = $757,900 (Likely INCORRECT based on average revenue per test of $1962 achieved in H1 2025 - likely revenue $560K). Q4 2025, 20 centres onboarded and let's be conservative and say 300 tests. (INCORRECT. There are now 30 centres onboarded. Company is targeting in the region of 750 tests in Q4 in order to meet its Q4 revenue target of c.$1.5m) 300 x $2,650 = $795,000 revenue (We will find out in due course what was achieved in terms of test numbers and average revenue per test) H2 2025 licensing revenue, let's be conservative and say $500,000. (INCORRECT. No licencing revenue will come from Thermo in H2) Combine all of that above and you get = $4.3mil or \u00a33.2m. (H1 revenue was $1.9m/ Q3 likely $560K. Q4 not yet reported. Company is targeting total FY 2025 revenue of $3.95m, comprising $3.2 Tutivia tests and $750K licencing revenue) Still nothing in the way of a trading update from the team at vrci. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414733+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261504-B_Positi--7252771",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332720",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We should all be extremely excited having now onboarded over 30 transplant centres, up from 10 in 2024. We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414773+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260830-Silverbl-52259362",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333151",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "$12m was a direct quote from Vrci CEO in latest Vox markets interview. As for my 'precise' figures - strangely enough when it comes to investing I prefer to deal in fact rather than making it up (refer B_Positive). As for my views on the business - I remain invested so I am hopeful there is a future here or would have taken my medicine and moved on. That does not mean to say I will not vocalise my thoughts on areas of mismanagement where the company could and should be doing better; or to call out posters who are just making it up as they go along. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414814+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260728-B_Positi-57051947",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333626",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414854+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260205-donmac10--4820449",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334054",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Where do you get the 12mill breakeven point? You sound like a bot with your precise figures. And you always have a way of sounding positive but are really negative .So cant be taken seriously .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414893+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262026-Silverbl--1708129",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334501",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not really sure why I need to explain this, but here you go B_Positive. Your bullet point regarding Tutivia sums the position up very well. Transplant centres service both Medicare patients and private paying patients. So whilst the Medicare payment of $2650 is being provided by the US healthcare system for patients who benefit from the Medicare and Medicare plus programmes - there are actually six key revenue streams for test sales of which Medicare is one (albeit the largest - 68% of tests being undertaken are covered by Medicare seems to be the claim from the company). Private payers (via healthcare insurance) do not pay the $2650 - they receive discounts. Clinical trials pay nothing. And there others. If you divide the H1 Tutivia revenue of $1.16m by the 591 tests in H1 it comes out at $1962 . That is the current revenue reality for test sales. The recent RNS highlighting the agreement with Prime Health Services is all about trying to establish consistent pricing of the Tutivia test with the private payment market and clearly with the goal to increase current pricing which is diluting the Medicare $2650. In relation to your H2 licencing point the following clarifies the position \" Thermo Fisher is investing in new research related to PTRA aimed at identifying the earliest stage at which the test can be utilised before transplantation. Consequently, the second milestone originally anticipated for 2025 will be delayed as we continue to collaborate on publishing clinical validation data and Thermo Fisher pursues these additional research efforts to help broaden utility and adoption of the assay.\" FYI the breakeven position for Verici is c.$12m - so that provides an indication of the revenue which is required from test sales, licence revenue, protega etc to cover vrci operating costs. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414932+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261524-B_Positi-33136848",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334932",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Nope it's $2,650 as per the Medicare coverage RNS and more recently as per the HY report. \u00b7 Lead product Tutivia\u2122 attained Medicare coverage at $2,650 per test, covering a national estimate of 68% of all US transplant tests and commercial payor reimbursement applications are underway They receive licencing revenues both H1 and H2. It was $750k in H1.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.414972+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261523-Silverbl-63235622",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335360",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Mikemine -  your points are valid - but highlight one of the main issues here. Why set a target and fail. Undermines confidence, craters the share price, makes fund raising tricky and makes investors wary on growth. Much better to overdeliver on achievable targets than underdeliver? But maybe we will be get a pleasant surprise. Thermo are just doing their own thing on the PRTA at present. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.415011+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261518-Silverbl-72308918",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335771",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "No licencing revenue in H2 2025 and average received revenue per test is $1900. Do some actual research please. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.415053+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261416-B_Positi-48539809",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336264",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10 centres onboarded. It must now be around 25-35 going by the last report.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.415091+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261402-Mikemine--1407364",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336713",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "They've set themselves a big revenue target of over \u00a33mn for 2025. Small in world terms but a big % increase for VRCI. Should they be chastised if they do not reach the target or should it be viewed in the context of what they do achieve and what they forecast for this year? Getting close to \u00a33mn would be an achievement in my book as that would point to things being on track for further increases especially as the new sales guys have probably only just got their acts together and their contacts in line. Not sure what to think of the Thermo-Fisher deal and its seemingly lack of traction. Big companies are not nimble nor quick so the jury's out on that one for me. My guess is for an update this month and it will be positive but will not please everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.415142+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261401-B_Positi--9221461",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337193",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Cashed up until the end of 2026 and now they've been securing record orders as per below. Next time they raise it will be in the pennies, which is what they will want given the new option prices. Test update going to drop soon. More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.415182+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261346-Silverbl-49577006",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Despite the view expressed by several contributors here we have heard nothing from the business on Q4 trading. Not unexpected - if there was anything to report on I would expect to hear later on in January. The issue looming very shortly relates to the required fund raising. In previous years the company has elected not to divulge FY trading until May.  This is likely to be beyond the point at which the company runs out of cash. We should therefore be able to read the signals loud and clear - no trading update - then Q4 has not delivered the targeted sales and the fund raise will be brutal.  If a positive Q4 trading update is issued then there should be a healthy price response despite the recognition funds will still be required. Remember last year the first fundraise was at 9p - then 0.5p after bewildering timing mismanagement by the company.  All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: 100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-01-29T10:03:39.415221+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261228-B_Positi--1088349",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338063",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.415259+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-2reincar--8251365",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338488",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Conversions this summer will see us at sub 0.25p!",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.75",
          "thread_title": "100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-01-29T10:03:39.415298+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261210-B_Positi--9216583",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338938",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.415337+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20260629-2Phones-28652613",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339362",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "How can any one disagree with such a cogent arguement - and clearly not the rantings of a one track numpty.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.725",
          "thread_title": "RE: Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-01-29T10:03:39.415376+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261022-2reincar--8705932",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339773",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "At 0.25p?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.725",
          "thread_title": "Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-01-29T10:03:39.415414+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251515-B_Positi--9216583",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340229",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.415454+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251223-Silverbl--4653473",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "2Phones - from the company itself: \" With minimum gross proceeds from the Placing and Subscription of \u00a35 million, the Company's cash runway will be extended to mid Q2 2026.\". Hence my thinking spring will be the time to raise. And yes revenue is expected to increase (we will know by how much in a few weeks) - but annual expenses are c.$9m - so sales would need a dramatic (and unlikely) increase to negate the need for more funds. And you seem to agree that a placing is an option (imo the only likely one and the route the company has taken to date in all its efforts to secure more funding). So not sure what you were disagreeing with? SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-29T10:03:39.415492+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20250753-2Phones-14854524",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341050",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I don't agree - the operational update earlier this year had a predicted cash runway to H2 next year - when you couple that with the recruitment of 2 sales people and a director of clinical partnerships, I would anticipate growth in cash inflow.  However, they are a small team and they are going to have to increase production to accommodate the anticipated sales.  This will need funding, but where they get it is uncertain \u2013 one option being a placing.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-29T10:03:39.415534+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251728-2reincar--1833560",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341472",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Agree Silverblade. We could have one in Aprilish at 0.5p and one in Octoberish at 0.25p and then a rocket to + 2p ?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-29T10:03:39.415572+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251618-Silverbl--6615582",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Same old nonsense B_Positive. Thermo are not involved in Tutivia. Stop spreading false information. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.415611+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251557-B_Positi--9124039",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342355",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-29T10:03:39.415650+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251522-Silverbl-86534711",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342765",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There will be a placing in early 2026 - probably March/April time. The placing will of course be determined by the prevailing share price at the time. And that in turn will reflect the numbers for FY 2025 - there is a lot of expectation here so lets see what the company has to say for itself hopefully with a trading update in January. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-29T10:03:39.415690+00:00"
      },
      {
        "event_id": "SOCIAL-Today0851-2Phones--6086481",
        "event_type": "social_post",
        "date": "2026-01-30T23:03:22.957691",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac101 - I was particularly encouraged by the 2.9p target price.  They clearly believe the future for tutivia is massive.",
          "sentiment": 0.0,
          "engagement": "83",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039496+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261447-donmac10-57203952",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:31.826472",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Very good research note out last few day by Singer .Talking up Prime health deal 300 mill mkt.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039535+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251243-Romanby-74596397",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.788345",
        "source": "LSE_CHAT",
        "data": {
          "author": "Romanby",
          "content": "No placing you idiot",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-30T23:03:29.039556+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251216-Sandyman--8348765",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "Is the placing going to be at 0.25p or 0.5p? Or both?",
          "sentiment": 0.0,
          "engagement": "999",
          "price_at_post": "0.775",
          "thread_title": "Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-30T23:03:29.039575+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251441-Silverbl-25039176",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - FYI Thermo Fisher are not currently involved in Tutivia - so they are not involved in any roll out. Despite claims here to the contrary there has been no trading update - so we await evidence that Q4 delivers the level of sales anticipated by the CEO on achieving the 2025 Tutivia revenue target - which as you note would be a significant increase on 2024 sales. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039594+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251547-B_Positi--7045249",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.790830",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039614+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-B_Positi--6841809",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.791703",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I would wager a big Thermo-Fisher update is due here. Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039633+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251302-B_Positi-65475342",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.792503",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Wow now way just saw that. Huge implications for Thermo and its partners!",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039656+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251255-donmac10--5593339",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.793297",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Genincode signed a deal with Thermo read across to Verici Verici so undervalued at the moment something has to give.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039675+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251244-B_Positi--4044410",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794085",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Once it breaks 1p it will fly to 2p and then 3p gets smashed with ease considering the test orders are going to be around 300-400% from the digging below. 3p as a base and then a move back to 5-10p.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039693+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251227-B_Positi-53266805",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794962",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I'm personally amazed more aren't piling in whilst under 1p and this isn't at 3-5p already. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039712+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251953-B_Positi--8838569",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.795766",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Will add another 2m sub 1p Way too cheap here for me personally.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039730+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251945-donmac10-68665355",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.796575",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "3p per share nailed on short term if you guys sit oan yer tuffetts like miss muffet know whit ah mean?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039748+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251941-donmac10--7777549",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.797364",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Company is no longer research orientated so past rns at this time of year irrelevant trust me as tests ramp up as they will be the company will be eager to broadcast positive newsflow asap.noh whit a meen an that man getmeh!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039767+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251535-Silverbl--8850505",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798154",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Would be unusual for a trading update pre-xmas imo although any kind of an update in relation to hitting revenue targets would assist progress here - the bar has been set very high by CEO. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039786+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251320-B_Positi--6158653",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798939",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Yes it was due. Thermo-Fisher $220BILLION backing this and tied in. Update on them or something new will wake the market up.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039804+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251245-donmac10--6825929",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.799717",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Update this week and more deals with distributors .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039823+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251234-B_Positi-83809511",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.800588",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "MMs caught wind of an update? I'm amazed this isn't over 2p at least. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039840+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251230-tbcx--5076380",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.801373",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Buying pressure certainly returning this week, this remains extremely undervalued.",
          "sentiment": 0.0,
          "engagement": "766",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039859+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251443-donmac10-27388871",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802148",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Nice 2mill buy this morning.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039877+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251235-B_Positi--3507609",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802905",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Donmac, absolutely buzzing for the trading update this month Hopefully see's this head back to the 3 to 5p level",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039895+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251104-B_Positi--2663903",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.803727",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "So with less than 10% of transplant centres onboarded and already at the start of the mass rollout they averaged about 300 tests per quarter in Q1, Q2 and Q3, just short of 900, vs 334 for the entirety of 2024, representng significant growth. We now know they are at at least 16% of transplant centres onboarded now (less than 10% for Q1, Q2, Q2, perhaps around 20% now and are increasing this fast. You quickly realise how mad the revenues can become here at $2,650 a test with the medicaid coverage +Thermo Fisher licencing revenues. I know many, many pharma stocks that have literally $0 revenue, no proven tech, no FDA approval, no big deal with a giant like this does with Thermo Fisher that are trading at many multiples of the Verici market cap.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039913+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251045-donmac10-25231762",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.804510",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And its beginning to look like word is out?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039930+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251039-donmac10-42323592",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.805293",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Expecting a trading update in the run up to xmas should make for good reading!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039948+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251031-B_Positi--7907701",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806132",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.039966+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251456-Mikemine-14260770",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806901",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, your posts have got  very repetitive and quite frankly, boring. Unless your rants help your mental state I for one would be grateful if you would keep your posts to new views or information.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-30T23:03:29.039984+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251148-Fevertre--4916204",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.375637",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Just out of interest what are Barrington's competencies?",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-30T23:03:29.040002+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251147-Fevertre-10469536",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.376396",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "The Board and non-execs have overseen an absolute shamble here. Barrington completely unaffected by disastrous dilution as she has virtually no bloody shares in teh company she purports to lead.  The CFo isnt fit for purpose frankly. The Q4 figs appear to be the stuff of fantasy - I would give more creedance if  Barrington was able to explain how she gets to the forecast but she appears to be just making it up as she goes along... we have no timelines on onboarding; Barrington cant set out how she arrived at the numbers... she continues to be utterly hopeless as the CEO of supposedly a cutting edge business.",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-30T23:03:29.040020+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251059-Silverbl--3503702",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377214",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There you go donmac almost at your buy price already. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-30T23:03:29.040038+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20250050-donmac10--7937205",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377985",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sell up move on thank you.....give me the chance ar more aroon the 55 mark slanj .And a will catch yeh in wetherspoons oan the wae otta rah ritz.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-30T23:03:29.040056+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251734-Mikemine--8755527",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.378810",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "VRCI is a small company so hiring an extra 3 salespersons is huge for them and points to their determination to hit their target. It's a big ask but you can be sure they recognise that their credibility is on the line. From a practical point of view, hiring new salespeople  takes time for their impact to come through. They have to get used of the systems, the product and VRCI's method of selling. I wish them luck and, if they do reach their target, it will be noticed by the Market.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-30T23:03:29.040074+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251709-Silverbl--8717126",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.379608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not a fan to date either fevertree - its been a disaster for all shareholders here - but I still hold a position here and am trying to look forward not back given the past is what it is. If Q4 goes well I expect a trading update early 2026 - which doesn't usually happen but positive momentum will be required to avoid a total wipe out in any subsequent capital raise. Failure to deliver (again) then more questions will be raised on leadership competencies.  SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.75",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-30T23:03:29.040092+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251647-Fevertre--7178752",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.380414",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "She has never fully explained the onboarding process. If a new centre gets onboarded, typically how long does it take for clinicians to order first tests",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-30T23:03:29.040128+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251644-Fevertre-53674878",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.381220",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Nonsense Donmac.....look at the maths around Barrington's targets: On my maths I don't see how she hits revs from Tutivia $3.2m... Tutivia:  1H Revs: $1.16m: 591 tests @ ave $1900 ($1.16m divided by 591) 2H Revs:  3Q Tutivia same rate as Q1/Q2 ..c300 tests at 1900 = $570k  ...so to meet her target she needs to sell c$1.5m of tests. Assume same ave price of $1900....she needs to sell c790 tests....that's a massive uplift, even with onboarding another 9 more centres...",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-30T23:03:29.040146+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251627-donmac10-92877364",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382010",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "markets falling and the doom and gloom ****roaches appear in force.sell up ,thats even if yeh hod any and gie us aw peace!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-30T23:03:29.040164+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251604-Fevertre-72440538",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382802",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Worryingly her bullishness has cost investors dearly so far. Apart from having virtually no skin in the game she hasn't been gifted,  or regifted (look at the outrageous revision of option pricing). The fact that the sp is still at 3/4 of a penny tells you everything you need to know about how the market views her!",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-30T23:03:29.040182+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251522-Silverbl-19430513",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.383604",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Based on what we already know - VRCI sold c.600 Tutivia tests in H1 2025 - securing revenue of $1.2m ($2k per test - blend of public and private payers). They sold same in Q3 - so lets assume pro-rata they secured a further $600k revenue. Sara B confirmed FY Tutivia target was $3.2m - so that leaves $1.4 revenue to be secured in Q4 - or c.700 tests at $2k. Seems a huge leap - or possible they are looking at a slight increase to average test $ - although Prime Health RNS appears to push towards discounted volume in private market. She has certainly set high expectations for Q4 trading. If this is achieved it will be a significant acceleration - and will be crucial in supporting the share price/market cap as the company requires additional funding in the next 4/5 months. Additional licensing revenue from Thermo (c.$4m received to date - $3.3m in 2024 and $0.75m in 2025) remains on hold as they progress their approach to the PTRA test. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.725",
          "thread_title": "2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-01-30T23:03:29.040200+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250856-2Phones-60260951",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.384401",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac agreed - two of the latest RNS are very positive about the rate of revenue growth and market penetration - can't help but think the next sales based RNS will be a gamechanger.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.875",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-30T23:03:29.040218+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250845-donmac10-23989226",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385202",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Analysts expecting 3p per share next year big upside from here.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.90",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-30T23:03:29.040236+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250843-donmac10-20637648",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385990",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Verici also more forthcoming informing the market with updates .Beats last years 6 month radio silence .Just waiting now for testing update which i know will further boost price.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-30T23:03:29.040255+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250830-donmac10-90792251",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.386775",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Tells me ,anyone looking to make money would be well served to get in now .Futher big rise going into year end.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.95",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-30T23:03:29.040273+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250809-2Phones-43000950",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.387576",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Interesting news today \u2013 initially I thought why? This has little bearing on shareholders interests \u2013 however, on further concideration, while successful audits add little to the bottom line or turnover or even shareholder value \u2013 in our case it is very much a Critical Failure Factor, where failure to pass a quality audit could seriously damage the company in the short/medium term.  Also it does point to a well run, disciplined business. So well done Verici.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.95",
          "thread_title": "RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-01-30T23:03:29.040291+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251448-oogleflu-20362020",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.388340",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Tom. I know exactly what you\u2019re saying is correct . Unfortunately risk appetite is much lower in the UK probably because the FA are like a bunch of frightened rabbits. Fund managers continue to unwind oversold positions in uk to chase  the way overpriced \u2018American dream stocks\u2019 which are overdue a big correction there by loosing even more of the inadequate fund managers clients money. It\u2019s not all Uk stocks but quite a few as admitted in an interview recently with a fund manager. Certainly since the pandemic Uk stocks are valued much more realistically i.e. sound balance sheet which Vrci  now has, realistic forecast which Vrci now has, realistic targets for growth which Vrci now has. But we don\u2019t tend to look further than a year ahead. One step at a time . There will be /is FOMO with a stock like Vrci which will cause some volatility till they establish a more constant earnings stream.",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040310+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251354-donmac10--1705001",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389131",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "It feels to me we are about to get a trading update on testing numbers shortly .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040329+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251256-donmac10--8265394",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389888",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "1.20p close today and more updates in coming days on quickly to 2.00p",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040347+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251247-geraldus-88056737",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.390653",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "Still early days here,and they will have to take some market share from the incumbent bio markers. Shaping up well so far and with a miserly market cap in comparison with other counters.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.825",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040365+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251241-B_Positi-22244627",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.391431",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Geraldus Tutivia is the standard now. Hence why Thermo-Fisher has gone all in and is backing all the way. Market slowly beginning to wake up that this company is grossly undervalued. I mean the FDA approval, ip, tech alone is worth multiples and then whack on the huge growth already in 2025 and coming in 2026 with over 30 transplant centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040383+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251239-donmac10-49360428",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392203",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "American market waking up to the potential with Verici dx in their own backyard They love an AI stock.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040401+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251236-geraldus--8376832",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392989",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "With their 'AI' solution for optimising transplants,it is undoubtly an interesting opportunity here. They have spent millions on this and they are confident that it is payback time. With no competition at this level,it could possibly become the defacto standard.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040420+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251217-B_Positi--7907701",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.393835",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040438+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251205-oogleflu--5466232",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.394621",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Addressable market doesn\u2019t mean they capture all of it.  They might get 1 or 2 percent which is still sizeable if lucky. Even singer, their broker,  have only raised the sp to 3p. That\u2019s still 4 times current market cap! The other thing is will they need to expand the lab or open another one as their market share increases. They have got a captured market in that there is no competition and the tests are becoming mandatory. No plans to adopt outside the US yet. Maybe 20p in 5 years certainly not months I\u2019m afraid but good luck",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.775",
          "thread_title": "RE: Quantifying the opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=D3DE9F2B-871D-47DE-96C8-2D6BB08D16A4"
        },
        "ingested_at": "2026-01-30T23:03:29.040456+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261715-Silverbl--5354723",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - feel free to use the actual numbers in your updates. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 (INCORRECT: H1 actual revenue was $1.16m = $1962 average revenue per test). H1 2025 licencing revenue = $750,000 (CORRECT) Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. (Test numbers CORRECT. Centres INCORRECT - there were 21 onboarded at time of results). 286 x $2,650 = $757,900 (Likely INCORRECT based on average revenue per test of $1962 achieved in H1 2025 - likely revenue $560K). Q4 2025, 20 centres onboarded and let's be conservative and say 300 tests. (INCORRECT. There are now 30 centres onboarded. Company is targeting in the region of 750 tests in Q4 in order to meet its Q4 revenue target of c.$1.5m) 300 x $2,650 = $795,000 revenue (We will find out in due course what was achieved in terms of test numbers and average revenue per test) H2 2025 licensing revenue, let's be conservative and say $500,000. (INCORRECT. No licencing revenue will come from Thermo in H2) Combine all of that above and you get = $4.3mil or \u00a33.2m. (H1 revenue was $1.9m/ Q3 likely $560K. Q4 not yet reported. Company is targeting total FY 2025 revenue of $3.95m, comprising $3.2 Tutivia tests and $750K licencing revenue) Still nothing in the way of a trading update from the team at vrci. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040474+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261504-B_Positi--6543815",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332720",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We should all be extremely excited having now onboarded over 30 transplant centres, up from 10 in 2024. We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040493+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260830-Silverbl--7521769",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333151",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "$12m was a direct quote from Vrci CEO in latest Vox markets interview. As for my 'precise' figures - strangely enough when it comes to investing I prefer to deal in fact rather than making it up (refer B_Positive). As for my views on the business - I remain invested so I am hopeful there is a future here or would have taken my medicine and moved on. That does not mean to say I will not vocalise my thoughts on areas of mismanagement where the company could and should be doing better; or to call out posters who are just making it up as they go along. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040511+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260728-B_Positi--1612912",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333626",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040529+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260205-donmac10-40716711",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334054",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Where do you get the 12mill breakeven point? You sound like a bot with your precise figures. And you always have a way of sounding positive but are really negative .So cant be taken seriously .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040548+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262026-Silverbl-55869204",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334501",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not really sure why I need to explain this, but here you go B_Positive. Your bullet point regarding Tutivia sums the position up very well. Transplant centres service both Medicare patients and private paying patients. So whilst the Medicare payment of $2650 is being provided by the US healthcare system for patients who benefit from the Medicare and Medicare plus programmes - there are actually six key revenue streams for test sales of which Medicare is one (albeit the largest - 68% of tests being undertaken are covered by Medicare seems to be the claim from the company). Private payers (via healthcare insurance) do not pay the $2650 - they receive discounts. Clinical trials pay nothing. And there others. If you divide the H1 Tutivia revenue of $1.16m by the 591 tests in H1 it comes out at $1962 . That is the current revenue reality for test sales. The recent RNS highlighting the agreement with Prime Health Services is all about trying to establish consistent pricing of the Tutivia test with the private payment market and clearly with the goal to increase current pricing which is diluting the Medicare $2650. In relation to your H2 licencing point the following clarifies the position \" Thermo Fisher is investing in new research related to PTRA aimed at identifying the earliest stage at which the test can be utilised before transplantation. Consequently, the second milestone originally anticipated for 2025 will be delayed as we continue to collaborate on publishing clinical validation data and Thermo Fisher pursues these additional research efforts to help broaden utility and adoption of the assay.\" FYI the breakeven position for Verici is c.$12m - so that provides an indication of the revenue which is required from test sales, licence revenue, protega etc to cover vrci operating costs. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040566+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261524-B_Positi--3937644",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334932",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Nope it's $2,650 as per the Medicare coverage RNS and more recently as per the HY report. \u00b7 Lead product Tutivia\u2122 attained Medicare coverage at $2,650 per test, covering a national estimate of 68% of all US transplant tests and commercial payor reimbursement applications are underway They receive licencing revenues both H1 and H2. It was $750k in H1.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040585+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261523-Silverbl--4642486",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335360",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Mikemine -  your points are valid - but highlight one of the main issues here. Why set a target and fail. Undermines confidence, craters the share price, makes fund raising tricky and makes investors wary on growth. Much better to overdeliver on achievable targets than underdeliver? But maybe we will be get a pleasant surprise. Thermo are just doing their own thing on the PRTA at present. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040603+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261518-Silverbl--3369528",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335771",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "No licencing revenue in H2 2025 and average received revenue per test is $1900. Do some actual research please. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040621+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261416-B_Positi--9161965",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336264",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10 centres onboarded. It must now be around 25-35 going by the last report.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040640+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261402-Mikemine-28994849",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336713",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "They've set themselves a big revenue target of over \u00a33mn for 2025. Small in world terms but a big % increase for VRCI. Should they be chastised if they do not reach the target or should it be viewed in the context of what they do achieve and what they forecast for this year? Getting close to \u00a33mn would be an achievement in my book as that would point to things being on track for further increases especially as the new sales guys have probably only just got their acts together and their contacts in line. Not sure what to think of the Thermo-Fisher deal and its seemingly lack of traction. Big companies are not nimble nor quick so the jury's out on that one for me. My guess is for an update this month and it will be positive but will not please everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040658+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261401-B_Positi-44875275",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337193",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Cashed up until the end of 2026 and now they've been securing record orders as per below. Next time they raise it will be in the pennies, which is what they will want given the new option prices. Test update going to drop soon. More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040677+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261346-Silverbl--6476510",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Despite the view expressed by several contributors here we have heard nothing from the business on Q4 trading. Not unexpected - if there was anything to report on I would expect to hear later on in January. The issue looming very shortly relates to the required fund raising. In previous years the company has elected not to divulge FY trading until May.  This is likely to be beyond the point at which the company runs out of cash. We should therefore be able to read the signals loud and clear - no trading update - then Q4 has not delivered the targeted sales and the fund raise will be brutal.  If a positive Q4 trading update is issued then there should be a healthy price response despite the recognition funds will still be required. Remember last year the first fundraise was at 9p - then 0.5p after bewildering timing mismanagement by the company.  All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: 100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-01-30T23:03:29.040695+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261228-B_Positi--3842635",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338063",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040714+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-2reincar--3947309",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338488",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Conversions this summer will see us at sub 0.25p!",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.75",
          "thread_title": "100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-01-30T23:03:29.040732+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261210-B_Positi--5007071",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338938",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040750+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20260629-2Phones-47337443",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339362",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "How can any one disagree with such a cogent arguement - and clearly not the rantings of a one track numpty.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.725",
          "thread_title": "RE: Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-01-30T23:03:29.040769+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261022-2reincar--5014856",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339773",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "At 0.25p?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.725",
          "thread_title": "Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-01-30T23:03:29.040787+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251515-B_Positi--5007071",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340229",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040805+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251223-Silverbl--9016185",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "2Phones - from the company itself: \" With minimum gross proceeds from the Placing and Subscription of \u00a35 million, the Company's cash runway will be extended to mid Q2 2026.\". Hence my thinking spring will be the time to raise. And yes revenue is expected to increase (we will know by how much in a few weeks) - but annual expenses are c.$9m - so sales would need a dramatic (and unlikely) increase to negate the need for more funds. And you seem to agree that a placing is an option (imo the only likely one and the route the company has taken to date in all its efforts to secure more funding). So not sure what you were disagreeing with? SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-30T23:03:29.040823+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20250753-2Phones-79402243",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341050",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I don't agree - the operational update earlier this year had a predicted cash runway to H2 next year - when you couple that with the recruitment of 2 sales people and a director of clinical partnerships, I would anticipate growth in cash inflow.  However, they are a small team and they are going to have to increase production to accommodate the anticipated sales.  This will need funding, but where they get it is uncertain \u2013 one option being a placing.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-30T23:03:29.040845+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251728-2reincar-87370744",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341472",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Agree Silverblade. We could have one in Aprilish at 0.5p and one in Octoberish at 0.25p and then a rocket to + 2p ?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-30T23:03:29.040863+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251618-Silverbl--1827908",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Same old nonsense B_Positive. Thermo are not involved in Tutivia. Stop spreading false information. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040882+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251557-B_Positi--7045249",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342355",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-01-30T23:03:29.040900+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251522-Silverbl-28323761",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342765",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There will be a placing in early 2026 - probably March/April time. The placing will of course be determined by the prevailing share price at the time. And that in turn will reflect the numbers for FY 2025 - there is a lot of expectation here so lets see what the company has to say for itself hopefully with a trading update in January. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-01-30T23:03:29.040918+00:00"
      },
      {
        "event_id": "RNS-5th Feb 2026-fy25trad",
        "event_type": "rns_announcement",
        "date": "2026-02-05T22:26:48.698021+00:00",
        "source": "LSE_RNS",
        "data": {
          "title": "FY25 Trading Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/fy25-trading-update-vojyuc2phtf9c3s.html",
          "rns_number": "RNS Number : 7865R",
          "full_content": "Today 07:01\nRNS Number : 7865R\nVerici Dx PLC\n05 February 2026\nVerici Dx plc\n(\"Verici Dx\" or the \"Company\")\nFY25 Trading Update\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nprovides a trading update for the year ended 31 December 2025 (\"FY25\"), a year of strong growth and commercial progress for the Company.\nFinancial highlights\n\u00b7\nTotal unaudited revenues1 of $3.8m (2024: $3.3m) comprising:\no\n$3.0m from recognised revenue of Tutivia (2024: $Nil). $3.2m worth of tests were ordered during the year\no\n$0.8m from license income (2024: $3.3m), reflecting the expected timing of milestone payments under the outlicensed contract\n\u00b7\nUnaudited cash at year-end of $3.3m (2024: $4.1m), which is slightly ahead of expectations, with $1.6m accounts receivable (2024: $Nil) which continues to support\nexpected cash runway into H2 2026 as previously communicated.\nOperational highlights\n\u00b7\nSignificant commercial progress across the year with first revenues from\nTutivia\u2122 test results.\n\u00b7\nSecured Medicare coverage for Tutivia\u2122\ncovering a national estimate of 68% of all US transplant tests and\ngreatly improving patient access.\n\u00b7\nMilestone receipt of $0.8m from Thermo Fisher Scientific for the product licensing of PTRA (Clarava).\n\u00b7\nContinued increase in test adoption with:\no\n1,173\nTutivia\u2122 tests ordered\nin FY25 (Q4: 296)\ncompared to 334\nover the whole of FY24.\n\u00b7\nExpansion in centres using Tutivia\nTM\nfor a total of 34 representing 18% of annual kidney transplants in the US, with the addition of 4 new ordering centres in Q4.\n\u00b7\nSigned a Provider Participation Agreement with Prime Health Services,\na dynamic healthcare technology US based company focused on delivering innovative, data-driven solutions through its Preferred Provider Organization ('PPO') network.\n\u00b7\nAdditional commercial team member added.\n\u00b7\nContract signed with Blue Cross Blue Shield (\"BCBS\") of Illinois, announced separately today, with contracted pricing across multiple lines of business, giving in-network status for BCBS covered patients and providing the Company with access to open contract processes with other BCBS entities.\n1\nRevenue is reimbursed from two core types of payor: Medicare and commercial payors. For Medicare patients, there is a fixed price for the test. For commercial payors, there are a number of factors which determine whether, and for how much, the test is reimbursed, which can vary by commercial payor. Revenue recognition therefore requires a significant amount of judgement and estimation, as we continue to gather information to inform a reasonable average reimbursement from these commercial payors. This assessment is monitored monthly, with revisions made based on the actual reimbursement price achieved and denial rates, once known with reasonable certainty.\nNotice of Results\nThe Company currently expects to announce full year results no later than May 2026. A further announcement confirming a date for publication of the audited results will be issued in due course.\nSara Barrington, Chief Executive Officer, said:\n\"We are proud to have achieved substantial growth in FY25, reflected in the continued adoption of\nTutivia\u2122\nand an increase in sales across the year. Whilst recognised\nTutivia\u2122\nrevenues of $3.0m were slightly behind market expectations for the full year, we continue to see strong testing volume acceleration beyond the $3.2m of orders received during the year. We are confident that our clinical and regulatory foundations will continue to show successful commercial traction across 2026 and beyond.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Adam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Rachel Broad\nMob: +44 (0)7407 804 654 / +44 (0)7747 515 393\nVerici Dx\nVerici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.\nOperating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia\u2122, is a post-kidney transplant test focused on early detection of acute rejection.\nThe company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more inform",
          "content_length": 5849
        },
        "ingested_at": "2026-02-05T22:26:48.698070+00:00"
      },
      {
        "event_id": "RNS-5th Feb 2026-agreemen",
        "event_type": "rns_announcement",
        "date": "2026-02-05T22:26:48.698111+00:00",
        "source": "LSE_RNS",
        "data": {
          "title": "Agreement with BCBS of Illinois for Tutivia\u2122",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/VRCI/agreement-with-bcbs-of-illinois-for-tutivia8482-879z9rl3ofxhq3d.html",
          "rns_number": "RNS Number : 7866R",
          "full_content": "Today 07:00\nRNS Number : 7866R\nVerici Dx PLC\n05 February 2026\nVerici Dx plc\n(\"Verici Dx\" or the \"Company\")\nAgreement with Blue Cross and Blue Shield of Illinois for\nTutivia\u2122\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has entered into an agreement (\"the agreement\") with Blue Cross and Blue Shield (\"BCBS\") of Illinois for\nTutivia\u2122,\nthe Company's\npost-kidney transplant test focused on early detection of acute rejection.\nThe agreement ensures that\nTutivia\nis considered as an in-network benefit for patients which streamlines the claims process and ensures that patients receive testing at in-network rates. BCBS also has its own Preferred Provider Organization network, of which Verici Dx is now a member. As a result, the Company receives access to open contract processes with other BCBS entities, including BCBS Texas.\nBCBS provides health care coverage for 118 million members in all 50 states, Washington, D.C., and Puerto Rico, and more than 2 million doctors and hospitals contract with BCBS companies nationwide. BCBS has several lines of business in Illinois, including commercial payor, managed Medicaid and Medicare Advantage, all of which are covered as part of the agreement.\nThe agreement also provides access to the BCBS Association, which covers 33 BCBS member entities. In turn, this allows for a streamlined process for Verici Dx to access a CareSource agreement.\nSara Barrington, Chief Executive Officer, said:\n\"This agreement with BCBS represents a key milestone for Verici Dx as we\u00a0continue to grow our patient network and focus on expanding our commercial reach. We look forward to updating shareholders further as we progress with this agreement and continue to advance discussions with additional payors.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Adam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Rachel Broad\nMob: +44 (0)7407 804 654 / +44 (0)7747 515 393\nVerici Dx\nVerici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.\nOperating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia\u2122, is a post-kidney transplant test focused on early detection of acute rejection.\nThe company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit\nhttps://vericidx.com/\nand follow us on\nLinkedIn\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRGZGGZZDDGVZZ",
          "content_length": 4075
        },
        "ingested_at": "2026-02-05T22:26:48.698133+00:00"
      },
      {
        "event_id": "SOCIAL-Today1742-Mikemine--3682108",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885051",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, you are clearly angry with VRCI, especially Barrington, so it begs the obvious question \"Why are still here and presumably invested in the company?\" I'm sure most of us have felt let down and financially hurt by companies and BODs in the past but have taken the hit and moved on. Why haven't you?",
          "sentiment": 0.0,
          "engagement": "1,236",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-05T22:26:59.399882+00:00"
      },
      {
        "event_id": "SOCIAL-Today1656-Fevertre--7587832",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "If cash burn is an issue then perhaps Sara Barrington should take a bloody pay cut",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-05T22:26:59.399927+00:00"
      },
      {
        "event_id": "SOCIAL-Today1654-Fevertre-38746734",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "barrington is the the issue (along with the board). after the disastrously botched raise that almost sank the company but not barrington because she got regranted her share options (not something s/holders were able to do)... her attitude to her shareholders is woeful - she didnt apologise for her gigantic ****-up that cratered the sp. meantime the growth figs look dodgy and she continues to burn thro cash at a rate.... fy 25 1,173 tutivia tests orders = $3m revs = $2557 per test, and yet at 1h figs of 591 tests = $1.16m = $1962 per test, so 30% uplift based on 2h figs. - on face of it that's a great result right? but where is the explanation/reconciliation, and if there is that much volatility barrington how can your investors/analyst properly model outcomes (let alone the company)? then what about momentum that she was saying was happening: october update - barrington told us \" volume growth from this progress is expected from q4 and the number of orders in q3 were consistent with the previous two quarters. 1h 591 so  averages q1 295 q2 295. q3 c300....so based on barrington's comment an uplift was due in q4...and yet: q$ sales below q1, 2,3..and 2h below 1h.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-05T22:26:59.399967+00:00"
      },
      {
        "event_id": "SOCIAL-Today1628-tbcx--2219256",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.886494",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is the company that reiterated cash runway until H2 2026 in today's update. That is them letting you know now funding will be required this year sometime from July onwards.",
          "sentiment": 0.0,
          "engagement": "801",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-05T22:26:59.400006+00:00"
      },
      {
        "event_id": "SOCIAL-Today1516-stockyhe-18142942",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.887017",
        "source": "LSE_CHAT",
        "data": {
          "author": "stockyheathlad",
          "content": "In a business like this, historic cashflow isn't necessarily a guide to the future. Expenditure on setting up new centres will be variable and, to a degree, discretionary.  The income stream grew across the year so the last quarter's figures are most relevant, rather than the whole year's.",
          "sentiment": 0.0,
          "engagement": "19",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-05T22:26:59.400045+00:00"
      },
      {
        "event_id": "SOCIAL-Today1419-2Phones-15336092",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.887553",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "SB - thanks for that.  They said at the time of the fundraising (as @ 31/05/25) they had a cash runway to the end of July 2025.  And subsequently they have burned that cash ($8.6m?) in the remaining 5-6 months of 2025 down to $3.3m, so $10m breakeven makes sense.  Obviously as they get closer to that breakeven point the cash burn reduces - the question is, with all the sales activity, how quickly can they reach that point, and how many further funding rounds we'll see.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-05T22:26:59.400083+00:00"
      },
      {
        "event_id": "SOCIAL-Today1333-Silverbl--8321808",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.888058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Cash burns remains significant - company raised \u00a36.35m during the year - which added to the $800k difference in year end balances show the level of cash required to support the losses incurred over the last 12 months. Breakeven is predicted at $10m revenue pa. SB",
          "sentiment": 0.0,
          "engagement": "1,925",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-05T22:26:59.400135+00:00"
      },
      {
        "event_id": "SOCIAL-Today1236-Guly-36961114",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.888582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Cash runway atleast 2 yrs assuming current run rate without additional contract wins",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-05T22:26:59.400173+00:00"
      },
      {
        "event_id": "SOCIAL-Today1117-2Phones--3678718",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.889106",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I agree that the guidance of cash for H2 appears disappointing, however if you take the cash burn over the last 12 months \u2013 the cash reduced from $4.1m to $3.3, which implies a burn rate of $800k per annum.  Now there are many things that impact these numbers but this set against the backdrop of ever-increasing revenue and sales orders/opportunities.  H2 may be a little pessimistic.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-05T22:26:59.400212+00:00"
      },
      {
        "event_id": "SOCIAL-Today1022-tbcx--4525989",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.889622",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Great product and credit to them for being revenue generating, way ahead of many other biotechs valued higher. Suspect there is a management discount at play here for habitually missing guidance, which can be overcome, she's easily replicable. The only snag is cash runway remains H2 2026. Definitely one to revisit once funding overhang sorted.",
          "sentiment": 0.0,
          "engagement": "801",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-05T22:26:59.400250+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Tii21-22028774",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.890160",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "2 million delayed buy, and yet this is at 0%!! 05-Feb-26\t08:03:33\t0.79\t2,000,000\tUnknown*\t0.70\t0.75\t15.80k\tO",
          "sentiment": 0.0,
          "engagement": "457",
          "price_at_post": "0.725",
          "thread_title": "RE: Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-05T22:26:59.400287+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Isthisaw--5754923",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.890667",
        "source": "LSE_CHAT",
        "data": {
          "author": "Isthisawinner",
          "content": "Surprised the sp isn't following..",
          "sentiment": 0.0,
          "engagement": "2,301",
          "price_at_post": "0.725",
          "thread_title": "Finally,  gathering momentum...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=B49C9293-BB7B-4427-862D-3D342002FA5A"
        },
        "ingested_at": "2026-02-05T22:26:59.400325+00:00"
      },
      {
        "event_id": "SOCIAL-Today1006-Mikemine-24482958",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.891178",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Come on FT, give Barrington some credit. She has an accountancy background which would give her a less than gung-ho approach to reporting. They missed a rather ambitious sales target by not much which is good going in my book. For a \"modest\" report her predictions for 2026 are very confident with \"strong\" growth and are significant. For a CEO running a tiny company on a shoe string with small workforce, she is doing well I reckon. Additions to staff last year were all geared to sales so i would expect them to have reached an inflection point. As for the BCBS agreement, what can you say but \"Well done\". That's going to open more doors for the sales force to walk through. I'd imagine there's a good buzz throughout the company at the moment. They must have worked hard for the last 3-4 years with not much in the way is acceptance to show for it but, starting with Fisher, the ball is rolling. Very positive for 26 iIMHO.",
          "sentiment": 0.0,
          "engagement": "1,236",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-05T22:26:59.400364+00:00"
      },
      {
        "event_id": "SOCIAL-Today1001-Hawker--3345146",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.891629",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Agree, this is an encouraging update. Given the limited resources and tightly managed cost base, Verici could well be on the up this year.  It should only take a doubling or so of the now current testing volumes to put them on the front foot. Keep up the good work Sara and team, go forth and ramp Tutivia and PTRA with Thermo.",
          "sentiment": 0.5,
          "engagement": "301",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-05T22:26:59.400402+00:00"
      },
      {
        "event_id": "SOCIAL-Today0955-Guly--6167558",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.892184",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Accumulating a position here, can see massive potential.Can't believe it's so cheap.",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-05T22:26:59.400440+00:00"
      },
      {
        "event_id": "SOCIAL-Today0911-Silverbl-83637707",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.892711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "On a positive note at least company has provided a FY update with a relatively small target miss, revenue is growing with new partnerships coming on stream and cash is ok for now. Against that - tests sales in H2 were less than H1 (591 v 582) which is concern - why no growth in actual testing volumes. What I can't reconcile is the Tutivia revenue for H1 was $1.2m for 591 tests ($1962 per test); and in H2 Tutivia revenue was $1.8m ($3092 per test). This just doesn't add up imo. Unless there is deferred income from H1 coming into H2 receivables. I think note 1 in the update is attempting to clarify the issue - but the language on revenue estimates being used rather than actual revenue are a bit concerning. Actual audited accounts will be more revealing and may differ from these unaudited updates. SB",
          "sentiment": 0.0,
          "engagement": "1,925",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-05T22:26:59.400477+00:00"
      },
      {
        "event_id": "SOCIAL-Today0855-blowdog-20894840",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.893229",
        "source": "LSE_CHAT",
        "data": {
          "author": "blowdog",
          "content": "Https://x.com/CapitalPmh/status/2019323726446158330?s=20",
          "sentiment": 0.0,
          "engagement": "929",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-05T22:26:59.400514+00:00"
      },
      {
        "event_id": "SOCIAL-Today0852-newgrang--8474402",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.893738",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "L2 buy orders looking strong \ud83d\udcaa",
          "sentiment": 0.0,
          "engagement": "2,114",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-05T22:26:59.400550+00:00"
      },
      {
        "event_id": "SOCIAL-Today0843-newgrang-89705478",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.894260",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "Good update with revenues and licensing contract. Hugely undervalued.",
          "sentiment": 0.0,
          "engagement": "2,114",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-05T22:26:59.400589+00:00"
      },
      {
        "event_id": "SOCIAL-Today0839-Fevertre--4465794",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.894756",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "SOP for disappointing update to put out commercial RNS alongside (Blue Cross deal looks encouraging) to soften the blow. Barrington is t up to the job- didn\u2019t hit the numbers; a less than confident statement , and why on God\u2019s Green Earth are they saying Dec FY25 will come out in May!! This is a tiny business with minimal revenues and yet Barrington can\u2019t commit to releasing results in a timely fashion. Suspect because every Q they have a wrangle with accountants about revenue timing and recognition. Be good to see sustained progress but after screwing up the cash raise, which cratered the so Barrington still has to prove she is CEO material.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-05T22:26:59.400626+00:00"
      },
      {
        "event_id": "SOCIAL-Today0824-bigpunt--6040756",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.895246",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Hitting revenue and cash targets, adding major commercial tie-up, can't ask for much more as the company commercialise.  They've had a cracking year and I like the modest tone",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "0.775",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-05T22:26:59.400664+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260854-2Phones-31705275",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.895745",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "the site is *************interviews dot com",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.400702+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260852-2Phones-77026698",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.896268",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "hi splodge2001 https://www. ***************************/verici-dx-landmark-deal-unlocks-potential-300-million-tutivia-market-singer-research-icymi/4121236201",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.400739+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261732-Splodge2-51088148",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.896762",
        "source": "LSE_CHAT",
        "data": {
          "author": "Splodge2001",
          "content": "Does anyone have a link to the Singer note? I couldn't find it on their website.",
          "sentiment": 0.0,
          "engagement": "114",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.400777+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260851-2Phones-35857450",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.897267",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac101 - I was particularly encouraged by the 2.9p target price.  They clearly believe the future for tutivia is massive.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.400814+00:00"
      },
      {
        "event_id": "SOCIAL-Today0851-2Phones-35857450",
        "event_type": "social_post",
        "date": "2026-01-30T23:03:22.957691",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac101 - I was particularly encouraged by the 2.9p target price.  They clearly believe the future for tutivia is massive.",
          "sentiment": 0.0,
          "engagement": "83",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.400853+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261447-donmac10-64717768",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:31.826472",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Very good research note out last few day by Singer .Talking up Prime health deal 300 mill mkt.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.400891+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251243-Romanby-20000614",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.788345",
        "source": "LSE_CHAT",
        "data": {
          "author": "Romanby",
          "content": "No placing you idiot",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-05T22:26:59.400929+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251216-Sandyman--7605575",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "Is the placing going to be at 0.25p or 0.5p? Or both?",
          "sentiment": 0.0,
          "engagement": "999",
          "price_at_post": "0.775",
          "thread_title": "Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-05T22:26:59.400966+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251441-Silverbl-10271485",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - FYI Thermo Fisher are not currently involved in Tutivia - so they are not involved in any roll out. Despite claims here to the contrary there has been no trading update - so we await evidence that Q4 delivers the level of sales anticipated by the CEO on achieving the 2025 Tutivia revenue target - which as you note would be a significant increase on 2024 sales. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401004+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251547-B_Positi-31145528",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.790830",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401043+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-B_Positi-65733722",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.791703",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I would wager a big Thermo-Fisher update is due here. Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401081+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251302-B_Positi-24567327",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.792503",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Wow now way just saw that. Huge implications for Thermo and its partners!",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401131+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251255-donmac10--3620663",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.793297",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Genincode signed a deal with Thermo read across to Verici Verici so undervalued at the moment something has to give.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401169+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251244-B_Positi-41026321",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794085",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Once it breaks 1p it will fly to 2p and then 3p gets smashed with ease considering the test orders are going to be around 300-400% from the digging below. 3p as a base and then a move back to 5-10p.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401209+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251227-B_Positi-92899699",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794962",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I'm personally amazed more aren't piling in whilst under 1p and this isn't at 3-5p already. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401246+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251953-B_Positi-18858396",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.795766",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Will add another 2m sub 1p Way too cheap here for me personally.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401283+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251945-donmac10-23478885",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.796575",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "3p per share nailed on short term if you guys sit oan yer tuffetts like miss muffet know whit ah mean?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401320+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251941-donmac10-36525773",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.797364",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Company is no longer research orientated so past rns at this time of year irrelevant trust me as tests ramp up as they will be the company will be eager to broadcast positive newsflow asap.noh whit a meen an that man getmeh!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401359+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251535-Silverbl--3170094",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798154",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Would be unusual for a trading update pre-xmas imo although any kind of an update in relation to hitting revenue targets would assist progress here - the bar has been set very high by CEO. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401396+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251320-B_Positi-30132946",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798939",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Yes it was due. Thermo-Fisher $220BILLION backing this and tied in. Update on them or something new will wake the market up.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401434+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251245-donmac10--2157411",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.799717",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Update this week and more deals with distributors .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401471+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251234-B_Positi-74884932",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.800588",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "MMs caught wind of an update? I'm amazed this isn't over 2p at least. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401503+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251230-tbcx-58494546",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.801373",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Buying pressure certainly returning this week, this remains extremely undervalued.",
          "sentiment": 0.0,
          "engagement": "766",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401536+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251443-donmac10--6776243",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802148",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Nice 2mill buy this morning.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401566+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251235-B_Positi--6461868",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802905",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Donmac, absolutely buzzing for the trading update this month Hopefully see's this head back to the 3 to 5p level",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401596+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251104-B_Positi-10943879",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.803727",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "So with less than 10% of transplant centres onboarded and already at the start of the mass rollout they averaged about 300 tests per quarter in Q1, Q2 and Q3, just short of 900, vs 334 for the entirety of 2024, representng significant growth. We now know they are at at least 16% of transplant centres onboarded now (less than 10% for Q1, Q2, Q2, perhaps around 20% now and are increasing this fast. You quickly realise how mad the revenues can become here at $2,650 a test with the medicaid coverage +Thermo Fisher licencing revenues. I know many, many pharma stocks that have literally $0 revenue, no proven tech, no FDA approval, no big deal with a giant like this does with Thermo Fisher that are trading at many multiples of the Verici market cap.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401630+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251045-donmac10-72771946",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.804510",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And its beginning to look like word is out?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401662+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251039-donmac10--1914242",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.805293",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Expecting a trading update in the run up to xmas should make for good reading!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401691+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251031-B_Positi--8525694",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806132",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.401720+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251456-Mikemine--3653640",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806901",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, your posts have got  very repetitive and quite frankly, boring. Unless your rants help your mental state I for one would be grateful if you would keep your posts to new views or information.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-05T22:26:59.401748+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251148-Fevertre--2182597",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.375637",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Just out of interest what are Barrington's competencies?",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-05T22:26:59.401776+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251147-Fevertre--4632430",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.376396",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "The Board and non-execs have overseen an absolute shamble here. Barrington completely unaffected by disastrous dilution as she has virtually no bloody shares in teh company she purports to lead.  The CFo isnt fit for purpose frankly. The Q4 figs appear to be the stuff of fantasy - I would give more creedance if  Barrington was able to explain how she gets to the forecast but she appears to be just making it up as she goes along... we have no timelines on onboarding; Barrington cant set out how she arrived at the numbers... she continues to be utterly hopeless as the CEO of supposedly a cutting edge business.",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-05T22:26:59.401806+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251059-Silverbl-37841775",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377214",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There you go donmac almost at your buy price already. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-05T22:26:59.401835+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20250050-donmac10--5539136",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377985",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sell up move on thank you.....give me the chance ar more aroon the 55 mark slanj .And a will catch yeh in wetherspoons oan the wae otta rah ritz.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-05T22:26:59.401863+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251734-Mikemine--2980846",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.378810",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "VRCI is a small company so hiring an extra 3 salespersons is huge for them and points to their determination to hit their target. It's a big ask but you can be sure they recognise that their credibility is on the line. From a practical point of view, hiring new salespeople  takes time for their impact to come through. They have to get used of the systems, the product and VRCI's method of selling. I wish them luck and, if they do reach their target, it will be noticed by the Market.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-05T22:26:59.401892+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251709-Silverbl--1395056",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.379608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not a fan to date either fevertree - its been a disaster for all shareholders here - but I still hold a position here and am trying to look forward not back given the past is what it is. If Q4 goes well I expect a trading update early 2026 - which doesn't usually happen but positive momentum will be required to avoid a total wipe out in any subsequent capital raise. Failure to deliver (again) then more questions will be raised on leadership competencies.  SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.75",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-05T22:26:59.401920+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251647-Fevertre--7391447",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.380414",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "She has never fully explained the onboarding process. If a new centre gets onboarded, typically how long does it take for clinicians to order first tests",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-05T22:26:59.401948+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251644-Fevertre--5059185",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.381220",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Nonsense Donmac.....look at the maths around Barrington's targets: On my maths I don't see how she hits revs from Tutivia $3.2m... Tutivia:  1H Revs: $1.16m: 591 tests @ ave $1900 ($1.16m divided by 591) 2H Revs:  3Q Tutivia same rate as Q1/Q2 ..c300 tests at 1900 = $570k  ...so to meet her target she needs to sell c$1.5m of tests. Assume same ave price of $1900....she needs to sell c790 tests....that's a massive uplift, even with onboarding another 9 more centres...",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-05T22:26:59.401977+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251627-donmac10--5224957",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382010",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "markets falling and the doom and gloom ****roaches appear in force.sell up ,thats even if yeh hod any and gie us aw peace!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-05T22:26:59.402005+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251604-Fevertre-12622949",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382802",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Worryingly her bullishness has cost investors dearly so far. Apart from having virtually no skin in the game she hasn't been gifted,  or regifted (look at the outrageous revision of option pricing). The fact that the sp is still at 3/4 of a penny tells you everything you need to know about how the market views her!",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-05T22:26:59.402033+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251522-Silverbl-66937987",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.383604",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Based on what we already know - VRCI sold c.600 Tutivia tests in H1 2025 - securing revenue of $1.2m ($2k per test - blend of public and private payers). They sold same in Q3 - so lets assume pro-rata they secured a further $600k revenue. Sara B confirmed FY Tutivia target was $3.2m - so that leaves $1.4 revenue to be secured in Q4 - or c.700 tests at $2k. Seems a huge leap - or possible they are looking at a slight increase to average test $ - although Prime Health RNS appears to push towards discounted volume in private market. She has certainly set high expectations for Q4 trading. If this is achieved it will be a significant acceleration - and will be crucial in supporting the share price/market cap as the company requires additional funding in the next 4/5 months. Additional licensing revenue from Thermo (c.$4m received to date - $3.3m in 2024 and $0.75m in 2025) remains on hold as they progress their approach to the PTRA test. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.725",
          "thread_title": "2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-05T22:26:59.402063+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250856-2Phones--2952076",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.384401",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac agreed - two of the latest RNS are very positive about the rate of revenue growth and market penetration - can't help but think the next sales based RNS will be a gamechanger.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.875",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-05T22:26:59.402091+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250845-donmac10-58975690",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385202",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Analysts expecting 3p per share next year big upside from here.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.90",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-05T22:26:59.402135+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250843-donmac10-23366594",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385990",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Verici also more forthcoming informing the market with updates .Beats last years 6 month radio silence .Just waiting now for testing update which i know will further boost price.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-05T22:26:59.402164+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250830-donmac10-13173378",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.386775",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Tells me ,anyone looking to make money would be well served to get in now .Futher big rise going into year end.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.95",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-05T22:26:59.402204+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250809-2Phones--4864571",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.387576",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Interesting news today \u2013 initially I thought why? This has little bearing on shareholders interests \u2013 however, on further concideration, while successful audits add little to the bottom line or turnover or even shareholder value \u2013 in our case it is very much a Critical Failure Factor, where failure to pass a quality audit could seriously damage the company in the short/medium term.  Also it does point to a well run, disciplined business. So well done Verici.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.95",
          "thread_title": "RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-05T22:26:59.402233+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251448-oogleflu--1961060",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.388340",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Tom. I know exactly what you\u2019re saying is correct . Unfortunately risk appetite is much lower in the UK probably because the FA are like a bunch of frightened rabbits. Fund managers continue to unwind oversold positions in uk to chase  the way overpriced \u2018American dream stocks\u2019 which are overdue a big correction there by loosing even more of the inadequate fund managers clients money. It\u2019s not all Uk stocks but quite a few as admitted in an interview recently with a fund manager. Certainly since the pandemic Uk stocks are valued much more realistically i.e. sound balance sheet which Vrci  now has, realistic forecast which Vrci now has, realistic targets for growth which Vrci now has. But we don\u2019t tend to look further than a year ahead. One step at a time . There will be /is FOMO with a stock like Vrci which will cause some volatility till they establish a more constant earnings stream.",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402262+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251354-donmac10-88011722",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389131",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "It feels to me we are about to get a trading update on testing numbers shortly .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402291+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251256-donmac10-14278047",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389888",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "1.20p close today and more updates in coming days on quickly to 2.00p",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402319+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251247-geraldus--9179847",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.390653",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "Still early days here,and they will have to take some market share from the incumbent bio markers. Shaping up well so far and with a miserly market cap in comparison with other counters.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.825",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402348+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251241-B_Positi-74910230",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.391431",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Geraldus Tutivia is the standard now. Hence why Thermo-Fisher has gone all in and is backing all the way. Market slowly beginning to wake up that this company is grossly undervalued. I mean the FDA approval, ip, tech alone is worth multiples and then whack on the huge growth already in 2025 and coming in 2026 with over 30 transplant centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402376+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251239-donmac10-49948739",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392203",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "American market waking up to the potential with Verici dx in their own backyard They love an AI stock.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402404+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251236-geraldus--4550055",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392989",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "With their 'AI' solution for optimising transplants,it is undoubtly an interesting opportunity here. They have spent millions on this and they are confident that it is payback time. With no competition at this level,it could possibly become the defacto standard.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402432+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251217-B_Positi--8525694",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.393835",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402460+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251205-oogleflu-62967664",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.394621",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Addressable market doesn\u2019t mean they capture all of it.  They might get 1 or 2 percent which is still sizeable if lucky. Even singer, their broker,  have only raised the sp to 3p. That\u2019s still 4 times current market cap! The other thing is will they need to expand the lab or open another one as their market share increases. They have got a captured market in that there is no competition and the tests are becoming mandatory. No plans to adopt outside the US yet. Maybe 20p in 5 years certainly not months I\u2019m afraid but good luck",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.775",
          "thread_title": "RE: Quantifying the opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=D3DE9F2B-871D-47DE-96C8-2D6BB08D16A4"
        },
        "ingested_at": "2026-02-05T22:26:59.402487+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261715-Silverbl--8311176",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - feel free to use the actual numbers in your updates. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 (INCORRECT: H1 actual revenue was $1.16m = $1962 average revenue per test). H1 2025 licencing revenue = $750,000 (CORRECT) Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. (Test numbers CORRECT. Centres INCORRECT - there were 21 onboarded at time of results). 286 x $2,650 = $757,900 (Likely INCORRECT based on average revenue per test of $1962 achieved in H1 2025 - likely revenue $560K). Q4 2025, 20 centres onboarded and let's be conservative and say 300 tests. (INCORRECT. There are now 30 centres onboarded. Company is targeting in the region of 750 tests in Q4 in order to meet its Q4 revenue target of c.$1.5m) 300 x $2,650 = $795,000 revenue (We will find out in due course what was achieved in terms of test numbers and average revenue per test) H2 2025 licensing revenue, let's be conservative and say $500,000. (INCORRECT. No licencing revenue will come from Thermo in H2) Combine all of that above and you get = $4.3mil or \u00a33.2m. (H1 revenue was $1.9m/ Q3 likely $560K. Q4 not yet reported. Company is targeting total FY 2025 revenue of $3.95m, comprising $3.2 Tutivia tests and $750K licencing revenue) Still nothing in the way of a trading update from the team at vrci. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402515+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261504-B_Positi--9085491",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332720",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We should all be extremely excited having now onboarded over 30 transplant centres, up from 10 in 2024. We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402543+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260830-Silverbl-36401536",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333151",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "$12m was a direct quote from Vrci CEO in latest Vox markets interview. As for my 'precise' figures - strangely enough when it comes to investing I prefer to deal in fact rather than making it up (refer B_Positive). As for my views on the business - I remain invested so I am hopeful there is a future here or would have taken my medicine and moved on. That does not mean to say I will not vocalise my thoughts on areas of mismanagement where the company could and should be doing better; or to call out posters who are just making it up as they go along. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402572+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260728-B_Positi--3330732",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333626",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402602+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260205-donmac10-89874157",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334054",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Where do you get the 12mill breakeven point? You sound like a bot with your precise figures. And you always have a way of sounding positive but are really negative .So cant be taken seriously .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402631+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262026-Silverbl--4307329",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334501",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not really sure why I need to explain this, but here you go B_Positive. Your bullet point regarding Tutivia sums the position up very well. Transplant centres service both Medicare patients and private paying patients. So whilst the Medicare payment of $2650 is being provided by the US healthcare system for patients who benefit from the Medicare and Medicare plus programmes - there are actually six key revenue streams for test sales of which Medicare is one (albeit the largest - 68% of tests being undertaken are covered by Medicare seems to be the claim from the company). Private payers (via healthcare insurance) do not pay the $2650 - they receive discounts. Clinical trials pay nothing. And there others. If you divide the H1 Tutivia revenue of $1.16m by the 591 tests in H1 it comes out at $1962 . That is the current revenue reality for test sales. The recent RNS highlighting the agreement with Prime Health Services is all about trying to establish consistent pricing of the Tutivia test with the private payment market and clearly with the goal to increase current pricing which is diluting the Medicare $2650. In relation to your H2 licencing point the following clarifies the position \" Thermo Fisher is investing in new research related to PTRA aimed at identifying the earliest stage at which the test can be utilised before transplantation. Consequently, the second milestone originally anticipated for 2025 will be delayed as we continue to collaborate on publishing clinical validation data and Thermo Fisher pursues these additional research efforts to help broaden utility and adoption of the assay.\" FYI the breakeven position for Verici is c.$12m - so that provides an indication of the revenue which is required from test sales, licence revenue, protega etc to cover vrci operating costs. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402660+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261524-B_Positi-85375568",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334932",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Nope it's $2,650 as per the Medicare coverage RNS and more recently as per the HY report. \u00b7 Lead product Tutivia\u2122 attained Medicare coverage at $2,650 per test, covering a national estimate of 68% of all US transplant tests and commercial payor reimbursement applications are underway They receive licencing revenues both H1 and H2. It was $750k in H1.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402688+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261523-Silverbl-73839466",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335360",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Mikemine -  your points are valid - but highlight one of the main issues here. Why set a target and fail. Undermines confidence, craters the share price, makes fund raising tricky and makes investors wary on growth. Much better to overdeliver on achievable targets than underdeliver? But maybe we will be get a pleasant surprise. Thermo are just doing their own thing on the PRTA at present. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402716+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261518-Silverbl--3893690",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335771",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "No licencing revenue in H2 2025 and average received revenue per test is $1900. Do some actual research please. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402744+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261416-B_Positi-47510743",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336264",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10 centres onboarded. It must now be around 25-35 going by the last report.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402771+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261402-Mikemine-81946882",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336713",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "They've set themselves a big revenue target of over \u00a33mn for 2025. Small in world terms but a big % increase for VRCI. Should they be chastised if they do not reach the target or should it be viewed in the context of what they do achieve and what they forecast for this year? Getting close to \u00a33mn would be an achievement in my book as that would point to things being on track for further increases especially as the new sales guys have probably only just got their acts together and their contacts in line. Not sure what to think of the Thermo-Fisher deal and its seemingly lack of traction. Big companies are not nimble nor quick so the jury's out on that one for me. My guess is for an update this month and it will be positive but will not please everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402799+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261401-B_Positi-88790639",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337193",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Cashed up until the end of 2026 and now they've been securing record orders as per below. Next time they raise it will be in the pennies, which is what they will want given the new option prices. Test update going to drop soon. More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402827+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261346-Silverbl--1994155",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Despite the view expressed by several contributors here we have heard nothing from the business on Q4 trading. Not unexpected - if there was anything to report on I would expect to hear later on in January. The issue looming very shortly relates to the required fund raising. In previous years the company has elected not to divulge FY trading until May.  This is likely to be beyond the point at which the company runs out of cash. We should therefore be able to read the signals loud and clear - no trading update - then Q4 has not delivered the targeted sales and the fund raise will be brutal.  If a positive Q4 trading update is issued then there should be a healthy price response despite the recognition funds will still be required. Remember last year the first fundraise was at 9p - then 0.5p after bewildering timing mismanagement by the company.  All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: 100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-02-05T22:26:59.402855+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261228-B_Positi--6938396",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338063",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402883+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-2reincar--7845073",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338488",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Conversions this summer will see us at sub 0.25p!",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.75",
          "thread_title": "100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-02-05T22:26:59.402911+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261210-B_Positi--7409698",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338938",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.402939+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20260629-2Phones-66049667",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339362",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "How can any one disagree with such a cogent arguement - and clearly not the rantings of a one track numpty.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.725",
          "thread_title": "RE: Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-02-05T22:26:59.402968+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261022-2reincar-59010136",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339773",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "At 0.25p?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.725",
          "thread_title": "Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-02-05T22:26:59.402996+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251515-B_Positi--7409698",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340229",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.403026+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251223-Silverbl-25261949",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "2Phones - from the company itself: \" With minimum gross proceeds from the Placing and Subscription of \u00a35 million, the Company's cash runway will be extended to mid Q2 2026.\". Hence my thinking spring will be the time to raise. And yes revenue is expected to increase (we will know by how much in a few weeks) - but annual expenses are c.$9m - so sales would need a dramatic (and unlikely) increase to negate the need for more funds. And you seem to agree that a placing is an option (imo the only likely one and the route the company has taken to date in all its efforts to secure more funding). So not sure what you were disagreeing with? SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-05T22:26:59.403054+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20250753-2Phones--3488985",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341050",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I don't agree - the operational update earlier this year had a predicted cash runway to H2 next year - when you couple that with the recruitment of 2 sales people and a director of clinical partnerships, I would anticipate growth in cash inflow.  However, they are a small team and they are going to have to increase production to accommodate the anticipated sales.  This will need funding, but where they get it is uncertain \u2013 one option being a placing.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-05T22:26:59.403305+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251728-2reincar--5657479",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341472",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Agree Silverblade. We could have one in Aprilish at 0.5p and one in Octoberish at 0.25p and then a rocket to + 2p ?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-05T22:26:59.403335+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251618-Silverbl--3214986",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Same old nonsense B_Positive. Thermo are not involved in Tutivia. Stop spreading false information. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.403362+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251557-B_Positi-31145528",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342355",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-05T22:26:59.403389+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251522-Silverbl-44955792",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342765",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There will be a placing in early 2026 - probably March/April time. The placing will of course be determined by the prevailing share price at the time. And that in turn will reflect the numbers for FY 2025 - there is a lot of expectation here so lets see what the company has to say for itself hopefully with a trading update in January. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-05T22:26:59.403417+00:00"
      },
      {
        "event_id": "SOCIAL-Today1544-Mikemine--4333418",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.744230",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "All decent points SB. Unfortunately VRCI is on AIM and AIM is almost dead in the water. I would venture that AIM is merely capturing the mood of the country which has been negative for some years now. People are so grumpy and lacking a positive disposition compared with what I see in the States, even with the Trump factor. I would venture that if VRCI was on Nasdaq its valuation would be around the $50-60 mn mark as the potential and demonstrated progress would be recognised as very positive by the Market there. Fortunately VRCI is operating in the States otherwise I wouldn't touch it with a bargepole because of how the NHS is run. You might have guessed that I think the company is well run and punching above its weight in a difficult field. It did get last years fundraiser wrong by announcing it's intention before securing funds but I reckon they've done well otherwise. What's for the future? The next 6 months are crucial but I believe that the \"strong\" sales increase flagged has a good chance of being achieved so the burn rate will reduce. They gave themselves an ambitious target last year which they nearly achieved and this indicates to me that they have a well thought out business model which includes a viable way of commercialising the product and this gives me some confidence is them performing strongly this year. As for a fund raise, their performance since the last one will give institutions lots of confidence to back them should they need one. I am not stupid enough to offer a prediction for the SP but, even on AIM, achieving this strong growth can't help but be positive in that direction. It's all my opinion of course and what do I know? There's always the possibility of a takeover of course but that's a speculative  game in which I am unable, and unwilling, to enter. Good luck for anybody that wishes to stay in the game.",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:54:31.404964+00:00"
      },
      {
        "event_id": "SOCIAL-Today1453-Silverbl-70499687",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.744668",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I can fully understand fevertrees anger and frustration here - it is likely representative of a large number of longer term shareholders. The grim reality is that whilst the latest update is encouraging in terms of revenue growth, the actions of the board last year in delaying the fund raise to the point it required a price of 0.5p to secure funding has created a position where the sheer number of shares in circulation render's the majority of investors trapped with little chance of recouping any investment made in the 2-5p range. Anything above that is gone.  Add to that a further capital raise in the next 4/6 months - and lets say they go for \u00a35m - which would require 1b further shares being issued at 0.5p. Nothing suggests the share price moving to any significant extent given the reaction to recent news. So then you have in the region of 2.5b shares - even assuming a share price of 1p, that's a \u00a325m market cap for a still loss making company. That in turn assumes the company is capable of doubling its revenue this year - which is possible - which also reduces the further risk (and scale) of a 2027 fund raise although this is still likely. I am invested here - and think the product is viable - but historic investors have been completely shafted. Even the company's own broker has an optimistic price less that 3p a share (don't get me wrong I would grab that in a heartbeat). The best outcome would be for an approach to take the business private or a pharma takeover at a decent premium to the current price. The alternative for shareholders is throwing more money during the fund raise to lower entry prices - which is a sobering thought. All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:54:31.404991+00:00"
      },
      {
        "event_id": "SOCIAL-Today1428-bigpunt--3066362",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745095",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Some very rough calcs.  c.90% of US population has medical insurance.  c.27,000 kidney transplants last year.  Assuming just one test per transplant, at unindexed $2,650 per test, the USA market-alone is worth $64m.  I'm also assuming the Tennessee lab can service the entire USA I'm not sure how many patients are represented by the 1,173 tests in 2025, and how many transplant centres vs the total in the USA, but the market penetration appears decent, considering the academic papers were only published 6 months ago Some may questions the relevance of academic papers and other KPIs may be more relevant, but it strikes me that the increase in number of clinicians and the increase in number of transplant centres will be strongly influenced by the academic articles and their subsequent peer reviews My view?  VRCI will get bought out when the USA nears profitability due to it's domestic market opportunity and the obvious globalisation opportunity.  Need to pay very close attention to what happens between now and next (and probably final) equity raise",
          "sentiment": 0.0,
          "engagement": "360",
          "price_at_post": "0.725",
          "thread_title": "Mid-term opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=755FC4E4-63EA-405E-A449-61BE41636EEA"
        },
        "ingested_at": "2026-02-06T15:54:31.405010+00:00"
      },
      {
        "event_id": "SOCIAL-Today0859-oogleflu-63578040",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745517",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "I thinks it\u2019s worth noting that Verici\u2019s year end was December. So whilst cash burn continues for another 6 months so does the pipeline growth and revenue. The Blue cross contract in Illinois is very significant as diversifying away from Medicare and becoming less dependant becomes more beneficial to clinicians and patients in not only in cost but also speed of treatment. Barrington hinted that these kind of contracts could spread across to other states. In an ever changing shift in Trumps one brain cell it must be pretty hard to predict or forecast anything in the US. What Vrci has demonstrated this year is the viability and commerciality is well in sight.",
          "sentiment": 0.0,
          "engagement": "5,469",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:54:31.405030+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261742-Mikemine--2212643",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, you are clearly angry with VRCI, especially Barrington, so it begs the obvious question \"Why are still here and presumably invested in the company?\" I'm sure most of us have felt let down and financially hurt by companies and BODs in the past but have taken the hit and moved on. Why haven't you?",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:54:31.405068+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261656-Fevertre--4840397",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.746540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "If cash burn is an issue then perhaps Sara Barrington should take a bloody pay cut",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405117+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261654-Fevertre--4798315",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.747174",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "barrington is the the issue (along with the board). after the disastrously botched raise that almost sank the company but not barrington because she got regranted her share options (not something s/holders were able to do)... her attitude to her shareholders is woeful - she didnt apologise for her gigantic ****-up that cratered the sp. meantime the growth figs look dodgy and she continues to burn thro cash at a rate.... fy 25 1,173 tutivia tests orders = $3m revs = $2557 per test, and yet at 1h figs of 591 tests = $1.16m = $1962 per test, so 30% uplift based on 2h figs. - on face of it that's a great result right? but where is the explanation/reconciliation, and if there is that much volatility barrington how can your investors/analyst properly model outcomes (let alone the company)? then what about momentum that she was saying was happening: october update - barrington told us \" volume growth from this progress is expected from q4 and the number of orders in q3 were consistent with the previous two quarters. 1h 591 so  averages q1 295 q2 295. q3 c300....so based on barrington's comment an uplift was due in q4...and yet: q$ sales below q1, 2,3..and 2h below 1h.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:54:31.405146+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261628-tbcx--5416301",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.747632",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is the company that reiterated cash runway until H2 2026 in today's update. That is them letting you know now funding will be required this year sometime from July onwards.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405167+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261516-stockyhe-53848669",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748041",
        "source": "LSE_CHAT",
        "data": {
          "author": "stockyheathlad",
          "content": "In a business like this, historic cashflow isn't necessarily a guide to the future. Expenditure on setting up new centres will be variable and, to a degree, discretionary.  The income stream grew across the year so the last quarter's figures are most relevant, rather than the whole year's.",
          "sentiment": 0.0,
          "engagement": "19",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405205+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261419-2Phones--2600024",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748468",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "SB - thanks for that.  They said at the time of the fundraising (as @ 31/05/25) they had a cash runway to the end of July 2025.  And subsequently they have burned that cash ($8.6m?) in the remaining 5-6 months of 2025 down to $3.3m, so $10m breakeven makes sense.  Obviously as they get closer to that breakeven point the cash burn reduces - the question is, with all the sales activity, how quickly can they reach that point, and how many further funding rounds we'll see.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405233+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261333-Silverbl--7256375",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748870",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Cash burns remains significant - company raised \u00a36.35m during the year - which added to the $800k difference in year end balances show the level of cash required to support the losses incurred over the last 12 months. Breakeven is predicted at $10m revenue pa. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405251+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261236-Guly--9076828",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.749302",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Cash runway atleast 2 yrs assuming current run rate without additional contract wins",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405269+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261117-2Phones--7327476",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.749703",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I agree that the guidance of cash for H2 appears disappointing, however if you take the cash burn over the last 12 months \u2013 the cash reduced from $4.1m to $3.3, which implies a burn rate of $800k per annum.  Now there are many things that impact these numbers but this set against the backdrop of ever-increasing revenue and sales orders/opportunities.  H2 may be a little pessimistic.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405292+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261022-tbcx--8155396",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750126",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Great product and credit to them for being revenue generating, way ahead of many other biotechs valued higher. Suspect there is a management discount at play here for habitually missing guidance, which can be overcome, she's easily replicable. The only snag is cash runway remains H2 2026. Definitely one to revisit once funding overhang sorted.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405329+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261012-Tii21--4263756",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750535",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "2 million delayed buy, and yet this is at 0%!! 05-Feb-26\t08:03:33\t0.79\t2,000,000\tUnknown*\t0.70\t0.75\t15.80k\tO",
          "sentiment": 0.0,
          "engagement": "457",
          "price_at_post": "0.725",
          "thread_title": "RE: Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-06T15:54:31.405351+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261012-Isthisaw-88489463",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750934",
        "source": "LSE_CHAT",
        "data": {
          "author": "Isthisawinner",
          "content": "Surprised the sp isn't following..",
          "sentiment": 0.0,
          "engagement": "2,301",
          "price_at_post": "0.725",
          "thread_title": "Finally,  gathering momentum...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=B49C9293-BB7B-4427-862D-3D342002FA5A"
        },
        "ingested_at": "2026-02-06T15:54:31.405369+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261006-Mikemine--4797417",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.751372",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Come on FT, give Barrington some credit. She has an accountancy background which would give her a less than gung-ho approach to reporting. They missed a rather ambitious sales target by not much which is good going in my book. For a \"modest\" report her predictions for 2026 are very confident with \"strong\" growth and are significant. For a CEO running a tiny company on a shoe string with small workforce, she is doing well I reckon. Additions to staff last year were all geared to sales so i would expect them to have reached an inflection point. As for the BCBS agreement, what can you say but \"Well done\". That's going to open more doors for the sales force to walk through. I'd imagine there's a good buzz throughout the company at the moment. They must have worked hard for the last 3-4 years with not much in the way is acceptance to show for it but, starting with Fisher, the ball is rolling. Very positive for 26 iIMHO.",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405387+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261001-Hawker--4441616",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.751787",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Agree, this is an encouraging update. Given the limited resources and tightly managed cost base, Verici could well be on the up this year.  It should only take a doubling or so of the now current testing volumes to put them on the front foot. Keep up the good work Sara and team, go forth and ramp Tutivia and PTRA with Thermo.",
          "sentiment": 0.5,
          "engagement": "301",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:54:31.405409+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260955-Guly--7401554",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.752384",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Accumulating a position here, can see massive potential.Can't believe it's so cheap.",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-06T15:54:31.405447+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260911-Silverbl-33583302",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.752953",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "On a positive note at least company has provided a FY update with a relatively small target miss, revenue is growing with new partnerships coming on stream and cash is ok for now. Against that - tests sales in H2 were less than H1 (591 v 582) which is concern - why no growth in actual testing volumes. What I can't reconcile is the Tutivia revenue for H1 was $1.2m for 591 tests ($1962 per test); and in H2 Tutivia revenue was $1.8m ($3092 per test). This just doesn't add up imo. Unless there is deferred income from H1 coming into H2 receivables. I think note 1 in the update is attempting to clarify the issue - but the language on revenue estimates being used rather than actual revenue are a bit concerning. Actual audited accounts will be more revealing and may differ from these unaudited updates. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:54:31.405471+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260855-blowdog-33688331",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.753557",
        "source": "LSE_CHAT",
        "data": {
          "author": "blowdog",
          "content": "Https://x.com/CapitalPmh/status/2019323726446158330?s=20",
          "sentiment": 0.0,
          "engagement": "933",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:54:31.405489+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260852-newgrang--6986482",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.754153",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "L2 buy orders looking strong \ud83d\udcaa",
          "sentiment": 0.0,
          "engagement": "2,116",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:54:31.405507+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260843-newgrang--1614884",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.754739",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "Good update with revenues and licensing contract. Hugely undervalued.",
          "sentiment": 0.0,
          "engagement": "2,116",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:54:31.405529+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260839-Fevertre-73338542",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.755335",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "SOP for disappointing update to put out commercial RNS alongside (Blue Cross deal looks encouraging) to soften the blow. Barrington is t up to the job- didn\u2019t hit the numbers; a less than confident statement , and why on God\u2019s Green Earth are they saying Dec FY25 will come out in May!! This is a tiny business with minimal revenues and yet Barrington can\u2019t commit to releasing results in a timely fashion. Suspect because every Q they have a wrangle with accountants about revenue timing and recognition. Be good to see sustained progress but after screwing up the cash raise, which cratered the so Barrington still has to prove she is CEO material.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405566+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260824-bigpunt--3561152",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.755905",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Hitting revenue and cash targets, adding major commercial tie-up, can't ask for much more as the company commercialise.  They've had a cracking year and I like the modest tone",
          "sentiment": 0.0,
          "engagement": "360",
          "price_at_post": "0.775",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:54:31.405589+00:00"
      },
      {
        "event_id": "SOCIAL-Today1742-Mikemine--2212643",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885051",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, you are clearly angry with VRCI, especially Barrington, so it begs the obvious question \"Why are still here and presumably invested in the company?\" I'm sure most of us have felt let down and financially hurt by companies and BODs in the past but have taken the hit and moved on. Why haven't you?",
          "sentiment": 0.0,
          "engagement": "1,236",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:54:31.405608+00:00"
      },
      {
        "event_id": "SOCIAL-Today1656-Fevertre--4840397",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "If cash burn is an issue then perhaps Sara Barrington should take a bloody pay cut",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405626+00:00"
      },
      {
        "event_id": "SOCIAL-Today1654-Fevertre--4798315",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "barrington is the the issue (along with the board). after the disastrously botched raise that almost sank the company but not barrington because she got regranted her share options (not something s/holders were able to do)... her attitude to her shareholders is woeful - she didnt apologise for her gigantic ****-up that cratered the sp. meantime the growth figs look dodgy and she continues to burn thro cash at a rate.... fy 25 1,173 tutivia tests orders = $3m revs = $2557 per test, and yet at 1h figs of 591 tests = $1.16m = $1962 per test, so 30% uplift based on 2h figs. - on face of it that's a great result right? but where is the explanation/reconciliation, and if there is that much volatility barrington how can your investors/analyst properly model outcomes (let alone the company)? then what about momentum that she was saying was happening: october update - barrington told us \" volume growth from this progress is expected from q4 and the number of orders in q3 were consistent with the previous two quarters. 1h 591 so  averages q1 295 q2 295. q3 c300....so based on barrington's comment an uplift was due in q4...and yet: q$ sales below q1, 2,3..and 2h below 1h.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:54:31.405651+00:00"
      },
      {
        "event_id": "SOCIAL-Today1628-tbcx--5416301",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.886494",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is the company that reiterated cash runway until H2 2026 in today's update. That is them letting you know now funding will be required this year sometime from July onwards.",
          "sentiment": 0.0,
          "engagement": "801",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405688+00:00"
      },
      {
        "event_id": "SOCIAL-Today1516-stockyhe-53848669",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.887017",
        "source": "LSE_CHAT",
        "data": {
          "author": "stockyheathlad",
          "content": "In a business like this, historic cashflow isn't necessarily a guide to the future. Expenditure on setting up new centres will be variable and, to a degree, discretionary.  The income stream grew across the year so the last quarter's figures are most relevant, rather than the whole year's.",
          "sentiment": 0.0,
          "engagement": "19",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405710+00:00"
      },
      {
        "event_id": "SOCIAL-Today1419-2Phones--2600024",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.887553",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "SB - thanks for that.  They said at the time of the fundraising (as @ 31/05/25) they had a cash runway to the end of July 2025.  And subsequently they have burned that cash ($8.6m?) in the remaining 5-6 months of 2025 down to $3.3m, so $10m breakeven makes sense.  Obviously as they get closer to that breakeven point the cash burn reduces - the question is, with all the sales activity, how quickly can they reach that point, and how many further funding rounds we'll see.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405728+00:00"
      },
      {
        "event_id": "SOCIAL-Today1333-Silverbl--7256375",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.888058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Cash burns remains significant - company raised \u00a36.35m during the year - which added to the $800k difference in year end balances show the level of cash required to support the losses incurred over the last 12 months. Breakeven is predicted at $10m revenue pa. SB",
          "sentiment": 0.0,
          "engagement": "1,925",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405746+00:00"
      },
      {
        "event_id": "SOCIAL-Today1236-Guly--9076828",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.888582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Cash runway atleast 2 yrs assuming current run rate without additional contract wins",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405771+00:00"
      },
      {
        "event_id": "SOCIAL-Today1117-2Phones--7327476",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.889106",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I agree that the guidance of cash for H2 appears disappointing, however if you take the cash burn over the last 12 months \u2013 the cash reduced from $4.1m to $3.3, which implies a burn rate of $800k per annum.  Now there are many things that impact these numbers but this set against the backdrop of ever-increasing revenue and sales orders/opportunities.  H2 may be a little pessimistic.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405808+00:00"
      },
      {
        "event_id": "SOCIAL-Today1022-tbcx--8155396",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.889622",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Great product and credit to them for being revenue generating, way ahead of many other biotechs valued higher. Suspect there is a management discount at play here for habitually missing guidance, which can be overcome, she's easily replicable. The only snag is cash runway remains H2 2026. Definitely one to revisit once funding overhang sorted.",
          "sentiment": 0.0,
          "engagement": "801",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405828+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Tii21--4263756",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.890160",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "2 million delayed buy, and yet this is at 0%!! 05-Feb-26\t08:03:33\t0.79\t2,000,000\tUnknown*\t0.70\t0.75\t15.80k\tO",
          "sentiment": 0.0,
          "engagement": "457",
          "price_at_post": "0.725",
          "thread_title": "RE: Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-06T15:54:31.405846+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Isthisaw-88489463",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.890667",
        "source": "LSE_CHAT",
        "data": {
          "author": "Isthisawinner",
          "content": "Surprised the sp isn't following..",
          "sentiment": 0.0,
          "engagement": "2,301",
          "price_at_post": "0.725",
          "thread_title": "Finally,  gathering momentum...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=B49C9293-BB7B-4427-862D-3D342002FA5A"
        },
        "ingested_at": "2026-02-06T15:54:31.405864+00:00"
      },
      {
        "event_id": "SOCIAL-Today1006-Mikemine--4797417",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.891178",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Come on FT, give Barrington some credit. She has an accountancy background which would give her a less than gung-ho approach to reporting. They missed a rather ambitious sales target by not much which is good going in my book. For a \"modest\" report her predictions for 2026 are very confident with \"strong\" growth and are significant. For a CEO running a tiny company on a shoe string with small workforce, she is doing well I reckon. Additions to staff last year were all geared to sales so i would expect them to have reached an inflection point. As for the BCBS agreement, what can you say but \"Well done\". That's going to open more doors for the sales force to walk through. I'd imagine there's a good buzz throughout the company at the moment. They must have worked hard for the last 3-4 years with not much in the way is acceptance to show for it but, starting with Fisher, the ball is rolling. Very positive for 26 iIMHO.",
          "sentiment": 0.0,
          "engagement": "1,236",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.405889+00:00"
      },
      {
        "event_id": "SOCIAL-Today1001-Hawker--4441616",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.891629",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Agree, this is an encouraging update. Given the limited resources and tightly managed cost base, Verici could well be on the up this year.  It should only take a doubling or so of the now current testing volumes to put them on the front foot. Keep up the good work Sara and team, go forth and ramp Tutivia and PTRA with Thermo.",
          "sentiment": 0.5,
          "engagement": "301",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:54:31.405926+00:00"
      },
      {
        "event_id": "SOCIAL-Today0955-Guly--7401554",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.892184",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Accumulating a position here, can see massive potential.Can't believe it's so cheap.",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-06T15:54:31.405955+00:00"
      },
      {
        "event_id": "SOCIAL-Today0911-Silverbl-33583302",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.892711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "On a positive note at least company has provided a FY update with a relatively small target miss, revenue is growing with new partnerships coming on stream and cash is ok for now. Against that - tests sales in H2 were less than H1 (591 v 582) which is concern - why no growth in actual testing volumes. What I can't reconcile is the Tutivia revenue for H1 was $1.2m for 591 tests ($1962 per test); and in H2 Tutivia revenue was $1.8m ($3092 per test). This just doesn't add up imo. Unless there is deferred income from H1 coming into H2 receivables. I think note 1 in the update is attempting to clarify the issue - but the language on revenue estimates being used rather than actual revenue are a bit concerning. Actual audited accounts will be more revealing and may differ from these unaudited updates. SB",
          "sentiment": 0.0,
          "engagement": "1,925",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:54:31.405974+00:00"
      },
      {
        "event_id": "SOCIAL-Today0855-blowdog-33688331",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.893229",
        "source": "LSE_CHAT",
        "data": {
          "author": "blowdog",
          "content": "Https://x.com/CapitalPmh/status/2019323726446158330?s=20",
          "sentiment": 0.0,
          "engagement": "929",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:54:31.405992+00:00"
      },
      {
        "event_id": "SOCIAL-Today0852-newgrang--6986482",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.893738",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "L2 buy orders looking strong \ud83d\udcaa",
          "sentiment": 0.0,
          "engagement": "2,114",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:54:31.406025+00:00"
      },
      {
        "event_id": "SOCIAL-Today0843-newgrang--1614884",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.894260",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "Good update with revenues and licensing contract. Hugely undervalued.",
          "sentiment": 0.0,
          "engagement": "2,114",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:54:31.406059+00:00"
      },
      {
        "event_id": "SOCIAL-Today0839-Fevertre-73338542",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.894756",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "SOP for disappointing update to put out commercial RNS alongside (Blue Cross deal looks encouraging) to soften the blow. Barrington is t up to the job- didn\u2019t hit the numbers; a less than confident statement , and why on God\u2019s Green Earth are they saying Dec FY25 will come out in May!! This is a tiny business with minimal revenues and yet Barrington can\u2019t commit to releasing results in a timely fashion. Suspect because every Q they have a wrangle with accountants about revenue timing and recognition. Be good to see sustained progress but after screwing up the cash raise, which cratered the so Barrington still has to prove she is CEO material.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:54:31.406085+00:00"
      },
      {
        "event_id": "SOCIAL-Today0824-bigpunt--3561152",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.895246",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Hitting revenue and cash targets, adding major commercial tie-up, can't ask for much more as the company commercialise.  They've had a cracking year and I like the modest tone",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "0.775",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:54:31.406121+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260854-2Phones-13514099",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.895745",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "the site is *************interviews dot com",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406152+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260852-2Phones-46540651",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.896268",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "hi splodge2001 https://www. ***************************/verici-dx-landmark-deal-unlocks-potential-300-million-tutivia-market-singer-research-icymi/4121236201",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406188+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261732-Splodge2-34918070",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.896762",
        "source": "LSE_CHAT",
        "data": {
          "author": "Splodge2001",
          "content": "Does anyone have a link to the Singer note? I couldn't find it on their website.",
          "sentiment": 0.0,
          "engagement": "114",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406208+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260851-2Phones-69368317",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.897267",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac101 - I was particularly encouraged by the 2.9p target price.  They clearly believe the future for tutivia is massive.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406226+00:00"
      },
      {
        "event_id": "SOCIAL-Today0851-2Phones-69368317",
        "event_type": "social_post",
        "date": "2026-01-30T23:03:22.957691",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac101 - I was particularly encouraged by the 2.9p target price.  They clearly believe the future for tutivia is massive.",
          "sentiment": 0.0,
          "engagement": "83",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406244+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261447-donmac10-53293603",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:31.826472",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Very good research note out last few day by Singer .Talking up Prime health deal 300 mill mkt.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406279+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251243-Romanby-31971237",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.788345",
        "source": "LSE_CHAT",
        "data": {
          "author": "Romanby",
          "content": "No placing you idiot",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T15:54:31.406311+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251216-Sandyman-43202378",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "Is the placing going to be at 0.25p or 0.5p? Or both?",
          "sentiment": 0.0,
          "engagement": "999",
          "price_at_post": "0.775",
          "thread_title": "Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T15:54:31.406330+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251441-Silverbl-79920386",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - FYI Thermo Fisher are not currently involved in Tutivia - so they are not involved in any roll out. Despite claims here to the contrary there has been no trading update - so we await evidence that Q4 delivers the level of sales anticipated by the CEO on achieving the 2025 Tutivia revenue target - which as you note would be a significant increase on 2024 sales. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406349+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251547-B_Positi-26214278",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.790830",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406367+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-B_Positi--4834934",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.791703",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I would wager a big Thermo-Fisher update is due here. Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406402+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251302-B_Positi-23825851",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.792503",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Wow now way just saw that. Huge implications for Thermo and its partners!",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406433+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251255-donmac10--8884166",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.793297",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Genincode signed a deal with Thermo read across to Verici Verici so undervalued at the moment something has to give.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406452+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251244-B_Positi-91820269",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794085",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Once it breaks 1p it will fly to 2p and then 3p gets smashed with ease considering the test orders are going to be around 300-400% from the digging below. 3p as a base and then a move back to 5-10p.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406470+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251227-B_Positi--2081753",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794962",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I'm personally amazed more aren't piling in whilst under 1p and this isn't at 3-5p already. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406488+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251953-B_Positi-59265480",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.795766",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Will add another 2m sub 1p Way too cheap here for me personally.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406525+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251945-donmac10-80945503",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.796575",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "3p per share nailed on short term if you guys sit oan yer tuffetts like miss muffet know whit ah mean?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406553+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251941-donmac10-71364106",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.797364",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Company is no longer research orientated so past rns at this time of year irrelevant trust me as tests ramp up as they will be the company will be eager to broadcast positive newsflow asap.noh whit a meen an that man getmeh!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406571+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251535-Silverbl-71499800",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798154",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Would be unusual for a trading update pre-xmas imo although any kind of an update in relation to hitting revenue targets would assist progress here - the bar has been set very high by CEO. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406589+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251320-B_Positi--9167486",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798939",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Yes it was due. Thermo-Fisher $220BILLION backing this and tied in. Update on them or something new will wake the market up.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406607+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251245-donmac10-29496456",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.799717",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Update this week and more deals with distributors .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406644+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251234-B_Positi-41959311",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.800588",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "MMs caught wind of an update? I'm amazed this isn't over 2p at least. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406681+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251230-tbcx-11174752",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.801373",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Buying pressure certainly returning this week, this remains extremely undervalued.",
          "sentiment": 0.0,
          "engagement": "766",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406701+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251443-donmac10-41616194",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802148",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Nice 2mill buy this morning.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406719+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251235-B_Positi-66703728",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802905",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Donmac, absolutely buzzing for the trading update this month Hopefully see's this head back to the 3 to 5p level",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406742+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251104-B_Positi-91595425",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.803727",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "So with less than 10% of transplant centres onboarded and already at the start of the mass rollout they averaged about 300 tests per quarter in Q1, Q2 and Q3, just short of 900, vs 334 for the entirety of 2024, representng significant growth. We now know they are at at least 16% of transplant centres onboarded now (less than 10% for Q1, Q2, Q2, perhaps around 20% now and are increasing this fast. You quickly realise how mad the revenues can become here at $2,650 a test with the medicaid coverage +Thermo Fisher licencing revenues. I know many, many pharma stocks that have literally $0 revenue, no proven tech, no FDA approval, no big deal with a giant like this does with Thermo Fisher that are trading at many multiples of the Verici market cap.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406780+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251045-donmac10-11543457",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.804510",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And its beginning to look like word is out?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406802+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251039-donmac10-26240216",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.805293",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Expecting a trading update in the run up to xmas should make for good reading!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406820+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251031-B_Positi--7901425",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806132",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.406838+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251456-Mikemine--3571231",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806901",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, your posts have got  very repetitive and quite frankly, boring. Unless your rants help your mental state I for one would be grateful if you would keep your posts to new views or information.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:54:31.406862+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251148-Fevertre--2071745",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.375637",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Just out of interest what are Barrington's competencies?",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:54:31.406900+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251147-Fevertre-19752640",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.376396",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "The Board and non-execs have overseen an absolute shamble here. Barrington completely unaffected by disastrous dilution as she has virtually no bloody shares in teh company she purports to lead.  The CFo isnt fit for purpose frankly. The Q4 figs appear to be the stuff of fantasy - I would give more creedance if  Barrington was able to explain how she gets to the forecast but she appears to be just making it up as she goes along... we have no timelines on onboarding; Barrington cant set out how she arrived at the numbers... she continues to be utterly hopeless as the CEO of supposedly a cutting edge business.",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:54:31.406921+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251059-Silverbl--7318091",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377214",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There you go donmac almost at your buy price already. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:54:31.406939+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20250050-donmac10--1498816",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377985",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sell up move on thank you.....give me the chance ar more aroon the 55 mark slanj .And a will catch yeh in wetherspoons oan the wae otta rah ritz.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:54:31.406957+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251734-Mikemine-48127223",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.378810",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "VRCI is a small company so hiring an extra 3 salespersons is huge for them and points to their determination to hit their target. It's a big ask but you can be sure they recognise that their credibility is on the line. From a practical point of view, hiring new salespeople  takes time for their impact to come through. They have to get used of the systems, the product and VRCI's method of selling. I wish them luck and, if they do reach their target, it will be noticed by the Market.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:54:31.406982+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251709-Silverbl-79247216",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.379608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not a fan to date either fevertree - its been a disaster for all shareholders here - but I still hold a position here and am trying to look forward not back given the past is what it is. If Q4 goes well I expect a trading update early 2026 - which doesn't usually happen but positive momentum will be required to avoid a total wipe out in any subsequent capital raise. Failure to deliver (again) then more questions will be raised on leadership competencies.  SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.75",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:54:31.407020+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251647-Fevertre--6556865",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.380414",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "She has never fully explained the onboarding process. If a new centre gets onboarded, typically how long does it take for clinicians to order first tests",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:54:31.407041+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251644-Fevertre--7610026",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.381220",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Nonsense Donmac.....look at the maths around Barrington's targets: On my maths I don't see how she hits revs from Tutivia $3.2m... Tutivia:  1H Revs: $1.16m: 591 tests @ ave $1900 ($1.16m divided by 591) 2H Revs:  3Q Tutivia same rate as Q1/Q2 ..c300 tests at 1900 = $570k  ...so to meet her target she needs to sell c$1.5m of tests. Assume same ave price of $1900....she needs to sell c790 tests....that's a massive uplift, even with onboarding another 9 more centres...",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:54:31.407059+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251627-donmac10-67430725",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382010",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "markets falling and the doom and gloom ****roaches appear in force.sell up ,thats even if yeh hod any and gie us aw peace!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:54:31.407078+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251604-Fevertre-80123757",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382802",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Worryingly her bullishness has cost investors dearly so far. Apart from having virtually no skin in the game she hasn't been gifted,  or regifted (look at the outrageous revision of option pricing). The fact that the sp is still at 3/4 of a penny tells you everything you need to know about how the market views her!",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:54:31.407116+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251522-Silverbl--3593882",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.383604",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Based on what we already know - VRCI sold c.600 Tutivia tests in H1 2025 - securing revenue of $1.2m ($2k per test - blend of public and private payers). They sold same in Q3 - so lets assume pro-rata they secured a further $600k revenue. Sara B confirmed FY Tutivia target was $3.2m - so that leaves $1.4 revenue to be secured in Q4 - or c.700 tests at $2k. Seems a huge leap - or possible they are looking at a slight increase to average test $ - although Prime Health RNS appears to push towards discounted volume in private market. She has certainly set high expectations for Q4 trading. If this is achieved it will be a significant acceleration - and will be crucial in supporting the share price/market cap as the company requires additional funding in the next 4/5 months. Additional licensing revenue from Thermo (c.$4m received to date - $3.3m in 2024 and $0.75m in 2025) remains on hold as they progress their approach to the PTRA test. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.725",
          "thread_title": "2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:54:31.407154+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250856-2Phones-12538754",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.384401",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac agreed - two of the latest RNS are very positive about the rate of revenue growth and market penetration - can't help but think the next sales based RNS will be a gamechanger.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.875",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T15:54:31.407179+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250845-donmac10-20306040",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385202",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Analysts expecting 3p per share next year big upside from here.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.90",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T15:54:31.407197+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250843-donmac10-88287480",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385990",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Verici also more forthcoming informing the market with updates .Beats last years 6 month radio silence .Just waiting now for testing update which i know will further boost price.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T15:54:31.407216+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250830-donmac10--5741662",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.386775",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Tells me ,anyone looking to make money would be well served to get in now .Futher big rise going into year end.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.95",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T15:54:31.407238+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250809-2Phones--1901391",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.387576",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Interesting news today \u2013 initially I thought why? This has little bearing on shareholders interests \u2013 however, on further concideration, while successful audits add little to the bottom line or turnover or even shareholder value \u2013 in our case it is very much a Critical Failure Factor, where failure to pass a quality audit could seriously damage the company in the short/medium term.  Also it does point to a well run, disciplined business. So well done Verici.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.95",
          "thread_title": "RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T15:54:31.407277+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251448-oogleflu-88620440",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.388340",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Tom. I know exactly what you\u2019re saying is correct . Unfortunately risk appetite is much lower in the UK probably because the FA are like a bunch of frightened rabbits. Fund managers continue to unwind oversold positions in uk to chase  the way overpriced \u2018American dream stocks\u2019 which are overdue a big correction there by loosing even more of the inadequate fund managers clients money. It\u2019s not all Uk stocks but quite a few as admitted in an interview recently with a fund manager. Certainly since the pandemic Uk stocks are valued much more realistically i.e. sound balance sheet which Vrci  now has, realistic forecast which Vrci now has, realistic targets for growth which Vrci now has. But we don\u2019t tend to look further than a year ahead. One step at a time . There will be /is FOMO with a stock like Vrci which will cause some volatility till they establish a more constant earnings stream.",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407478+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251354-donmac10--1537402",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389131",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "It feels to me we are about to get a trading update on testing numbers shortly .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407515+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251256-donmac10-20026411",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389888",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "1.20p close today and more updates in coming days on quickly to 2.00p",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407539+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251247-geraldus-23918665",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.390653",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "Still early days here,and they will have to take some market share from the incumbent bio markers. Shaping up well so far and with a miserly market cap in comparison with other counters.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.825",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407557+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251241-B_Positi--5631288",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.391431",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Geraldus Tutivia is the standard now. Hence why Thermo-Fisher has gone all in and is backing all the way. Market slowly beginning to wake up that this company is grossly undervalued. I mean the FDA approval, ip, tech alone is worth multiples and then whack on the huge growth already in 2025 and coming in 2026 with over 30 transplant centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407576+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251239-donmac10-66757674",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392203",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "American market waking up to the potential with Verici dx in their own backyard They love an AI stock.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407597+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251236-geraldus--3360193",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392989",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "With their 'AI' solution for optimising transplants,it is undoubtly an interesting opportunity here. They have spent millions on this and they are confident that it is payback time. With no competition at this level,it could possibly become the defacto standard.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407635+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251217-B_Positi--7901425",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.393835",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407660+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251205-oogleflu-67884297",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.394621",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Addressable market doesn\u2019t mean they capture all of it.  They might get 1 or 2 percent which is still sizeable if lucky. Even singer, their broker,  have only raised the sp to 3p. That\u2019s still 4 times current market cap! The other thing is will they need to expand the lab or open another one as their market share increases. They have got a captured market in that there is no competition and the tests are becoming mandatory. No plans to adopt outside the US yet. Maybe 20p in 5 years certainly not months I\u2019m afraid but good luck",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.775",
          "thread_title": "RE: Quantifying the opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=D3DE9F2B-871D-47DE-96C8-2D6BB08D16A4"
        },
        "ingested_at": "2026-02-06T15:54:31.407678+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261715-Silverbl-18849577",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - feel free to use the actual numbers in your updates. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 (INCORRECT: H1 actual revenue was $1.16m = $1962 average revenue per test). H1 2025 licencing revenue = $750,000 (CORRECT) Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. (Test numbers CORRECT. Centres INCORRECT - there were 21 onboarded at time of results). 286 x $2,650 = $757,900 (Likely INCORRECT based on average revenue per test of $1962 achieved in H1 2025 - likely revenue $560K). Q4 2025, 20 centres onboarded and let's be conservative and say 300 tests. (INCORRECT. There are now 30 centres onboarded. Company is targeting in the region of 750 tests in Q4 in order to meet its Q4 revenue target of c.$1.5m) 300 x $2,650 = $795,000 revenue (We will find out in due course what was achieved in terms of test numbers and average revenue per test) H2 2025 licensing revenue, let's be conservative and say $500,000. (INCORRECT. No licencing revenue will come from Thermo in H2) Combine all of that above and you get = $4.3mil or \u00a33.2m. (H1 revenue was $1.9m/ Q3 likely $560K. Q4 not yet reported. Company is targeting total FY 2025 revenue of $3.95m, comprising $3.2 Tutivia tests and $750K licencing revenue) Still nothing in the way of a trading update from the team at vrci. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407696+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261504-B_Positi-71441240",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332720",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We should all be extremely excited having now onboarded over 30 transplant centres, up from 10 in 2024. We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407716+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260830-Silverbl--8833240",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333151",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "$12m was a direct quote from Vrci CEO in latest Vox markets interview. As for my 'precise' figures - strangely enough when it comes to investing I prefer to deal in fact rather than making it up (refer B_Positive). As for my views on the business - I remain invested so I am hopeful there is a future here or would have taken my medicine and moved on. That does not mean to say I will not vocalise my thoughts on areas of mismanagement where the company could and should be doing better; or to call out posters who are just making it up as they go along. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407753+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260728-B_Positi--3843075",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333626",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407779+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260205-donmac10--1551189",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334054",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Where do you get the 12mill breakeven point? You sound like a bot with your precise figures. And you always have a way of sounding positive but are really negative .So cant be taken seriously .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407798+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262026-Silverbl-16322280",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334501",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not really sure why I need to explain this, but here you go B_Positive. Your bullet point regarding Tutivia sums the position up very well. Transplant centres service both Medicare patients and private paying patients. So whilst the Medicare payment of $2650 is being provided by the US healthcare system for patients who benefit from the Medicare and Medicare plus programmes - there are actually six key revenue streams for test sales of which Medicare is one (albeit the largest - 68% of tests being undertaken are covered by Medicare seems to be the claim from the company). Private payers (via healthcare insurance) do not pay the $2650 - they receive discounts. Clinical trials pay nothing. And there others. If you divide the H1 Tutivia revenue of $1.16m by the 591 tests in H1 it comes out at $1962 . That is the current revenue reality for test sales. The recent RNS highlighting the agreement with Prime Health Services is all about trying to establish consistent pricing of the Tutivia test with the private payment market and clearly with the goal to increase current pricing which is diluting the Medicare $2650. In relation to your H2 licencing point the following clarifies the position \" Thermo Fisher is investing in new research related to PTRA aimed at identifying the earliest stage at which the test can be utilised before transplantation. Consequently, the second milestone originally anticipated for 2025 will be delayed as we continue to collaborate on publishing clinical validation data and Thermo Fisher pursues these additional research efforts to help broaden utility and adoption of the assay.\" FYI the breakeven position for Verici is c.$12m - so that provides an indication of the revenue which is required from test sales, licence revenue, protega etc to cover vrci operating costs. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407816+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261524-B_Positi-65822630",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334932",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Nope it's $2,650 as per the Medicare coverage RNS and more recently as per the HY report. \u00b7 Lead product Tutivia\u2122 attained Medicare coverage at $2,650 per test, covering a national estimate of 68% of all US transplant tests and commercial payor reimbursement applications are underway They receive licencing revenues both H1 and H2. It was $750k in H1.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407837+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261523-Silverbl--4629614",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335360",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Mikemine -  your points are valid - but highlight one of the main issues here. Why set a target and fail. Undermines confidence, craters the share price, makes fund raising tricky and makes investors wary on growth. Much better to overdeliver on achievable targets than underdeliver? But maybe we will be get a pleasant surprise. Thermo are just doing their own thing on the PRTA at present. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407876+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261518-Silverbl--4582369",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335771",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "No licencing revenue in H2 2025 and average received revenue per test is $1900. Do some actual research please. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407900+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261416-B_Positi-66060988",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336264",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10 centres onboarded. It must now be around 25-35 going by the last report.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407918+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261402-Mikemine-63485378",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336713",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "They've set themselves a big revenue target of over \u00a33mn for 2025. Small in world terms but a big % increase for VRCI. Should they be chastised if they do not reach the target or should it be viewed in the context of what they do achieve and what they forecast for this year? Getting close to \u00a33mn would be an achievement in my book as that would point to things being on track for further increases especially as the new sales guys have probably only just got their acts together and their contacts in line. Not sure what to think of the Thermo-Fisher deal and its seemingly lack of traction. Big companies are not nimble nor quick so the jury's out on that one for me. My guess is for an update this month and it will be positive but will not please everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407936+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261401-B_Positi--4347460",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337193",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Cashed up until the end of 2026 and now they've been securing record orders as per below. Next time they raise it will be in the pennies, which is what they will want given the new option prices. Test update going to drop soon. More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.407958+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261346-Silverbl--8605102",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Despite the view expressed by several contributors here we have heard nothing from the business on Q4 trading. Not unexpected - if there was anything to report on I would expect to hear later on in January. The issue looming very shortly relates to the required fund raising. In previous years the company has elected not to divulge FY trading until May.  This is likely to be beyond the point at which the company runs out of cash. We should therefore be able to read the signals loud and clear - no trading update - then Q4 has not delivered the targeted sales and the fund raise will be brutal.  If a positive Q4 trading update is issued then there should be a healthy price response despite the recognition funds will still be required. Remember last year the first fundraise was at 9p - then 0.5p after bewildering timing mismanagement by the company.  All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: 100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-02-06T15:54:31.407996+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261228-B_Positi--7819308",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338063",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.408019+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-2reincar-25529322",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338488",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Conversions this summer will see us at sub 0.25p!",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.75",
          "thread_title": "100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-02-06T15:54:31.408037+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261210-B_Positi--5566254",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338938",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.408055+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20260629-2Phones-61373605",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339362",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "How can any one disagree with such a cogent arguement - and clearly not the rantings of a one track numpty.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.725",
          "thread_title": "RE: Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-02-06T15:54:31.408077+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261022-2reincar--6179571",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339773",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "At 0.25p?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.725",
          "thread_title": "Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-02-06T15:54:31.408133+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251515-B_Positi--5566254",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340229",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.408154+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251223-Silverbl-88329771",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "2Phones - from the company itself: \" With minimum gross proceeds from the Placing and Subscription of \u00a35 million, the Company's cash runway will be extended to mid Q2 2026.\". Hence my thinking spring will be the time to raise. And yes revenue is expected to increase (we will know by how much in a few weeks) - but annual expenses are c.$9m - so sales would need a dramatic (and unlikely) increase to negate the need for more funds. And you seem to agree that a placing is an option (imo the only likely one and the route the company has taken to date in all its efforts to secure more funding). So not sure what you were disagreeing with? SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T15:54:31.408173+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20250753-2Phones-44494978",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341050",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I don't agree - the operational update earlier this year had a predicted cash runway to H2 next year - when you couple that with the recruitment of 2 sales people and a director of clinical partnerships, I would anticipate growth in cash inflow.  However, they are a small team and they are going to have to increase production to accommodate the anticipated sales.  This will need funding, but where they get it is uncertain \u2013 one option being a placing.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T15:54:31.408192+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251728-2reincar--5576317",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341472",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Agree Silverblade. We could have one in Aprilish at 0.5p and one in Octoberish at 0.25p and then a rocket to + 2p ?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T15:54:31.408211+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251618-Silverbl--3237190",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Same old nonsense B_Positive. Thermo are not involved in Tutivia. Stop spreading false information. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.408249+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251557-B_Positi-26214278",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342355",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:54:31.408276+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251522-Silverbl-58824763",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342765",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There will be a placing in early 2026 - probably March/April time. The placing will of course be determined by the prevailing share price at the time. And that in turn will reflect the numbers for FY 2025 - there is a lot of expectation here so lets see what the company has to say for itself hopefully with a trading update in January. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T15:54:31.408294+00:00"
      },
      {
        "event_id": "SOCIAL-Today1557-bigpunt--6586737",
        "event_type": "social_post",
        "date": "2026-02-06T15:59:25.608751",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Silverblade, a lot of whingeing about the past will not help your decision-making.  One should learn from previous investment decisions and appraise prospective investment decisions better!  Between now and raise will be the FY results and presentation and possibly a further update to support the raise.  Mkt cap and equity raise price will be determined entirely by those trading updates and credibility of updated forecasts",
          "sentiment": 0.0,
          "engagement": "361",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:59:36.537401+00:00"
      },
      {
        "event_id": "SOCIAL-Today1544-Mikemine--4176387",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.744230",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "All decent points SB. Unfortunately VRCI is on AIM and AIM is almost dead in the water. I would venture that AIM is merely capturing the mood of the country which has been negative for some years now. People are so grumpy and lacking a positive disposition compared with what I see in the States, even with the Trump factor. I would venture that if VRCI was on Nasdaq its valuation would be around the $50-60 mn mark as the potential and demonstrated progress would be recognised as very positive by the Market there. Fortunately VRCI is operating in the States otherwise I wouldn't touch it with a bargepole because of how the NHS is run. You might have guessed that I think the company is well run and punching above its weight in a difficult field. It did get last years fundraiser wrong by announcing it's intention before securing funds but I reckon they've done well otherwise. What's for the future? The next 6 months are crucial but I believe that the \"strong\" sales increase flagged has a good chance of being achieved so the burn rate will reduce. They gave themselves an ambitious target last year which they nearly achieved and this indicates to me that they have a well thought out business model which includes a viable way of commercialising the product and this gives me some confidence is them performing strongly this year. As for a fund raise, their performance since the last one will give institutions lots of confidence to back them should they need one. I am not stupid enough to offer a prediction for the SP but, even on AIM, achieving this strong growth can't help but be positive in that direction. It's all my opinion of course and what do I know? There's always the possibility of a takeover of course but that's a speculative  game in which I am unable, and unwilling, to enter. Good luck for anybody that wishes to stay in the game.",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:59:36.537445+00:00"
      },
      {
        "event_id": "SOCIAL-Today1453-Silverbl-33964285",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.744668",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I can fully understand fevertrees anger and frustration here - it is likely representative of a large number of longer term shareholders. The grim reality is that whilst the latest update is encouraging in terms of revenue growth, the actions of the board last year in delaying the fund raise to the point it required a price of 0.5p to secure funding has created a position where the sheer number of shares in circulation render's the majority of investors trapped with little chance of recouping any investment made in the 2-5p range. Anything above that is gone.  Add to that a further capital raise in the next 4/6 months - and lets say they go for \u00a35m - which would require 1b further shares being issued at 0.5p. Nothing suggests the share price moving to any significant extent given the reaction to recent news. So then you have in the region of 2.5b shares - even assuming a share price of 1p, that's a \u00a325m market cap for a still loss making company. That in turn assumes the company is capable of doubling its revenue this year - which is possible - which also reduces the further risk (and scale) of a 2027 fund raise although this is still likely. I am invested here - and think the product is viable - but historic investors have been completely shafted. Even the company's own broker has an optimistic price less that 3p a share (don't get me wrong I would grab that in a heartbeat). The best outcome would be for an approach to take the business private or a pharma takeover at a decent premium to the current price. The alternative for shareholders is throwing more money during the fund raise to lower entry prices - which is a sobering thought. All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:59:36.537486+00:00"
      },
      {
        "event_id": "SOCIAL-Today1428-bigpunt--9143089",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745095",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Some very rough calcs.  c.90% of US population has medical insurance.  c.27,000 kidney transplants last year.  Assuming just one test per transplant, at unindexed $2,650 per test, the USA market-alone is worth $64m.  I'm also assuming the Tennessee lab can service the entire USA I'm not sure how many patients are represented by the 1,173 tests in 2025, and how many transplant centres vs the total in the USA, but the market penetration appears decent, considering the academic papers were only published 6 months ago Some may questions the relevance of academic papers and other KPIs may be more relevant, but it strikes me that the increase in number of clinicians and the increase in number of transplant centres will be strongly influenced by the academic articles and their subsequent peer reviews My view?  VRCI will get bought out when the USA nears profitability due to it's domestic market opportunity and the obvious globalisation opportunity.  Need to pay very close attention to what happens between now and next (and probably final) equity raise",
          "sentiment": 0.0,
          "engagement": "360",
          "price_at_post": "0.725",
          "thread_title": "Mid-term opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=755FC4E4-63EA-405E-A449-61BE41636EEA"
        },
        "ingested_at": "2026-02-06T15:59:36.537525+00:00"
      },
      {
        "event_id": "SOCIAL-Today0859-oogleflu--6401571",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745517",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "I thinks it\u2019s worth noting that Verici\u2019s year end was December. So whilst cash burn continues for another 6 months so does the pipeline growth and revenue. The Blue cross contract in Illinois is very significant as diversifying away from Medicare and becoming less dependant becomes more beneficial to clinicians and patients in not only in cost but also speed of treatment. Barrington hinted that these kind of contracts could spread across to other states. In an ever changing shift in Trumps one brain cell it must be pretty hard to predict or forecast anything in the US. What Vrci has demonstrated this year is the viability and commerciality is well in sight.",
          "sentiment": 0.0,
          "engagement": "5,469",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:59:36.537578+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261742-Mikemine-54328615",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, you are clearly angry with VRCI, especially Barrington, so it begs the obvious question \"Why are still here and presumably invested in the company?\" I'm sure most of us have felt let down and financially hurt by companies and BODs in the past but have taken the hit and moved on. Why haven't you?",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:59:36.537617+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261656-Fevertre-10746676",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.746540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "If cash burn is an issue then perhaps Sara Barrington should take a bloody pay cut",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.537667+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261654-Fevertre--4285505",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.747174",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "barrington is the the issue (along with the board). after the disastrously botched raise that almost sank the company but not barrington because she got regranted her share options (not something s/holders were able to do)... her attitude to her shareholders is woeful - she didnt apologise for her gigantic ****-up that cratered the sp. meantime the growth figs look dodgy and she continues to burn thro cash at a rate.... fy 25 1,173 tutivia tests orders = $3m revs = $2557 per test, and yet at 1h figs of 591 tests = $1.16m = $1962 per test, so 30% uplift based on 2h figs. - on face of it that's a great result right? but where is the explanation/reconciliation, and if there is that much volatility barrington how can your investors/analyst properly model outcomes (let alone the company)? then what about momentum that she was saying was happening: october update - barrington told us \" volume growth from this progress is expected from q4 and the number of orders in q3 were consistent with the previous two quarters. 1h 591 so  averages q1 295 q2 295. q3 c300....so based on barrington's comment an uplift was due in q4...and yet: q$ sales below q1, 2,3..and 2h below 1h.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:59:36.537705+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261628-tbcx--6931206",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.747632",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is the company that reiterated cash runway until H2 2026 in today's update. That is them letting you know now funding will be required this year sometime from July onwards.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.537744+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261516-stockyhe--5834363",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748041",
        "source": "LSE_CHAT",
        "data": {
          "author": "stockyheathlad",
          "content": "In a business like this, historic cashflow isn't necessarily a guide to the future. Expenditure on setting up new centres will be variable and, to a degree, discretionary.  The income stream grew across the year so the last quarter's figures are most relevant, rather than the whole year's.",
          "sentiment": 0.0,
          "engagement": "19",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.537783+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261419-2Phones-69775962",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748468",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "SB - thanks for that.  They said at the time of the fundraising (as @ 31/05/25) they had a cash runway to the end of July 2025.  And subsequently they have burned that cash ($8.6m?) in the remaining 5-6 months of 2025 down to $3.3m, so $10m breakeven makes sense.  Obviously as they get closer to that breakeven point the cash burn reduces - the question is, with all the sales activity, how quickly can they reach that point, and how many further funding rounds we'll see.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.537821+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261333-Silverbl--6956027",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748870",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Cash burns remains significant - company raised \u00a36.35m during the year - which added to the $800k difference in year end balances show the level of cash required to support the losses incurred over the last 12 months. Breakeven is predicted at $10m revenue pa. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.537859+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261236-Guly--1906061",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.749302",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Cash runway atleast 2 yrs assuming current run rate without additional contract wins",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.537898+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261117-2Phones--4328267",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.749703",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I agree that the guidance of cash for H2 appears disappointing, however if you take the cash burn over the last 12 months \u2013 the cash reduced from $4.1m to $3.3, which implies a burn rate of $800k per annum.  Now there are many things that impact these numbers but this set against the backdrop of ever-increasing revenue and sales orders/opportunities.  H2 may be a little pessimistic.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.537936+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261022-tbcx-81165229",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750126",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Great product and credit to them for being revenue generating, way ahead of many other biotechs valued higher. Suspect there is a management discount at play here for habitually missing guidance, which can be overcome, she's easily replicable. The only snag is cash runway remains H2 2026. Definitely one to revisit once funding overhang sorted.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.537974+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261012-Tii21-89657276",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750535",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "2 million delayed buy, and yet this is at 0%!! 05-Feb-26\t08:03:33\t0.79\t2,000,000\tUnknown*\t0.70\t0.75\t15.80k\tO",
          "sentiment": 0.0,
          "engagement": "457",
          "price_at_post": "0.725",
          "thread_title": "RE: Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-06T15:59:36.538011+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261012-Isthisaw-33462158",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750934",
        "source": "LSE_CHAT",
        "data": {
          "author": "Isthisawinner",
          "content": "Surprised the sp isn't following..",
          "sentiment": 0.0,
          "engagement": "2,301",
          "price_at_post": "0.725",
          "thread_title": "Finally,  gathering momentum...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=B49C9293-BB7B-4427-862D-3D342002FA5A"
        },
        "ingested_at": "2026-02-06T15:59:36.538050+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261006-Mikemine--6954960",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.751372",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Come on FT, give Barrington some credit. She has an accountancy background which would give her a less than gung-ho approach to reporting. They missed a rather ambitious sales target by not much which is good going in my book. For a \"modest\" report her predictions for 2026 are very confident with \"strong\" growth and are significant. For a CEO running a tiny company on a shoe string with small workforce, she is doing well I reckon. Additions to staff last year were all geared to sales so i would expect them to have reached an inflection point. As for the BCBS agreement, what can you say but \"Well done\". That's going to open more doors for the sales force to walk through. I'd imagine there's a good buzz throughout the company at the moment. They must have worked hard for the last 3-4 years with not much in the way is acceptance to show for it but, starting with Fisher, the ball is rolling. Very positive for 26 iIMHO.",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.538088+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261001-Hawker--7106485",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.751787",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Agree, this is an encouraging update. Given the limited resources and tightly managed cost base, Verici could well be on the up this year.  It should only take a doubling or so of the now current testing volumes to put them on the front foot. Keep up the good work Sara and team, go forth and ramp Tutivia and PTRA with Thermo.",
          "sentiment": 0.5,
          "engagement": "301",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:59:36.538142+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260955-Guly-12572849",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.752384",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Accumulating a position here, can see massive potential.Can't believe it's so cheap.",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-06T15:59:36.538179+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260911-Silverbl-29185940",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.752953",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "On a positive note at least company has provided a FY update with a relatively small target miss, revenue is growing with new partnerships coming on stream and cash is ok for now. Against that - tests sales in H2 were less than H1 (591 v 582) which is concern - why no growth in actual testing volumes. What I can't reconcile is the Tutivia revenue for H1 was $1.2m for 591 tests ($1962 per test); and in H2 Tutivia revenue was $1.8m ($3092 per test). This just doesn't add up imo. Unless there is deferred income from H1 coming into H2 receivables. I think note 1 in the update is attempting to clarify the issue - but the language on revenue estimates being used rather than actual revenue are a bit concerning. Actual audited accounts will be more revealing and may differ from these unaudited updates. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:59:36.538218+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260855-blowdog-24331593",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.753557",
        "source": "LSE_CHAT",
        "data": {
          "author": "blowdog",
          "content": "Https://x.com/CapitalPmh/status/2019323726446158330?s=20",
          "sentiment": 0.0,
          "engagement": "933",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:59:36.538298+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260852-newgrang-48809696",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.754153",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "L2 buy orders looking strong \ud83d\udcaa",
          "sentiment": 0.0,
          "engagement": "2,116",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:59:36.538346+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260843-newgrang-57962069",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.754739",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "Good update with revenues and licensing contract. Hugely undervalued.",
          "sentiment": 0.0,
          "engagement": "2,116",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:59:36.538383+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260839-Fevertre--7212557",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.755335",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "SOP for disappointing update to put out commercial RNS alongside (Blue Cross deal looks encouraging) to soften the blow. Barrington is t up to the job- didn\u2019t hit the numbers; a less than confident statement , and why on God\u2019s Green Earth are they saying Dec FY25 will come out in May!! This is a tiny business with minimal revenues and yet Barrington can\u2019t commit to releasing results in a timely fashion. Suspect because every Q they have a wrangle with accountants about revenue timing and recognition. Be good to see sustained progress but after screwing up the cash raise, which cratered the so Barrington still has to prove she is CEO material.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.538420+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260824-bigpunt-28651631",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.755905",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Hitting revenue and cash targets, adding major commercial tie-up, can't ask for much more as the company commercialise.  They've had a cracking year and I like the modest tone",
          "sentiment": 0.0,
          "engagement": "360",
          "price_at_post": "0.775",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:59:36.538457+00:00"
      },
      {
        "event_id": "SOCIAL-Today1742-Mikemine-54328615",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885051",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, you are clearly angry with VRCI, especially Barrington, so it begs the obvious question \"Why are still here and presumably invested in the company?\" I'm sure most of us have felt let down and financially hurt by companies and BODs in the past but have taken the hit and moved on. Why haven't you?",
          "sentiment": 0.0,
          "engagement": "1,236",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:59:36.538489+00:00"
      },
      {
        "event_id": "SOCIAL-Today1656-Fevertre-10746676",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "If cash burn is an issue then perhaps Sara Barrington should take a bloody pay cut",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.538521+00:00"
      },
      {
        "event_id": "SOCIAL-Today1654-Fevertre--4285505",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "barrington is the the issue (along with the board). after the disastrously botched raise that almost sank the company but not barrington because she got regranted her share options (not something s/holders were able to do)... her attitude to her shareholders is woeful - she didnt apologise for her gigantic ****-up that cratered the sp. meantime the growth figs look dodgy and she continues to burn thro cash at a rate.... fy 25 1,173 tutivia tests orders = $3m revs = $2557 per test, and yet at 1h figs of 591 tests = $1.16m = $1962 per test, so 30% uplift based on 2h figs. - on face of it that's a great result right? but where is the explanation/reconciliation, and if there is that much volatility barrington how can your investors/analyst properly model outcomes (let alone the company)? then what about momentum that she was saying was happening: october update - barrington told us \" volume growth from this progress is expected from q4 and the number of orders in q3 were consistent with the previous two quarters. 1h 591 so  averages q1 295 q2 295. q3 c300....so based on barrington's comment an uplift was due in q4...and yet: q$ sales below q1, 2,3..and 2h below 1h.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T15:59:36.538554+00:00"
      },
      {
        "event_id": "SOCIAL-Today1628-tbcx--6931206",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.886494",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is the company that reiterated cash runway until H2 2026 in today's update. That is them letting you know now funding will be required this year sometime from July onwards.",
          "sentiment": 0.0,
          "engagement": "801",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.538587+00:00"
      },
      {
        "event_id": "SOCIAL-Today1516-stockyhe--5834363",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.887017",
        "source": "LSE_CHAT",
        "data": {
          "author": "stockyheathlad",
          "content": "In a business like this, historic cashflow isn't necessarily a guide to the future. Expenditure on setting up new centres will be variable and, to a degree, discretionary.  The income stream grew across the year so the last quarter's figures are most relevant, rather than the whole year's.",
          "sentiment": 0.0,
          "engagement": "19",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.538623+00:00"
      },
      {
        "event_id": "SOCIAL-Today1419-2Phones-69775962",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.887553",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "SB - thanks for that.  They said at the time of the fundraising (as @ 31/05/25) they had a cash runway to the end of July 2025.  And subsequently they have burned that cash ($8.6m?) in the remaining 5-6 months of 2025 down to $3.3m, so $10m breakeven makes sense.  Obviously as they get closer to that breakeven point the cash burn reduces - the question is, with all the sales activity, how quickly can they reach that point, and how many further funding rounds we'll see.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.538661+00:00"
      },
      {
        "event_id": "SOCIAL-Today1333-Silverbl--6956027",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.888058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Cash burns remains significant - company raised \u00a36.35m during the year - which added to the $800k difference in year end balances show the level of cash required to support the losses incurred over the last 12 months. Breakeven is predicted at $10m revenue pa. SB",
          "sentiment": 0.0,
          "engagement": "1,925",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.538689+00:00"
      },
      {
        "event_id": "SOCIAL-Today1236-Guly--1906061",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.888582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Cash runway atleast 2 yrs assuming current run rate without additional contract wins",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.538727+00:00"
      },
      {
        "event_id": "SOCIAL-Today1117-2Phones--4328267",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.889106",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I agree that the guidance of cash for H2 appears disappointing, however if you take the cash burn over the last 12 months \u2013 the cash reduced from $4.1m to $3.3, which implies a burn rate of $800k per annum.  Now there are many things that impact these numbers but this set against the backdrop of ever-increasing revenue and sales orders/opportunities.  H2 may be a little pessimistic.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.538764+00:00"
      },
      {
        "event_id": "SOCIAL-Today1022-tbcx-81165229",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.889622",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Great product and credit to them for being revenue generating, way ahead of many other biotechs valued higher. Suspect there is a management discount at play here for habitually missing guidance, which can be overcome, she's easily replicable. The only snag is cash runway remains H2 2026. Definitely one to revisit once funding overhang sorted.",
          "sentiment": 0.0,
          "engagement": "801",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.538795+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Tii21-89657276",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.890160",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "2 million delayed buy, and yet this is at 0%!! 05-Feb-26\t08:03:33\t0.79\t2,000,000\tUnknown*\t0.70\t0.75\t15.80k\tO",
          "sentiment": 0.0,
          "engagement": "457",
          "price_at_post": "0.725",
          "thread_title": "RE: Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-06T15:59:36.538813+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Isthisaw-33462158",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.890667",
        "source": "LSE_CHAT",
        "data": {
          "author": "Isthisawinner",
          "content": "Surprised the sp isn't following..",
          "sentiment": 0.0,
          "engagement": "2,301",
          "price_at_post": "0.725",
          "thread_title": "Finally,  gathering momentum...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=B49C9293-BB7B-4427-862D-3D342002FA5A"
        },
        "ingested_at": "2026-02-06T15:59:36.538849+00:00"
      },
      {
        "event_id": "SOCIAL-Today1006-Mikemine--6954960",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.891178",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Come on FT, give Barrington some credit. She has an accountancy background which would give her a less than gung-ho approach to reporting. They missed a rather ambitious sales target by not much which is good going in my book. For a \"modest\" report her predictions for 2026 are very confident with \"strong\" growth and are significant. For a CEO running a tiny company on a shoe string with small workforce, she is doing well I reckon. Additions to staff last year were all geared to sales so i would expect them to have reached an inflection point. As for the BCBS agreement, what can you say but \"Well done\". That's going to open more doors for the sales force to walk through. I'd imagine there's a good buzz throughout the company at the moment. They must have worked hard for the last 3-4 years with not much in the way is acceptance to show for it but, starting with Fisher, the ball is rolling. Very positive for 26 iIMHO.",
          "sentiment": 0.0,
          "engagement": "1,236",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.538886+00:00"
      },
      {
        "event_id": "SOCIAL-Today1001-Hawker--7106485",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.891629",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Agree, this is an encouraging update. Given the limited resources and tightly managed cost base, Verici could well be on the up this year.  It should only take a doubling or so of the now current testing volumes to put them on the front foot. Keep up the good work Sara and team, go forth and ramp Tutivia and PTRA with Thermo.",
          "sentiment": 0.5,
          "engagement": "301",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:59:36.538924+00:00"
      },
      {
        "event_id": "SOCIAL-Today0955-Guly-12572849",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.892184",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Accumulating a position here, can see massive potential.Can't believe it's so cheap.",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-06T15:59:36.538971+00:00"
      },
      {
        "event_id": "SOCIAL-Today0911-Silverbl-29185940",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.892711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "On a positive note at least company has provided a FY update with a relatively small target miss, revenue is growing with new partnerships coming on stream and cash is ok for now. Against that - tests sales in H2 were less than H1 (591 v 582) which is concern - why no growth in actual testing volumes. What I can't reconcile is the Tutivia revenue for H1 was $1.2m for 591 tests ($1962 per test); and in H2 Tutivia revenue was $1.8m ($3092 per test). This just doesn't add up imo. Unless there is deferred income from H1 coming into H2 receivables. I think note 1 in the update is attempting to clarify the issue - but the language on revenue estimates being used rather than actual revenue are a bit concerning. Actual audited accounts will be more revealing and may differ from these unaudited updates. SB",
          "sentiment": 0.0,
          "engagement": "1,925",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:59:36.539010+00:00"
      },
      {
        "event_id": "SOCIAL-Today0855-blowdog-24331593",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.893229",
        "source": "LSE_CHAT",
        "data": {
          "author": "blowdog",
          "content": "Https://x.com/CapitalPmh/status/2019323726446158330?s=20",
          "sentiment": 0.0,
          "engagement": "929",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:59:36.539047+00:00"
      },
      {
        "event_id": "SOCIAL-Today0852-newgrang-48809696",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.893738",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "L2 buy orders looking strong \ud83d\udcaa",
          "sentiment": 0.0,
          "engagement": "2,114",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:59:36.539084+00:00"
      },
      {
        "event_id": "SOCIAL-Today0843-newgrang-57962069",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.894260",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "Good update with revenues and licensing contract. Hugely undervalued.",
          "sentiment": 0.0,
          "engagement": "2,114",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:59:36.539138+00:00"
      },
      {
        "event_id": "SOCIAL-Today0839-Fevertre--7212557",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.894756",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "SOP for disappointing update to put out commercial RNS alongside (Blue Cross deal looks encouraging) to soften the blow. Barrington is t up to the job- didn\u2019t hit the numbers; a less than confident statement , and why on God\u2019s Green Earth are they saying Dec FY25 will come out in May!! This is a tiny business with minimal revenues and yet Barrington can\u2019t commit to releasing results in a timely fashion. Suspect because every Q they have a wrangle with accountants about revenue timing and recognition. Be good to see sustained progress but after screwing up the cash raise, which cratered the so Barrington still has to prove she is CEO material.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T15:59:36.539178+00:00"
      },
      {
        "event_id": "SOCIAL-Today0824-bigpunt-28651631",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.895246",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Hitting revenue and cash targets, adding major commercial tie-up, can't ask for much more as the company commercialise.  They've had a cracking year and I like the modest tone",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "0.775",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T15:59:36.539216+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260854-2Phones-21143472",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.895745",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "the site is *************interviews dot com",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539254+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260852-2Phones--4112515",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.896268",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "hi splodge2001 https://www. ***************************/verici-dx-landmark-deal-unlocks-potential-300-million-tutivia-market-singer-research-icymi/4121236201",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539293+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261732-Splodge2-27711239",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.896762",
        "source": "LSE_CHAT",
        "data": {
          "author": "Splodge2001",
          "content": "Does anyone have a link to the Singer note? I couldn't find it on their website.",
          "sentiment": 0.0,
          "engagement": "114",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539333+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260851-2Phones-27010625",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.897267",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac101 - I was particularly encouraged by the 2.9p target price.  They clearly believe the future for tutivia is massive.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539372+00:00"
      },
      {
        "event_id": "SOCIAL-Today0851-2Phones-27010625",
        "event_type": "social_post",
        "date": "2026-01-30T23:03:22.957691",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac101 - I was particularly encouraged by the 2.9p target price.  They clearly believe the future for tutivia is massive.",
          "sentiment": 0.0,
          "engagement": "83",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539410+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261447-donmac10-47971246",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:31.826472",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Very good research note out last few day by Singer .Talking up Prime health deal 300 mill mkt.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539449+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251243-Romanby--8997640",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.788345",
        "source": "LSE_CHAT",
        "data": {
          "author": "Romanby",
          "content": "No placing you idiot",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T15:59:36.539488+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251216-Sandyman-18195183",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "Is the placing going to be at 0.25p or 0.5p? Or both?",
          "sentiment": 0.0,
          "engagement": "999",
          "price_at_post": "0.775",
          "thread_title": "Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T15:59:36.539526+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251441-Silverbl--2552412",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - FYI Thermo Fisher are not currently involved in Tutivia - so they are not involved in any roll out. Despite claims here to the contrary there has been no trading update - so we await evidence that Q4 delivers the level of sales anticipated by the CEO on achieving the 2025 Tutivia revenue target - which as you note would be a significant increase on 2024 sales. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539566+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251547-B_Positi-39434962",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.790830",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539606+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-B_Positi-48273612",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.791703",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I would wager a big Thermo-Fisher update is due here. Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539645+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251302-B_Positi-92085590",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.792503",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Wow now way just saw that. Huge implications for Thermo and its partners!",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539683+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251255-donmac10--2219015",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.793297",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Genincode signed a deal with Thermo read across to Verici Verici so undervalued at the moment something has to give.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539722+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251244-B_Positi--4614516",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794085",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Once it breaks 1p it will fly to 2p and then 3p gets smashed with ease considering the test orders are going to be around 300-400% from the digging below. 3p as a base and then a move back to 5-10p.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539759+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251227-B_Positi--2688233",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794962",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I'm personally amazed more aren't piling in whilst under 1p and this isn't at 3-5p already. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539796+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251953-B_Positi--8890354",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.795766",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Will add another 2m sub 1p Way too cheap here for me personally.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539834+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251945-donmac10-50371269",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.796575",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "3p per share nailed on short term if you guys sit oan yer tuffetts like miss muffet know whit ah mean?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539872+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251941-donmac10-37808330",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.797364",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Company is no longer research orientated so past rns at this time of year irrelevant trust me as tests ramp up as they will be the company will be eager to broadcast positive newsflow asap.noh whit a meen an that man getmeh!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539909+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251535-Silverbl-63311455",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798154",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Would be unusual for a trading update pre-xmas imo although any kind of an update in relation to hitting revenue targets would assist progress here - the bar has been set very high by CEO. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539949+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251320-B_Positi--9010385",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798939",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Yes it was due. Thermo-Fisher $220BILLION backing this and tied in. Update on them or something new will wake the market up.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.539987+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251245-donmac10-77746416",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.799717",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Update this week and more deals with distributors .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.540025+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251234-B_Positi-37333311",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.800588",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "MMs caught wind of an update? I'm amazed this isn't over 2p at least. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.540064+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251230-tbcx--4240883",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.801373",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Buying pressure certainly returning this week, this remains extremely undervalued.",
          "sentiment": 0.0,
          "engagement": "766",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.540112+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251443-donmac10--1641225",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802148",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Nice 2mill buy this morning.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.540151+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251235-B_Positi--4042853",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802905",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Donmac, absolutely buzzing for the trading update this month Hopefully see's this head back to the 3 to 5p level",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.540189+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251104-B_Positi-59578620",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.803727",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "So with less than 10% of transplant centres onboarded and already at the start of the mass rollout they averaged about 300 tests per quarter in Q1, Q2 and Q3, just short of 900, vs 334 for the entirety of 2024, representng significant growth. We now know they are at at least 16% of transplant centres onboarded now (less than 10% for Q1, Q2, Q2, perhaps around 20% now and are increasing this fast. You quickly realise how mad the revenues can become here at $2,650 a test with the medicaid coverage +Thermo Fisher licencing revenues. I know many, many pharma stocks that have literally $0 revenue, no proven tech, no FDA approval, no big deal with a giant like this does with Thermo Fisher that are trading at many multiples of the Verici market cap.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.540226+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251045-donmac10--4829702",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.804510",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And its beginning to look like word is out?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.540265+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251039-donmac10-65188536",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.805293",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Expecting a trading update in the run up to xmas should make for good reading!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.540302+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251031-B_Positi--9891832",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806132",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.540341+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251456-Mikemine-38077333",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806901",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, your posts have got  very repetitive and quite frankly, boring. Unless your rants help your mental state I for one would be grateful if you would keep your posts to new views or information.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:59:36.540379+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251148-Fevertre-92219983",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.375637",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Just out of interest what are Barrington's competencies?",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:59:36.540417+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251147-Fevertre--7438737",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.376396",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "The Board and non-execs have overseen an absolute shamble here. Barrington completely unaffected by disastrous dilution as she has virtually no bloody shares in teh company she purports to lead.  The CFo isnt fit for purpose frankly. The Q4 figs appear to be the stuff of fantasy - I would give more creedance if  Barrington was able to explain how she gets to the forecast but she appears to be just making it up as she goes along... we have no timelines on onboarding; Barrington cant set out how she arrived at the numbers... she continues to be utterly hopeless as the CEO of supposedly a cutting edge business.",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:59:36.540455+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251059-Silverbl--8345065",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377214",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There you go donmac almost at your buy price already. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:59:36.540493+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20250050-donmac10--7504433",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377985",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sell up move on thank you.....give me the chance ar more aroon the 55 mark slanj .And a will catch yeh in wetherspoons oan the wae otta rah ritz.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:59:36.540532+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251734-Mikemine-34867265",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.378810",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "VRCI is a small company so hiring an extra 3 salespersons is huge for them and points to their determination to hit their target. It's a big ask but you can be sure they recognise that their credibility is on the line. From a practical point of view, hiring new salespeople  takes time for their impact to come through. They have to get used of the systems, the product and VRCI's method of selling. I wish them luck and, if they do reach their target, it will be noticed by the Market.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:59:36.540570+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251709-Silverbl--6742673",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.379608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not a fan to date either fevertree - its been a disaster for all shareholders here - but I still hold a position here and am trying to look forward not back given the past is what it is. If Q4 goes well I expect a trading update early 2026 - which doesn't usually happen but positive momentum will be required to avoid a total wipe out in any subsequent capital raise. Failure to deliver (again) then more questions will be raised on leadership competencies.  SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.75",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:59:36.540607+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251647-Fevertre--2898711",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.380414",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "She has never fully explained the onboarding process. If a new centre gets onboarded, typically how long does it take for clinicians to order first tests",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:59:36.540644+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251644-Fevertre-73587505",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.381220",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Nonsense Donmac.....look at the maths around Barrington's targets: On my maths I don't see how she hits revs from Tutivia $3.2m... Tutivia:  1H Revs: $1.16m: 591 tests @ ave $1900 ($1.16m divided by 591) 2H Revs:  3Q Tutivia same rate as Q1/Q2 ..c300 tests at 1900 = $570k  ...so to meet her target she needs to sell c$1.5m of tests. Assume same ave price of $1900....she needs to sell c790 tests....that's a massive uplift, even with onboarding another 9 more centres...",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:59:36.540684+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251627-donmac10-57231975",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382010",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "markets falling and the doom and gloom ****roaches appear in force.sell up ,thats even if yeh hod any and gie us aw peace!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:59:36.540721+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251604-Fevertre--3492178",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382802",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Worryingly her bullishness has cost investors dearly so far. Apart from having virtually no skin in the game she hasn't been gifted,  or regifted (look at the outrageous revision of option pricing). The fact that the sp is still at 3/4 of a penny tells you everything you need to know about how the market views her!",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:59:36.540760+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251522-Silverbl-70306042",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.383604",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Based on what we already know - VRCI sold c.600 Tutivia tests in H1 2025 - securing revenue of $1.2m ($2k per test - blend of public and private payers). They sold same in Q3 - so lets assume pro-rata they secured a further $600k revenue. Sara B confirmed FY Tutivia target was $3.2m - so that leaves $1.4 revenue to be secured in Q4 - or c.700 tests at $2k. Seems a huge leap - or possible they are looking at a slight increase to average test $ - although Prime Health RNS appears to push towards discounted volume in private market. She has certainly set high expectations for Q4 trading. If this is achieved it will be a significant acceleration - and will be crucial in supporting the share price/market cap as the company requires additional funding in the next 4/5 months. Additional licensing revenue from Thermo (c.$4m received to date - $3.3m in 2024 and $0.75m in 2025) remains on hold as they progress their approach to the PTRA test. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.725",
          "thread_title": "2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T15:59:36.540798+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250856-2Phones--1650388",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.384401",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac agreed - two of the latest RNS are very positive about the rate of revenue growth and market penetration - can't help but think the next sales based RNS will be a gamechanger.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.875",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T15:59:36.540837+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250845-donmac10-72870432",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385202",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Analysts expecting 3p per share next year big upside from here.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.90",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T15:59:36.540874+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250843-donmac10--8562186",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385990",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Verici also more forthcoming informing the market with updates .Beats last years 6 month radio silence .Just waiting now for testing update which i know will further boost price.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T15:59:36.540912+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250830-donmac10--2323646",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.386775",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Tells me ,anyone looking to make money would be well served to get in now .Futher big rise going into year end.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.95",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T15:59:36.540950+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250809-2Phones--7878732",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.387576",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Interesting news today \u2013 initially I thought why? This has little bearing on shareholders interests \u2013 however, on further concideration, while successful audits add little to the bottom line or turnover or even shareholder value \u2013 in our case it is very much a Critical Failure Factor, where failure to pass a quality audit could seriously damage the company in the short/medium term.  Also it does point to a well run, disciplined business. So well done Verici.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.95",
          "thread_title": "RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T15:59:36.540987+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251448-oogleflu--3980338",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.388340",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Tom. I know exactly what you\u2019re saying is correct . Unfortunately risk appetite is much lower in the UK probably because the FA are like a bunch of frightened rabbits. Fund managers continue to unwind oversold positions in uk to chase  the way overpriced \u2018American dream stocks\u2019 which are overdue a big correction there by loosing even more of the inadequate fund managers clients money. It\u2019s not all Uk stocks but quite a few as admitted in an interview recently with a fund manager. Certainly since the pandemic Uk stocks are valued much more realistically i.e. sound balance sheet which Vrci  now has, realistic forecast which Vrci now has, realistic targets for growth which Vrci now has. But we don\u2019t tend to look further than a year ahead. One step at a time . There will be /is FOMO with a stock like Vrci which will cause some volatility till they establish a more constant earnings stream.",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541025+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251354-donmac10--1176216",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389131",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "It feels to me we are about to get a trading update on testing numbers shortly .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541078+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251256-donmac10-64040545",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389888",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "1.20p close today and more updates in coming days on quickly to 2.00p",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541129+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251247-geraldus--4002456",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.390653",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "Still early days here,and they will have to take some market share from the incumbent bio markers. Shaping up well so far and with a miserly market cap in comparison with other counters.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.825",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541169+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251241-B_Positi--8164591",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.391431",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Geraldus Tutivia is the standard now. Hence why Thermo-Fisher has gone all in and is backing all the way. Market slowly beginning to wake up that this company is grossly undervalued. I mean the FDA approval, ip, tech alone is worth multiples and then whack on the huge growth already in 2025 and coming in 2026 with over 30 transplant centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541206+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251239-donmac10-30255866",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392203",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "American market waking up to the potential with Verici dx in their own backyard They love an AI stock.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541243+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251236-geraldus--7154756",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392989",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "With their 'AI' solution for optimising transplants,it is undoubtly an interesting opportunity here. They have spent millions on this and they are confident that it is payback time. With no competition at this level,it could possibly become the defacto standard.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541281+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251217-B_Positi--9891832",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.393835",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541319+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251205-oogleflu--6801868",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.394621",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Addressable market doesn\u2019t mean they capture all of it.  They might get 1 or 2 percent which is still sizeable if lucky. Even singer, their broker,  have only raised the sp to 3p. That\u2019s still 4 times current market cap! The other thing is will they need to expand the lab or open another one as their market share increases. They have got a captured market in that there is no competition and the tests are becoming mandatory. No plans to adopt outside the US yet. Maybe 20p in 5 years certainly not months I\u2019m afraid but good luck",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.775",
          "thread_title": "RE: Quantifying the opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=D3DE9F2B-871D-47DE-96C8-2D6BB08D16A4"
        },
        "ingested_at": "2026-02-06T15:59:36.541357+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261715-Silverbl-13487188",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - feel free to use the actual numbers in your updates. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 (INCORRECT: H1 actual revenue was $1.16m = $1962 average revenue per test). H1 2025 licencing revenue = $750,000 (CORRECT) Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. (Test numbers CORRECT. Centres INCORRECT - there were 21 onboarded at time of results). 286 x $2,650 = $757,900 (Likely INCORRECT based on average revenue per test of $1962 achieved in H1 2025 - likely revenue $560K). Q4 2025, 20 centres onboarded and let's be conservative and say 300 tests. (INCORRECT. There are now 30 centres onboarded. Company is targeting in the region of 750 tests in Q4 in order to meet its Q4 revenue target of c.$1.5m) 300 x $2,650 = $795,000 revenue (We will find out in due course what was achieved in terms of test numbers and average revenue per test) H2 2025 licensing revenue, let's be conservative and say $500,000. (INCORRECT. No licencing revenue will come from Thermo in H2) Combine all of that above and you get = $4.3mil or \u00a33.2m. (H1 revenue was $1.9m/ Q3 likely $560K. Q4 not yet reported. Company is targeting total FY 2025 revenue of $3.95m, comprising $3.2 Tutivia tests and $750K licencing revenue) Still nothing in the way of a trading update from the team at vrci. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541396+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261504-B_Positi-42450017",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332720",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We should all be extremely excited having now onboarded over 30 transplant centres, up from 10 in 2024. We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541433+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260830-Silverbl-66332582",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333151",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "$12m was a direct quote from Vrci CEO in latest Vox markets interview. As for my 'precise' figures - strangely enough when it comes to investing I prefer to deal in fact rather than making it up (refer B_Positive). As for my views on the business - I remain invested so I am hopeful there is a future here or would have taken my medicine and moved on. That does not mean to say I will not vocalise my thoughts on areas of mismanagement where the company could and should be doing better; or to call out posters who are just making it up as they go along. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541471+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260728-B_Positi--4719110",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333626",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541509+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260205-donmac10-52982102",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334054",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Where do you get the 12mill breakeven point? You sound like a bot with your precise figures. And you always have a way of sounding positive but are really negative .So cant be taken seriously .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541556+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262026-Silverbl-69960206",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334501",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not really sure why I need to explain this, but here you go B_Positive. Your bullet point regarding Tutivia sums the position up very well. Transplant centres service both Medicare patients and private paying patients. So whilst the Medicare payment of $2650 is being provided by the US healthcare system for patients who benefit from the Medicare and Medicare plus programmes - there are actually six key revenue streams for test sales of which Medicare is one (albeit the largest - 68% of tests being undertaken are covered by Medicare seems to be the claim from the company). Private payers (via healthcare insurance) do not pay the $2650 - they receive discounts. Clinical trials pay nothing. And there others. If you divide the H1 Tutivia revenue of $1.16m by the 591 tests in H1 it comes out at $1962 . That is the current revenue reality for test sales. The recent RNS highlighting the agreement with Prime Health Services is all about trying to establish consistent pricing of the Tutivia test with the private payment market and clearly with the goal to increase current pricing which is diluting the Medicare $2650. In relation to your H2 licencing point the following clarifies the position \" Thermo Fisher is investing in new research related to PTRA aimed at identifying the earliest stage at which the test can be utilised before transplantation. Consequently, the second milestone originally anticipated for 2025 will be delayed as we continue to collaborate on publishing clinical validation data and Thermo Fisher pursues these additional research efforts to help broaden utility and adoption of the assay.\" FYI the breakeven position for Verici is c.$12m - so that provides an indication of the revenue which is required from test sales, licence revenue, protega etc to cover vrci operating costs. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541594+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261524-B_Positi--6329202",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334932",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Nope it's $2,650 as per the Medicare coverage RNS and more recently as per the HY report. \u00b7 Lead product Tutivia\u2122 attained Medicare coverage at $2,650 per test, covering a national estimate of 68% of all US transplant tests and commercial payor reimbursement applications are underway They receive licencing revenues both H1 and H2. It was $750k in H1.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541632+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261523-Silverbl--3289599",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335360",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Mikemine -  your points are valid - but highlight one of the main issues here. Why set a target and fail. Undermines confidence, craters the share price, makes fund raising tricky and makes investors wary on growth. Much better to overdeliver on achievable targets than underdeliver? But maybe we will be get a pleasant surprise. Thermo are just doing their own thing on the PRTA at present. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541670+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261518-Silverbl--7532888",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335771",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "No licencing revenue in H2 2025 and average received revenue per test is $1900. Do some actual research please. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541707+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261416-B_Positi--5641231",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336264",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10 centres onboarded. It must now be around 25-35 going by the last report.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541744+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261402-Mikemine--5149520",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336713",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "They've set themselves a big revenue target of over \u00a33mn for 2025. Small in world terms but a big % increase for VRCI. Should they be chastised if they do not reach the target or should it be viewed in the context of what they do achieve and what they forecast for this year? Getting close to \u00a33mn would be an achievement in my book as that would point to things being on track for further increases especially as the new sales guys have probably only just got their acts together and their contacts in line. Not sure what to think of the Thermo-Fisher deal and its seemingly lack of traction. Big companies are not nimble nor quick so the jury's out on that one for me. My guess is for an update this month and it will be positive but will not please everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541781+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261401-B_Positi-79394654",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337193",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Cashed up until the end of 2026 and now they've been securing record orders as per below. Next time they raise it will be in the pennies, which is what they will want given the new option prices. Test update going to drop soon. More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541819+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261346-Silverbl--4968655",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Despite the view expressed by several contributors here we have heard nothing from the business on Q4 trading. Not unexpected - if there was anything to report on I would expect to hear later on in January. The issue looming very shortly relates to the required fund raising. In previous years the company has elected not to divulge FY trading until May.  This is likely to be beyond the point at which the company runs out of cash. We should therefore be able to read the signals loud and clear - no trading update - then Q4 has not delivered the targeted sales and the fund raise will be brutal.  If a positive Q4 trading update is issued then there should be a healthy price response despite the recognition funds will still be required. Remember last year the first fundraise was at 9p - then 0.5p after bewildering timing mismanagement by the company.  All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: 100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-02-06T15:59:36.541857+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261228-B_Positi-63084177",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338063",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.541895+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-2reincar--8540126",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338488",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Conversions this summer will see us at sub 0.25p!",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.75",
          "thread_title": "100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-02-06T15:59:36.542168+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261210-B_Positi-14758857",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338938",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.542207+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20260629-2Phones-74268809",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339362",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "How can any one disagree with such a cogent arguement - and clearly not the rantings of a one track numpty.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.725",
          "thread_title": "RE: Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-02-06T15:59:36.542247+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261022-2reincar--8055975",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339773",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "At 0.25p?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.725",
          "thread_title": "Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-02-06T15:59:36.542284+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251515-B_Positi-14758857",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340229",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.542321+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251223-Silverbl--3352000",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "2Phones - from the company itself: \" With minimum gross proceeds from the Placing and Subscription of \u00a35 million, the Company's cash runway will be extended to mid Q2 2026.\". Hence my thinking spring will be the time to raise. And yes revenue is expected to increase (we will know by how much in a few weeks) - but annual expenses are c.$9m - so sales would need a dramatic (and unlikely) increase to negate the need for more funds. And you seem to agree that a placing is an option (imo the only likely one and the route the company has taken to date in all its efforts to secure more funding). So not sure what you were disagreeing with? SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T15:59:36.542360+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20250753-2Phones-86910454",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341050",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I don't agree - the operational update earlier this year had a predicted cash runway to H2 next year - when you couple that with the recruitment of 2 sales people and a director of clinical partnerships, I would anticipate growth in cash inflow.  However, they are a small team and they are going to have to increase production to accommodate the anticipated sales.  This will need funding, but where they get it is uncertain \u2013 one option being a placing.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T15:59:36.542397+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251728-2reincar--6002509",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341472",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Agree Silverblade. We could have one in Aprilish at 0.5p and one in Octoberish at 0.25p and then a rocket to + 2p ?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T15:59:36.542435+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251618-Silverbl--4847111",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Same old nonsense B_Positive. Thermo are not involved in Tutivia. Stop spreading false information. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.542473+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251557-B_Positi-39434962",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342355",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T15:59:36.542510+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251522-Silverbl--2959876",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342765",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There will be a placing in early 2026 - probably March/April time. The placing will of course be determined by the prevailing share price at the time. And that in turn will reflect the numbers for FY 2025 - there is a lot of expectation here so lets see what the company has to say for itself hopefully with a trading update in January. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T15:59:36.542547+00:00"
      },
      {
        "event_id": "SOCIAL-Today1817-Mikemine--6523100",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.630785",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "One thing I'd forgotten was that they didn't get Medicare's approval until April and medicare pays for 70% of VRCI's revenue. I'm not surprised they missed their target. It looks like they would have easily reached their target if they had Medicare on board from January 1st.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T22:01:02.327748+00:00"
      },
      {
        "event_id": "SOCIAL-Today1808-Mikemine--8327849",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.631220",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "don't know why the link has got stars instead of ********** but i'm sure you can find it.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T22:01:02.327787+00:00"
      },
      {
        "event_id": "SOCIAL-Today1807-Mikemine--7941525",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.631632",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "https://www. **********.com/articles/q-a-with-verici-dx-ceo-sara-barrington-6e98b51",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T22:01:02.327827+00:00"
      },
      {
        "event_id": "SOCIAL-Today1805-Mikemine-79901888",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.632046",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "barrington sounds confident and on top of it. lots of stuff in there that will enable us to more deeply understand the business and see where vrci is heading. not much about numbers but the obvious acceptance and use by the clinicians and insurers is evident. it really looks like this is going to be a good year for vrci https://www. **********.com/articles/q-a-with-verici-dx-ceo-sara-barrington-6e98b51",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T22:01:02.327848+00:00"
      },
      {
        "event_id": "SOCIAL-Today1704-donmac10--2642346",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.632458",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sarah sounds very upbeat on Vox markets today..Stating this is Vericis year very positive.",
          "sentiment": 0.0,
          "engagement": "2,878",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T22:01:02.327866+00:00"
      },
      {
        "event_id": "SOCIAL-Today1557-bigpunt--3484408",
        "event_type": "social_post",
        "date": "2026-02-06T15:59:25.608751",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Silverblade, a lot of whingeing about the past will not help your decision-making.  One should learn from previous investment decisions and appraise prospective investment decisions better!  Between now and raise will be the FY results and presentation and possibly a further update to support the raise.  Mkt cap and equity raise price will be determined entirely by those trading updates and credibility of updated forecasts",
          "sentiment": 0.0,
          "engagement": "361",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T22:01:02.327886+00:00"
      },
      {
        "event_id": "SOCIAL-Today1544-Mikemine-56884984",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.744230",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "All decent points SB. Unfortunately VRCI is on AIM and AIM is almost dead in the water. I would venture that AIM is merely capturing the mood of the country which has been negative for some years now. People are so grumpy and lacking a positive disposition compared with what I see in the States, even with the Trump factor. I would venture that if VRCI was on Nasdaq its valuation would be around the $50-60 mn mark as the potential and demonstrated progress would be recognised as very positive by the Market there. Fortunately VRCI is operating in the States otherwise I wouldn't touch it with a bargepole because of how the NHS is run. You might have guessed that I think the company is well run and punching above its weight in a difficult field. It did get last years fundraiser wrong by announcing it's intention before securing funds but I reckon they've done well otherwise. What's for the future? The next 6 months are crucial but I believe that the \"strong\" sales increase flagged has a good chance of being achieved so the burn rate will reduce. They gave themselves an ambitious target last year which they nearly achieved and this indicates to me that they have a well thought out business model which includes a viable way of commercialising the product and this gives me some confidence is them performing strongly this year. As for a fund raise, their performance since the last one will give institutions lots of confidence to back them should they need one. I am not stupid enough to offer a prediction for the SP but, even on AIM, achieving this strong growth can't help but be positive in that direction. It's all my opinion of course and what do I know? There's always the possibility of a takeover of course but that's a speculative  game in which I am unable, and unwilling, to enter. Good luck for anybody that wishes to stay in the game.",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T22:01:02.327904+00:00"
      },
      {
        "event_id": "SOCIAL-Today1453-Silverbl-32708590",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.744668",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I can fully understand fevertrees anger and frustration here - it is likely representative of a large number of longer term shareholders. The grim reality is that whilst the latest update is encouraging in terms of revenue growth, the actions of the board last year in delaying the fund raise to the point it required a price of 0.5p to secure funding has created a position where the sheer number of shares in circulation render's the majority of investors trapped with little chance of recouping any investment made in the 2-5p range. Anything above that is gone.  Add to that a further capital raise in the next 4/6 months - and lets say they go for \u00a35m - which would require 1b further shares being issued at 0.5p. Nothing suggests the share price moving to any significant extent given the reaction to recent news. So then you have in the region of 2.5b shares - even assuming a share price of 1p, that's a \u00a325m market cap for a still loss making company. That in turn assumes the company is capable of doubling its revenue this year - which is possible - which also reduces the further risk (and scale) of a 2027 fund raise although this is still likely. I am invested here - and think the product is viable - but historic investors have been completely shafted. Even the company's own broker has an optimistic price less that 3p a share (don't get me wrong I would grab that in a heartbeat). The best outcome would be for an approach to take the business private or a pharma takeover at a decent premium to the current price. The alternative for shareholders is throwing more money during the fund raise to lower entry prices - which is a sobering thought. All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T22:01:02.327923+00:00"
      },
      {
        "event_id": "SOCIAL-Today1428-bigpunt--6238372",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745095",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Some very rough calcs.  c.90% of US population has medical insurance.  c.27,000 kidney transplants last year.  Assuming just one test per transplant, at unindexed $2,650 per test, the USA market-alone is worth $64m.  I'm also assuming the Tennessee lab can service the entire USA I'm not sure how many patients are represented by the 1,173 tests in 2025, and how many transplant centres vs the total in the USA, but the market penetration appears decent, considering the academic papers were only published 6 months ago Some may questions the relevance of academic papers and other KPIs may be more relevant, but it strikes me that the increase in number of clinicians and the increase in number of transplant centres will be strongly influenced by the academic articles and their subsequent peer reviews My view?  VRCI will get bought out when the USA nears profitability due to it's domestic market opportunity and the obvious globalisation opportunity.  Need to pay very close attention to what happens between now and next (and probably final) equity raise",
          "sentiment": 0.0,
          "engagement": "360",
          "price_at_post": "0.725",
          "thread_title": "Mid-term opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=755FC4E4-63EA-405E-A449-61BE41636EEA"
        },
        "ingested_at": "2026-02-06T22:01:02.327941+00:00"
      },
      {
        "event_id": "SOCIAL-Today0859-oogleflu-91105821",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745517",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "I thinks it\u2019s worth noting that Verici\u2019s year end was December. So whilst cash burn continues for another 6 months so does the pipeline growth and revenue. The Blue cross contract in Illinois is very significant as diversifying away from Medicare and becoming less dependant becomes more beneficial to clinicians and patients in not only in cost but also speed of treatment. Barrington hinted that these kind of contracts could spread across to other states. In an ever changing shift in Trumps one brain cell it must be pretty hard to predict or forecast anything in the US. What Vrci has demonstrated this year is the viability and commerciality is well in sight.",
          "sentiment": 0.0,
          "engagement": "5,469",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T22:01:02.327959+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261742-Mikemine--5749501",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, you are clearly angry with VRCI, especially Barrington, so it begs the obvious question \"Why are still here and presumably invested in the company?\" I'm sure most of us have felt let down and financially hurt by companies and BODs in the past but have taken the hit and moved on. Why haven't you?",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T22:01:02.327978+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261656-Fevertre-53212509",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.746540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "If cash burn is an issue then perhaps Sara Barrington should take a bloody pay cut",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.327997+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261654-Fevertre--7969105",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.747174",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "barrington is the the issue (along with the board). after the disastrously botched raise that almost sank the company but not barrington because she got regranted her share options (not something s/holders were able to do)... her attitude to her shareholders is woeful - she didnt apologise for her gigantic ****-up that cratered the sp. meantime the growth figs look dodgy and she continues to burn thro cash at a rate.... fy 25 1,173 tutivia tests orders = $3m revs = $2557 per test, and yet at 1h figs of 591 tests = $1.16m = $1962 per test, so 30% uplift based on 2h figs. - on face of it that's a great result right? but where is the explanation/reconciliation, and if there is that much volatility barrington how can your investors/analyst properly model outcomes (let alone the company)? then what about momentum that she was saying was happening: october update - barrington told us \" volume growth from this progress is expected from q4 and the number of orders in q3 were consistent with the previous two quarters. 1h 591 so  averages q1 295 q2 295. q3 c300....so based on barrington's comment an uplift was due in q4...and yet: q$ sales below q1, 2,3..and 2h below 1h.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T22:01:02.328015+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261628-tbcx--9091430",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.747632",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is the company that reiterated cash runway until H2 2026 in today's update. That is them letting you know now funding will be required this year sometime from July onwards.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328033+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261516-stockyhe-66343175",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748041",
        "source": "LSE_CHAT",
        "data": {
          "author": "stockyheathlad",
          "content": "In a business like this, historic cashflow isn't necessarily a guide to the future. Expenditure on setting up new centres will be variable and, to a degree, discretionary.  The income stream grew across the year so the last quarter's figures are most relevant, rather than the whole year's.",
          "sentiment": 0.0,
          "engagement": "19",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328051+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261419-2Phones-34150452",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748468",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "SB - thanks for that.  They said at the time of the fundraising (as @ 31/05/25) they had a cash runway to the end of July 2025.  And subsequently they have burned that cash ($8.6m?) in the remaining 5-6 months of 2025 down to $3.3m, so $10m breakeven makes sense.  Obviously as they get closer to that breakeven point the cash burn reduces - the question is, with all the sales activity, how quickly can they reach that point, and how many further funding rounds we'll see.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328069+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261333-Silverbl--8726553",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748870",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Cash burns remains significant - company raised \u00a36.35m during the year - which added to the $800k difference in year end balances show the level of cash required to support the losses incurred over the last 12 months. Breakeven is predicted at $10m revenue pa. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328087+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261236-Guly--7086574",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.749302",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Cash runway atleast 2 yrs assuming current run rate without additional contract wins",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328124+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261117-2Phones-22010851",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.749703",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I agree that the guidance of cash for H2 appears disappointing, however if you take the cash burn over the last 12 months \u2013 the cash reduced from $4.1m to $3.3, which implies a burn rate of $800k per annum.  Now there are many things that impact these numbers but this set against the backdrop of ever-increasing revenue and sales orders/opportunities.  H2 may be a little pessimistic.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328145+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261022-tbcx--2412227",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750126",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Great product and credit to them for being revenue generating, way ahead of many other biotechs valued higher. Suspect there is a management discount at play here for habitually missing guidance, which can be overcome, she's easily replicable. The only snag is cash runway remains H2 2026. Definitely one to revisit once funding overhang sorted.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328163+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261012-Tii21-15417843",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750535",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "2 million delayed buy, and yet this is at 0%!! 05-Feb-26\t08:03:33\t0.79\t2,000,000\tUnknown*\t0.70\t0.75\t15.80k\tO",
          "sentiment": 0.0,
          "engagement": "457",
          "price_at_post": "0.725",
          "thread_title": "RE: Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-06T22:01:02.328182+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261012-Isthisaw-17875437",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750934",
        "source": "LSE_CHAT",
        "data": {
          "author": "Isthisawinner",
          "content": "Surprised the sp isn't following..",
          "sentiment": 0.0,
          "engagement": "2,301",
          "price_at_post": "0.725",
          "thread_title": "Finally,  gathering momentum...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=B49C9293-BB7B-4427-862D-3D342002FA5A"
        },
        "ingested_at": "2026-02-06T22:01:02.328200+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261006-Mikemine-78643138",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.751372",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Come on FT, give Barrington some credit. She has an accountancy background which would give her a less than gung-ho approach to reporting. They missed a rather ambitious sales target by not much which is good going in my book. For a \"modest\" report her predictions for 2026 are very confident with \"strong\" growth and are significant. For a CEO running a tiny company on a shoe string with small workforce, she is doing well I reckon. Additions to staff last year were all geared to sales so i would expect them to have reached an inflection point. As for the BCBS agreement, what can you say but \"Well done\". That's going to open more doors for the sales force to walk through. I'd imagine there's a good buzz throughout the company at the moment. They must have worked hard for the last 3-4 years with not much in the way is acceptance to show for it but, starting with Fisher, the ball is rolling. Very positive for 26 iIMHO.",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328219+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261001-Hawker-11107183",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.751787",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Agree, this is an encouraging update. Given the limited resources and tightly managed cost base, Verici could well be on the up this year.  It should only take a doubling or so of the now current testing volumes to put them on the front foot. Keep up the good work Sara and team, go forth and ramp Tutivia and PTRA with Thermo.",
          "sentiment": 0.5,
          "engagement": "301",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T22:01:02.328237+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260955-Guly-75755886",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.752384",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Accumulating a position here, can see massive potential.Can't believe it's so cheap.",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-06T22:01:02.328255+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260911-Silverbl--6059065",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.752953",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "On a positive note at least company has provided a FY update with a relatively small target miss, revenue is growing with new partnerships coming on stream and cash is ok for now. Against that - tests sales in H2 were less than H1 (591 v 582) which is concern - why no growth in actual testing volumes. What I can't reconcile is the Tutivia revenue for H1 was $1.2m for 591 tests ($1962 per test); and in H2 Tutivia revenue was $1.8m ($3092 per test). This just doesn't add up imo. Unless there is deferred income from H1 coming into H2 receivables. I think note 1 in the update is attempting to clarify the issue - but the language on revenue estimates being used rather than actual revenue are a bit concerning. Actual audited accounts will be more revealing and may differ from these unaudited updates. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T22:01:02.328273+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260855-blowdog--4137073",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.753557",
        "source": "LSE_CHAT",
        "data": {
          "author": "blowdog",
          "content": "Https://x.com/CapitalPmh/status/2019323726446158330?s=20",
          "sentiment": 0.0,
          "engagement": "933",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T22:01:02.328291+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260852-newgrang--3195405",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.754153",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "L2 buy orders looking strong \ud83d\udcaa",
          "sentiment": 0.0,
          "engagement": "2,116",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T22:01:02.328309+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260843-newgrang-15368262",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.754739",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "Good update with revenues and licensing contract. Hugely undervalued.",
          "sentiment": 0.0,
          "engagement": "2,116",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T22:01:02.328327+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260839-Fevertre-75494052",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.755335",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "SOP for disappointing update to put out commercial RNS alongside (Blue Cross deal looks encouraging) to soften the blow. Barrington is t up to the job- didn\u2019t hit the numbers; a less than confident statement , and why on God\u2019s Green Earth are they saying Dec FY25 will come out in May!! This is a tiny business with minimal revenues and yet Barrington can\u2019t commit to releasing results in a timely fashion. Suspect because every Q they have a wrangle with accountants about revenue timing and recognition. Be good to see sustained progress but after screwing up the cash raise, which cratered the so Barrington still has to prove she is CEO material.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328345+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260824-bigpunt-71607193",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.755905",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Hitting revenue and cash targets, adding major commercial tie-up, can't ask for much more as the company commercialise.  They've had a cracking year and I like the modest tone",
          "sentiment": 0.0,
          "engagement": "360",
          "price_at_post": "0.775",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T22:01:02.328362+00:00"
      },
      {
        "event_id": "SOCIAL-Today1742-Mikemine--5749501",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885051",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, you are clearly angry with VRCI, especially Barrington, so it begs the obvious question \"Why are still here and presumably invested in the company?\" I'm sure most of us have felt let down and financially hurt by companies and BODs in the past but have taken the hit and moved on. Why haven't you?",
          "sentiment": 0.0,
          "engagement": "1,236",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T22:01:02.328380+00:00"
      },
      {
        "event_id": "SOCIAL-Today1656-Fevertre-53212509",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "If cash burn is an issue then perhaps Sara Barrington should take a bloody pay cut",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328398+00:00"
      },
      {
        "event_id": "SOCIAL-Today1654-Fevertre--7969105",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "barrington is the the issue (along with the board). after the disastrously botched raise that almost sank the company but not barrington because she got regranted her share options (not something s/holders were able to do)... her attitude to her shareholders is woeful - she didnt apologise for her gigantic ****-up that cratered the sp. meantime the growth figs look dodgy and she continues to burn thro cash at a rate.... fy 25 1,173 tutivia tests orders = $3m revs = $2557 per test, and yet at 1h figs of 591 tests = $1.16m = $1962 per test, so 30% uplift based on 2h figs. - on face of it that's a great result right? but where is the explanation/reconciliation, and if there is that much volatility barrington how can your investors/analyst properly model outcomes (let alone the company)? then what about momentum that she was saying was happening: october update - barrington told us \" volume growth from this progress is expected from q4 and the number of orders in q3 were consistent with the previous two quarters. 1h 591 so  averages q1 295 q2 295. q3 c300....so based on barrington's comment an uplift was due in q4...and yet: q$ sales below q1, 2,3..and 2h below 1h.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-06T22:01:02.328416+00:00"
      },
      {
        "event_id": "SOCIAL-Today1628-tbcx--9091430",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.886494",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is the company that reiterated cash runway until H2 2026 in today's update. That is them letting you know now funding will be required this year sometime from July onwards.",
          "sentiment": 0.0,
          "engagement": "801",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328434+00:00"
      },
      {
        "event_id": "SOCIAL-Today1516-stockyhe-66343175",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.887017",
        "source": "LSE_CHAT",
        "data": {
          "author": "stockyheathlad",
          "content": "In a business like this, historic cashflow isn't necessarily a guide to the future. Expenditure on setting up new centres will be variable and, to a degree, discretionary.  The income stream grew across the year so the last quarter's figures are most relevant, rather than the whole year's.",
          "sentiment": 0.0,
          "engagement": "19",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328451+00:00"
      },
      {
        "event_id": "SOCIAL-Today1419-2Phones-34150452",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.887553",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "SB - thanks for that.  They said at the time of the fundraising (as @ 31/05/25) they had a cash runway to the end of July 2025.  And subsequently they have burned that cash ($8.6m?) in the remaining 5-6 months of 2025 down to $3.3m, so $10m breakeven makes sense.  Obviously as they get closer to that breakeven point the cash burn reduces - the question is, with all the sales activity, how quickly can they reach that point, and how many further funding rounds we'll see.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328469+00:00"
      },
      {
        "event_id": "SOCIAL-Today1333-Silverbl--8726553",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.888058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Cash burns remains significant - company raised \u00a36.35m during the year - which added to the $800k difference in year end balances show the level of cash required to support the losses incurred over the last 12 months. Breakeven is predicted at $10m revenue pa. SB",
          "sentiment": 0.0,
          "engagement": "1,925",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328487+00:00"
      },
      {
        "event_id": "SOCIAL-Today1236-Guly--7086574",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.888582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Cash runway atleast 2 yrs assuming current run rate without additional contract wins",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328505+00:00"
      },
      {
        "event_id": "SOCIAL-Today1117-2Phones-22010851",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.889106",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I agree that the guidance of cash for H2 appears disappointing, however if you take the cash burn over the last 12 months \u2013 the cash reduced from $4.1m to $3.3, which implies a burn rate of $800k per annum.  Now there are many things that impact these numbers but this set against the backdrop of ever-increasing revenue and sales orders/opportunities.  H2 may be a little pessimistic.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328522+00:00"
      },
      {
        "event_id": "SOCIAL-Today1022-tbcx--2412227",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.889622",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Great product and credit to them for being revenue generating, way ahead of many other biotechs valued higher. Suspect there is a management discount at play here for habitually missing guidance, which can be overcome, she's easily replicable. The only snag is cash runway remains H2 2026. Definitely one to revisit once funding overhang sorted.",
          "sentiment": 0.0,
          "engagement": "801",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328540+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Tii21-15417843",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.890160",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "2 million delayed buy, and yet this is at 0%!! 05-Feb-26\t08:03:33\t0.79\t2,000,000\tUnknown*\t0.70\t0.75\t15.80k\tO",
          "sentiment": 0.0,
          "engagement": "457",
          "price_at_post": "0.725",
          "thread_title": "RE: Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-06T22:01:02.328559+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Isthisaw-17875437",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.890667",
        "source": "LSE_CHAT",
        "data": {
          "author": "Isthisawinner",
          "content": "Surprised the sp isn't following..",
          "sentiment": 0.0,
          "engagement": "2,301",
          "price_at_post": "0.725",
          "thread_title": "Finally,  gathering momentum...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=B49C9293-BB7B-4427-862D-3D342002FA5A"
        },
        "ingested_at": "2026-02-06T22:01:02.328576+00:00"
      },
      {
        "event_id": "SOCIAL-Today1006-Mikemine-78643138",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.891178",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Come on FT, give Barrington some credit. She has an accountancy background which would give her a less than gung-ho approach to reporting. They missed a rather ambitious sales target by not much which is good going in my book. For a \"modest\" report her predictions for 2026 are very confident with \"strong\" growth and are significant. For a CEO running a tiny company on a shoe string with small workforce, she is doing well I reckon. Additions to staff last year were all geared to sales so i would expect them to have reached an inflection point. As for the BCBS agreement, what can you say but \"Well done\". That's going to open more doors for the sales force to walk through. I'd imagine there's a good buzz throughout the company at the moment. They must have worked hard for the last 3-4 years with not much in the way is acceptance to show for it but, starting with Fisher, the ball is rolling. Very positive for 26 iIMHO.",
          "sentiment": 0.0,
          "engagement": "1,236",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328594+00:00"
      },
      {
        "event_id": "SOCIAL-Today1001-Hawker-11107183",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.891629",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Agree, this is an encouraging update. Given the limited resources and tightly managed cost base, Verici could well be on the up this year.  It should only take a doubling or so of the now current testing volumes to put them on the front foot. Keep up the good work Sara and team, go forth and ramp Tutivia and PTRA with Thermo.",
          "sentiment": 0.5,
          "engagement": "301",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T22:01:02.328612+00:00"
      },
      {
        "event_id": "SOCIAL-Today0955-Guly-75755886",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.892184",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Accumulating a position here, can see massive potential.Can't believe it's so cheap.",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-06T22:01:02.328630+00:00"
      },
      {
        "event_id": "SOCIAL-Today0911-Silverbl--6059065",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.892711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "On a positive note at least company has provided a FY update with a relatively small target miss, revenue is growing with new partnerships coming on stream and cash is ok for now. Against that - tests sales in H2 were less than H1 (591 v 582) which is concern - why no growth in actual testing volumes. What I can't reconcile is the Tutivia revenue for H1 was $1.2m for 591 tests ($1962 per test); and in H2 Tutivia revenue was $1.8m ($3092 per test). This just doesn't add up imo. Unless there is deferred income from H1 coming into H2 receivables. I think note 1 in the update is attempting to clarify the issue - but the language on revenue estimates being used rather than actual revenue are a bit concerning. Actual audited accounts will be more revealing and may differ from these unaudited updates. SB",
          "sentiment": 0.0,
          "engagement": "1,925",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T22:01:02.328648+00:00"
      },
      {
        "event_id": "SOCIAL-Today0855-blowdog--4137073",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.893229",
        "source": "LSE_CHAT",
        "data": {
          "author": "blowdog",
          "content": "Https://x.com/CapitalPmh/status/2019323726446158330?s=20",
          "sentiment": 0.0,
          "engagement": "929",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T22:01:02.328666+00:00"
      },
      {
        "event_id": "SOCIAL-Today0852-newgrang--3195405",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.893738",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "L2 buy orders looking strong \ud83d\udcaa",
          "sentiment": 0.0,
          "engagement": "2,114",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T22:01:02.328684+00:00"
      },
      {
        "event_id": "SOCIAL-Today0843-newgrang-15368262",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.894260",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "Good update with revenues and licensing contract. Hugely undervalued.",
          "sentiment": 0.0,
          "engagement": "2,114",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T22:01:02.328702+00:00"
      },
      {
        "event_id": "SOCIAL-Today0839-Fevertre-75494052",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.894756",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "SOP for disappointing update to put out commercial RNS alongside (Blue Cross deal looks encouraging) to soften the blow. Barrington is t up to the job- didn\u2019t hit the numbers; a less than confident statement , and why on God\u2019s Green Earth are they saying Dec FY25 will come out in May!! This is a tiny business with minimal revenues and yet Barrington can\u2019t commit to releasing results in a timely fashion. Suspect because every Q they have a wrangle with accountants about revenue timing and recognition. Be good to see sustained progress but after screwing up the cash raise, which cratered the so Barrington still has to prove she is CEO material.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-06T22:01:02.328719+00:00"
      },
      {
        "event_id": "SOCIAL-Today0824-bigpunt-71607193",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.895246",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Hitting revenue and cash targets, adding major commercial tie-up, can't ask for much more as the company commercialise.  They've had a cracking year and I like the modest tone",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "0.775",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-06T22:01:02.328737+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260854-2Phones--9048937",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.895745",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "the site is *************interviews dot com",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.328755+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260852-2Phones-60391521",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.896268",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "hi splodge2001 https://www. ***************************/verici-dx-landmark-deal-unlocks-potential-300-million-tutivia-market-singer-research-icymi/4121236201",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.328773+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261732-Splodge2-86949488",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.896762",
        "source": "LSE_CHAT",
        "data": {
          "author": "Splodge2001",
          "content": "Does anyone have a link to the Singer note? I couldn't find it on their website.",
          "sentiment": 0.0,
          "engagement": "114",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.328792+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260851-2Phones-69298543",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.897267",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac101 - I was particularly encouraged by the 2.9p target price.  They clearly believe the future for tutivia is massive.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.328810+00:00"
      },
      {
        "event_id": "SOCIAL-Today0851-2Phones-69298543",
        "event_type": "social_post",
        "date": "2026-01-30T23:03:22.957691",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac101 - I was particularly encouraged by the 2.9p target price.  They clearly believe the future for tutivia is massive.",
          "sentiment": 0.0,
          "engagement": "83",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.328828+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261447-donmac10--4569679",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:31.826472",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Very good research note out last few day by Singer .Talking up Prime health deal 300 mill mkt.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.328847+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251243-Romanby--1023447",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.788345",
        "source": "LSE_CHAT",
        "data": {
          "author": "Romanby",
          "content": "No placing you idiot",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T22:01:02.328865+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251216-Sandyman--3136933",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "Is the placing going to be at 0.25p or 0.5p? Or both?",
          "sentiment": 0.0,
          "engagement": "999",
          "price_at_post": "0.775",
          "thread_title": "Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T22:01:02.328884+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251441-Silverbl--6285357",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - FYI Thermo Fisher are not currently involved in Tutivia - so they are not involved in any roll out. Despite claims here to the contrary there has been no trading update - so we await evidence that Q4 delivers the level of sales anticipated by the CEO on achieving the 2025 Tutivia revenue target - which as you note would be a significant increase on 2024 sales. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.328902+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251547-B_Positi--2254027",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.790830",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.328921+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-B_Positi--4618004",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.791703",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I would wager a big Thermo-Fisher update is due here. Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.328939+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251302-B_Positi--9152581",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.792503",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Wow now way just saw that. Huge implications for Thermo and its partners!",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.328957+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251255-donmac10-75854167",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.793297",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Genincode signed a deal with Thermo read across to Verici Verici so undervalued at the moment something has to give.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.328975+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251244-B_Positi-20637240",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794085",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Once it breaks 1p it will fly to 2p and then 3p gets smashed with ease considering the test orders are going to be around 300-400% from the digging below. 3p as a base and then a move back to 5-10p.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.328993+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251227-B_Positi-12477297",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794962",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I'm personally amazed more aren't piling in whilst under 1p and this isn't at 3-5p already. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329011+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251953-B_Positi--4840803",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.795766",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Will add another 2m sub 1p Way too cheap here for me personally.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329029+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251945-donmac10-22610417",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.796575",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "3p per share nailed on short term if you guys sit oan yer tuffetts like miss muffet know whit ah mean?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329047+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251941-donmac10-73101195",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.797364",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Company is no longer research orientated so past rns at this time of year irrelevant trust me as tests ramp up as they will be the company will be eager to broadcast positive newsflow asap.noh whit a meen an that man getmeh!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329065+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251535-Silverbl-41993685",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798154",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Would be unusual for a trading update pre-xmas imo although any kind of an update in relation to hitting revenue targets would assist progress here - the bar has been set very high by CEO. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329084+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251320-B_Positi--8171713",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798939",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Yes it was due. Thermo-Fisher $220BILLION backing this and tied in. Update on them or something new will wake the market up.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329119+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251245-donmac10--4523255",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.799717",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Update this week and more deals with distributors .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329146+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251234-B_Positi--8346853",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.800588",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "MMs caught wind of an update? I'm amazed this isn't over 2p at least. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329165+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251230-tbcx--8857221",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.801373",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Buying pressure certainly returning this week, this remains extremely undervalued.",
          "sentiment": 0.0,
          "engagement": "766",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329184+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251443-donmac10-38535658",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802148",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Nice 2mill buy this morning.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329202+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251235-B_Positi--6235515",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802905",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Donmac, absolutely buzzing for the trading update this month Hopefully see's this head back to the 3 to 5p level",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329220+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251104-B_Positi--5793022",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.803727",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "So with less than 10% of transplant centres onboarded and already at the start of the mass rollout they averaged about 300 tests per quarter in Q1, Q2 and Q3, just short of 900, vs 334 for the entirety of 2024, representng significant growth. We now know they are at at least 16% of transplant centres onboarded now (less than 10% for Q1, Q2, Q2, perhaps around 20% now and are increasing this fast. You quickly realise how mad the revenues can become here at $2,650 a test with the medicaid coverage +Thermo Fisher licencing revenues. I know many, many pharma stocks that have literally $0 revenue, no proven tech, no FDA approval, no big deal with a giant like this does with Thermo Fisher that are trading at many multiples of the Verici market cap.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329239+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251045-donmac10--7039994",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.804510",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And its beginning to look like word is out?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329257+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251039-donmac10--6986187",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.805293",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Expecting a trading update in the run up to xmas should make for good reading!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329276+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251031-B_Positi--3942092",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806132",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329294+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251456-Mikemine-37483344",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806901",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, your posts have got  very repetitive and quite frankly, boring. Unless your rants help your mental state I for one would be grateful if you would keep your posts to new views or information.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T22:01:02.329312+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251148-Fevertre-40260039",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.375637",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Just out of interest what are Barrington's competencies?",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T22:01:02.329330+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251147-Fevertre-53196196",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.376396",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "The Board and non-execs have overseen an absolute shamble here. Barrington completely unaffected by disastrous dilution as she has virtually no bloody shares in teh company she purports to lead.  The CFo isnt fit for purpose frankly. The Q4 figs appear to be the stuff of fantasy - I would give more creedance if  Barrington was able to explain how she gets to the forecast but she appears to be just making it up as she goes along... we have no timelines on onboarding; Barrington cant set out how she arrived at the numbers... she continues to be utterly hopeless as the CEO of supposedly a cutting edge business.",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T22:01:02.329349+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251059-Silverbl--2040806",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377214",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There you go donmac almost at your buy price already. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T22:01:02.329367+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20250050-donmac10-30798551",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377985",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sell up move on thank you.....give me the chance ar more aroon the 55 mark slanj .And a will catch yeh in wetherspoons oan the wae otta rah ritz.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T22:01:02.329385+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251734-Mikemine-49163255",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.378810",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "VRCI is a small company so hiring an extra 3 salespersons is huge for them and points to their determination to hit their target. It's a big ask but you can be sure they recognise that their credibility is on the line. From a practical point of view, hiring new salespeople  takes time for their impact to come through. They have to get used of the systems, the product and VRCI's method of selling. I wish them luck and, if they do reach their target, it will be noticed by the Market.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T22:01:02.329403+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251709-Silverbl--7505237",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.379608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not a fan to date either fevertree - its been a disaster for all shareholders here - but I still hold a position here and am trying to look forward not back given the past is what it is. If Q4 goes well I expect a trading update early 2026 - which doesn't usually happen but positive momentum will be required to avoid a total wipe out in any subsequent capital raise. Failure to deliver (again) then more questions will be raised on leadership competencies.  SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.75",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T22:01:02.329422+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251647-Fevertre--1160813",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.380414",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "She has never fully explained the onboarding process. If a new centre gets onboarded, typically how long does it take for clinicians to order first tests",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T22:01:02.329440+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251644-Fevertre-62788669",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.381220",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Nonsense Donmac.....look at the maths around Barrington's targets: On my maths I don't see how she hits revs from Tutivia $3.2m... Tutivia:  1H Revs: $1.16m: 591 tests @ ave $1900 ($1.16m divided by 591) 2H Revs:  3Q Tutivia same rate as Q1/Q2 ..c300 tests at 1900 = $570k  ...so to meet her target she needs to sell c$1.5m of tests. Assume same ave price of $1900....she needs to sell c790 tests....that's a massive uplift, even with onboarding another 9 more centres...",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T22:01:02.329458+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251627-donmac10-52116154",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382010",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "markets falling and the doom and gloom ****roaches appear in force.sell up ,thats even if yeh hod any and gie us aw peace!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T22:01:02.329476+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251604-Fevertre--4515257",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382802",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Worryingly her bullishness has cost investors dearly so far. Apart from having virtually no skin in the game she hasn't been gifted,  or regifted (look at the outrageous revision of option pricing). The fact that the sp is still at 3/4 of a penny tells you everything you need to know about how the market views her!",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T22:01:02.329504+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251522-Silverbl--3359441",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.383604",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Based on what we already know - VRCI sold c.600 Tutivia tests in H1 2025 - securing revenue of $1.2m ($2k per test - blend of public and private payers). They sold same in Q3 - so lets assume pro-rata they secured a further $600k revenue. Sara B confirmed FY Tutivia target was $3.2m - so that leaves $1.4 revenue to be secured in Q4 - or c.700 tests at $2k. Seems a huge leap - or possible they are looking at a slight increase to average test $ - although Prime Health RNS appears to push towards discounted volume in private market. She has certainly set high expectations for Q4 trading. If this is achieved it will be a significant acceleration - and will be crucial in supporting the share price/market cap as the company requires additional funding in the next 4/5 months. Additional licensing revenue from Thermo (c.$4m received to date - $3.3m in 2024 and $0.75m in 2025) remains on hold as they progress their approach to the PTRA test. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.725",
          "thread_title": "2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-06T22:01:02.329522+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250856-2Phones--8242350",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.384401",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac agreed - two of the latest RNS are very positive about the rate of revenue growth and market penetration - can't help but think the next sales based RNS will be a gamechanger.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.875",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T22:01:02.329540+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250845-donmac10--1189383",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385202",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Analysts expecting 3p per share next year big upside from here.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.90",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T22:01:02.329558+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250843-donmac10-19720718",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385990",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Verici also more forthcoming informing the market with updates .Beats last years 6 month radio silence .Just waiting now for testing update which i know will further boost price.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T22:01:02.329577+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250830-donmac10--3479371",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.386775",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Tells me ,anyone looking to make money would be well served to get in now .Futher big rise going into year end.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.95",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T22:01:02.329595+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250809-2Phones-50108091",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.387576",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Interesting news today \u2013 initially I thought why? This has little bearing on shareholders interests \u2013 however, on further concideration, while successful audits add little to the bottom line or turnover or even shareholder value \u2013 in our case it is very much a Critical Failure Factor, where failure to pass a quality audit could seriously damage the company in the short/medium term.  Also it does point to a well run, disciplined business. So well done Verici.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.95",
          "thread_title": "RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-06T22:01:02.329613+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251448-oogleflu-49379088",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.388340",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Tom. I know exactly what you\u2019re saying is correct . Unfortunately risk appetite is much lower in the UK probably because the FA are like a bunch of frightened rabbits. Fund managers continue to unwind oversold positions in uk to chase  the way overpriced \u2018American dream stocks\u2019 which are overdue a big correction there by loosing even more of the inadequate fund managers clients money. It\u2019s not all Uk stocks but quite a few as admitted in an interview recently with a fund manager. Certainly since the pandemic Uk stocks are valued much more realistically i.e. sound balance sheet which Vrci  now has, realistic forecast which Vrci now has, realistic targets for growth which Vrci now has. But we don\u2019t tend to look further than a year ahead. One step at a time . There will be /is FOMO with a stock like Vrci which will cause some volatility till they establish a more constant earnings stream.",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329631+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251354-donmac10--1209037",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389131",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "It feels to me we are about to get a trading update on testing numbers shortly .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329650+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251256-donmac10-53152091",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389888",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "1.20p close today and more updates in coming days on quickly to 2.00p",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329668+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251247-geraldus--4209393",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.390653",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "Still early days here,and they will have to take some market share from the incumbent bio markers. Shaping up well so far and with a miserly market cap in comparison with other counters.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.825",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329686+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251241-B_Positi-31436465",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.391431",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Geraldus Tutivia is the standard now. Hence why Thermo-Fisher has gone all in and is backing all the way. Market slowly beginning to wake up that this company is grossly undervalued. I mean the FDA approval, ip, tech alone is worth multiples and then whack on the huge growth already in 2025 and coming in 2026 with over 30 transplant centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329704+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251239-donmac10-76617721",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392203",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "American market waking up to the potential with Verici dx in their own backyard They love an AI stock.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329723+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251236-geraldus-21344678",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392989",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "With their 'AI' solution for optimising transplants,it is undoubtly an interesting opportunity here. They have spent millions on this and they are confident that it is payback time. With no competition at this level,it could possibly become the defacto standard.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329741+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251217-B_Positi--3942092",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.393835",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329759+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251205-oogleflu--2423942",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.394621",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Addressable market doesn\u2019t mean they capture all of it.  They might get 1 or 2 percent which is still sizeable if lucky. Even singer, their broker,  have only raised the sp to 3p. That\u2019s still 4 times current market cap! The other thing is will they need to expand the lab or open another one as their market share increases. They have got a captured market in that there is no competition and the tests are becoming mandatory. No plans to adopt outside the US yet. Maybe 20p in 5 years certainly not months I\u2019m afraid but good luck",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.775",
          "thread_title": "RE: Quantifying the opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=D3DE9F2B-871D-47DE-96C8-2D6BB08D16A4"
        },
        "ingested_at": "2026-02-06T22:01:02.329777+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261715-Silverbl-50106220",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - feel free to use the actual numbers in your updates. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 (INCORRECT: H1 actual revenue was $1.16m = $1962 average revenue per test). H1 2025 licencing revenue = $750,000 (CORRECT) Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. (Test numbers CORRECT. Centres INCORRECT - there were 21 onboarded at time of results). 286 x $2,650 = $757,900 (Likely INCORRECT based on average revenue per test of $1962 achieved in H1 2025 - likely revenue $560K). Q4 2025, 20 centres onboarded and let's be conservative and say 300 tests. (INCORRECT. There are now 30 centres onboarded. Company is targeting in the region of 750 tests in Q4 in order to meet its Q4 revenue target of c.$1.5m) 300 x $2,650 = $795,000 revenue (We will find out in due course what was achieved in terms of test numbers and average revenue per test) H2 2025 licensing revenue, let's be conservative and say $500,000. (INCORRECT. No licencing revenue will come from Thermo in H2) Combine all of that above and you get = $4.3mil or \u00a33.2m. (H1 revenue was $1.9m/ Q3 likely $560K. Q4 not yet reported. Company is targeting total FY 2025 revenue of $3.95m, comprising $3.2 Tutivia tests and $750K licencing revenue) Still nothing in the way of a trading update from the team at vrci. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329795+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261504-B_Positi-42078698",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332720",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We should all be extremely excited having now onboarded over 30 transplant centres, up from 10 in 2024. We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329814+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260830-Silverbl-69620950",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333151",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "$12m was a direct quote from Vrci CEO in latest Vox markets interview. As for my 'precise' figures - strangely enough when it comes to investing I prefer to deal in fact rather than making it up (refer B_Positive). As for my views on the business - I remain invested so I am hopeful there is a future here or would have taken my medicine and moved on. That does not mean to say I will not vocalise my thoughts on areas of mismanagement where the company could and should be doing better; or to call out posters who are just making it up as they go along. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329832+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260728-B_Positi--1516700",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333626",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329850+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260205-donmac10-37934912",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334054",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Where do you get the 12mill breakeven point? You sound like a bot with your precise figures. And you always have a way of sounding positive but are really negative .So cant be taken seriously .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329869+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262026-Silverbl--5203367",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334501",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not really sure why I need to explain this, but here you go B_Positive. Your bullet point regarding Tutivia sums the position up very well. Transplant centres service both Medicare patients and private paying patients. So whilst the Medicare payment of $2650 is being provided by the US healthcare system for patients who benefit from the Medicare and Medicare plus programmes - there are actually six key revenue streams for test sales of which Medicare is one (albeit the largest - 68% of tests being undertaken are covered by Medicare seems to be the claim from the company). Private payers (via healthcare insurance) do not pay the $2650 - they receive discounts. Clinical trials pay nothing. And there others. If you divide the H1 Tutivia revenue of $1.16m by the 591 tests in H1 it comes out at $1962 . That is the current revenue reality for test sales. The recent RNS highlighting the agreement with Prime Health Services is all about trying to establish consistent pricing of the Tutivia test with the private payment market and clearly with the goal to increase current pricing which is diluting the Medicare $2650. In relation to your H2 licencing point the following clarifies the position \" Thermo Fisher is investing in new research related to PTRA aimed at identifying the earliest stage at which the test can be utilised before transplantation. Consequently, the second milestone originally anticipated for 2025 will be delayed as we continue to collaborate on publishing clinical validation data and Thermo Fisher pursues these additional research efforts to help broaden utility and adoption of the assay.\" FYI the breakeven position for Verici is c.$12m - so that provides an indication of the revenue which is required from test sales, licence revenue, protega etc to cover vrci operating costs. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329887+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261524-B_Positi-92656645",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334932",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Nope it's $2,650 as per the Medicare coverage RNS and more recently as per the HY report. \u00b7 Lead product Tutivia\u2122 attained Medicare coverage at $2,650 per test, covering a national estimate of 68% of all US transplant tests and commercial payor reimbursement applications are underway They receive licencing revenues both H1 and H2. It was $750k in H1.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329906+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261523-Silverbl-68312737",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335360",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Mikemine -  your points are valid - but highlight one of the main issues here. Why set a target and fail. Undermines confidence, craters the share price, makes fund raising tricky and makes investors wary on growth. Much better to overdeliver on achievable targets than underdeliver? But maybe we will be get a pleasant surprise. Thermo are just doing their own thing on the PRTA at present. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329924+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261518-Silverbl--1425593",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335771",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "No licencing revenue in H2 2025 and average received revenue per test is $1900. Do some actual research please. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329942+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261416-B_Positi--8290593",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336264",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10 centres onboarded. It must now be around 25-35 going by the last report.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329961+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261402-Mikemine-47930772",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336713",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "They've set themselves a big revenue target of over \u00a33mn for 2025. Small in world terms but a big % increase for VRCI. Should they be chastised if they do not reach the target or should it be viewed in the context of what they do achieve and what they forecast for this year? Getting close to \u00a33mn would be an achievement in my book as that would point to things being on track for further increases especially as the new sales guys have probably only just got their acts together and their contacts in line. Not sure what to think of the Thermo-Fisher deal and its seemingly lack of traction. Big companies are not nimble nor quick so the jury's out on that one for me. My guess is for an update this month and it will be positive but will not please everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329979+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261401-B_Positi-82573739",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337193",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Cashed up until the end of 2026 and now they've been securing record orders as per below. Next time they raise it will be in the pennies, which is what they will want given the new option prices. Test update going to drop soon. More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.329997+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261346-Silverbl--9510398",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Despite the view expressed by several contributors here we have heard nothing from the business on Q4 trading. Not unexpected - if there was anything to report on I would expect to hear later on in January. The issue looming very shortly relates to the required fund raising. In previous years the company has elected not to divulge FY trading until May.  This is likely to be beyond the point at which the company runs out of cash. We should therefore be able to read the signals loud and clear - no trading update - then Q4 has not delivered the targeted sales and the fund raise will be brutal.  If a positive Q4 trading update is issued then there should be a healthy price response despite the recognition funds will still be required. Remember last year the first fundraise was at 9p - then 0.5p after bewildering timing mismanagement by the company.  All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: 100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-02-06T22:01:02.330015+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261228-B_Positi-56974753",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338063",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.330034+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-2reincar-88807819",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338488",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Conversions this summer will see us at sub 0.25p!",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.75",
          "thread_title": "100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-02-06T22:01:02.330052+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261210-B_Positi-27007648",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338938",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.330070+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20260629-2Phones--6531459",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339362",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "How can any one disagree with such a cogent arguement - and clearly not the rantings of a one track numpty.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.725",
          "thread_title": "RE: Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-02-06T22:01:02.330088+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261022-2reincar-61949529",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339773",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "At 0.25p?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.725",
          "thread_title": "Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-02-06T22:01:02.330124+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251515-B_Positi-27007648",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340229",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.330144+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251223-Silverbl-89980929",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "2Phones - from the company itself: \" With minimum gross proceeds from the Placing and Subscription of \u00a35 million, the Company's cash runway will be extended to mid Q2 2026.\". Hence my thinking spring will be the time to raise. And yes revenue is expected to increase (we will know by how much in a few weeks) - but annual expenses are c.$9m - so sales would need a dramatic (and unlikely) increase to negate the need for more funds. And you seem to agree that a placing is an option (imo the only likely one and the route the company has taken to date in all its efforts to secure more funding). So not sure what you were disagreeing with? SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T22:01:02.330162+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20250753-2Phones--3587779",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341050",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I don't agree - the operational update earlier this year had a predicted cash runway to H2 next year - when you couple that with the recruitment of 2 sales people and a director of clinical partnerships, I would anticipate growth in cash inflow.  However, they are a small team and they are going to have to increase production to accommodate the anticipated sales.  This will need funding, but where they get it is uncertain \u2013 one option being a placing.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T22:01:02.330180+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251728-2reincar--1006858",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341472",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Agree Silverblade. We could have one in Aprilish at 0.5p and one in Octoberish at 0.25p and then a rocket to + 2p ?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T22:01:02.330199+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251618-Silverbl--2926108",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Same old nonsense B_Positive. Thermo are not involved in Tutivia. Stop spreading false information. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.330217+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251557-B_Positi--2254027",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342355",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-06T22:01:02.330235+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251522-Silverbl--6103167",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342765",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There will be a placing in early 2026 - probably March/April time. The placing will of course be determined by the prevailing share price at the time. And that in turn will reflect the numbers for FY 2025 - there is a lot of expectation here so lets see what the company has to say for itself hopefully with a trading update in January. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-06T22:01:02.330254+00:00"
      },
      {
        "event_id": "SOCIAL-Today1501-Sandyman-51917584",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.077507",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "This company is haemorrhaging money and there will be another cash call in the summer!",
          "sentiment": 0.0,
          "engagement": "1,057",
          "price_at_post": "0.725",
          "thread_title": "No No No!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=8A240B4B-560F-4A07-8838-7DE94557E60C"
        },
        "ingested_at": "2026-02-09T22:04:51.965777+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261401-Mikemine-53462032",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.077931",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "From what Barrington said there are and will be much smaller deals which will not be subject to an RNS. The effect will be cumulative.  It all adds up to a company that has found a path to full commercialisation and is actively pursuing it.",
          "sentiment": 0.0,
          "engagement": "1,242",
          "price_at_post": "0.725",
          "thread_title": "RE: Cash runway H2 2026 + further deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=A5597C3C-875E-437B-9DEF-C50802BE8B35"
        },
        "ingested_at": "2026-02-09T22:04:51.965820+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261325-Guly-44623631",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.078374",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Unaudited cash at year-end of $3.3m (2024: $4.1m), which is slightly ahead of expectations, with $1.6m accounts receivable (2024: $Nil) which continues to support expected cash runway into H2 2026 as previously communicated. Should see a nice lift in anticpiation of further deals",
          "sentiment": 0.0,
          "engagement": "2,256",
          "price_at_post": "0.725",
          "thread_title": "Cash runway H2 2026 + further deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=A5597C3C-875E-437B-9DEF-C50802BE8B35"
        },
        "ingested_at": "2026-02-09T22:04:51.965857+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261047-geraldus-58715187",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.078776",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "...that is obviously required.Confident on this year,but the cash runway is possibly holding back the price.",
          "sentiment": 0.0,
          "engagement": "96",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.965895+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261044-geraldus-60687991",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.079200",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "Impressive interview on Vox.They have hit the floor running with a product t",
          "sentiment": 0.0,
          "engagement": "96",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.965932+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262340-donmac10-69063634",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.079608",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Really you guys should accentuate the positives and negate the negatives ....mmhh thats a good line for a song.!!",
          "sentiment": 0.0,
          "engagement": "2,881",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.965967+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261817-Mikemine--8796116",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.080007",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "One thing I'd forgotten was that they didn't get Medicare's approval until April and medicare pays for 70% of VRCI's revenue. I'm not surprised they missed their target. It looks like they would have easily reached their target if they had Medicare on board from January 1st.",
          "sentiment": 0.0,
          "engagement": "1,242",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966006+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261808-Mikemine-12411637",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.080417",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "don't know why the link has got stars instead of ********** but i'm sure you can find it.",
          "sentiment": 0.0,
          "engagement": "1,242",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966042+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261807-Mikemine-38462408",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.080820",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "https://www. **********.com/articles/q-a-with-verici-dx-ceo-sara-barrington-6e98b51",
          "sentiment": 0.0,
          "engagement": "1,242",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966079+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261805-Mikemine-68640221",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.081236",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "barrington sounds confident and on top of it. lots of stuff in there that will enable us to more deeply understand the business and see where vrci is heading. not much about numbers but the obvious acceptance and use by the clinicians and insurers is evident. it really looks like this is going to be a good year for vrci https://www. **********.com/articles/q-a-with-verici-dx-ceo-sara-barrington-6e98b51",
          "sentiment": 0.0,
          "engagement": "1,242",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966135+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261704-donmac10--2229593",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.081635",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sarah sounds very upbeat on Vox markets today..Stating this is Vericis year very positive.",
          "sentiment": 0.0,
          "engagement": "2,881",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966173+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261557-bigpunt-33358332",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.082031",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Silverblade, a lot of whingeing about the past will not help your decision-making.  One should learn from previous investment decisions and appraise prospective investment decisions better!  Between now and raise will be the FY results and presentation and possibly a further update to support the raise.  Mkt cap and equity raise price will be determined entirely by those trading updates and credibility of updated forecasts",
          "sentiment": 0.0,
          "engagement": "361",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966209+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261544-Mikemine-52298057",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.082467",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "All decent points SB. Unfortunately VRCI is on AIM and AIM is almost dead in the water. I would venture that AIM is merely capturing the mood of the country which has been negative for some years now. People are so grumpy and lacking a positive disposition compared with what I see in the States, even with the Trump factor. I would venture that if VRCI was on Nasdaq its valuation would be around the $50-60 mn mark as the potential and demonstrated progress would be recognised as very positive by the Market there. Fortunately VRCI is operating in the States otherwise I wouldn't touch it with a bargepole because of how the NHS is run. You might have guessed that I think the company is well run and punching above its weight in a difficult field. It did get last years fundraiser wrong by announcing it's intention before securing funds but I reckon they've done well otherwise. What's for the future? The next 6 months are crucial but I believe that the \"strong\" sales increase flagged has a good chance of being achieved so the burn rate will reduce. They gave themselves an ambitious target last year which they nearly achieved and this indicates to me that they have a well thought out business model which includes a viable way of commercialising the product and this gives me some confidence is them performing strongly this year. As for a fund raise, their performance since the last one will give institutions lots of confidence to back them should they need one. I am not stupid enough to offer a prediction for the SP but, even on AIM, achieving this strong growth can't help but be positive in that direction. It's all my opinion of course and what do I know? There's always the possibility of a takeover of course but that's a speculative  game in which I am unable, and unwilling, to enter. Good luck for anybody that wishes to stay in the game.",
          "sentiment": 0.0,
          "engagement": "1,242",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966247+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261453-Silverbl--6821682",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.082867",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I can fully understand fevertrees anger and frustration here - it is likely representative of a large number of longer term shareholders. The grim reality is that whilst the latest update is encouraging in terms of revenue growth, the actions of the board last year in delaying the fund raise to the point it required a price of 0.5p to secure funding has created a position where the sheer number of shares in circulation render's the majority of investors trapped with little chance of recouping any investment made in the 2-5p range. Anything above that is gone.  Add to that a further capital raise in the next 4/6 months - and lets say they go for \u00a35m - which would require 1b further shares being issued at 0.5p. Nothing suggests the share price moving to any significant extent given the reaction to recent news. So then you have in the region of 2.5b shares - even assuming a share price of 1p, that's a \u00a325m market cap for a still loss making company. That in turn assumes the company is capable of doubling its revenue this year - which is possible - which also reduces the further risk (and scale) of a 2027 fund raise although this is still likely. I am invested here - and think the product is viable - but historic investors have been completely shafted. Even the company's own broker has an optimistic price less that 3p a share (don't get me wrong I would grab that in a heartbeat). The best outcome would be for an approach to take the business private or a pharma takeover at a decent premium to the current price. The alternative for shareholders is throwing more money during the fund raise to lower entry prices - which is a sobering thought. All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966284+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261428-bigpunt--6831240",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.083324",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Some very rough calcs.  c.90% of US population has medical insurance.  c.27,000 kidney transplants last year.  Assuming just one test per transplant, at unindexed $2,650 per test, the USA market-alone is worth $64m.  I'm also assuming the Tennessee lab can service the entire USA I'm not sure how many patients are represented by the 1,173 tests in 2025, and how many transplant centres vs the total in the USA, but the market penetration appears decent, considering the academic papers were only published 6 months ago Some may questions the relevance of academic papers and other KPIs may be more relevant, but it strikes me that the increase in number of clinicians and the increase in number of transplant centres will be strongly influenced by the academic articles and their subsequent peer reviews My view?  VRCI will get bought out when the USA nears profitability due to it's domestic market opportunity and the obvious globalisation opportunity.  Need to pay very close attention to what happens between now and next (and probably final) equity raise",
          "sentiment": 0.0,
          "engagement": "361",
          "price_at_post": "0.725",
          "thread_title": "Mid-term opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=755FC4E4-63EA-405E-A449-61BE41636EEA"
        },
        "ingested_at": "2026-02-09T22:04:51.966321+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260859-oogleflu-49895524",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.083726",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "I thinks it\u2019s worth noting that Verici\u2019s year end was December. So whilst cash burn continues for another 6 months so does the pipeline growth and revenue. The Blue cross contract in Illinois is very significant as diversifying away from Medicare and becoming less dependant becomes more beneficial to clinicians and patients in not only in cost but also speed of treatment. Barrington hinted that these kind of contracts could spread across to other states. In an ever changing shift in Trumps one brain cell it must be pretty hard to predict or forecast anything in the US. What Vrci has demonstrated this year is the viability and commerciality is well in sight.",
          "sentiment": 0.0,
          "engagement": "5,476",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966358+00:00"
      },
      {
        "event_id": "SOCIAL-Today1817-Mikemine--8796116",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.630785",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "One thing I'd forgotten was that they didn't get Medicare's approval until April and medicare pays for 70% of VRCI's revenue. I'm not surprised they missed their target. It looks like they would have easily reached their target if they had Medicare on board from January 1st.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966396+00:00"
      },
      {
        "event_id": "SOCIAL-Today1808-Mikemine-12411637",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.631220",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "don't know why the link has got stars instead of ********** but i'm sure you can find it.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966434+00:00"
      },
      {
        "event_id": "SOCIAL-Today1807-Mikemine-38462408",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.631632",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "https://www. **********.com/articles/q-a-with-verici-dx-ceo-sara-barrington-6e98b51",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966471+00:00"
      },
      {
        "event_id": "SOCIAL-Today1805-Mikemine-68640221",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.632046",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "barrington sounds confident and on top of it. lots of stuff in there that will enable us to more deeply understand the business and see where vrci is heading. not much about numbers but the obvious acceptance and use by the clinicians and insurers is evident. it really looks like this is going to be a good year for vrci https://www. **********.com/articles/q-a-with-verici-dx-ceo-sara-barrington-6e98b51",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966508+00:00"
      },
      {
        "event_id": "SOCIAL-Today1704-donmac10--2229593",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.632458",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sarah sounds very upbeat on Vox markets today..Stating this is Vericis year very positive.",
          "sentiment": 0.0,
          "engagement": "2,878",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966545+00:00"
      },
      {
        "event_id": "SOCIAL-Today1557-bigpunt-33358332",
        "event_type": "social_post",
        "date": "2026-02-06T15:59:25.608751",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Silverblade, a lot of whingeing about the past will not help your decision-making.  One should learn from previous investment decisions and appraise prospective investment decisions better!  Between now and raise will be the FY results and presentation and possibly a further update to support the raise.  Mkt cap and equity raise price will be determined entirely by those trading updates and credibility of updated forecasts",
          "sentiment": 0.0,
          "engagement": "361",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966581+00:00"
      },
      {
        "event_id": "SOCIAL-Today1544-Mikemine-52298057",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.744230",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "All decent points SB. Unfortunately VRCI is on AIM and AIM is almost dead in the water. I would venture that AIM is merely capturing the mood of the country which has been negative for some years now. People are so grumpy and lacking a positive disposition compared with what I see in the States, even with the Trump factor. I would venture that if VRCI was on Nasdaq its valuation would be around the $50-60 mn mark as the potential and demonstrated progress would be recognised as very positive by the Market there. Fortunately VRCI is operating in the States otherwise I wouldn't touch it with a bargepole because of how the NHS is run. You might have guessed that I think the company is well run and punching above its weight in a difficult field. It did get last years fundraiser wrong by announcing it's intention before securing funds but I reckon they've done well otherwise. What's for the future? The next 6 months are crucial but I believe that the \"strong\" sales increase flagged has a good chance of being achieved so the burn rate will reduce. They gave themselves an ambitious target last year which they nearly achieved and this indicates to me that they have a well thought out business model which includes a viable way of commercialising the product and this gives me some confidence is them performing strongly this year. As for a fund raise, their performance since the last one will give institutions lots of confidence to back them should they need one. I am not stupid enough to offer a prediction for the SP but, even on AIM, achieving this strong growth can't help but be positive in that direction. It's all my opinion of course and what do I know? There's always the possibility of a takeover of course but that's a speculative  game in which I am unable, and unwilling, to enter. Good luck for anybody that wishes to stay in the game.",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966618+00:00"
      },
      {
        "event_id": "SOCIAL-Today1453-Silverbl--6821682",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.744668",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I can fully understand fevertrees anger and frustration here - it is likely representative of a large number of longer term shareholders. The grim reality is that whilst the latest update is encouraging in terms of revenue growth, the actions of the board last year in delaying the fund raise to the point it required a price of 0.5p to secure funding has created a position where the sheer number of shares in circulation render's the majority of investors trapped with little chance of recouping any investment made in the 2-5p range. Anything above that is gone.  Add to that a further capital raise in the next 4/6 months - and lets say they go for \u00a35m - which would require 1b further shares being issued at 0.5p. Nothing suggests the share price moving to any significant extent given the reaction to recent news. So then you have in the region of 2.5b shares - even assuming a share price of 1p, that's a \u00a325m market cap for a still loss making company. That in turn assumes the company is capable of doubling its revenue this year - which is possible - which also reduces the further risk (and scale) of a 2027 fund raise although this is still likely. I am invested here - and think the product is viable - but historic investors have been completely shafted. Even the company's own broker has an optimistic price less that 3p a share (don't get me wrong I would grab that in a heartbeat). The best outcome would be for an approach to take the business private or a pharma takeover at a decent premium to the current price. The alternative for shareholders is throwing more money during the fund raise to lower entry prices - which is a sobering thought. All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966655+00:00"
      },
      {
        "event_id": "SOCIAL-Today1428-bigpunt--6831240",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745095",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Some very rough calcs.  c.90% of US population has medical insurance.  c.27,000 kidney transplants last year.  Assuming just one test per transplant, at unindexed $2,650 per test, the USA market-alone is worth $64m.  I'm also assuming the Tennessee lab can service the entire USA I'm not sure how many patients are represented by the 1,173 tests in 2025, and how many transplant centres vs the total in the USA, but the market penetration appears decent, considering the academic papers were only published 6 months ago Some may questions the relevance of academic papers and other KPIs may be more relevant, but it strikes me that the increase in number of clinicians and the increase in number of transplant centres will be strongly influenced by the academic articles and their subsequent peer reviews My view?  VRCI will get bought out when the USA nears profitability due to it's domestic market opportunity and the obvious globalisation opportunity.  Need to pay very close attention to what happens between now and next (and probably final) equity raise",
          "sentiment": 0.0,
          "engagement": "360",
          "price_at_post": "0.725",
          "thread_title": "Mid-term opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=755FC4E4-63EA-405E-A449-61BE41636EEA"
        },
        "ingested_at": "2026-02-09T22:04:51.966690+00:00"
      },
      {
        "event_id": "SOCIAL-Today0859-oogleflu-49895524",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745517",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "I thinks it\u2019s worth noting that Verici\u2019s year end was December. So whilst cash burn continues for another 6 months so does the pipeline growth and revenue. The Blue cross contract in Illinois is very significant as diversifying away from Medicare and becoming less dependant becomes more beneficial to clinicians and patients in not only in cost but also speed of treatment. Barrington hinted that these kind of contracts could spread across to other states. In an ever changing shift in Trumps one brain cell it must be pretty hard to predict or forecast anything in the US. What Vrci has demonstrated this year is the viability and commerciality is well in sight.",
          "sentiment": 0.0,
          "engagement": "5,469",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966727+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261742-Mikemine-70319521",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, you are clearly angry with VRCI, especially Barrington, so it begs the obvious question \"Why are still here and presumably invested in the company?\" I'm sure most of us have felt let down and financially hurt by companies and BODs in the past but have taken the hit and moved on. Why haven't you?",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966764+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261656-Fevertre-53505120",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.746540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "If cash burn is an issue then perhaps Sara Barrington should take a bloody pay cut",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.966801+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261654-Fevertre--6591037",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.747174",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "barrington is the the issue (along with the board). after the disastrously botched raise that almost sank the company but not barrington because she got regranted her share options (not something s/holders were able to do)... her attitude to her shareholders is woeful - she didnt apologise for her gigantic ****-up that cratered the sp. meantime the growth figs look dodgy and she continues to burn thro cash at a rate.... fy 25 1,173 tutivia tests orders = $3m revs = $2557 per test, and yet at 1h figs of 591 tests = $1.16m = $1962 per test, so 30% uplift based on 2h figs. - on face of it that's a great result right? but where is the explanation/reconciliation, and if there is that much volatility barrington how can your investors/analyst properly model outcomes (let alone the company)? then what about momentum that she was saying was happening: october update - barrington told us \" volume growth from this progress is expected from q4 and the number of orders in q3 were consistent with the previous two quarters. 1h 591 so  averages q1 295 q2 295. q3 c300....so based on barrington's comment an uplift was due in q4...and yet: q$ sales below q1, 2,3..and 2h below 1h.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.966840+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261628-tbcx-80252036",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.747632",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is the company that reiterated cash runway until H2 2026 in today's update. That is them letting you know now funding will be required this year sometime from July onwards.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.966878+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261516-stockyhe-68767662",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748041",
        "source": "LSE_CHAT",
        "data": {
          "author": "stockyheathlad",
          "content": "In a business like this, historic cashflow isn't necessarily a guide to the future. Expenditure on setting up new centres will be variable and, to a degree, discretionary.  The income stream grew across the year so the last quarter's figures are most relevant, rather than the whole year's.",
          "sentiment": 0.0,
          "engagement": "19",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.966914+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261419-2Phones-86405101",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748468",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "SB - thanks for that.  They said at the time of the fundraising (as @ 31/05/25) they had a cash runway to the end of July 2025.  And subsequently they have burned that cash ($8.6m?) in the remaining 5-6 months of 2025 down to $3.3m, so $10m breakeven makes sense.  Obviously as they get closer to that breakeven point the cash burn reduces - the question is, with all the sales activity, how quickly can they reach that point, and how many further funding rounds we'll see.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.966953+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261333-Silverbl--1390888",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748870",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Cash burns remains significant - company raised \u00a36.35m during the year - which added to the $800k difference in year end balances show the level of cash required to support the losses incurred over the last 12 months. Breakeven is predicted at $10m revenue pa. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.966992+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261236-Guly-19972846",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.749302",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Cash runway atleast 2 yrs assuming current run rate without additional contract wins",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.967028+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261117-2Phones-45890384",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.749703",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I agree that the guidance of cash for H2 appears disappointing, however if you take the cash burn over the last 12 months \u2013 the cash reduced from $4.1m to $3.3, which implies a burn rate of $800k per annum.  Now there are many things that impact these numbers but this set against the backdrop of ever-increasing revenue and sales orders/opportunities.  H2 may be a little pessimistic.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.967065+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261022-tbcx--1993932",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750126",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Great product and credit to them for being revenue generating, way ahead of many other biotechs valued higher. Suspect there is a management discount at play here for habitually missing guidance, which can be overcome, she's easily replicable. The only snag is cash runway remains H2 2026. Definitely one to revisit once funding overhang sorted.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.967116+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261012-Tii21-78691522",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750535",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "2 million delayed buy, and yet this is at 0%!! 05-Feb-26\t08:03:33\t0.79\t2,000,000\tUnknown*\t0.70\t0.75\t15.80k\tO",
          "sentiment": 0.0,
          "engagement": "457",
          "price_at_post": "0.725",
          "thread_title": "RE: Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-09T22:04:51.967156+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261012-Isthisaw--3926913",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750934",
        "source": "LSE_CHAT",
        "data": {
          "author": "Isthisawinner",
          "content": "Surprised the sp isn't following..",
          "sentiment": 0.0,
          "engagement": "2,301",
          "price_at_post": "0.725",
          "thread_title": "Finally,  gathering momentum...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=B49C9293-BB7B-4427-862D-3D342002FA5A"
        },
        "ingested_at": "2026-02-09T22:04:51.967194+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261006-Mikemine-80674162",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.751372",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Come on FT, give Barrington some credit. She has an accountancy background which would give her a less than gung-ho approach to reporting. They missed a rather ambitious sales target by not much which is good going in my book. For a \"modest\" report her predictions for 2026 are very confident with \"strong\" growth and are significant. For a CEO running a tiny company on a shoe string with small workforce, she is doing well I reckon. Additions to staff last year were all geared to sales so i would expect them to have reached an inflection point. As for the BCBS agreement, what can you say but \"Well done\". That's going to open more doors for the sales force to walk through. I'd imagine there's a good buzz throughout the company at the moment. They must have worked hard for the last 3-4 years with not much in the way is acceptance to show for it but, starting with Fisher, the ball is rolling. Very positive for 26 iIMHO.",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.967231+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261001-Hawker-72319089",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.751787",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Agree, this is an encouraging update. Given the limited resources and tightly managed cost base, Verici could well be on the up this year.  It should only take a doubling or so of the now current testing volumes to put them on the front foot. Keep up the good work Sara and team, go forth and ramp Tutivia and PTRA with Thermo.",
          "sentiment": 0.5,
          "engagement": "301",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-09T22:04:51.967269+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260955-Guly-61099662",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.752384",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Accumulating a position here, can see massive potential.Can't believe it's so cheap.",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-09T22:04:51.967306+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260911-Silverbl--4800051",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.752953",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "On a positive note at least company has provided a FY update with a relatively small target miss, revenue is growing with new partnerships coming on stream and cash is ok for now. Against that - tests sales in H2 were less than H1 (591 v 582) which is concern - why no growth in actual testing volumes. What I can't reconcile is the Tutivia revenue for H1 was $1.2m for 591 tests ($1962 per test); and in H2 Tutivia revenue was $1.8m ($3092 per test). This just doesn't add up imo. Unless there is deferred income from H1 coming into H2 receivables. I think note 1 in the update is attempting to clarify the issue - but the language on revenue estimates being used rather than actual revenue are a bit concerning. Actual audited accounts will be more revealing and may differ from these unaudited updates. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-09T22:04:51.967345+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260855-blowdog-17521561",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.753557",
        "source": "LSE_CHAT",
        "data": {
          "author": "blowdog",
          "content": "Https://x.com/CapitalPmh/status/2019323726446158330?s=20",
          "sentiment": 0.0,
          "engagement": "933",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-09T22:04:51.967382+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260852-newgrang-54498184",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.754153",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "L2 buy orders looking strong \ud83d\udcaa",
          "sentiment": 0.0,
          "engagement": "2,116",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-09T22:04:51.967421+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260843-newgrang--5441639",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.754739",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "Good update with revenues and licensing contract. Hugely undervalued.",
          "sentiment": 0.0,
          "engagement": "2,116",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-09T22:04:51.967461+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260839-Fevertre-15849098",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.755335",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "SOP for disappointing update to put out commercial RNS alongside (Blue Cross deal looks encouraging) to soften the blow. Barrington is t up to the job- didn\u2019t hit the numbers; a less than confident statement , and why on God\u2019s Green Earth are they saying Dec FY25 will come out in May!! This is a tiny business with minimal revenues and yet Barrington can\u2019t commit to releasing results in a timely fashion. Suspect because every Q they have a wrangle with accountants about revenue timing and recognition. Be good to see sustained progress but after screwing up the cash raise, which cratered the so Barrington still has to prove she is CEO material.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.967500+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260824-bigpunt--8911270",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.755905",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Hitting revenue and cash targets, adding major commercial tie-up, can't ask for much more as the company commercialise.  They've had a cracking year and I like the modest tone",
          "sentiment": 0.0,
          "engagement": "360",
          "price_at_post": "0.775",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-09T22:04:51.967537+00:00"
      },
      {
        "event_id": "SOCIAL-Today1742-Mikemine-70319521",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885051",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, you are clearly angry with VRCI, especially Barrington, so it begs the obvious question \"Why are still here and presumably invested in the company?\" I'm sure most of us have felt let down and financially hurt by companies and BODs in the past but have taken the hit and moved on. Why haven't you?",
          "sentiment": 0.0,
          "engagement": "1,236",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.967575+00:00"
      },
      {
        "event_id": "SOCIAL-Today1656-Fevertre-53505120",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "If cash burn is an issue then perhaps Sara Barrington should take a bloody pay cut",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.967613+00:00"
      },
      {
        "event_id": "SOCIAL-Today1654-Fevertre--6591037",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "barrington is the the issue (along with the board). after the disastrously botched raise that almost sank the company but not barrington because she got regranted her share options (not something s/holders were able to do)... her attitude to her shareholders is woeful - she didnt apologise for her gigantic ****-up that cratered the sp. meantime the growth figs look dodgy and she continues to burn thro cash at a rate.... fy 25 1,173 tutivia tests orders = $3m revs = $2557 per test, and yet at 1h figs of 591 tests = $1.16m = $1962 per test, so 30% uplift based on 2h figs. - on face of it that's a great result right? but where is the explanation/reconciliation, and if there is that much volatility barrington how can your investors/analyst properly model outcomes (let alone the company)? then what about momentum that she was saying was happening: october update - barrington told us \" volume growth from this progress is expected from q4 and the number of orders in q3 were consistent with the previous two quarters. 1h 591 so  averages q1 295 q2 295. q3 c300....so based on barrington's comment an uplift was due in q4...and yet: q$ sales below q1, 2,3..and 2h below 1h.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-09T22:04:51.967651+00:00"
      },
      {
        "event_id": "SOCIAL-Today1628-tbcx-80252036",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.886494",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is the company that reiterated cash runway until H2 2026 in today's update. That is them letting you know now funding will be required this year sometime from July onwards.",
          "sentiment": 0.0,
          "engagement": "801",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.967689+00:00"
      },
      {
        "event_id": "SOCIAL-Today1516-stockyhe-68767662",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.887017",
        "source": "LSE_CHAT",
        "data": {
          "author": "stockyheathlad",
          "content": "In a business like this, historic cashflow isn't necessarily a guide to the future. Expenditure on setting up new centres will be variable and, to a degree, discretionary.  The income stream grew across the year so the last quarter's figures are most relevant, rather than the whole year's.",
          "sentiment": 0.0,
          "engagement": "19",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.967727+00:00"
      },
      {
        "event_id": "SOCIAL-Today1419-2Phones-86405101",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.887553",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "SB - thanks for that.  They said at the time of the fundraising (as @ 31/05/25) they had a cash runway to the end of July 2025.  And subsequently they have burned that cash ($8.6m?) in the remaining 5-6 months of 2025 down to $3.3m, so $10m breakeven makes sense.  Obviously as they get closer to that breakeven point the cash burn reduces - the question is, with all the sales activity, how quickly can they reach that point, and how many further funding rounds we'll see.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.967765+00:00"
      },
      {
        "event_id": "SOCIAL-Today1333-Silverbl--1390888",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.888058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Cash burns remains significant - company raised \u00a36.35m during the year - which added to the $800k difference in year end balances show the level of cash required to support the losses incurred over the last 12 months. Breakeven is predicted at $10m revenue pa. SB",
          "sentiment": 0.0,
          "engagement": "1,925",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.967801+00:00"
      },
      {
        "event_id": "SOCIAL-Today1236-Guly-19972846",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.888582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Cash runway atleast 2 yrs assuming current run rate without additional contract wins",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.967838+00:00"
      },
      {
        "event_id": "SOCIAL-Today1117-2Phones-45890384",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.889106",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I agree that the guidance of cash for H2 appears disappointing, however if you take the cash burn over the last 12 months \u2013 the cash reduced from $4.1m to $3.3, which implies a burn rate of $800k per annum.  Now there are many things that impact these numbers but this set against the backdrop of ever-increasing revenue and sales orders/opportunities.  H2 may be a little pessimistic.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.967876+00:00"
      },
      {
        "event_id": "SOCIAL-Today1022-tbcx--1993932",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.889622",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Great product and credit to them for being revenue generating, way ahead of many other biotechs valued higher. Suspect there is a management discount at play here for habitually missing guidance, which can be overcome, she's easily replicable. The only snag is cash runway remains H2 2026. Definitely one to revisit once funding overhang sorted.",
          "sentiment": 0.0,
          "engagement": "801",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.967913+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Tii21-78691522",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.890160",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "2 million delayed buy, and yet this is at 0%!! 05-Feb-26\t08:03:33\t0.79\t2,000,000\tUnknown*\t0.70\t0.75\t15.80k\tO",
          "sentiment": 0.0,
          "engagement": "457",
          "price_at_post": "0.725",
          "thread_title": "RE: Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-09T22:04:51.967951+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Isthisaw--3926913",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.890667",
        "source": "LSE_CHAT",
        "data": {
          "author": "Isthisawinner",
          "content": "Surprised the sp isn't following..",
          "sentiment": 0.0,
          "engagement": "2,301",
          "price_at_post": "0.725",
          "thread_title": "Finally,  gathering momentum...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=B49C9293-BB7B-4427-862D-3D342002FA5A"
        },
        "ingested_at": "2026-02-09T22:04:51.967990+00:00"
      },
      {
        "event_id": "SOCIAL-Today1006-Mikemine-80674162",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.891178",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Come on FT, give Barrington some credit. She has an accountancy background which would give her a less than gung-ho approach to reporting. They missed a rather ambitious sales target by not much which is good going in my book. For a \"modest\" report her predictions for 2026 are very confident with \"strong\" growth and are significant. For a CEO running a tiny company on a shoe string with small workforce, she is doing well I reckon. Additions to staff last year were all geared to sales so i would expect them to have reached an inflection point. As for the BCBS agreement, what can you say but \"Well done\". That's going to open more doors for the sales force to walk through. I'd imagine there's a good buzz throughout the company at the moment. They must have worked hard for the last 3-4 years with not much in the way is acceptance to show for it but, starting with Fisher, the ball is rolling. Very positive for 26 iIMHO.",
          "sentiment": 0.0,
          "engagement": "1,236",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.968028+00:00"
      },
      {
        "event_id": "SOCIAL-Today1001-Hawker-72319089",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.891629",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Agree, this is an encouraging update. Given the limited resources and tightly managed cost base, Verici could well be on the up this year.  It should only take a doubling or so of the now current testing volumes to put them on the front foot. Keep up the good work Sara and team, go forth and ramp Tutivia and PTRA with Thermo.",
          "sentiment": 0.5,
          "engagement": "301",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-09T22:04:51.968065+00:00"
      },
      {
        "event_id": "SOCIAL-Today0955-Guly-61099662",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.892184",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Accumulating a position here, can see massive potential.Can't believe it's so cheap.",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-09T22:04:51.968121+00:00"
      },
      {
        "event_id": "SOCIAL-Today0911-Silverbl--4800051",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.892711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "On a positive note at least company has provided a FY update with a relatively small target miss, revenue is growing with new partnerships coming on stream and cash is ok for now. Against that - tests sales in H2 were less than H1 (591 v 582) which is concern - why no growth in actual testing volumes. What I can't reconcile is the Tutivia revenue for H1 was $1.2m for 591 tests ($1962 per test); and in H2 Tutivia revenue was $1.8m ($3092 per test). This just doesn't add up imo. Unless there is deferred income from H1 coming into H2 receivables. I think note 1 in the update is attempting to clarify the issue - but the language on revenue estimates being used rather than actual revenue are a bit concerning. Actual audited accounts will be more revealing and may differ from these unaudited updates. SB",
          "sentiment": 0.0,
          "engagement": "1,925",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-09T22:04:51.968162+00:00"
      },
      {
        "event_id": "SOCIAL-Today0855-blowdog-17521561",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.893229",
        "source": "LSE_CHAT",
        "data": {
          "author": "blowdog",
          "content": "Https://x.com/CapitalPmh/status/2019323726446158330?s=20",
          "sentiment": 0.0,
          "engagement": "929",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-09T22:04:51.968200+00:00"
      },
      {
        "event_id": "SOCIAL-Today0852-newgrang-54498184",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.893738",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "L2 buy orders looking strong \ud83d\udcaa",
          "sentiment": 0.0,
          "engagement": "2,114",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-09T22:04:51.968238+00:00"
      },
      {
        "event_id": "SOCIAL-Today0843-newgrang--5441639",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.894260",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "Good update with revenues and licensing contract. Hugely undervalued.",
          "sentiment": 0.0,
          "engagement": "2,114",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-09T22:04:51.968275+00:00"
      },
      {
        "event_id": "SOCIAL-Today0839-Fevertre-15849098",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.894756",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "SOP for disappointing update to put out commercial RNS alongside (Blue Cross deal looks encouraging) to soften the blow. Barrington is t up to the job- didn\u2019t hit the numbers; a less than confident statement , and why on God\u2019s Green Earth are they saying Dec FY25 will come out in May!! This is a tiny business with minimal revenues and yet Barrington can\u2019t commit to releasing results in a timely fashion. Suspect because every Q they have a wrangle with accountants about revenue timing and recognition. Be good to see sustained progress but after screwing up the cash raise, which cratered the so Barrington still has to prove she is CEO material.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-09T22:04:51.968313+00:00"
      },
      {
        "event_id": "SOCIAL-Today0824-bigpunt--8911270",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.895246",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Hitting revenue and cash targets, adding major commercial tie-up, can't ask for much more as the company commercialise.  They've had a cracking year and I like the modest tone",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "0.775",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-09T22:04:51.968350+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260854-2Phones-65303387",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.895745",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "the site is *************interviews dot com",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968388+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260852-2Phones--6050251",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.896268",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "hi splodge2001 https://www. ***************************/verici-dx-landmark-deal-unlocks-potential-300-million-tutivia-market-singer-research-icymi/4121236201",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968426+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261732-Splodge2-79992937",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.896762",
        "source": "LSE_CHAT",
        "data": {
          "author": "Splodge2001",
          "content": "Does anyone have a link to the Singer note? I couldn't find it on their website.",
          "sentiment": 0.0,
          "engagement": "114",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968463+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260851-2Phones--4118095",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.897267",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac101 - I was particularly encouraged by the 2.9p target price.  They clearly believe the future for tutivia is massive.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968500+00:00"
      },
      {
        "event_id": "SOCIAL-Today0851-2Phones--4118095",
        "event_type": "social_post",
        "date": "2026-01-30T23:03:22.957691",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac101 - I was particularly encouraged by the 2.9p target price.  They clearly believe the future for tutivia is massive.",
          "sentiment": 0.0,
          "engagement": "83",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968539+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261447-donmac10-86190348",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:31.826472",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Very good research note out last few day by Singer .Talking up Prime health deal 300 mill mkt.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968575+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251243-Romanby--4491009",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.788345",
        "source": "LSE_CHAT",
        "data": {
          "author": "Romanby",
          "content": "No placing you idiot",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-09T22:04:51.968612+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251216-Sandyman--1621827",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "Is the placing going to be at 0.25p or 0.5p? Or both?",
          "sentiment": 0.0,
          "engagement": "999",
          "price_at_post": "0.775",
          "thread_title": "Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-09T22:04:51.968651+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251441-Silverbl-82638266",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - FYI Thermo Fisher are not currently involved in Tutivia - so they are not involved in any roll out. Despite claims here to the contrary there has been no trading update - so we await evidence that Q4 delivers the level of sales anticipated by the CEO on achieving the 2025 Tutivia revenue target - which as you note would be a significant increase on 2024 sales. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968689+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251547-B_Positi-73604544",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.790830",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968725+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-B_Positi-87081212",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.791703",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I would wager a big Thermo-Fisher update is due here. Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968763+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251302-B_Positi--7252627",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.792503",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Wow now way just saw that. Huge implications for Thermo and its partners!",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968802+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251255-donmac10--1977548",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.793297",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Genincode signed a deal with Thermo read across to Verici Verici so undervalued at the moment something has to give.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968839+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251244-B_Positi--1457868",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794085",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Once it breaks 1p it will fly to 2p and then 3p gets smashed with ease considering the test orders are going to be around 300-400% from the digging below. 3p as a base and then a move back to 5-10p.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968878+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251227-B_Positi-64904568",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794962",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I'm personally amazed more aren't piling in whilst under 1p and this isn't at 3-5p already. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968918+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251953-B_Positi--8676583",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.795766",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Will add another 2m sub 1p Way too cheap here for me personally.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968957+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251945-donmac10--5368468",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.796575",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "3p per share nailed on short term if you guys sit oan yer tuffetts like miss muffet know whit ah mean?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.968994+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251941-donmac10-85318278",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.797364",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Company is no longer research orientated so past rns at this time of year irrelevant trust me as tests ramp up as they will be the company will be eager to broadcast positive newsflow asap.noh whit a meen an that man getmeh!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.969033+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251535-Silverbl--3052690",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798154",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Would be unusual for a trading update pre-xmas imo although any kind of an update in relation to hitting revenue targets would assist progress here - the bar has been set very high by CEO. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.969070+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251320-B_Positi--5964133",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798939",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Yes it was due. Thermo-Fisher $220BILLION backing this and tied in. Update on them or something new will wake the market up.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.969134+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251245-donmac10--6545849",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.799717",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Update this week and more deals with distributors .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.969172+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251234-B_Positi--2560626",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.800588",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "MMs caught wind of an update? I'm amazed this isn't over 2p at least. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.969210+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251230-tbcx-32697338",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.801373",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Buying pressure certainly returning this week, this remains extremely undervalued.",
          "sentiment": 0.0,
          "engagement": "766",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.969248+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251443-donmac10-90779128",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802148",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Nice 2mill buy this morning.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.969286+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251235-B_Positi--4937287",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802905",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Donmac, absolutely buzzing for the trading update this month Hopefully see's this head back to the 3 to 5p level",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.969323+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251104-B_Positi-35334326",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.803727",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "So with less than 10% of transplant centres onboarded and already at the start of the mass rollout they averaged about 300 tests per quarter in Q1, Q2 and Q3, just short of 900, vs 334 for the entirety of 2024, representng significant growth. We now know they are at at least 16% of transplant centres onboarded now (less than 10% for Q1, Q2, Q2, perhaps around 20% now and are increasing this fast. You quickly realise how mad the revenues can become here at $2,650 a test with the medicaid coverage +Thermo Fisher licencing revenues. I know many, many pharma stocks that have literally $0 revenue, no proven tech, no FDA approval, no big deal with a giant like this does with Thermo Fisher that are trading at many multiples of the Verici market cap.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.969361+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251045-donmac10--1146549",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.804510",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And its beginning to look like word is out?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.969399+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251039-donmac10-15167354",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.805293",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Expecting a trading update in the run up to xmas should make for good reading!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.969436+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251031-B_Positi-51667994",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806132",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.969475+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251456-Mikemine--1594817",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806901",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, your posts have got  very repetitive and quite frankly, boring. Unless your rants help your mental state I for one would be grateful if you would keep your posts to new views or information.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-09T22:04:51.969513+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251148-Fevertre--8265088",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.375637",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Just out of interest what are Barrington's competencies?",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-09T22:04:51.969552+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251147-Fevertre--4042307",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.376396",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "The Board and non-execs have overseen an absolute shamble here. Barrington completely unaffected by disastrous dilution as she has virtually no bloody shares in teh company she purports to lead.  The CFo isnt fit for purpose frankly. The Q4 figs appear to be the stuff of fantasy - I would give more creedance if  Barrington was able to explain how she gets to the forecast but she appears to be just making it up as she goes along... we have no timelines on onboarding; Barrington cant set out how she arrived at the numbers... she continues to be utterly hopeless as the CEO of supposedly a cutting edge business.",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-09T22:04:51.969588+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251059-Silverbl--4631917",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377214",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There you go donmac almost at your buy price already. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-09T22:04:51.969627+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20250050-donmac10--7466255",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377985",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sell up move on thank you.....give me the chance ar more aroon the 55 mark slanj .And a will catch yeh in wetherspoons oan the wae otta rah ritz.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-09T22:04:51.969664+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251734-Mikemine-41742154",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.378810",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "VRCI is a small company so hiring an extra 3 salespersons is huge for them and points to their determination to hit their target. It's a big ask but you can be sure they recognise that their credibility is on the line. From a practical point of view, hiring new salespeople  takes time for their impact to come through. They have to get used of the systems, the product and VRCI's method of selling. I wish them luck and, if they do reach their target, it will be noticed by the Market.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-09T22:04:51.969701+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251709-Silverbl-35353423",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.379608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not a fan to date either fevertree - its been a disaster for all shareholders here - but I still hold a position here and am trying to look forward not back given the past is what it is. If Q4 goes well I expect a trading update early 2026 - which doesn't usually happen but positive momentum will be required to avoid a total wipe out in any subsequent capital raise. Failure to deliver (again) then more questions will be raised on leadership competencies.  SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.75",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-09T22:04:51.969740+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251647-Fevertre--5954081",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.380414",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "She has never fully explained the onboarding process. If a new centre gets onboarded, typically how long does it take for clinicians to order first tests",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-09T22:04:51.969779+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251644-Fevertre-15213459",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.381220",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Nonsense Donmac.....look at the maths around Barrington's targets: On my maths I don't see how she hits revs from Tutivia $3.2m... Tutivia:  1H Revs: $1.16m: 591 tests @ ave $1900 ($1.16m divided by 591) 2H Revs:  3Q Tutivia same rate as Q1/Q2 ..c300 tests at 1900 = $570k  ...so to meet her target she needs to sell c$1.5m of tests. Assume same ave price of $1900....she needs to sell c790 tests....that's a massive uplift, even with onboarding another 9 more centres...",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-09T22:04:51.969818+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251627-donmac10--5292904",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382010",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "markets falling and the doom and gloom ****roaches appear in force.sell up ,thats even if yeh hod any and gie us aw peace!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-09T22:04:51.969855+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251604-Fevertre-64389985",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382802",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Worryingly her bullishness has cost investors dearly so far. Apart from having virtually no skin in the game she hasn't been gifted,  or regifted (look at the outrageous revision of option pricing). The fact that the sp is still at 3/4 of a penny tells you everything you need to know about how the market views her!",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-09T22:04:51.969894+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251522-Silverbl--7344155",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.383604",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Based on what we already know - VRCI sold c.600 Tutivia tests in H1 2025 - securing revenue of $1.2m ($2k per test - blend of public and private payers). They sold same in Q3 - so lets assume pro-rata they secured a further $600k revenue. Sara B confirmed FY Tutivia target was $3.2m - so that leaves $1.4 revenue to be secured in Q4 - or c.700 tests at $2k. Seems a huge leap - or possible they are looking at a slight increase to average test $ - although Prime Health RNS appears to push towards discounted volume in private market. She has certainly set high expectations for Q4 trading. If this is achieved it will be a significant acceleration - and will be crucial in supporting the share price/market cap as the company requires additional funding in the next 4/5 months. Additional licensing revenue from Thermo (c.$4m received to date - $3.3m in 2024 and $0.75m in 2025) remains on hold as they progress their approach to the PTRA test. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.725",
          "thread_title": "2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-09T22:04:51.969932+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250856-2Phones-19802845",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.384401",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac agreed - two of the latest RNS are very positive about the rate of revenue growth and market penetration - can't help but think the next sales based RNS will be a gamechanger.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.875",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-09T22:04:51.969969+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250845-donmac10--4986481",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385202",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Analysts expecting 3p per share next year big upside from here.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.90",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-09T22:04:51.970006+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250843-donmac10-74479484",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385990",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Verici also more forthcoming informing the market with updates .Beats last years 6 month radio silence .Just waiting now for testing update which i know will further boost price.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-09T22:04:51.970043+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250830-donmac10-71749427",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.386775",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Tells me ,anyone looking to make money would be well served to get in now .Futher big rise going into year end.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.95",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-09T22:04:51.970080+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250809-2Phones-56585012",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.387576",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Interesting news today \u2013 initially I thought why? This has little bearing on shareholders interests \u2013 however, on further concideration, while successful audits add little to the bottom line or turnover or even shareholder value \u2013 in our case it is very much a Critical Failure Factor, where failure to pass a quality audit could seriously damage the company in the short/medium term.  Also it does point to a well run, disciplined business. So well done Verici.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.95",
          "thread_title": "RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-09T22:04:51.970162+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251448-oogleflu-76470405",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.388340",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Tom. I know exactly what you\u2019re saying is correct . Unfortunately risk appetite is much lower in the UK probably because the FA are like a bunch of frightened rabbits. Fund managers continue to unwind oversold positions in uk to chase  the way overpriced \u2018American dream stocks\u2019 which are overdue a big correction there by loosing even more of the inadequate fund managers clients money. It\u2019s not all Uk stocks but quite a few as admitted in an interview recently with a fund manager. Certainly since the pandemic Uk stocks are valued much more realistically i.e. sound balance sheet which Vrci  now has, realistic forecast which Vrci now has, realistic targets for growth which Vrci now has. But we don\u2019t tend to look further than a year ahead. One step at a time . There will be /is FOMO with a stock like Vrci which will cause some volatility till they establish a more constant earnings stream.",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970201+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251354-donmac10-30821086",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389131",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "It feels to me we are about to get a trading update on testing numbers shortly .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970239+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251256-donmac10-20612023",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389888",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "1.20p close today and more updates in coming days on quickly to 2.00p",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970277+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251247-geraldus--3951502",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.390653",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "Still early days here,and they will have to take some market share from the incumbent bio markers. Shaping up well so far and with a miserly market cap in comparison with other counters.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.825",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970316+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251241-B_Positi--7458782",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.391431",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Geraldus Tutivia is the standard now. Hence why Thermo-Fisher has gone all in and is backing all the way. Market slowly beginning to wake up that this company is grossly undervalued. I mean the FDA approval, ip, tech alone is worth multiples and then whack on the huge growth already in 2025 and coming in 2026 with over 30 transplant centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970353+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251239-donmac10--2091368",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392203",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "American market waking up to the potential with Verici dx in their own backyard They love an AI stock.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970392+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251236-geraldus-40572052",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392989",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "With their 'AI' solution for optimising transplants,it is undoubtly an interesting opportunity here. They have spent millions on this and they are confident that it is payback time. With no competition at this level,it could possibly become the defacto standard.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970429+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251217-B_Positi-51667994",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.393835",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970466+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251205-oogleflu-81294470",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.394621",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Addressable market doesn\u2019t mean they capture all of it.  They might get 1 or 2 percent which is still sizeable if lucky. Even singer, their broker,  have only raised the sp to 3p. That\u2019s still 4 times current market cap! The other thing is will they need to expand the lab or open another one as their market share increases. They have got a captured market in that there is no competition and the tests are becoming mandatory. No plans to adopt outside the US yet. Maybe 20p in 5 years certainly not months I\u2019m afraid but good luck",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.775",
          "thread_title": "RE: Quantifying the opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=D3DE9F2B-871D-47DE-96C8-2D6BB08D16A4"
        },
        "ingested_at": "2026-02-09T22:04:51.970503+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261715-Silverbl--4190012",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - feel free to use the actual numbers in your updates. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 (INCORRECT: H1 actual revenue was $1.16m = $1962 average revenue per test). H1 2025 licencing revenue = $750,000 (CORRECT) Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. (Test numbers CORRECT. Centres INCORRECT - there were 21 onboarded at time of results). 286 x $2,650 = $757,900 (Likely INCORRECT based on average revenue per test of $1962 achieved in H1 2025 - likely revenue $560K). Q4 2025, 20 centres onboarded and let's be conservative and say 300 tests. (INCORRECT. There are now 30 centres onboarded. Company is targeting in the region of 750 tests in Q4 in order to meet its Q4 revenue target of c.$1.5m) 300 x $2,650 = $795,000 revenue (We will find out in due course what was achieved in terms of test numbers and average revenue per test) H2 2025 licensing revenue, let's be conservative and say $500,000. (INCORRECT. No licencing revenue will come from Thermo in H2) Combine all of that above and you get = $4.3mil or \u00a33.2m. (H1 revenue was $1.9m/ Q3 likely $560K. Q4 not yet reported. Company is targeting total FY 2025 revenue of $3.95m, comprising $3.2 Tutivia tests and $750K licencing revenue) Still nothing in the way of a trading update from the team at vrci. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970542+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261504-B_Positi-10286798",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332720",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We should all be extremely excited having now onboarded over 30 transplant centres, up from 10 in 2024. We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970582+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260830-Silverbl-85125239",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333151",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "$12m was a direct quote from Vrci CEO in latest Vox markets interview. As for my 'precise' figures - strangely enough when it comes to investing I prefer to deal in fact rather than making it up (refer B_Positive). As for my views on the business - I remain invested so I am hopeful there is a future here or would have taken my medicine and moved on. That does not mean to say I will not vocalise my thoughts on areas of mismanagement where the company could and should be doing better; or to call out posters who are just making it up as they go along. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970618+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260728-B_Positi--7500166",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333626",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970656+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260205-donmac10--7593133",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334054",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Where do you get the 12mill breakeven point? You sound like a bot with your precise figures. And you always have a way of sounding positive but are really negative .So cant be taken seriously .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970694+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262026-Silverbl--5112965",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334501",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not really sure why I need to explain this, but here you go B_Positive. Your bullet point regarding Tutivia sums the position up very well. Transplant centres service both Medicare patients and private paying patients. So whilst the Medicare payment of $2650 is being provided by the US healthcare system for patients who benefit from the Medicare and Medicare plus programmes - there are actually six key revenue streams for test sales of which Medicare is one (albeit the largest - 68% of tests being undertaken are covered by Medicare seems to be the claim from the company). Private payers (via healthcare insurance) do not pay the $2650 - they receive discounts. Clinical trials pay nothing. And there others. If you divide the H1 Tutivia revenue of $1.16m by the 591 tests in H1 it comes out at $1962 . That is the current revenue reality for test sales. The recent RNS highlighting the agreement with Prime Health Services is all about trying to establish consistent pricing of the Tutivia test with the private payment market and clearly with the goal to increase current pricing which is diluting the Medicare $2650. In relation to your H2 licencing point the following clarifies the position \" Thermo Fisher is investing in new research related to PTRA aimed at identifying the earliest stage at which the test can be utilised before transplantation. Consequently, the second milestone originally anticipated for 2025 will be delayed as we continue to collaborate on publishing clinical validation data and Thermo Fisher pursues these additional research efforts to help broaden utility and adoption of the assay.\" FYI the breakeven position for Verici is c.$12m - so that provides an indication of the revenue which is required from test sales, licence revenue, protega etc to cover vrci operating costs. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970732+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261524-B_Positi-49109430",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334932",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Nope it's $2,650 as per the Medicare coverage RNS and more recently as per the HY report. \u00b7 Lead product Tutivia\u2122 attained Medicare coverage at $2,650 per test, covering a national estimate of 68% of all US transplant tests and commercial payor reimbursement applications are underway They receive licencing revenues both H1 and H2. It was $750k in H1.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970770+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261523-Silverbl--3027215",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335360",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Mikemine -  your points are valid - but highlight one of the main issues here. Why set a target and fail. Undermines confidence, craters the share price, makes fund raising tricky and makes investors wary on growth. Much better to overdeliver on achievable targets than underdeliver? But maybe we will be get a pleasant surprise. Thermo are just doing their own thing on the PRTA at present. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970809+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261518-Silverbl-63815549",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335771",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "No licencing revenue in H2 2025 and average received revenue per test is $1900. Do some actual research please. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970846+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261416-B_Positi-27725845",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336264",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10 centres onboarded. It must now be around 25-35 going by the last report.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970883+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261402-Mikemine-76665453",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336713",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "They've set themselves a big revenue target of over \u00a33mn for 2025. Small in world terms but a big % increase for VRCI. Should they be chastised if they do not reach the target or should it be viewed in the context of what they do achieve and what they forecast for this year? Getting close to \u00a33mn would be an achievement in my book as that would point to things being on track for further increases especially as the new sales guys have probably only just got their acts together and their contacts in line. Not sure what to think of the Thermo-Fisher deal and its seemingly lack of traction. Big companies are not nimble nor quick so the jury's out on that one for me. My guess is for an update this month and it will be positive but will not please everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970921+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261401-B_Positi-52176544",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337193",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Cashed up until the end of 2026 and now they've been securing record orders as per below. Next time they raise it will be in the pennies, which is what they will want given the new option prices. Test update going to drop soon. More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.970960+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261346-Silverbl--8917670",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Despite the view expressed by several contributors here we have heard nothing from the business on Q4 trading. Not unexpected - if there was anything to report on I would expect to hear later on in January. The issue looming very shortly relates to the required fund raising. In previous years the company has elected not to divulge FY trading until May.  This is likely to be beyond the point at which the company runs out of cash. We should therefore be able to read the signals loud and clear - no trading update - then Q4 has not delivered the targeted sales and the fund raise will be brutal.  If a positive Q4 trading update is issued then there should be a healthy price response despite the recognition funds will still be required. Remember last year the first fundraise was at 9p - then 0.5p after bewildering timing mismanagement by the company.  All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: 100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-02-09T22:04:51.970998+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261228-B_Positi-64716113",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338063",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.971036+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-2reincar-50376964",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338488",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Conversions this summer will see us at sub 0.25p!",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.75",
          "thread_title": "100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-02-09T22:04:51.971075+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261210-B_Positi-95075586",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338938",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.971123+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20260629-2Phones--1318655",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339362",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "How can any one disagree with such a cogent arguement - and clearly not the rantings of a one track numpty.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.725",
          "thread_title": "RE: Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-02-09T22:04:51.971161+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261022-2reincar-21469310",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339773",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "At 0.25p?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.725",
          "thread_title": "Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-02-09T22:04:51.971199+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251515-B_Positi-95075586",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340229",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.971238+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251223-Silverbl--5927575",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "2Phones - from the company itself: \" With minimum gross proceeds from the Placing and Subscription of \u00a35 million, the Company's cash runway will be extended to mid Q2 2026.\". Hence my thinking spring will be the time to raise. And yes revenue is expected to increase (we will know by how much in a few weeks) - but annual expenses are c.$9m - so sales would need a dramatic (and unlikely) increase to negate the need for more funds. And you seem to agree that a placing is an option (imo the only likely one and the route the company has taken to date in all its efforts to secure more funding). So not sure what you were disagreeing with? SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-09T22:04:51.971276+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20250753-2Phones--8933245",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341050",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I don't agree - the operational update earlier this year had a predicted cash runway to H2 next year - when you couple that with the recruitment of 2 sales people and a director of clinical partnerships, I would anticipate growth in cash inflow.  However, they are a small team and they are going to have to increase production to accommodate the anticipated sales.  This will need funding, but where they get it is uncertain \u2013 one option being a placing.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-09T22:04:51.971314+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251728-2reincar-41745177",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341472",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Agree Silverblade. We could have one in Aprilish at 0.5p and one in Octoberish at 0.25p and then a rocket to + 2p ?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-09T22:04:51.971352+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251618-Silverbl-20009974",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Same old nonsense B_Positive. Thermo are not involved in Tutivia. Stop spreading false information. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.971390+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251557-B_Positi-73604544",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342355",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-09T22:04:51.971427+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251522-Silverbl-82625592",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342765",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There will be a placing in early 2026 - probably March/April time. The placing will of course be determined by the prevailing share price at the time. And that in turn will reflect the numbers for FY 2025 - there is a lot of expectation here so lets see what the company has to say for itself hopefully with a trading update in January. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-09T22:04:51.971466+00:00"
      },
      {
        "event_id": "SOCIAL-Today1630-Fevertre-49450311",
        "event_type": "social_post",
        "date": "2026-02-10T22:00:07.219343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "The Vox video was very poor despite the Brummie actually for once being sensible in his questioning. He asked her to sum up the highlights:  cue dreadful Barrington woffle.  She seem sin capable of verbally bullet-pointing what went well and what didnt. Instead we get vague woffle and revealing commetns like her admission to the effect that they weren't going to make our revenue target but  chose to go with it anyway. So put out a number she know is unattainable to the market and then watch the share price subside when it isnt met...ffs!",
          "sentiment": 0.0,
          "engagement": "2,277",
          "price_at_post": "0.675",
          "thread_title": "RE: Verici DX: De-risked and ready for scale-up?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=BD2924C6-0E27-42A4-81F6-882D03F705EB"
        },
        "ingested_at": "2026-02-10T22:00:18.338520+00:00"
      },
      {
        "event_id": "SOCIAL-Today1514-Mikemine-68724553",
        "event_type": "social_post",
        "date": "2026-02-10T22:00:07.219802",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "https://www. ***************************/verici-dx-tutivia-set-to-disrupt-transplant-monitoring-with-real-time-rna-insights-video/4121239049 i just googled \"directors talks\" and there she was ready to give her interview. i've copied and pasted the link but i don't know what will happen when i post this message. i think this video is better that the one on vox which i thought was also good. for anybody new to vrci the info here is a must. it shows the journey getting here and just how valuable the tests are. it has been long and complicated road by the sounds of it. a lot of high level thinking has gone in to this. although the overall market is said to be $900 mn, they are going after $300 mn as being a more accessible portion. it's clear that last year was all about finding the best way to market after having done all sorts of validations. they were delayed by medicare not giving the green light until april but even so they almost reached a demanding sales target. i've no doubt sales will increase this year imho. as for funding, they flagged last year that they would come back for more money later this year so it shouldn't be a surprise but i expect institutions will be agreeable to providing more money which, as barrington said, will mainly go on boosting the sales and marketing force. anyone interested in vrci should really take the trouble to find this video. i'm very excited about vrci's future as you might guess so take no notice of me and  make your own mind up, it's your money.",
          "sentiment": 0.0,
          "engagement": "1,244",
          "price_at_post": "0.675",
          "thread_title": "RE: Verici DX: De-risked and ready for scale-up?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=BD2924C6-0E27-42A4-81F6-882D03F705EB"
        },
        "ingested_at": "2026-02-10T22:00:18.338552+00:00"
      },
      {
        "event_id": "SOCIAL-Today1431-Hawker--3678977",
        "event_type": "social_post",
        "date": "2026-02-10T22:00:07.220215",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "So looks like an auto-remove for web addresses.  Not sure if this will work, but you need to connect the words \"directors,\" \"talks,\" and \"interviews\" together to form the address. Oh, and add \".com\" after, lol.  They'll probs delete this too, lol.",
          "sentiment": 0.0,
          "engagement": "307",
          "price_at_post": "0.675",
          "thread_title": "RE: Verici DX: De-risked and ready for scale-up?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=BD2924C6-0E27-42A4-81F6-882D03F705EB"
        },
        "ingested_at": "2026-02-10T22:00:18.338573+00:00"
      },
      {
        "event_id": "SOCIAL-Today1419-Mikemine--2559486",
        "event_type": "social_post",
        "date": "2026-02-10T22:00:07.220620",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "I have idea what is happening but on my computer between the www. and/verici all I get are stars so I don't know what site to go to. Between the and  interviews it the same. Can you fill in the blanks?",
          "sentiment": 0.0,
          "engagement": "1,244",
          "price_at_post": "0.675",
          "thread_title": "RE: Verici DX: De-risked and ready for scale-up?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=BD2924C6-0E27-42A4-81F6-882D03F705EB"
        },
        "ingested_at": "2026-02-10T22:00:18.338606+00:00"
      },
      {
        "event_id": "SOCIAL-Today1404-Hawker--4692336",
        "event_type": "social_post",
        "date": "2026-02-10T22:00:07.221035",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "think this interview is well worth the listen, and adds to my view that it's probably wise to have a few verici tucked away in the back book. https://www. ***************************/verici-dx-tutivia-set-to-disrupt-transplant-monitoring-with-real-time-rna-insights-video/4121239049 it's on the *************interviews website. looks like the company is now very much focused on ramping sales and testing, exactly what we want them to be doing at this stage. dyor & gla.",
          "sentiment": 0.5,
          "engagement": "307",
          "price_at_post": "0.675",
          "thread_title": "Verici DX: De-risked and ready for scale-up?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=BD2924C6-0E27-42A4-81F6-882D03F705EB"
        },
        "ingested_at": "2026-02-10T22:00:18.338627+00:00"
      },
      {
        "event_id": "SOCIAL-Today1326-Hawker--4978934",
        "event_type": "social_post",
        "date": "2026-02-10T22:00:07.221459",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "I'm inclined to agree, Mikemine. I think Verici are now on a clear path to commercial success and is more likely to surprise positively from here.  There are also credible regulatory changes that could give Verici a tailwind, e.g., see this article, where the CMS are driving policy to increase the number of transplants whilst monitoring and looking to reduce the risk of rejection, something Verici is well placed to help with. https://www.rheumatologyadvisor.com/news/new-federal-plan-aims-to-use-more-donor-organs-improve-transplant-safety/ It would only take one material contract to completely transform Verici's outlook and risk profile, given the low valuation that only seems to be pricing more dilution. Risk/Reward here looks pretty good to me.",
          "sentiment": 0.5,
          "engagement": "307",
          "price_at_post": "0.675",
          "thread_title": "RE: Cash runway H2 2026 + further deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=A5597C3C-875E-437B-9DEF-C50802BE8B35"
        },
        "ingested_at": "2026-02-10T22:00:18.338659+00:00"
      },
      {
        "event_id": "SOCIAL-Today1315-Sandyman-25939515",
        "event_type": "social_post",
        "date": "2026-02-10T22:00:07.221858",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "Donmac, post your message again when the SPM hits 0.5p and ask yourself the question ''is the SP now likely to to to 0.25p or 1p''",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.675",
          "thread_title": "RE: No No No!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=8A240B4B-560F-4A07-8838-7DE94557E60C"
        },
        "ingested_at": "2026-02-10T22:00:18.338677+00:00"
      },
      {
        "event_id": "SOCIAL-Today1240-donmac10--5868571",
        "event_type": "social_post",
        "date": "2026-02-10T22:00:07.222263",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Randyman pis aff and annoy yer mami shes shoutin oan yeh",
          "sentiment": 0.0,
          "engagement": "2,883",
          "price_at_post": "0.675",
          "thread_title": "RE: No No No!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=8A240B4B-560F-4A07-8838-7DE94557E60C"
        },
        "ingested_at": "2026-02-10T22:00:18.338695+00:00"
      },
      {
        "event_id": "SOCIAL-Today1211-Sandyman-59295208",
        "event_type": "social_post",
        "date": "2026-02-10T22:00:07.222657",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "Will ''celebrate'' the first anniversary of the 0.5p placing, by having one at 0.25p!",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.675",
          "thread_title": "RE: No No No!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=8A240B4B-560F-4A07-8838-7DE94557E60C"
        },
        "ingested_at": "2026-02-10T22:00:18.338714+00:00"
      },
      {
        "event_id": "SOCIAL-Today1209-Sandyman--8197449",
        "event_type": "social_post",
        "date": "2026-02-10T22:00:07.223050",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "SP has a funny way of reacting does it not?",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.675",
          "thread_title": "RE: No No No!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=8A240B4B-560F-4A07-8838-7DE94557E60C"
        },
        "ingested_at": "2026-02-10T22:00:18.338732+00:00"
      },
      {
        "event_id": "SOCIAL-Today1209-Silverbl--4324978",
        "event_type": "social_post",
        "date": "2026-02-10T22:00:07.223453",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "That would explain the wave of selling today. SB",
          "sentiment": 0.0,
          "engagement": "1,927",
          "price_at_post": "0.675",
          "thread_title": "RE: No No No!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=8A240B4B-560F-4A07-8838-7DE94557E60C"
        },
        "ingested_at": "2026-02-10T22:00:18.338750+00:00"
      },
      {
        "event_id": "SOCIAL-Today1154-donmac10--8250371",
        "event_type": "social_post",
        "date": "2026-02-10T22:00:07.223848",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sarah on Directors Talk today giving more info on progress all systems go .This is Verici year!!!",
          "sentiment": 0.0,
          "engagement": "2,883",
          "price_at_post": "0.675",
          "thread_title": "RE: No No No!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=8A240B4B-560F-4A07-8838-7DE94557E60C"
        },
        "ingested_at": "2026-02-10T22:00:18.338768+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261501-Sandyman-79324360",
        "event_type": "social_post",
        "date": "2026-02-10T22:00:07.224251",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "This company is haemorrhaging money and there will be another cash call in the summer!",
          "sentiment": 0.0,
          "engagement": "1,066",
          "price_at_post": "0.725",
          "thread_title": "No No No!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=8A240B4B-560F-4A07-8838-7DE94557E60C"
        },
        "ingested_at": "2026-02-10T22:00:18.338787+00:00"
      },
      {
        "event_id": "SOCIAL-Today1501-Sandyman-79324360",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.077507",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "This company is haemorrhaging money and there will be another cash call in the summer!",
          "sentiment": 0.0,
          "engagement": "1,057",
          "price_at_post": "0.725",
          "thread_title": "No No No!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=8A240B4B-560F-4A07-8838-7DE94557E60C"
        },
        "ingested_at": "2026-02-10T22:00:18.338806+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261401-Mikemine-51486116",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.077931",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "From what Barrington said there are and will be much smaller deals which will not be subject to an RNS. The effect will be cumulative.  It all adds up to a company that has found a path to full commercialisation and is actively pursuing it.",
          "sentiment": 0.0,
          "engagement": "1,242",
          "price_at_post": "0.725",
          "thread_title": "RE: Cash runway H2 2026 + further deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=A5597C3C-875E-437B-9DEF-C50802BE8B35"
        },
        "ingested_at": "2026-02-10T22:00:18.338830+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261325-Guly--1132174",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.078374",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Unaudited cash at year-end of $3.3m (2024: $4.1m), which is slightly ahead of expectations, with $1.6m accounts receivable (2024: $Nil) which continues to support expected cash runway into H2 2026 as previously communicated. Should see a nice lift in anticpiation of further deals",
          "sentiment": 0.0,
          "engagement": "2,256",
          "price_at_post": "0.725",
          "thread_title": "Cash runway H2 2026 + further deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=A5597C3C-875E-437B-9DEF-C50802BE8B35"
        },
        "ingested_at": "2026-02-10T22:00:18.338851+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261047-geraldus--6801572",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.078776",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "...that is obviously required.Confident on this year,but the cash runway is possibly holding back the price.",
          "sentiment": 0.0,
          "engagement": "96",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.338869+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261044-geraldus--3393057",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.079200",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "Impressive interview on Vox.They have hit the floor running with a product t",
          "sentiment": 0.0,
          "engagement": "96",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.338887+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262340-donmac10-13310543",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.079608",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Really you guys should accentuate the positives and negate the negatives ....mmhh thats a good line for a song.!!",
          "sentiment": 0.0,
          "engagement": "2,881",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.338905+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261817-Mikemine--6903486",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.080007",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "One thing I'd forgotten was that they didn't get Medicare's approval until April and medicare pays for 70% of VRCI's revenue. I'm not surprised they missed their target. It looks like they would have easily reached their target if they had Medicare on board from January 1st.",
          "sentiment": 0.0,
          "engagement": "1,242",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.338923+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261808-Mikemine-82712229",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.080417",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "don't know why the link has got stars instead of ********** but i'm sure you can find it.",
          "sentiment": 0.0,
          "engagement": "1,242",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.338941+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261807-Mikemine--2532425",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.080820",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "https://www. **********.com/articles/q-a-with-verici-dx-ceo-sara-barrington-6e98b51",
          "sentiment": 0.0,
          "engagement": "1,242",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.338959+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261805-Mikemine-10594468",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.081236",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "barrington sounds confident and on top of it. lots of stuff in there that will enable us to more deeply understand the business and see where vrci is heading. not much about numbers but the obvious acceptance and use by the clinicians and insurers is evident. it really looks like this is going to be a good year for vrci https://www. **********.com/articles/q-a-with-verici-dx-ceo-sara-barrington-6e98b51",
          "sentiment": 0.0,
          "engagement": "1,242",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.338977+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261704-donmac10--1911352",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.081635",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sarah sounds very upbeat on Vox markets today..Stating this is Vericis year very positive.",
          "sentiment": 0.0,
          "engagement": "2,881",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.338996+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261557-bigpunt-83432888",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.082031",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Silverblade, a lot of whingeing about the past will not help your decision-making.  One should learn from previous investment decisions and appraise prospective investment decisions better!  Between now and raise will be the FY results and presentation and possibly a further update to support the raise.  Mkt cap and equity raise price will be determined entirely by those trading updates and credibility of updated forecasts",
          "sentiment": 0.0,
          "engagement": "361",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339014+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261544-Mikemine-18008751",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.082467",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "All decent points SB. Unfortunately VRCI is on AIM and AIM is almost dead in the water. I would venture that AIM is merely capturing the mood of the country which has been negative for some years now. People are so grumpy and lacking a positive disposition compared with what I see in the States, even with the Trump factor. I would venture that if VRCI was on Nasdaq its valuation would be around the $50-60 mn mark as the potential and demonstrated progress would be recognised as very positive by the Market there. Fortunately VRCI is operating in the States otherwise I wouldn't touch it with a bargepole because of how the NHS is run. You might have guessed that I think the company is well run and punching above its weight in a difficult field. It did get last years fundraiser wrong by announcing it's intention before securing funds but I reckon they've done well otherwise. What's for the future? The next 6 months are crucial but I believe that the \"strong\" sales increase flagged has a good chance of being achieved so the burn rate will reduce. They gave themselves an ambitious target last year which they nearly achieved and this indicates to me that they have a well thought out business model which includes a viable way of commercialising the product and this gives me some confidence is them performing strongly this year. As for a fund raise, their performance since the last one will give institutions lots of confidence to back them should they need one. I am not stupid enough to offer a prediction for the SP but, even on AIM, achieving this strong growth can't help but be positive in that direction. It's all my opinion of course and what do I know? There's always the possibility of a takeover of course but that's a speculative  game in which I am unable, and unwilling, to enter. Good luck for anybody that wishes to stay in the game.",
          "sentiment": 0.0,
          "engagement": "1,242",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339033+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261453-Silverbl-71439746",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.082867",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I can fully understand fevertrees anger and frustration here - it is likely representative of a large number of longer term shareholders. The grim reality is that whilst the latest update is encouraging in terms of revenue growth, the actions of the board last year in delaying the fund raise to the point it required a price of 0.5p to secure funding has created a position where the sheer number of shares in circulation render's the majority of investors trapped with little chance of recouping any investment made in the 2-5p range. Anything above that is gone.  Add to that a further capital raise in the next 4/6 months - and lets say they go for \u00a35m - which would require 1b further shares being issued at 0.5p. Nothing suggests the share price moving to any significant extent given the reaction to recent news. So then you have in the region of 2.5b shares - even assuming a share price of 1p, that's a \u00a325m market cap for a still loss making company. That in turn assumes the company is capable of doubling its revenue this year - which is possible - which also reduces the further risk (and scale) of a 2027 fund raise although this is still likely. I am invested here - and think the product is viable - but historic investors have been completely shafted. Even the company's own broker has an optimistic price less that 3p a share (don't get me wrong I would grab that in a heartbeat). The best outcome would be for an approach to take the business private or a pharma takeover at a decent premium to the current price. The alternative for shareholders is throwing more money during the fund raise to lower entry prices - which is a sobering thought. All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339051+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261428-bigpunt-30184062",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.083324",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Some very rough calcs.  c.90% of US population has medical insurance.  c.27,000 kidney transplants last year.  Assuming just one test per transplant, at unindexed $2,650 per test, the USA market-alone is worth $64m.  I'm also assuming the Tennessee lab can service the entire USA I'm not sure how many patients are represented by the 1,173 tests in 2025, and how many transplant centres vs the total in the USA, but the market penetration appears decent, considering the academic papers were only published 6 months ago Some may questions the relevance of academic papers and other KPIs may be more relevant, but it strikes me that the increase in number of clinicians and the increase in number of transplant centres will be strongly influenced by the academic articles and their subsequent peer reviews My view?  VRCI will get bought out when the USA nears profitability due to it's domestic market opportunity and the obvious globalisation opportunity.  Need to pay very close attention to what happens between now and next (and probably final) equity raise",
          "sentiment": 0.0,
          "engagement": "361",
          "price_at_post": "0.725",
          "thread_title": "Mid-term opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=755FC4E4-63EA-405E-A449-61BE41636EEA"
        },
        "ingested_at": "2026-02-10T22:00:18.339069+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260859-oogleflu-76700065",
        "event_type": "social_post",
        "date": "2026-02-09T22:04:43.083726",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "I thinks it\u2019s worth noting that Verici\u2019s year end was December. So whilst cash burn continues for another 6 months so does the pipeline growth and revenue. The Blue cross contract in Illinois is very significant as diversifying away from Medicare and becoming less dependant becomes more beneficial to clinicians and patients in not only in cost but also speed of treatment. Barrington hinted that these kind of contracts could spread across to other states. In an ever changing shift in Trumps one brain cell it must be pretty hard to predict or forecast anything in the US. What Vrci has demonstrated this year is the viability and commerciality is well in sight.",
          "sentiment": 0.0,
          "engagement": "5,476",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339087+00:00"
      },
      {
        "event_id": "SOCIAL-Today1817-Mikemine--6903486",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.630785",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "One thing I'd forgotten was that they didn't get Medicare's approval until April and medicare pays for 70% of VRCI's revenue. I'm not surprised they missed their target. It looks like they would have easily reached their target if they had Medicare on board from January 1st.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339123+00:00"
      },
      {
        "event_id": "SOCIAL-Today1808-Mikemine-82712229",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.631220",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "don't know why the link has got stars instead of ********** but i'm sure you can find it.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339143+00:00"
      },
      {
        "event_id": "SOCIAL-Today1807-Mikemine--2532425",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.631632",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "https://www. **********.com/articles/q-a-with-verici-dx-ceo-sara-barrington-6e98b51",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339161+00:00"
      },
      {
        "event_id": "SOCIAL-Today1805-Mikemine-10594468",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.632046",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "barrington sounds confident and on top of it. lots of stuff in there that will enable us to more deeply understand the business and see where vrci is heading. not much about numbers but the obvious acceptance and use by the clinicians and insurers is evident. it really looks like this is going to be a good year for vrci https://www. **********.com/articles/q-a-with-verici-dx-ceo-sara-barrington-6e98b51",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339178+00:00"
      },
      {
        "event_id": "SOCIAL-Today1704-donmac10--1911352",
        "event_type": "social_post",
        "date": "2026-02-06T22:00:54.632458",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sarah sounds very upbeat on Vox markets today..Stating this is Vericis year very positive.",
          "sentiment": 0.0,
          "engagement": "2,878",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339196+00:00"
      },
      {
        "event_id": "SOCIAL-Today1557-bigpunt-83432888",
        "event_type": "social_post",
        "date": "2026-02-06T15:59:25.608751",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Silverblade, a lot of whingeing about the past will not help your decision-making.  One should learn from previous investment decisions and appraise prospective investment decisions better!  Between now and raise will be the FY results and presentation and possibly a further update to support the raise.  Mkt cap and equity raise price will be determined entirely by those trading updates and credibility of updated forecasts",
          "sentiment": 0.0,
          "engagement": "361",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339214+00:00"
      },
      {
        "event_id": "SOCIAL-Today1544-Mikemine-18008751",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.744230",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "All decent points SB. Unfortunately VRCI is on AIM and AIM is almost dead in the water. I would venture that AIM is merely capturing the mood of the country which has been negative for some years now. People are so grumpy and lacking a positive disposition compared with what I see in the States, even with the Trump factor. I would venture that if VRCI was on Nasdaq its valuation would be around the $50-60 mn mark as the potential and demonstrated progress would be recognised as very positive by the Market there. Fortunately VRCI is operating in the States otherwise I wouldn't touch it with a bargepole because of how the NHS is run. You might have guessed that I think the company is well run and punching above its weight in a difficult field. It did get last years fundraiser wrong by announcing it's intention before securing funds but I reckon they've done well otherwise. What's for the future? The next 6 months are crucial but I believe that the \"strong\" sales increase flagged has a good chance of being achieved so the burn rate will reduce. They gave themselves an ambitious target last year which they nearly achieved and this indicates to me that they have a well thought out business model which includes a viable way of commercialising the product and this gives me some confidence is them performing strongly this year. As for a fund raise, their performance since the last one will give institutions lots of confidence to back them should they need one. I am not stupid enough to offer a prediction for the SP but, even on AIM, achieving this strong growth can't help but be positive in that direction. It's all my opinion of course and what do I know? There's always the possibility of a takeover of course but that's a speculative  game in which I am unable, and unwilling, to enter. Good luck for anybody that wishes to stay in the game.",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339232+00:00"
      },
      {
        "event_id": "SOCIAL-Today1453-Silverbl-71439746",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.744668",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I can fully understand fevertrees anger and frustration here - it is likely representative of a large number of longer term shareholders. The grim reality is that whilst the latest update is encouraging in terms of revenue growth, the actions of the board last year in delaying the fund raise to the point it required a price of 0.5p to secure funding has created a position where the sheer number of shares in circulation render's the majority of investors trapped with little chance of recouping any investment made in the 2-5p range. Anything above that is gone.  Add to that a further capital raise in the next 4/6 months - and lets say they go for \u00a35m - which would require 1b further shares being issued at 0.5p. Nothing suggests the share price moving to any significant extent given the reaction to recent news. So then you have in the region of 2.5b shares - even assuming a share price of 1p, that's a \u00a325m market cap for a still loss making company. That in turn assumes the company is capable of doubling its revenue this year - which is possible - which also reduces the further risk (and scale) of a 2027 fund raise although this is still likely. I am invested here - and think the product is viable - but historic investors have been completely shafted. Even the company's own broker has an optimistic price less that 3p a share (don't get me wrong I would grab that in a heartbeat). The best outcome would be for an approach to take the business private or a pharma takeover at a decent premium to the current price. The alternative for shareholders is throwing more money during the fund raise to lower entry prices - which is a sobering thought. All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339250+00:00"
      },
      {
        "event_id": "SOCIAL-Today1428-bigpunt-30184062",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745095",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Some very rough calcs.  c.90% of US population has medical insurance.  c.27,000 kidney transplants last year.  Assuming just one test per transplant, at unindexed $2,650 per test, the USA market-alone is worth $64m.  I'm also assuming the Tennessee lab can service the entire USA I'm not sure how many patients are represented by the 1,173 tests in 2025, and how many transplant centres vs the total in the USA, but the market penetration appears decent, considering the academic papers were only published 6 months ago Some may questions the relevance of academic papers and other KPIs may be more relevant, but it strikes me that the increase in number of clinicians and the increase in number of transplant centres will be strongly influenced by the academic articles and their subsequent peer reviews My view?  VRCI will get bought out when the USA nears profitability due to it's domestic market opportunity and the obvious globalisation opportunity.  Need to pay very close attention to what happens between now and next (and probably final) equity raise",
          "sentiment": 0.0,
          "engagement": "360",
          "price_at_post": "0.725",
          "thread_title": "Mid-term opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=755FC4E4-63EA-405E-A449-61BE41636EEA"
        },
        "ingested_at": "2026-02-10T22:00:18.339267+00:00"
      },
      {
        "event_id": "SOCIAL-Today0859-oogleflu-76700065",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745517",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "I thinks it\u2019s worth noting that Verici\u2019s year end was December. So whilst cash burn continues for another 6 months so does the pipeline growth and revenue. The Blue cross contract in Illinois is very significant as diversifying away from Medicare and becoming less dependant becomes more beneficial to clinicians and patients in not only in cost but also speed of treatment. Barrington hinted that these kind of contracts could spread across to other states. In an ever changing shift in Trumps one brain cell it must be pretty hard to predict or forecast anything in the US. What Vrci has demonstrated this year is the viability and commerciality is well in sight.",
          "sentiment": 0.0,
          "engagement": "5,469",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339285+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261742-Mikemine-97983245",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.745980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, you are clearly angry with VRCI, especially Barrington, so it begs the obvious question \"Why are still here and presumably invested in the company?\" I'm sure most of us have felt let down and financially hurt by companies and BODs in the past but have taken the hit and moved on. Why haven't you?",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339302+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261656-Fevertre--6646756",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.746540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "If cash burn is an issue then perhaps Sara Barrington should take a bloody pay cut",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339320+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261654-Fevertre--4793900",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.747174",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "barrington is the the issue (along with the board). after the disastrously botched raise that almost sank the company but not barrington because she got regranted her share options (not something s/holders were able to do)... her attitude to her shareholders is woeful - she didnt apologise for her gigantic ****-up that cratered the sp. meantime the growth figs look dodgy and she continues to burn thro cash at a rate.... fy 25 1,173 tutivia tests orders = $3m revs = $2557 per test, and yet at 1h figs of 591 tests = $1.16m = $1962 per test, so 30% uplift based on 2h figs. - on face of it that's a great result right? but where is the explanation/reconciliation, and if there is that much volatility barrington how can your investors/analyst properly model outcomes (let alone the company)? then what about momentum that she was saying was happening: october update - barrington told us \" volume growth from this progress is expected from q4 and the number of orders in q3 were consistent with the previous two quarters. 1h 591 so  averages q1 295 q2 295. q3 c300....so based on barrington's comment an uplift was due in q4...and yet: q$ sales below q1, 2,3..and 2h below 1h.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339339+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261628-tbcx-58212237",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.747632",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is the company that reiterated cash runway until H2 2026 in today's update. That is them letting you know now funding will be required this year sometime from July onwards.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339357+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261516-stockyhe-63197282",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748041",
        "source": "LSE_CHAT",
        "data": {
          "author": "stockyheathlad",
          "content": "In a business like this, historic cashflow isn't necessarily a guide to the future. Expenditure on setting up new centres will be variable and, to a degree, discretionary.  The income stream grew across the year so the last quarter's figures are most relevant, rather than the whole year's.",
          "sentiment": 0.0,
          "engagement": "19",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339376+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261419-2Phones--2229759",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748468",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "SB - thanks for that.  They said at the time of the fundraising (as @ 31/05/25) they had a cash runway to the end of July 2025.  And subsequently they have burned that cash ($8.6m?) in the remaining 5-6 months of 2025 down to $3.3m, so $10m breakeven makes sense.  Obviously as they get closer to that breakeven point the cash burn reduces - the question is, with all the sales activity, how quickly can they reach that point, and how many further funding rounds we'll see.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339401+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261333-Silverbl--7972143",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.748870",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Cash burns remains significant - company raised \u00a36.35m during the year - which added to the $800k difference in year end balances show the level of cash required to support the losses incurred over the last 12 months. Breakeven is predicted at $10m revenue pa. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339419+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261236-Guly--6316774",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.749302",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Cash runway atleast 2 yrs assuming current run rate without additional contract wins",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339437+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261117-2Phones-78822264",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.749703",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I agree that the guidance of cash for H2 appears disappointing, however if you take the cash burn over the last 12 months \u2013 the cash reduced from $4.1m to $3.3, which implies a burn rate of $800k per annum.  Now there are many things that impact these numbers but this set against the backdrop of ever-increasing revenue and sales orders/opportunities.  H2 may be a little pessimistic.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339455+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261022-tbcx--4229932",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750126",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Great product and credit to them for being revenue generating, way ahead of many other biotechs valued higher. Suspect there is a management discount at play here for habitually missing guidance, which can be overcome, she's easily replicable. The only snag is cash runway remains H2 2026. Definitely one to revisit once funding overhang sorted.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339473+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261012-Tii21-12912680",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750535",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "2 million delayed buy, and yet this is at 0%!! 05-Feb-26\t08:03:33\t0.79\t2,000,000\tUnknown*\t0.70\t0.75\t15.80k\tO",
          "sentiment": 0.0,
          "engagement": "457",
          "price_at_post": "0.725",
          "thread_title": "RE: Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-10T22:00:18.339492+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261012-Isthisaw-42756883",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.750934",
        "source": "LSE_CHAT",
        "data": {
          "author": "Isthisawinner",
          "content": "Surprised the sp isn't following..",
          "sentiment": 0.0,
          "engagement": "2,301",
          "price_at_post": "0.725",
          "thread_title": "Finally,  gathering momentum...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=B49C9293-BB7B-4427-862D-3D342002FA5A"
        },
        "ingested_at": "2026-02-10T22:00:18.339510+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261006-Mikemine-84317086",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.751372",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Come on FT, give Barrington some credit. She has an accountancy background which would give her a less than gung-ho approach to reporting. They missed a rather ambitious sales target by not much which is good going in my book. For a \"modest\" report her predictions for 2026 are very confident with \"strong\" growth and are significant. For a CEO running a tiny company on a shoe string with small workforce, she is doing well I reckon. Additions to staff last year were all geared to sales so i would expect them to have reached an inflection point. As for the BCBS agreement, what can you say but \"Well done\". That's going to open more doors for the sales force to walk through. I'd imagine there's a good buzz throughout the company at the moment. They must have worked hard for the last 3-4 years with not much in the way is acceptance to show for it but, starting with Fisher, the ball is rolling. Very positive for 26 iIMHO.",
          "sentiment": 0.0,
          "engagement": "1,237",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339528+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261001-Hawker-61912557",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.751787",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Agree, this is an encouraging update. Given the limited resources and tightly managed cost base, Verici could well be on the up this year.  It should only take a doubling or so of the now current testing volumes to put them on the front foot. Keep up the good work Sara and team, go forth and ramp Tutivia and PTRA with Thermo.",
          "sentiment": 0.5,
          "engagement": "301",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-10T22:00:18.339546+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260955-Guly-66289333",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.752384",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Accumulating a position here, can see massive potential.Can't believe it's so cheap.",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-10T22:00:18.339569+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260911-Silverbl--2088341",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.752953",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "On a positive note at least company has provided a FY update with a relatively small target miss, revenue is growing with new partnerships coming on stream and cash is ok for now. Against that - tests sales in H2 were less than H1 (591 v 582) which is concern - why no growth in actual testing volumes. What I can't reconcile is the Tutivia revenue for H1 was $1.2m for 591 tests ($1962 per test); and in H2 Tutivia revenue was $1.8m ($3092 per test). This just doesn't add up imo. Unless there is deferred income from H1 coming into H2 receivables. I think note 1 in the update is attempting to clarify the issue - but the language on revenue estimates being used rather than actual revenue are a bit concerning. Actual audited accounts will be more revealing and may differ from these unaudited updates. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-10T22:00:18.339589+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260855-blowdog-32788093",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.753557",
        "source": "LSE_CHAT",
        "data": {
          "author": "blowdog",
          "content": "Https://x.com/CapitalPmh/status/2019323726446158330?s=20",
          "sentiment": 0.0,
          "engagement": "933",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-10T22:00:18.339607+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260852-newgrang--4566035",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.754153",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "L2 buy orders looking strong \ud83d\udcaa",
          "sentiment": 0.0,
          "engagement": "2,116",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-10T22:00:18.339626+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260843-newgrang-15284730",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.754739",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "Good update with revenues and licensing contract. Hugely undervalued.",
          "sentiment": 0.0,
          "engagement": "2,116",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-10T22:00:18.339644+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260839-Fevertre-41685335",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.755335",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "SOP for disappointing update to put out commercial RNS alongside (Blue Cross deal looks encouraging) to soften the blow. Barrington is t up to the job- didn\u2019t hit the numbers; a less than confident statement , and why on God\u2019s Green Earth are they saying Dec FY25 will come out in May!! This is a tiny business with minimal revenues and yet Barrington can\u2019t commit to releasing results in a timely fashion. Suspect because every Q they have a wrangle with accountants about revenue timing and recognition. Be good to see sustained progress but after screwing up the cash raise, which cratered the so Barrington still has to prove she is CEO material.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339662+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260824-bigpunt-59836216",
        "event_type": "social_post",
        "date": "2026-02-06T15:54:22.755905",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Hitting revenue and cash targets, adding major commercial tie-up, can't ask for much more as the company commercialise.  They've had a cracking year and I like the modest tone",
          "sentiment": 0.0,
          "engagement": "360",
          "price_at_post": "0.775",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-10T22:00:18.339681+00:00"
      },
      {
        "event_id": "SOCIAL-Today1742-Mikemine-97983245",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885051",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, you are clearly angry with VRCI, especially Barrington, so it begs the obvious question \"Why are still here and presumably invested in the company?\" I'm sure most of us have felt let down and financially hurt by companies and BODs in the past but have taken the hit and moved on. Why haven't you?",
          "sentiment": 0.0,
          "engagement": "1,236",
          "price_at_post": "0.725",
          "thread_title": "RE: Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339699+00:00"
      },
      {
        "event_id": "SOCIAL-Today1656-Fevertre--6646756",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "If cash burn is an issue then perhaps Sara Barrington should take a bloody pay cut",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339717+00:00"
      },
      {
        "event_id": "SOCIAL-Today1654-Fevertre--4793900",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.885994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "barrington is the the issue (along with the board). after the disastrously botched raise that almost sank the company but not barrington because she got regranted her share options (not something s/holders were able to do)... her attitude to her shareholders is woeful - she didnt apologise for her gigantic ****-up that cratered the sp. meantime the growth figs look dodgy and she continues to burn thro cash at a rate.... fy 25 1,173 tutivia tests orders = $3m revs = $2557 per test, and yet at 1h figs of 591 tests = $1.16m = $1962 per test, so 30% uplift based on 2h figs. - on face of it that's a great result right? but where is the explanation/reconciliation, and if there is that much volatility barrington how can your investors/analyst properly model outcomes (let alone the company)? then what about momentum that she was saying was happening: october update - barrington told us \" volume growth from this progress is expected from q4 and the number of orders in q3 were consistent with the previous two quarters. 1h 591 so  averages q1 295 q2 295. q3 c300....so based on barrington's comment an uplift was due in q4...and yet: q$ sales below q1, 2,3..and 2h below 1h.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Barrington's incapable of giving proper guidance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=41B503C2-6E69-427C-8F2D-F12E81868AAD"
        },
        "ingested_at": "2026-02-10T22:00:18.339735+00:00"
      },
      {
        "event_id": "SOCIAL-Today1628-tbcx-58212237",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.886494",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is the company that reiterated cash runway until H2 2026 in today's update. That is them letting you know now funding will be required this year sometime from July onwards.",
          "sentiment": 0.0,
          "engagement": "801",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339753+00:00"
      },
      {
        "event_id": "SOCIAL-Today1516-stockyhe-63197282",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.887017",
        "source": "LSE_CHAT",
        "data": {
          "author": "stockyheathlad",
          "content": "In a business like this, historic cashflow isn't necessarily a guide to the future. Expenditure on setting up new centres will be variable and, to a degree, discretionary.  The income stream grew across the year so the last quarter's figures are most relevant, rather than the whole year's.",
          "sentiment": 0.0,
          "engagement": "19",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339771+00:00"
      },
      {
        "event_id": "SOCIAL-Today1419-2Phones--2229759",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.887553",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "SB - thanks for that.  They said at the time of the fundraising (as @ 31/05/25) they had a cash runway to the end of July 2025.  And subsequently they have burned that cash ($8.6m?) in the remaining 5-6 months of 2025 down to $3.3m, so $10m breakeven makes sense.  Obviously as they get closer to that breakeven point the cash burn reduces - the question is, with all the sales activity, how quickly can they reach that point, and how many further funding rounds we'll see.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339788+00:00"
      },
      {
        "event_id": "SOCIAL-Today1333-Silverbl--7972143",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.888058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Cash burns remains significant - company raised \u00a36.35m during the year - which added to the $800k difference in year end balances show the level of cash required to support the losses incurred over the last 12 months. Breakeven is predicted at $10m revenue pa. SB",
          "sentiment": 0.0,
          "engagement": "1,925",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339806+00:00"
      },
      {
        "event_id": "SOCIAL-Today1236-Guly--6316774",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.888582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Cash runway atleast 2 yrs assuming current run rate without additional contract wins",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339824+00:00"
      },
      {
        "event_id": "SOCIAL-Today1117-2Phones-78822264",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.889106",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I agree that the guidance of cash for H2 appears disappointing, however if you take the cash burn over the last 12 months \u2013 the cash reduced from $4.1m to $3.3, which implies a burn rate of $800k per annum.  Now there are many things that impact these numbers but this set against the backdrop of ever-increasing revenue and sales orders/opportunities.  H2 may be a little pessimistic.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339841+00:00"
      },
      {
        "event_id": "SOCIAL-Today1022-tbcx--4229932",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.889622",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Great product and credit to them for being revenue generating, way ahead of many other biotechs valued higher. Suspect there is a management discount at play here for habitually missing guidance, which can be overcome, she's easily replicable. The only snag is cash runway remains H2 2026. Definitely one to revisit once funding overhang sorted.",
          "sentiment": 0.0,
          "engagement": "801",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339859+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Tii21-12912680",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.890160",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tii21",
          "content": "2 million delayed buy, and yet this is at 0%!! 05-Feb-26\t08:03:33\t0.79\t2,000,000\tUnknown*\t0.70\t0.75\t15.80k\tO",
          "sentiment": 0.0,
          "engagement": "457",
          "price_at_post": "0.725",
          "thread_title": "RE: Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-10T22:00:18.339877+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Isthisaw-42756883",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.890667",
        "source": "LSE_CHAT",
        "data": {
          "author": "Isthisawinner",
          "content": "Surprised the sp isn't following..",
          "sentiment": 0.0,
          "engagement": "2,301",
          "price_at_post": "0.725",
          "thread_title": "Finally,  gathering momentum...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=B49C9293-BB7B-4427-862D-3D342002FA5A"
        },
        "ingested_at": "2026-02-10T22:00:18.339895+00:00"
      },
      {
        "event_id": "SOCIAL-Today1006-Mikemine-84317086",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.891178",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Come on FT, give Barrington some credit. She has an accountancy background which would give her a less than gung-ho approach to reporting. They missed a rather ambitious sales target by not much which is good going in my book. For a \"modest\" report her predictions for 2026 are very confident with \"strong\" growth and are significant. For a CEO running a tiny company on a shoe string with small workforce, she is doing well I reckon. Additions to staff last year were all geared to sales so i would expect them to have reached an inflection point. As for the BCBS agreement, what can you say but \"Well done\". That's going to open more doors for the sales force to walk through. I'd imagine there's a good buzz throughout the company at the moment. They must have worked hard for the last 3-4 years with not much in the way is acceptance to show for it but, starting with Fisher, the ball is rolling. Very positive for 26 iIMHO.",
          "sentiment": 0.0,
          "engagement": "1,236",
          "price_at_post": "0.725",
          "thread_title": "RE: Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.339913+00:00"
      },
      {
        "event_id": "SOCIAL-Today1001-Hawker-61912557",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.891629",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Agree, this is an encouraging update. Given the limited resources and tightly managed cost base, Verici could well be on the up this year.  It should only take a doubling or so of the now current testing volumes to put them on the front foot. Keep up the good work Sara and team, go forth and ramp Tutivia and PTRA with Thermo.",
          "sentiment": 0.5,
          "engagement": "301",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-10T22:00:18.339937+00:00"
      },
      {
        "event_id": "SOCIAL-Today0955-Guly-66289333",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.892184",
        "source": "LSE_CHAT",
        "data": {
          "author": "Guly",
          "content": "Accumulating a position here, can see massive potential.Can't believe it's so cheap.",
          "sentiment": 0.0,
          "engagement": "2,255",
          "price_at_post": "0.725",
          "thread_title": "Target 8p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=6A7C74C0-1E63-4FC4-8E9D-FE8416F33D78"
        },
        "ingested_at": "2026-02-10T22:00:18.339955+00:00"
      },
      {
        "event_id": "SOCIAL-Today0911-Silverbl--2088341",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.892711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "On a positive note at least company has provided a FY update with a relatively small target miss, revenue is growing with new partnerships coming on stream and cash is ok for now. Against that - tests sales in H2 were less than H1 (591 v 582) which is concern - why no growth in actual testing volumes. What I can't reconcile is the Tutivia revenue for H1 was $1.2m for 591 tests ($1962 per test); and in H2 Tutivia revenue was $1.8m ($3092 per test). This just doesn't add up imo. Unless there is deferred income from H1 coming into H2 receivables. I think note 1 in the update is attempting to clarify the issue - but the language on revenue estimates being used rather than actual revenue are a bit concerning. Actual audited accounts will be more revealing and may differ from these unaudited updates. SB",
          "sentiment": 0.0,
          "engagement": "1,925",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-10T22:00:18.339973+00:00"
      },
      {
        "event_id": "SOCIAL-Today0855-blowdog-32788093",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.893229",
        "source": "LSE_CHAT",
        "data": {
          "author": "blowdog",
          "content": "Https://x.com/CapitalPmh/status/2019323726446158330?s=20",
          "sentiment": 0.0,
          "engagement": "929",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-10T22:00:18.339991+00:00"
      },
      {
        "event_id": "SOCIAL-Today0852-newgrang--4566035",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.893738",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "L2 buy orders looking strong \ud83d\udcaa",
          "sentiment": 0.0,
          "engagement": "2,114",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-10T22:00:18.340008+00:00"
      },
      {
        "event_id": "SOCIAL-Today0843-newgrang-15284730",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.894260",
        "source": "LSE_CHAT",
        "data": {
          "author": "newgrange",
          "content": "Good update with revenues and licensing contract. Hugely undervalued.",
          "sentiment": 0.0,
          "engagement": "2,114",
          "price_at_post": "0.725",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-10T22:00:18.340026+00:00"
      },
      {
        "event_id": "SOCIAL-Today0839-Fevertre-41685335",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.894756",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "SOP for disappointing update to put out commercial RNS alongside (Blue Cross deal looks encouraging) to soften the blow. Barrington is t up to the job- didn\u2019t hit the numbers; a less than confident statement , and why on God\u2019s Green Earth are they saying Dec FY25 will come out in May!! This is a tiny business with minimal revenues and yet Barrington can\u2019t commit to releasing results in a timely fashion. Suspect because every Q they have a wrangle with accountants about revenue timing and recognition. Be good to see sustained progress but after screwing up the cash raise, which cratered the so Barrington still has to prove she is CEO material.",
          "sentiment": 0.0,
          "engagement": "2,275",
          "price_at_post": "0.725",
          "thread_title": "Faith in the science, not same as faith in management",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=415E9D34-1718-44DC-AA79-49EA6FD67544"
        },
        "ingested_at": "2026-02-10T22:00:18.340044+00:00"
      },
      {
        "event_id": "SOCIAL-Today0824-bigpunt-59836216",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.895246",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigpunt",
          "content": "Hitting revenue and cash targets, adding major commercial tie-up, can't ask for much more as the company commercialise.  They've had a cracking year and I like the modest tone",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "0.775",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=D7349D5A-AFC8-46EA-9F76-78BC22AC2414"
        },
        "ingested_at": "2026-02-10T22:00:18.340062+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260854-2Phones-58951574",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.895745",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "the site is *************interviews dot com",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340079+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260852-2Phones-45685568",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.896268",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "hi splodge2001 https://www. ***************************/verici-dx-landmark-deal-unlocks-potential-300-million-tutivia-market-singer-research-icymi/4121236201",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340106+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261732-Splodge2--2518860",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.896762",
        "source": "LSE_CHAT",
        "data": {
          "author": "Splodge2001",
          "content": "Does anyone have a link to the Singer note? I couldn't find it on their website.",
          "sentiment": 0.0,
          "engagement": "114",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340146+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260851-2Phones-35313930",
        "event_type": "social_post",
        "date": "2026-02-05T22:26:52.897267",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac101 - I was particularly encouraged by the 2.9p target price.  They clearly believe the future for tutivia is massive.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340166+00:00"
      },
      {
        "event_id": "SOCIAL-Today0851-2Phones-35313930",
        "event_type": "social_post",
        "date": "2026-01-30T23:03:22.957691",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac101 - I was particularly encouraged by the 2.9p target price.  They clearly believe the future for tutivia is massive.",
          "sentiment": 0.0,
          "engagement": "83",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340183+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261447-donmac10-69378987",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:31.826472",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Very good research note out last few day by Singer .Talking up Prime health deal 300 mill mkt.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340201+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251243-Romanby-34797600",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.788345",
        "source": "LSE_CHAT",
        "data": {
          "author": "Romanby",
          "content": "No placing you idiot",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-10T22:00:18.340220+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251216-Sandyman-79553438",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "Is the placing going to be at 0.25p or 0.5p? Or both?",
          "sentiment": 0.0,
          "engagement": "999",
          "price_at_post": "0.775",
          "thread_title": "Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-10T22:00:18.340237+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251441-Silverbl--1539767",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.789938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - FYI Thermo Fisher are not currently involved in Tutivia - so they are not involved in any roll out. Despite claims here to the contrary there has been no trading update - so we await evidence that Q4 delivers the level of sales anticipated by the CEO on achieving the 2025 Tutivia revenue target - which as you note would be a significant increase on 2024 sales. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340256+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251547-B_Positi--7813381",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.790830",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340274+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-B_Positi--7258450",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.791703",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I would wager a big Thermo-Fisher update is due here. Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340292+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251302-B_Positi-80797707",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.792503",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Wow now way just saw that. Huge implications for Thermo and its partners!",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340315+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251255-donmac10-54240913",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.793297",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Genincode signed a deal with Thermo read across to Verici Verici so undervalued at the moment something has to give.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340334+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251244-B_Positi-73830659",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794085",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Once it breaks 1p it will fly to 2p and then 3p gets smashed with ease considering the test orders are going to be around 300-400% from the digging below. 3p as a base and then a move back to 5-10p.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.85",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340352+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251227-B_Positi--5376484",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.794962",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "I'm personally amazed more aren't piling in whilst under 1p and this isn't at 3-5p already. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340371+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251953-B_Positi-26532856",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.795766",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Will add another 2m sub 1p Way too cheap here for me personally.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340389+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251945-donmac10--3669254",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.796575",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "3p per share nailed on short term if you guys sit oan yer tuffetts like miss muffet know whit ah mean?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340406+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251941-donmac10--8820102",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.797364",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Company is no longer research orientated so past rns at this time of year irrelevant trust me as tests ramp up as they will be the company will be eager to broadcast positive newsflow asap.noh whit a meen an that man getmeh!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340424+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251535-Silverbl--5245878",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798154",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Would be unusual for a trading update pre-xmas imo although any kind of an update in relation to hitting revenue targets would assist progress here - the bar has been set very high by CEO. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340442+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251320-B_Positi--3180321",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.798939",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Yes it was due. Thermo-Fisher $220BILLION backing this and tied in. Update on them or something new will wake the market up.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340460+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251245-donmac10--4178398",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.799717",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Update this week and more deals with distributors .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340477+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251234-B_Positi--7708475",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.800588",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "MMs caught wind of an update? I'm amazed this isn't over 2p at least. There are pharma stocks that don't make a single cent trading at multiples of this. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340495+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251230-tbcx--8283486",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.801373",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "Buying pressure certainly returning this week, this remains extremely undervalued.",
          "sentiment": 0.0,
          "engagement": "766",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340513+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251443-donmac10--6673310",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802148",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Nice 2mill buy this morning.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340531+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251235-B_Positi--2936562",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.802905",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Donmac, absolutely buzzing for the trading update this month Hopefully see's this head back to the 3 to 5p level",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340548+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251104-B_Positi--5111903",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.803727",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "So with less than 10% of transplant centres onboarded and already at the start of the mass rollout they averaged about 300 tests per quarter in Q1, Q2 and Q3, just short of 900, vs 334 for the entirety of 2024, representng significant growth. We now know they are at at least 16% of transplant centres onboarded now (less than 10% for Q1, Q2, Q2, perhaps around 20% now and are increasing this fast. You quickly realise how mad the revenues can become here at $2,650 a test with the medicaid coverage +Thermo Fisher licencing revenues. I know many, many pharma stocks that have literally $0 revenue, no proven tech, no FDA approval, no big deal with a giant like this does with Thermo Fisher that are trading at many multiples of the Verici market cap.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340566+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251045-donmac10--5903184",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.804510",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "And its beginning to look like word is out?",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340584+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251039-donmac10-91889382",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.805293",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Expecting a trading update in the run up to xmas should make for good reading!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340601+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251031-B_Positi--5908752",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806132",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.70",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340619+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251456-Mikemine--5901014",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:34.806901",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Fevertreeman, your posts have got  very repetitive and quite frankly, boring. Unless your rants help your mental state I for one would be grateful if you would keep your posts to new views or information.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-10T22:00:18.340637+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251148-Fevertre-78196731",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.375637",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Just out of interest what are Barrington's competencies?",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-10T22:00:18.340655+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251147-Fevertre--1212177",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.376396",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "The Board and non-execs have overseen an absolute shamble here. Barrington completely unaffected by disastrous dilution as she has virtually no bloody shares in teh company she purports to lead.  The CFo isnt fit for purpose frankly. The Q4 figs appear to be the stuff of fantasy - I would give more creedance if  Barrington was able to explain how she gets to the forecast but she appears to be just making it up as she goes along... we have no timelines on onboarding; Barrington cant set out how she arrived at the numbers... she continues to be utterly hopeless as the CEO of supposedly a cutting edge business.",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-10T22:00:18.340673+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20251059-Silverbl--2461879",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377214",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There you go donmac almost at your buy price already. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.70",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-10T22:00:18.340691+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20250050-donmac10--7878578",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.377985",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Sell up move on thank you.....give me the chance ar more aroon the 55 mark slanj .And a will catch yeh in wetherspoons oan the wae otta rah ritz.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-10T22:00:18.340709+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251734-Mikemine-36908938",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.378810",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "VRCI is a small company so hiring an extra 3 salespersons is huge for them and points to their determination to hit their target. It's a big ask but you can be sure they recognise that their credibility is on the line. From a practical point of view, hiring new salespeople  takes time for their impact to come through. They have to get used of the systems, the product and VRCI's method of selling. I wish them luck and, if they do reach their target, it will be noticed by the Market.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-10T22:00:18.340726+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251709-Silverbl--8963938",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.379608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not a fan to date either fevertree - its been a disaster for all shareholders here - but I still hold a position here and am trying to look forward not back given the past is what it is. If Q4 goes well I expect a trading update early 2026 - which doesn't usually happen but positive momentum will be required to avoid a total wipe out in any subsequent capital raise. Failure to deliver (again) then more questions will be raised on leadership competencies.  SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.75",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-10T22:00:18.340744+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251647-Fevertre--8058296",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.380414",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "She has never fully explained the onboarding process. If a new centre gets onboarded, typically how long does it take for clinicians to order first tests",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-10T22:00:18.340762+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251644-Fevertre-21766021",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.381220",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Nonsense Donmac.....look at the maths around Barrington's targets: On my maths I don't see how she hits revs from Tutivia $3.2m... Tutivia:  1H Revs: $1.16m: 591 tests @ ave $1900 ($1.16m divided by 591) 2H Revs:  3Q Tutivia same rate as Q1/Q2 ..c300 tests at 1900 = $570k  ...so to meet her target she needs to sell c$1.5m of tests. Assume same ave price of $1900....she needs to sell c790 tests....that's a massive uplift, even with onboarding another 9 more centres...",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-10T22:00:18.340780+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251627-donmac10-78227159",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382010",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "markets falling and the doom and gloom ****roaches appear in force.sell up ,thats even if yeh hod any and gie us aw peace!",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-10T22:00:18.340798+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251604-Fevertre-36483218",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.382802",
        "source": "LSE_CHAT",
        "data": {
          "author": "Fevertreeman",
          "content": "Worryingly her bullishness has cost investors dearly so far. Apart from having virtually no skin in the game she hasn't been gifted,  or regifted (look at the outrageous revision of option pricing). The fact that the sp is still at 3/4 of a penny tells you everything you need to know about how the market views her!",
          "sentiment": 0.0,
          "engagement": "2,272",
          "price_at_post": "0.725",
          "thread_title": "RE: 2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-10T22:00:18.340816+00:00"
      },
      {
        "event_id": "SOCIAL-18Nov20251522-Silverbl-21199303",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.383604",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Based on what we already know - VRCI sold c.600 Tutivia tests in H1 2025 - securing revenue of $1.2m ($2k per test - blend of public and private payers). They sold same in Q3 - so lets assume pro-rata they secured a further $600k revenue. Sara B confirmed FY Tutivia target was $3.2m - so that leaves $1.4 revenue to be secured in Q4 - or c.700 tests at $2k. Seems a huge leap - or possible they are looking at a slight increase to average test $ - although Prime Health RNS appears to push towards discounted volume in private market. She has certainly set high expectations for Q4 trading. If this is achieved it will be a significant acceleration - and will be crucial in supporting the share price/market cap as the company requires additional funding in the next 4/5 months. Additional licensing revenue from Thermo (c.$4m received to date - $3.3m in 2024 and $0.75m in 2025) remains on hold as they progress their approach to the PTRA test. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "0.725",
          "thread_title": "2025 Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=6E1A4120-8D0F-428E-9C51-E7E40D6965CC"
        },
        "ingested_at": "2026-02-10T22:00:18.340835+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250856-2Phones--8565039",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.384401",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Donmac agreed - two of the latest RNS are very positive about the rate of revenue growth and market penetration - can't help but think the next sales based RNS will be a gamechanger.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.875",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-10T22:00:18.340859+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250845-donmac10-38181023",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385202",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Analysts expecting 3p per share next year big upside from here.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.90",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-10T22:00:18.340878+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250843-donmac10-81789311",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.385990",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Verici also more forthcoming informing the market with updates .Beats last years 6 month radio silence .Just waiting now for testing update which i know will further boost price.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-10T22:00:18.340896+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250830-donmac10-33848524",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.386775",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Tells me ,anyone looking to make money would be well served to get in now .Futher big rise going into year end.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.95",
          "thread_title": "RE: RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-10T22:00:18.340913+00:00"
      },
      {
        "event_id": "SOCIAL-12Nov20250809-2Phones--2925803",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.387576",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "Interesting news today \u2013 initially I thought why? This has little bearing on shareholders interests \u2013 however, on further concideration, while successful audits add little to the bottom line or turnover or even shareholder value \u2013 in our case it is very much a Critical Failure Factor, where failure to pass a quality audit could seriously damage the company in the short/medium term.  Also it does point to a well run, disciplined business. So well done Verici.",
          "sentiment": 0.0,
          "engagement": "81",
          "price_at_post": "0.95",
          "thread_title": "RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=77198BE6-A744-48EE-9FC8-D6B5719507BC"
        },
        "ingested_at": "2026-02-10T22:00:18.340931+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251448-oogleflu-85341374",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.388340",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Tom. I know exactly what you\u2019re saying is correct . Unfortunately risk appetite is much lower in the UK probably because the FA are like a bunch of frightened rabbits. Fund managers continue to unwind oversold positions in uk to chase  the way overpriced \u2018American dream stocks\u2019 which are overdue a big correction there by loosing even more of the inadequate fund managers clients money. It\u2019s not all Uk stocks but quite a few as admitted in an interview recently with a fund manager. Certainly since the pandemic Uk stocks are valued much more realistically i.e. sound balance sheet which Vrci  now has, realistic forecast which Vrci now has, realistic targets for growth which Vrci now has. But we don\u2019t tend to look further than a year ahead. One step at a time . There will be /is FOMO with a stock like Vrci which will cause some volatility till they establish a more constant earnings stream.",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340949+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251354-donmac10--5604265",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389131",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "It feels to me we are about to get a trading update on testing numbers shortly .",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.925",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340967+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251256-donmac10-19864195",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.389888",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "1.20p close today and more updates in coming days on quickly to 2.00p",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.875",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.340985+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251247-geraldus-84175884",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.390653",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "Still early days here,and they will have to take some market share from the incumbent bio markers. Shaping up well so far and with a miserly market cap in comparison with other counters.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.825",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341003+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251241-B_Positi-12951669",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.391431",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Geraldus Tutivia is the standard now. Hence why Thermo-Fisher has gone all in and is backing all the way. Market slowly beginning to wake up that this company is grossly undervalued. I mean the FDA approval, ip, tech alone is worth multiples and then whack on the huge growth already in 2025 and coming in 2026 with over 30 transplant centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341025+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251239-donmac10--4174260",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392203",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "American market waking up to the potential with Verici dx in their own backyard They love an AI stock.",
          "sentiment": 0.0,
          "engagement": "2,876",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341044+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251236-geraldus--9093825",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.392989",
        "source": "LSE_CHAT",
        "data": {
          "author": "geraldus",
          "content": "With their 'AI' solution for optimising transplants,it is undoubtly an interesting opportunity here. They have spent millions on this and they are confident that it is payback time. With no competition at this level,it could possibly become the defacto standard.",
          "sentiment": 0.0,
          "engagement": "94",
          "price_at_post": "0.80",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341062+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251217-B_Positi--5908752",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.393835",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,482",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341080+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251205-oogleflu--8836525",
        "event_type": "social_post",
        "date": "2026-01-29T10:03:39.394621",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Addressable market doesn\u2019t mean they capture all of it.  They might get 1 or 2 percent which is still sizeable if lucky. Even singer, their broker,  have only raised the sp to 3p. That\u2019s still 4 times current market cap! The other thing is will they need to expand the lab or open another one as their market share increases. They have got a captured market in that there is no competition and the tests are becoming mandatory. No plans to adopt outside the US yet. Maybe 20p in 5 years certainly not months I\u2019m afraid but good luck",
          "sentiment": 0.0,
          "engagement": "5,463",
          "price_at_post": "0.775",
          "thread_title": "RE: Quantifying the opportunity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&share=VRCI&thread=D3DE9F2B-871D-47DE-96C8-2D6BB08D16A4"
        },
        "ingested_at": "2026-02-10T22:00:18.341109+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261715-Silverbl-58741196",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "B_Positive - feel free to use the actual numbers in your updates. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 (INCORRECT: H1 actual revenue was $1.16m = $1962 average revenue per test). H1 2025 licencing revenue = $750,000 (CORRECT) Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. (Test numbers CORRECT. Centres INCORRECT - there were 21 onboarded at time of results). 286 x $2,650 = $757,900 (Likely INCORRECT based on average revenue per test of $1962 achieved in H1 2025 - likely revenue $560K). Q4 2025, 20 centres onboarded and let's be conservative and say 300 tests. (INCORRECT. There are now 30 centres onboarded. Company is targeting in the region of 750 tests in Q4 in order to meet its Q4 revenue target of c.$1.5m) 300 x $2,650 = $795,000 revenue (We will find out in due course what was achieved in terms of test numbers and average revenue per test) H2 2025 licensing revenue, let's be conservative and say $500,000. (INCORRECT. No licencing revenue will come from Thermo in H2) Combine all of that above and you get = $4.3mil or \u00a33.2m. (H1 revenue was $1.9m/ Q3 likely $560K. Q4 not yet reported. Company is targeting total FY 2025 revenue of $3.95m, comprising $3.2 Tutivia tests and $750K licencing revenue) Still nothing in the way of a trading update from the team at vrci. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341143+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261504-B_Positi-18782688",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.332720",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We should all be extremely excited having now onboarded over 30 transplant centres, up from 10 in 2024. We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341161+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260830-Silverbl--3198821",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333151",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "$12m was a direct quote from Vrci CEO in latest Vox markets interview. As for my 'precise' figures - strangely enough when it comes to investing I prefer to deal in fact rather than making it up (refer B_Positive). As for my views on the business - I remain invested so I am hopeful there is a future here or would have taken my medicine and moved on. That does not mean to say I will not vocalise my thoughts on areas of mismanagement where the company could and should be doing better; or to call out posters who are just making it up as they go along. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341179+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260728-B_Positi--8275032",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.333626",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "We know they've gone from 10 onboarded transplant centres to now over 30. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10-15 centres onboarded.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341197+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20260205-donmac10-54111594",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334054",
        "source": "LSE_CHAT",
        "data": {
          "author": "donmac101",
          "content": "Where do you get the 12mill breakeven point? You sound like a bot with your precise figures. And you always have a way of sounding positive but are really negative .So cant be taken seriously .",
          "sentiment": 0.0,
          "engagement": "2,871",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341222+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262026-Silverbl--5950590",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334501",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not really sure why I need to explain this, but here you go B_Positive. Your bullet point regarding Tutivia sums the position up very well. Transplant centres service both Medicare patients and private paying patients. So whilst the Medicare payment of $2650 is being provided by the US healthcare system for patients who benefit from the Medicare and Medicare plus programmes - there are actually six key revenue streams for test sales of which Medicare is one (albeit the largest - 68% of tests being undertaken are covered by Medicare seems to be the claim from the company). Private payers (via healthcare insurance) do not pay the $2650 - they receive discounts. Clinical trials pay nothing. And there others. If you divide the H1 Tutivia revenue of $1.16m by the 591 tests in H1 it comes out at $1962 . That is the current revenue reality for test sales. The recent RNS highlighting the agreement with Prime Health Services is all about trying to establish consistent pricing of the Tutivia test with the private payment market and clearly with the goal to increase current pricing which is diluting the Medicare $2650. In relation to your H2 licencing point the following clarifies the position \" Thermo Fisher is investing in new research related to PTRA aimed at identifying the earliest stage at which the test can be utilised before transplantation. Consequently, the second milestone originally anticipated for 2025 will be delayed as we continue to collaborate on publishing clinical validation data and Thermo Fisher pursues these additional research efforts to help broaden utility and adoption of the assay.\" FYI the breakeven position for Verici is c.$12m - so that provides an indication of the revenue which is required from test sales, licence revenue, protega etc to cover vrci operating costs. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341244+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261524-B_Positi-89293469",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.334932",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Nope it's $2,650 as per the Medicare coverage RNS and more recently as per the HY report. \u00b7 Lead product Tutivia\u2122 attained Medicare coverage at $2,650 per test, covering a national estimate of 68% of all US transplant tests and commercial payor reimbursement applications are underway They receive licencing revenues both H1 and H2. It was $750k in H1.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341263+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261523-Silverbl--8113003",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335360",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Mikemine -  your points are valid - but highlight one of the main issues here. Why set a target and fail. Undermines confidence, craters the share price, makes fund raising tricky and makes investors wary on growth. Much better to overdeliver on achievable targets than underdeliver? But maybe we will be get a pleasant surprise. Thermo are just doing their own thing on the PRTA at present. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341281+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261518-Silverbl-34232058",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.335771",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "No licencing revenue in H2 2025 and average received revenue per test is $1900. Do some actual research please. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341299+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261416-B_Positi-58962249",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336264",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. 591 tests x $2650 = $1,566,150 H1 2025 licencing revenue = $750,000. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. 286 x $2,650 = $757,900 Q4 2025, 20 centres onoboarded and let's be conservative and say 300 tests. 300 x $2,650 = $795,000 revenue. H2 2025 licening revenue, let's be conservative and say $500,000. Combine all of that above and you get = $4.3mil or \u00a33.2m. Revenue target comfortably achieved and beaten in this scenario. That's all with most of the year at just about 10 centres onboarded. It must now be around 25-35 going by the last report.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341316+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261402-Mikemine--5362166",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.336713",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "They've set themselves a big revenue target of over \u00a33mn for 2025. Small in world terms but a big % increase for VRCI. Should they be chastised if they do not reach the target or should it be viewed in the context of what they do achieve and what they forecast for this year? Getting close to \u00a33mn would be an achievement in my book as that would point to things being on track for further increases especially as the new sales guys have probably only just got their acts together and their contacts in line. Not sure what to think of the Thermo-Fisher deal and its seemingly lack of traction. Big companies are not nimble nor quick so the jury's out on that one for me. My guess is for an update this month and it will be positive but will not please everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341334+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261401-B_Positi-19781002",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337193",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Cashed up until the end of 2026 and now they've been securing record orders as per below. Next time they raise it will be in the pennies, which is what they will want given the new option prices. Test update going to drop soon. More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341352+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261346-Silverbl-81700083",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.337608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Despite the view expressed by several contributors here we have heard nothing from the business on Q4 trading. Not unexpected - if there was anything to report on I would expect to hear later on in January. The issue looming very shortly relates to the required fund raising. In previous years the company has elected not to divulge FY trading until May.  This is likely to be beyond the point at which the company runs out of cash. We should therefore be able to read the signals loud and clear - no trading update - then Q4 has not delivered the targeted sales and the fund raise will be brutal.  If a positive Q4 trading update is issued then there should be a healthy price response despite the recognition funds will still be required. Remember last year the first fundraise was at 9p - then 0.5p after bewildering timing mismanagement by the company.  All imo. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.75",
          "thread_title": "RE: 100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-02-10T22:00:18.341369+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261228-B_Positi--6397996",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338063",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "More likely to see this trading well north of 5p when considering the below: Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.75",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341387+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-2reincar--3698297",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338488",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Conversions this summer will see us at sub 0.25p!",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.75",
          "thread_title": "100% certain we will see \" death spiral\" funding!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=16D37389-63E5-48E2-A212-7CC26363E05F"
        },
        "ingested_at": "2026-02-10T22:00:18.341405+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261210-B_Positi--6901222",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.338938",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.725",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341428+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20260629-2Phones--8591137",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339362",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "How can any one disagree with such a cogent arguement - and clearly not the rantings of a one track numpty.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.725",
          "thread_title": "RE: Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-02-10T22:00:18.341447+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261022-2reincar-37847582",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.339773",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "At 0.25p?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.725",
          "thread_title": "Happy new year's placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=2F0ED449-4B95-4553-AFAC-B15F7B6ACD5A"
        },
        "ingested_at": "2026-02-10T22:00:18.341464+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251515-B_Positi--6901222",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340229",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Looking at the game changing increase in test ramp up I imagine they will be very eager to expand coverage to more sites. VRCI make $2,650 per Tutivia test + licening revenue from Thermo-Fisher. 334 Tutivia tests ordered for the whole of FY 2024. H1 2025 / Q1+ Q2 = 591 Tutivia\u2122 tests ordered with about 10-15 transplant centres onboarded. Q3 2025 286 tests ordered, as per investor presentation, with about 10-15 transplant centre onboarded. Q4 they anticipate significant growth and have now onboarded 30 transplant centres. So already FY-2025 is looking like several hundred % growth. The 30 transplant centres the company are signed up for = only 16% of transplant centres and they have increased the sales team to gain access into the rest. As 2025 wraps up with several hundred growth aniticpated over 2024, the company has positioned itself to have a monster 2026. That's assuming Thermo-Fisher doesn't just buyout this company soon.",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341482+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251223-Silverbl-53223834",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.340643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "2Phones - from the company itself: \" With minimum gross proceeds from the Placing and Subscription of \u00a35 million, the Company's cash runway will be extended to mid Q2 2026.\". Hence my thinking spring will be the time to raise. And yes revenue is expected to increase (we will know by how much in a few weeks) - but annual expenses are c.$9m - so sales would need a dramatic (and unlikely) increase to negate the need for more funds. And you seem to agree that a placing is an option (imo the only likely one and the route the company has taken to date in all its efforts to secure more funding). So not sure what you were disagreeing with? SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-10T22:00:18.341500+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20250753-2Phones-67193925",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341050",
        "source": "LSE_CHAT",
        "data": {
          "author": "2Phones",
          "content": "I don't agree - the operational update earlier this year had a predicted cash runway to H2 next year - when you couple that with the recruitment of 2 sales people and a director of clinical partnerships, I would anticipate growth in cash inflow.  However, they are a small team and they are going to have to increase production to accommodate the anticipated sales.  This will need funding, but where they get it is uncertain \u2013 one option being a placing.",
          "sentiment": 0.0,
          "engagement": "80",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-10T22:00:18.341518+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251728-2reincar-61973247",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341472",
        "source": "LSE_CHAT",
        "data": {
          "author": "2reincarnated",
          "content": "Agree Silverblade. We could have one in Aprilish at 0.5p and one in Octoberish at 0.25p and then a rocket to + 2p ?",
          "sentiment": 0.0,
          "engagement": "5,830",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-10T22:00:18.341537+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251618-Silverbl--9188492",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.341885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Same old nonsense B_Positive. Thermo are not involved in Tutivia. Stop spreading false information. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341554+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251557-B_Positi--7813381",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342355",
        "source": "LSE_CHAT",
        "data": {
          "author": "B_Positive",
          "content": "Worth a listen to how hard and fast the ramp up is anticipated to be here. https://www.youtube.com/watch?v=_BLF7WKbxuk Tutivia has no competition in the market, aka best in class. You will see that on a slide between 11:00-12:00. Absolutely insane this is down here considering Thermo Fisher rolling it out. Thermo backing Licences in FDA approval in Patents in Best in class and no competition 300-400% growth anticipated in 2025 at least looking at the test orders in Q1-Q3 before Q4 ramp up Total market dominance expectations",
          "sentiment": 0.0,
          "engagement": "4,403",
          "price_at_post": "0.775",
          "thread_title": "RE: Thermo-Fisher valued $200B+ behind VRCI. Mcap should be \u00a360-100m",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=74912613-A32F-4B2F-BD8D-270BA8AA6054"
        },
        "ingested_at": "2026-02-10T22:00:18.341572+00:00"
      },
      {
        "event_id": "SOCIAL-26Dec20251522-Silverbl-60354201",
        "event_type": "social_post",
        "date": "2026-01-24T01:57:04.342765",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "There will be a placing in early 2026 - probably March/April time. The placing will of course be determined by the prevailing share price at the time. And that in turn will reflect the numbers for FY 2025 - there is a lot of expectation here so lets see what the company has to say for itself hopefully with a trading update in January. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "0.775",
          "thread_title": "RE: Only one thing unclear about 2026!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=VRCI&thread=CE8CBECB-82AC-408C-88A9-4715D48E8F1F"
        },
        "ingested_at": "2026-02-10T22:00:18.341589+00:00"
      }
    ],
    "catalyst_dates": {
      "proxy_date": "2026-02-11"
    }
  },
  "ai_insights": {
    "company_30s": {
      "what_they_do": "VRCI.L",
      "why_they_matter": "Mining",
      "current_state": "TBD"
    },
    "whats_happening_now": {
      "rns_narrative": [
        "Most recent RNS under review"
      ],
      "crowd_tape": {
        "dominant_theme": "Community discussion tracked: 50 posts analyzed from chat",
        "bull_narrative": "Bullish sentiment present in chat discussions",
        "bear_narrative": "Bearish concerns also noted in community",
        "sentiment_shift": "Mixed sentiment observed in recent posts"
      },
      "attention_check": "102 total events analyzed"
    },
    "bottom_line": "Analysis complete with 102 events"
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "BIOTECH_PHARMA",
      "name": "Biotech & Pharma",
      "icon": "\ud83e\uddec",
      "color": "#10b981",
      "crash_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges",
        "Funding gaps (cash runway concerns)"
      ],
      "recovery_paths": [
        "Positive trial data (efficacy endpoints met)",
        "Regulatory approvals (FDA/EMA)",
        "Partnership deals (big pharma licensing)",
        "Orphan drug designation or fast track",
        "New trial initiations (pipeline expansion)"
      ],
      "active_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Patent expiry or IP challenges"
      ],
      "relevant_rns_count": 0,
      "key_metrics": [
        "Clinical stage (preclinical, Phase 1/2/3, commercialized)",
        "Cash runway (months until next funding)",
        "Addressable market size (indication)",
        "Trial enrollment progress",
        "Intellectual property strength"
      ]
    },
    "panic_analysis": {
      "panic_score": 42.8,
      "signal": "MODERATE_FEAR",
      "interpretation": "\ud83d\udfe1 Cautious sentiment - assess risk/reward",
      "breakdown": {
        "price_destruction": 12.8,
        "volume_death": 14,
        "social_silence": 6,
        "news_sentiment": 10
      },
      "is_opportunity": false,
      "opportunity_reason": "\ud83d\udcca Moderate fear detected - monitor for escalation"
    },
    "fear_vs_facts": {
      "fear_points": [],
      "facts_points": [],
      "verdict": "\u2696\ufe0f Mixed signals - Fear and facts balanced, wait for clarity"
    },
    "crashhunter_signals": [
      {
        "type": "BUILDING",
        "icon": "\ud83d\udcca",
        "text": "Building",
        "color": "#10b981"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "FY25 Trading Update",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Agreement with BCBS of Illinois for Tutivia\u2122",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Completion of CAP accreditation audit",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Provider Participation Agreement with Prime Health",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Completion of ISO 27001 surveillance audit",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "WATCH",
      "reason": "\u23f3 Monitor for timing regime change or panic escalation",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "43/100",
          "pass": false,
          "icon": "\ud83d\udfe2"
        },
        {
          "criterion": "Timing Regime",
          "value": "EARLY_BUILD",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "42/100",
          "pass": false,
          "icon": "\u26a0\ufe0f"
        },
        {
          "criterion": "Data Confidence",
          "value": "50/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "3 active",
          "pass": true,
          "icon": "\ud83e\uddec"
        }
      ],
      "pass_rate": "3/5"
    },
    "contrarian_panic": {
      "total_score": 24,
      "band": "\u26aa LOW COMPRESSION (Early/Weak)",
      "components": {
        "compression": {
          "score": 7,
          "max": 40,
          "signals_30d": 2,
          "signals_60d": 2,
          "signals_90d": 2,
          "signals_per_week": 0.15,
          "total_signals": 28,
          "rsi_extreme_count": 2,
          "rsi_ultra_count": 2,
          "escalation_count": 0,
          "density_score": 3,
          "rsi_score": 4,
          "escalation_score": 0,
          "description": "0.2 signals/week | 2 RSI<20 | Early stage"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "EXTREME CRASH BOTTOM",
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 1,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 5,
          "max": 15,
          "relative_volume": 2.11,
          "description": "Elevated volume - Some activity"
        },
        "pop_potential": {
          "score": 7,
          "max": 15,
          "best_historical_rally": 268.4,
          "avg_rally": 63.4,
          "signal_count": 28,
          "description": "Moderate performer (268%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation detected"
        }
      },
      "ticker": "VRCI.L",
      "signal_date": "2026-02-10",
      "total_signals_history": 28
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +14 (AI_Technical_Score=11.0/20)",
      "Drawdown reversion potential: +16 (Drawdown_Pct=81.9%)",
      "Volume confirmation: +10 (Relative_Volume=2.1)",
      "Pattern reliability: +0 (Rally_Count=0.0)",
      "Upside history: +2 (best_rally_pct=3%)"
    ],
    "technical_score": {
      "points": 14,
      "ai_score": 11.0,
      "reason": "AI Technical Score 11.0/20 translates to 14/25 points"
    },
    "drawdown_score": {
      "points": 16,
      "drawdown_pct": 81.87,
      "reason": "Drawdown of 81.9% gives 16/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.11,
      "reason": "Relative volume 2.11x gives 10 points"
    },
    "pattern_score": {
      "points": 0,
      "rally_count": 0.0,
      "reason": "0.0 historical rallies gives 0/15 points"
    },
    "upside_score": {
      "points": 2,
      "best_rally_pct": 2.94,
      "reason": "Best rally of 3% gives 2/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=EARLY_BUILD",
          "current_return_pct=2.9%"
        ]
      }
    ],
    "reasons_to_sell": []
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "EARLY_BUILD",
    "run_multiple": 0.2,
    "current_run_pct": 2.94,
    "avg_historical_run_pct": 2.94
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 42/100 APEX score. Historical data shows 0 rallies averaging 3% upside. Current position: +2.9%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Early accumulation phase. Watch for confirmation before committing size.",
    "confidence_explained": "Confidence 50/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": true
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  },
  "report_version": "5.0",
  "comprehensive_apex": {
    "score": 42,
    "rating": "LOW QUALITY",
    "color": "#ef4444",
    "calculation": "APEX Score: 42/100",
    "components": {
      "setup": {
        "score": 52,
        "weight": 0.25
      },
      "trust": {
        "score": 50,
        "weight": 0.2
      },
      "panic": {
        "score": 42.8,
        "weight": 0.3
      },
      "compression": {
        "score": 24,
        "weight": 0.25
      }
    },
    "timing": {
      "regime": "EARLY_BUILD",
      "multiplier": 1.0
    }
  }
};</script>
  <script src="../../apex_trust_panel.js"></script>
</body>
</html>
